0000885725-18-000021.txt : 20180501 0000885725-18-000021.hdr.sgml : 20180501 20180501063214 ACCESSION NUMBER: 0000885725-18-000021 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180501 DATE AS OF CHANGE: 20180501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 18793034 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 10-Q 1 q12018form10-q.htm 10-Q Q1 2018 Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
þ
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2018
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File No. 1-11083
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE
04-2695240
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MASSACHUSETTS 01752-1234
(Address of principal executive offices) (zip code)
(508) 683-4000
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer þ
Accelerated filer o
Non-Accelerated filer o (Do not check if a smaller reporting company)
Smaller reporting company o
 
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
 
 
Shares outstanding
Class
 
as of April 25, 2018
Common Stock, $0.01 par value
 
1,379,810,502



TABLE OF CONTENTS

 
 
Page No.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

2


PART I
FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

 
Three Months Ended
March 31,
in millions, except per share data
2018
 
2017
 
 
 
 
Net sales
$
2,379

 
$
2,160

Cost of products sold
672

 
650

Gross profit
1,707

 
1,510

 
 
 
 
Operating expenses:
 
 
 
Selling, general and administrative expenses
860

 
794

Research and development expenses
261

 
235

Royalty expense
18

 
17

Amortization expense
141

 
143

Intangible asset impairment charges
1

 

Contingent consideration expense (benefit)
5

 
(50
)
Restructuring charges (credits)
13

 
4

Litigation-related net charges (credits)

 
3

 
1,300

 
1,146

Operating income (loss)
407

 
364

 
 
 
 
Other income (expense):
 
 
 
Interest expense
(61
)
 
(57
)
Other, net
(23
)
 
(2
)
Income (loss) before income taxes
323

 
305

Income tax expense (benefit)
26

 
15

Net income (loss)
$
298

 
$
290

 
 
 
 
Net income (loss) per common share — basic
$
0.22

 
$
0.21

Net income (loss) per common share — assuming dilution
$
0.21

 
$
0.21

 
 
 
 
Weighted-average shares outstanding
 
 
 
Basic
1,376.5

 
1,365.4

Assuming dilution
1,396.8

 
1,390.2







See notes to the unaudited condensed consolidated financial statements.

3


BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

 
Three Months Ended
March 31,
(in millions)
2018
 
2017
Net income (loss)
$
298

 
$
290

Other comprehensive income (loss), net of tax:
 
 
 
Foreign currency translation adjustment
10

 
8

Net change in derivative financial instruments
(80
)
 
(55
)
Total other comprehensive income (loss)
(69
)
 
(47
)
Total comprehensive income (loss)
$
228

 
$
243











































See notes to the unaudited condensed consolidated financial statements.

4


BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
 
As of
 
March 31,
 
December 31,
in millions, except share and per share data
2018
 
2017
 
(unaudited)
 
 
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
287

 
$
188

Trade accounts receivable, net
1,580

 
1,548

Inventories
1,113

 
1,078

Prepaid income taxes
50

 
66

Other current assets
1,048

 
942

Total current assets
4,080

 
3,822

Property, plant and equipment, net
1,700

 
1,697

Goodwill
6,984

 
6,998

Other intangible assets, net
5,713

 
5,837

Other long-term assets
725

 
688

TOTAL ASSETS
$
19,202

 
$
19,042

 
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Current debt obligations
$
962

 
$
1,801

Accounts payable
404

 
530

Accrued expenses
2,447

 
2,456

Other current liabilities
1,174

 
867

Total current liabilities
4,988

 
5,654

Long-term debt
4,803

 
3,815

Deferred income taxes
128

 
191

Other long-term liabilities
2,254

 
2,370

 
 
 
 
Commitments and contingencies

 

 
 
 
 
Stockholders’ equity
 
 
 
Preferred stock, $0.01 par value - authorized 50,000,000 shares,
none issued and outstanding


 


Common stock, $0.01 par value - authorized 2,000,000,000 shares -
issued 1,627,188,009 shares as of March 31, 2018 and
1,621,062,898 shares as of December 31, 2017
16

 
16

Treasury stock, at cost - 247,566,270 shares as of March 31, 2018
and December 31, 2017
(1,717
)
 
(1,717
)
Additional paid-in capital
17,184

 
17,161

Accumulated deficit
(8,326
)
 
(8,390
)
Accumulated other comprehensive income (loss), net of tax
(128
)
 
(59
)
Total stockholders’ equity
7,030

 
7,012

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
$
19,202

 
$
19,042



See notes to the unaudited condensed consolidated financial statements.

5


BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

 
Three Months Ended
March 31,
(in millions)
2018
 
2017
 
 
 
(restated)
Cash provided by (used for) operating activities
$
193

 
$
(7
)
 
 
 
 
Investing activities:
 
 
 
Purchases of property, plant and equipment
(60
)
 
(112
)
Payments for acquisitions of businesses, net of cash acquired
(9
)
 

Payments for investments and acquisitions of certain technologies
(103
)
 
(28
)
Cash provided by (used for) investing activities
(173
)
 
(140
)
 
 
 
 
Financing activities:
 
 
 
Payment of contingent consideration amounts previously established in purchase accounting

 
(18
)
Payments on long-term borrowings
(602
)
 
(250
)
Proceeds from long-term borrowings, net of debt issuance and extinguishment costs
990

 

Net increase (decrease) in commercial paper
(316
)
 

Proceeds from borrowings on credit facilities
70

 
1,016

Payments on borrowings from credit facilities

 
(735
)
Cash used to net share settle employee equity awards
(50
)
 
(61
)
Proceeds from issuances of shares of common stock
38

 
33

Cash provided by (used for) financing activities
130

 
(15
)
 
 
 
 
Effect of foreign exchange rates on cash
1

 
1

 
 
 
 
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents
151

 
(161
)
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period
1,017

 
487

Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period
$
1,168

 
$
327

 
 
 
 
Supplemental Information
 
 
 
Stock-based compensation expense
$
36

 
$
30


Certain prior year balances related to restricted cash have been reclassified to reflect our adoption of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Update No. 2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash in the fourth quarter of 2017. Please refer to our most recent annual report on Form 10-K for additional details.














See notes to the unaudited condensed consolidated financial statements.

6


NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE A – BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K.

Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars. Prior year balances were subject to rounding.

Revision of Reportable Segments

Effective January 1, 2018, following organizational changes to align the company's business and organization structure focused on active implantable devices, we revised our reportable segments, in accordance with FASB ASC Topic 280, Segment Reporting. The revision reflects a reclassification of our Neuromodulation business from our Medical Surgical (MedSurg) segment to our newly created Rhythm and Neuro segment. We have revised prior year amounts to conform to the current year’s presentation (as denoted with an asterisk throughout *). There was no revision to operating segments or reporting units as a result of the organizational change. See Note C – Goodwill and Other Intangible Assets and Note K – Segment Reporting for further details.

Subsequent Events

We evaluate events occurring after the date of our most recent accompanying unaudited condensed consolidated balance sheets for potential recognition or disclosure in our financial statements. We did not identify any material subsequent events requiring adjustment to our accompanying unaudited condensed consolidated financial statements (recognized subsequent events) for the three months ended March 31, 2018. Those items requiring disclosure (unrecognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions and Strategic Investments and Note I – Commitments and Contingencies for more information.

Accounting Standards Implemented Since December 31, 2017

ASC Update No. 2014-09

In May 2014, the FASB issued ASC Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), which was subsequently updated. We adopted the standard as of January 1, 2018, using the modified retrospective method. Under this method, we applied FASB ASC Topic 606 to contracts that were not complete as of January 1, 2018 and recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings. Results for reporting periods beginning after January 1, 2018 are presented in accordance with FASB ASC Topic 606. Prior period amounts are not adjusted and are reported in accordance with legacy GAAP requirements in FASB ASC Topic 605, Revenue Recognition.

Due to the adoption of FASB ASC Topic 606, we recorded a net reduction to opening retained earnings of $177 million on January 1, 2018, primarily related to cost of providing non-contractual post-implant support to certain customers, which we deemed immaterial in the context of the arrangement. Upon the adoption of FASB ASC Topic 606, when we sell a device with an implied non-contractual post-implant support obligation, we forward accrue the cost of the service within Selling, general and administrative expenses and recognize it at the point in time the associated revenue is earned. We release the accrual over the related service period. These costs were previously expensed as incurred due to such service obligation being non-contractual.

The impact of adopting FASB ASC Topic 606 on our unaudited condensed consolidated balance sheets as of March 31, 2018, resulted in an increase in Other current liabilities of $59 million and an increase in Other long-term liabilities of $206 million, as a result of accruing for our post-implant support obligation. We also recorded deferred tax assets primarily related to post-implant support, resulting in an increase in Other long-term assets of $12 million and a reduction in Deferred income taxes of

7


$41 million. The remaining impact of adopting FASB ASC Topic 606 was not material to our financial position or results of operations.

Refer to Note L – Revenue for additional details.

ASC Update No. 2016-01

In January 2016, the FASB issued ASC Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The purpose of Update No. 2016-01 is to improve financial reporting for financial instruments by reducing the number of items recorded to other comprehensive income. We adopted Update No. 2016-01 in the first quarter of 2018, using both the modified retrospective and prospective methods. For publicly-held securities, we used the modified retrospective approach. Unrealized gains and losses previously recorded to other comprehensive income were reclassified to retained earnings and all future fair value changes will be recorded to net income. For privately-held securities, we elected the measurement alternative approach which is applied prospectively upon adoption. This approach requires entities to measure their investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The adoption of the standard did not have a material impact on our financial position or results of operations. The actual impact to future periods resulting from fair value changes of our equity investments is difficult to predict as it will depend on their future performance.

ASC Update No. 2016-16

In October 2016, the FASB issued ASC Update No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. The purpose of Update No. 2016-16 is to allow an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, as opposed to waiting until the asset is sold to a third party, or impaired. Update No. 2016-16 was effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. We adopted Update No. 2016-16 prospectively in the first quarter of 2018 and recognized a net reduction to opening retained earnings of $55 million for income tax consequences not previously recognized for intra-entity transfers of assets other than inventories. All future income tax consequences of intra-entity transfers of assets other than inventories will be recognized through income tax expense.

ASC Update No. 2017-12

In August 2017, the FASB issued ASC Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The purpose of Update No. 2017-12 is to simplify the application of hedge accounting and better align financial reporting of hedging relationships with risk management objectives. Update No. 2017-12 was effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. We early adopted Update No. 2017-12 in the first quarter of 2018. The adoption of the standard had no impact on our financial position or results of operations.

NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS

We did not close any material acquisitions during the first quarter of 2018 or 2017.

On April 30, 2018, we announced the closing of our acquisition of NxThera, Inc. (NxThera), a privately-held company based in Maple Grove, Minnesota. NxThera developed the Rezûm® System, a minimally invasive therapy in a growing category of treatment options for patients with benign prostatic hyperplasia (BPH). The transaction consists of an upfront cash payment of $306 million, and up to an additional $100 million in potential commercial milestone payments over the next four years. We have an existing minority investment in NxThera which is expected to result in a net upfront payment of approximately $240 million upon closing, and milestone payments of up to $85 million. NxThera will be integrated into our Urology and Pelvic Health business.

On April 16, 2018, we announced the closing of our acquisition of nVision Medical Corporation (nVision), a privately-held company focused on women’s health. nVision developed the first and only device cleared by the U.S. Food and Drug Administration (FDA) to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. The transaction consists of an upfront cash payment of $150 million, and up to an additional $125 million in potential clinical and commercial milestones over four years. nVision will be integrated into our Urology and Pelvic Health business.


8


Contingent Consideration

We recorded a net expense related to the changes in fair value of our contingent consideration liabilities of $5 million during the first quarter of 2018 and a net benefit related to the changes in fair value of our contingent consideration liabilities of $50 million during the first quarter of 2017. We made $28 million of contingent payments during the first quarter of 2017.

Changes in the fair value of our contingent consideration liabilities were as follows (in millions):
Balance as of December 31, 2017
$
169

Amounts recorded related to prior acquisitions
(22
)
Fair value adjustment
5

Balance as of March 31, 2018
$
152


As of March 31, 2018, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay was approximately $1.320 billion.

The recurring Level 3 fair value measurements of our contingent consideration liabilities include the following significant unobservable inputs:
Contingent Consideration Liabilities
Fair Value as of March 31, 2018
Valuation Technique
Unobservable Input
Range
R&D and Commercialization-based Milestones
$105 million
Discounted Cash Flow
Discount Rate
3%
Probability of Payment
17% - 100%
Projected Year of Payment
2018 - 2022
Revenue-based Payments
$48 million
Discounted Cash Flow
Discount Rate
11% - 15%
Projected Year of Payment
2018 - 2026

Projected contingent payment amounts related to some of our R&D, commercialization-based and revenue-based milestones are discounted back to the current period using a discounted cash flow (DCF) model. Projected revenues are based on our most recent internal operational budgets and long-range strategic plans. Increases in projected revenues and probabilities of payment may result in higher fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement.

Strategic Investments

On January 24, 2018, we closed an investment and entered into an acquisition option agreement with Millipede, Inc. (Millipede), a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation. Under the terms of the agreements, we have purchased a portion of the outstanding shares of Millipede along with newly issued shares of the company for a total consideration of $90 million. We also have the option to acquire the remaining shares of the company at any time prior to the completion of a first in human clinical study that meets certain parameters. Upon the completion of the clinical study, Millipede has the option to compel us to acquire the remaining shares of the company. Each company’s option period expires by the end of 2019. Completion of this acquisition would result in an additional $325 million payment by us at closing with a further $125 million becoming payable upon achievement of a commercial milestone.

The aggregate carrying amount of our strategic investments were comprised of the following categories:


 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Equity method investments
 
$
304

 
$
209

Measurement alternative investments
 
84

 
81

Publicly-held securities
 
12

 
15

Notes receivable
 
43

 
47

 
 
$
442

 
$
353



9


These investments are classified as other long-term assets within our accompanying unaudited condensed consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.

As of March 31, 2018, the book value of our equity method investments exceeded our share of the book value of the investees’ underlying net assets by approximately $335 million, which represents amortizable intangible assets and in-process research and development, corresponding deferred tax liabilities and goodwill.

NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows:
 
As of March 31, 2018
 
As of December 31, 2017
(in millions)
Gross Carrying
Amount
 
Accumulated
Amortization/
Write-offs
 
Gross Carrying
Amount
 
Accumulated
Amortization/
Write-offs
Amortizable intangible assets
 
 
 
 
 
 
 
Technology-related
$
9,396

 
$
(4,984
)
 
$
9,386

 
$
(4,880
)
Patents
517

 
(381
)
 
517

 
(379
)
Other intangible assets
1,636

 
(868
)
 
1,633

 
(838
)
 
$
11,549

 
$
(6,233
)
 
$
11,536

 
$
(6,097
)
Unamortizable intangible assets
 
 
 
 
 
 
 
Goodwill
$
16,884

 
$
(9,900
)
 
$
16,898

 
$
(9,900
)
In-process research and development (IPR&D)
278

 

 
278

 

Technology-related
120

 

 
120

 

 
$
17,281

 
$
(9,900
)
 
$
17,295

 
$
(9,900
)

The following represents our goodwill balance by global reportable segment:
(in millions)
MedSurg*
 
Rhythm and Neuro*
 
Cardiovascular
 
Total
Balance as of December 31, 2017
$
2,877

 
$
417

 
$
3,704

 
$
6,998

Impact of reportable segment revisions
(1,379
)
 
1,379

 

 

Impact of foreign currency fluctuations and other changes in carrying amount
1

 
(22
)
 
3

 
(17
)
Goodwill acquired
3

 

 

 
3

Balance as of March 31, 2018
$
1,503

 
$
1,774

 
$
3,707

 
$
6,984


We did not have any goodwill impairments in the three months ended March 31, 2018 or 2017. We test our goodwill balances during the second quarter of each year for impairment, or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. We have seven reporting units: Endoscopy, Urology and Pelvic Health, Cardiac Rhythm Management, Electrophysiology, Neuromodulation, Interventional Cardiology and Peripheral Interventions. As such, the first quarter change in our reportable segments, where Neuromodulation was reclassified from our MedSurg segment to our newly created Rhythm and Neuro segment did not trigger a goodwill impairment assessment or impact our total goodwill carrying value.

NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings or cash flows to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.


10


We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.
Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecast intercompany and third-party transactions and net investments in certain subsidiaries. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in British pound sterling, Euro and Japanese yen. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in other comprehensive income (OCI) and is included in the Accumulated other comprehensive income (loss), net of tax (AOCI) caption of our unaudited condensed consolidated balance sheets until the underlying third-party transaction occurs. When the related third-party transaction occurs we recognize the gain or loss to earnings within the Cost of products sold caption of our unaudited condensed consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the hedged forecast transaction becomes no longer probable of occurring, we reclassify the amount of gains or losses on the derivative instrument designated as a cash flow hedge to earnings at that time.

We also use forward currency contracts that are not part of designated hedging relationships under FASB ASC Topic 815 as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings and reflected within the Other, net caption of our unaudited condensed consolidated statements of operations.

Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. Under these agreements we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges under FASB ASC Topic 815.

The changes in the fair value of interest rate derivatives designated as fair value hedges and the changes in the fair value of the underlying hedged debt instrument generally offset and are recorded within the Interest expense caption of our unaudited condensed consolidated statements of operations. We record the changes in the fair value of interest rate derivatives designated as cash flow hedges within OCI and is included within the AOCI caption of our unaudited condensed consolidated balance sheets until the underlying hedged transaction occurs, at which time we recognize the gain or loss within Interest expense. In the event the hedging relationship is no longer effective, or if the hedged forecast transaction becomes no longer probable of occurring, we reclassify the amount of gains or losses on the interest rate derivative designated as a cash flow hedge to earnings at that time.

We are amortizing the realized gains or losses from interest rate derivative instruments previously designated as fair value or cash flow hedges into earnings as a component of Interest expense over the remaining term of the hedged item in accordance with FASB ASC Topic 815, so long as the hedge relationship remains effective. Prior to the adoption of ASC Update No. 2017-12, Derivatives and Hedging (Topic 815), the ineffective portion, if any, of our interest rate derivatives designated as either fair value or cash flow hedges was recognized in earnings in the period in which the hedging relationship exhibited ineffectiveness.


11


The following table presents the contractual amounts of our derivative instruments outstanding:
(in millions)
FASB ASC Topic 815 Designation
As of
March 31, 2018
 
December 31, 2017
Forward currency contracts
Cash flow hedge
$
3,595

 
$
3,252

Forward currency contracts
Non-designated
2,565

 
2,671

Total Notional Outstanding
 
$
6,161

 
$
5,923


The remaining time to maturity as of March 31, 2018 is within 60 months for all designated forward currency contracts and generally less than one year for all non-designated forward currency contracts.

We had no interest rate derivative instruments outstanding as of March 31, 2018 and December 31, 2017.

The following presents the effect of our derivative instruments designated as cash flow hedges under FASB ASC Topic 815 on our accompanying unaudited condensed consolidated statements of operations:
(in millions)
 
Location in Unaudited Condensed Consolidated Statements of Operations
Total Amounts Presented in Unaudited Condensed Consolidated Statements of Operations
 
Effective Amount
Recognized in OCI
 
Effective Amount Reclassified from AOCI into Earnings
 
 
Pre-Tax Gain (Loss)
Tax Benefit (Expense)
Gain (Loss) Net of Tax
 
Pre-Tax (Gain) Loss
Tax (Benefit) Expense
(Gain) Loss
Net of Tax
Three Months Ended March 31, 2018
 
 
 
 
 
 
 
 
 
 
 
Forward currency contracts
 
Cost of products sold
$
672

 
$
(118
)
$
27

$
(91
)
 
$
15

$
(3
)
$
12

 
 
 
 
 
$
(118
)
$
27

$
(91
)
 
$
15

$
(3
)
$
12

Three Months Ended March 31, 2017
 
 
 
 
 
 
 
 
 
 
 
Forward currency contracts
 
Cost of products sold
$
650

 
$
(58
)
$
21

$
(37
)
 
$
(28
)
$
10

$
(18
)
 
 
 
 
 
$
(58
)
$
21

$
(37
)
 
$
(28
)
$
10

$
(18
)

As of March 31, 2018, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as currency hedge contracts under FASB ASC Topic 815 that may be reclassified to earnings within the next twelve months are presented below:
(in millions)
Designated Derivative Instrument
 
FASB ASC Topic 815 Designation
 
Location in
Unaudited Condensed Consolidated Statements of Operations
Total Amounts
Presented in
Unaudited Condensed Consolidated
Statements of Operations
 
Amount of
Pre-Tax
Gain (Loss)
that may be Reclassified to Earnings
 
 
 
Interest rate derivative contracts
 
Fair value hedge
 
Interest expense
$
(61
)
 
$
12

Interest rate derivative contracts
 
Cash flow hedge
 
Interest expense
(61
)
 
1

Forward currency contracts
 
Cash flow hedge
 
Cost of products sold

672

 
(55
)

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
 
 
Location in
Unaudited Condensed Consolidated Statements of Operations
 
 
 
 
 
 
 
Three Months Ended March 31,
(in millions)
 
 
2018
 
2017
Net gain (loss) on currency hedge contracts
 
Other, net
 
$
(23
)
 
$
(17
)
Net gain (loss) on currency transaction exposures
 
Other, net
 
16

 
17

Net currency exchange gain (loss)
 
 
 
$
(8
)
 
$



12


Fair Value Measurements

FASB ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures, by considering the estimated amount we would receive or pay to transfer these instruments at the reporting date when taking into account current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.

The following are the balances of our derivative assets and liabilities:
 
Location in
Unaudited Condensed Consolidated
Balance Sheets (1)
As of
 
March 31,
 
December 31,
(in millions)
2018
 
2017
Derivative Assets:
 
 
 
 
Designated Derivative Instruments
 
 
 
 
Forward currency contracts
Other current assets
$
3

 
$
7

Forward currency contracts
Other long-term assets
15

 
57

 
 
17

 
64

Non-Designated Derivative Instruments
 
 
 
 
Forward currency contracts
Other current assets
15

 
18

Total Derivative Assets
 
$
32

 
$
82

 
 
 
 
 
Derivative Liabilities:
 
 
 
 
Designated Derivative Instruments
 
 
 
Forward currency contracts
Other current liabilities
$
54

 
$
37

Forward currency contracts
Other long-term liabilities
69

 
33

 
 
123

 
69

Non-Designated Derivative Instruments
 
 
 
 
Forward currency contracts
Other current liabilities
31

 
21

Total Derivative Liabilities
 
$
154

 
$
90


(1)
We classify derivative assets and liabilities as current when the remaining term of the derivative contract is one year or less.
Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

13


Assets and liabilities measured at fair value on a recurring basis consist of the following:
 
As of
 
March 31, 2018
 
December 31, 2017
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets
 
 
 

 
 
 
 
 
 
 
 

 
 
 
 
Money market and government funds
$
42

 
$

 
$

 
$
42

 
$
21

 
$

 
$

 
$
21

Publicly-held securities
12

 

 

 
12

 
15

 

 

 
15

Forward currency contracts

 
32

 

 
32

 

 
82

 

 
82

 
$
54

 
$
32

 
$

 
$
86

 
$
36

 
$
82

 
$

 
$
118

Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Forward currency contracts
$

 
$
154

 
$

 
$
154

 
$

 
$
90

 
$

 
$
90

Accrued contingent consideration

 

 
152

 
152

 

 

 
169

 
169

 
$

 
$
154

 
$
152

 
$
306

 
$

 
$
90

 
$
169

 
$
259


Our investments in money market and government funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as cash and cash equivalents within our accompanying unaudited condensed consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $42 million invested in money market and government funds as of March 31, 2018, we had $245 million in interest bearing and non-interest bearing bank accounts. In addition to $21 million invested in money market and government funds as of December 31, 2017, we had $167 million in interest bearing and non-interest bearing bank accounts.

Our recurring fair value measurements using significant unobservable inputs (Level 3) relate solely to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability.
Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods subsequent to initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments.

Refer to Note C – Goodwill and Other Intangible Assets for a discussion of the fair values and annual impairment tests of goodwill and our indefinite lived intangible assets.

The fair value of our outstanding debt obligations was $6.040 billion as of March 31, 2018 and $5.945 billion as of December 31, 2017. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, amortized cost for commercial paper and face value for term loans and credit facility borrowings outstanding. Refer to Note E – Borrowings and Credit Arrangements for a discussion of our debt obligations.


14


NOTE E – BORROWINGS AND CREDIT ARRANGEMENTS

We had total debt of $5.765 billion as of March 31, 2018 and $5.616 billion as of December 31, 2017. The debt maturity schedule for the significant components of our long-term debt obligations is presented below:
(in millions, except interest rates)
Issuance Date
Maturity Date
As of
 
Semi-annual Coupon Rate
March 31, 2018
 
December 31, 2017
 
October 2018 Notes
August 2013
October 2018

 

 
2.650
%
January 2020 Notes
December 2009
January 2020
850

 
850

 
6.000
%
May 2020 Notes
May 2015
May 2020
600

 
600

 
2.850
%
May 2022 Notes
May 2015
May 2022
500

 
500

 
3.375
%
October 2023 Notes
August 2013
October 2023
450

 
450

 
4.125
%
May 2025 Notes
May 2015
May 2025
750

 
750

 
3.850
%
March 2028 Notes
February 2018
March 2028
1,000

 

 
4.000
%
November 2035 Notes
November 2005
November 2035
350

 
350

 
7.000
%
January 2040 Notes
December 2009
January 2040
300

 
300

 
7.375
%
Unamortized Debt Issuance Discount
 
2020 - 2040
(14
)
 
(6
)
 
 
Unamortized Deferred Financing Costs
 
2020 - 2040
(19
)
 
(18
)
 
 
Unamortized Gain on Fair Value Hedges
 
2020 - 2023
35

 
38

 
 
Capital Lease Obligation
 
Various
1

 
1

 
 
Long-term debt
 
 
$
4,803

 
$
3,815

 
 
As of December 31, 2017, $600 million under the October 2018 Notes was outstanding and classified as short-term debt.
Note:
The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.

Revolving Credit Facility
As of March 31, 2018 and December 31, 2017, we maintained a $2.250 billion revolving credit facility (the 2017 Facility) with a global syndicate of commercial banks that matures on August 4, 2022. This facility provides backing for the commercial paper program described below. There were no amounts borrowed under our revolving credit facility as of March 31, 2018 and December 31, 2017.
The 2017 Facility requires that we maintain certain financial covenants, as follows:
 
Covenant Requirement
 
Actual
 
as of March 31, 2018
 
as of March 31, 2018
Maximum leverage ratio (1)
3.5 times
 
2.2 times

(1)
Ratio of total debt to consolidated EBITDA, as defined by the credit agreement, for the preceding four consecutive fiscal quarters.

The 2017 Facility provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of March 31, 2018, we had $415 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the 2017 Facility, are excluded from the calculation of consolidated EBITDA, as defined in the 2017 Facility, provided that the sum of any excluded net cash litigation payments does not exceed $2.624 billion in the aggregate. As of March 31, 2018, we had $1.690 billion of the legal exclusion remaining.

Any inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facility or seek waivers from compliance with these covenants, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all credit facility commitments would terminate and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our credit facility may negatively impact the credit ratings assigned to our commercial paper program which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

15


Commercial Paper
As of March 31, 2018, we had $886 million of commercial paper outstanding and $1.197 billion outstanding as of December 31, 2017. Our commercial paper program is backed by the 2017 Facility, which allows us to have a maximum of $2.250 billion in commercial paper outstanding. Outstanding commercial paper directly reduces borrowing capacity available under the 2017 Facility. As of March 31, 2018, the commercial paper issued and outstanding had a weighted average maturity of 22 days and a weighted average yield of 2.46 percent. As of December 31, 2017, the commercial paper issued and outstanding had a weighted average maturity of 38 days and a weighted average yield of 1.85 percent.

Senior Notes

We had senior notes outstanding of $4.800 billion as of March 31, 2018 and $4.400 billion as of December 31, 2017.

In February 2018, we completed an offering of $1.000 billion in aggregate principal amount of 4.000% senior notes, due March 2028. We used a portion of the net proceeds from the offering to repay the $600 million plus accrued interest of our 2.650% senior notes due in October 2018. The remaining proceeds were used to repay a portion of our outstanding commercial paper.

Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to borrowings under our credit and security facility, and to the extent borrowed by our subsidiaries, to liabilities of our subsidiaries (see Other Arrangements below).

Other Arrangements

As of March 31, 2018 and December 31, 2017, we maintained a $400 million credit and security facility secured by our U.S. trade receivables maturing in February 2019. We had outstanding borrowings of $70 million as of March 31, 2018 and no outstanding borrowings as of December 31, 2017 under our credit and security facility.

We have accounts receivable factoring programs in certain European countries that we account for as sales under FASB ASC Topic 860, Transfers and Servicing. These agreements provide for the sale of accounts receivable to third parties, of up to approximately $463 million as of March 31, 2018. We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. We de-recognized $178 million of receivables as of March 31, 2018 at an average interest rate of 2.1 percent and $171 million as of December 31, 2017 at an average interest rate of 1.8 percent.

In March 2018, we entered into a factoring agreement with a commercial Japanese bank. The agreement provides for the sale of accounts receivable and promissory notes of up to 30.000 billion Japanese yen (approximately $282 million as of March 31, 2018). We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. We de-recognized $95 million of receivables as of March 31, 2018 at an average interest rate of 0.5 percent.

In addition, we have uncommitted credit facilities with a commercial Japanese bank that provide for accounts receivable factoring and promissory notes discounting of up to 22.000 billion Japanese yen (approximately $207 million as of March 31, 2018). We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. We de-recognized $124 million of notes receivable as of March 31, 2018 at an average interest rate of 1.5 percent and $157 million of notes receivable as of December 31, 2017 at an average interest rate of 1.3 percent. De-recognized accounts and notes receivable are excluded from trade accounts receivable, net in the accompanying unaudited condensed consolidated balance sheets.

As of and through March 31, 2018, we were in compliance with all the required covenants related to our debt obligations. For additional information regarding the terms of our debt agreements, refer to Note E - Borrowings and Credit Arrangements of the consolidated financial statements in our most recent Annual Report on Form 10-K.

NOTE F – RESTRUCTURING-RELATED ACTIVITIES

2016 Restructuring Plan

On June 6, 2016, our Board of Directors approved and we committed to a restructuring initiative (the 2016 Restructuring Plan). The 2016 Restructuring Plan is intended to develop global commercialization, technology and manufacturing capabilities in key

16


growth markets and build on our Plant Network Optimization (PNO) strategy, which is intended to simplify our manufacturing plant structure by transferring certain production lines among facilities and expanding operational efficiencies in support of our operating income margin goals. Key activities under the 2016 Restructuring Plan include strengthening global infrastructure through evolving global real estate assets and workplaces, developing global commercial and technical competencies, enhancing manufacturing and distribution expertise in certain regions and continuing implementation of our PNO strategy. These activities were initiated in the second quarter of 2016 and are expected to be substantially complete by the end of 2018. We revised the original estimate for the costs and savings associated with the program in the first quarter of 2018, as approved by the Board of Directors.

The following table provides a summary of our estimates of costs associated with the 2016 Restructuring Plan by major type of cost:
Type of cost
Total Estimated Amount Expected to be Incurred
Restructuring charges:
 
Termination benefits
$100 million to $110 million
Other (1)
$25 million to $50 million
Restructuring-related expenses:
 
Other (2)
$150 million to $165 million
 
$275 million to $325 million

(1) Consists primarily of consulting fees and costs associated with contract cancellations.
(2) Comprised of other costs directly related to the 2016 Restructuring Plan, including program management, accelerated depreciation and costs to transfer product lines among facilities.

Approximately $250 million to $300 million of these charges are estimated to result in cash outlays.

The following presents these costs (credits) by major type and line item within our accompanying unaudited condensed consolidated statements of operations.
Three Months Ended March 31, 2018
 
 
 
 
 
 
 
(in millions)
Termination
Benefits
 
Transfer
Costs
 
Other
 
Total
Restructuring charges
$
12

 
$

 
$
1

 
$
13

Restructuring-related expenses:
 
 
 
 
 
 
 
Cost of products sold

 
7

 

 
7

Selling, general and administrative expenses

 

 
8

 
8

 

 
7

 
8

 
15

 
$
12

 
$
7

 
$
8

 
$
28

 
 
 
 
 
 
 
 
Three Months Ended March 31, 2017
 
 
 
 
 
 
 
 
 
(in millions)
Termination
Benefits
 
Accelerated
Depreciation
 
Transfer
Costs
 
Other
 
Total
Restructuring charges
$
3

 
$

 
$

 
$
1

 
$
4

Restructuring-related expenses:
 
 
 
 
 
 
 
 
 
Cost of products sold

 

 
12

 

 
12

Selling, general and administrative expenses

 
2

 

 
1

 
3

 

 
2

 
12

 
1

 
15

 
$
3

 
$
2

 
$
12

 
$
2

 
$
19



17


The following table presents cumulative restructuring and restructuring-related charges as of March 31, 2018, related to our 2016 Restructuring Plan by major type:
(in millions)
2016 Restructuring Plan
Termination benefits
$
61

Other (1)
16

Total restructuring charges
77

Accelerated depreciation
9

Transfer costs
68

Other (2)
15

Restructuring-related expenses
92

 
$
169

(1) Consists primarily of consulting fees and costs associated with contract cancellations.
(2) Comprised of other costs directly related to our Restructuring Plan, including program management, accelerated depreciation and costs to transfer product lines among facilities.

Cash payments associated with our 2016 Restructuring Plan were made using cash generated from operations and are comprised of the following:
(in millions)
2016 Restructuring Plan
Three Months Ended March 31, 2018
 
Termination benefits
$
8

Transfer costs
7

Other
9

 
$
25

 
 
Program to Date
 
Termination benefits
$
36

Transfer costs
67

Other
19

 
$
122


Our restructuring liability is primarily comprised of accruals for termination benefits. The following is a rollforward of the termination benefit liability associated with our 2016 Restructuring Plan, which is reported as a component of accrued expenses included in our accompanying unaudited condensed consolidated balance sheets:
(in millions)
2016 Restructuring Plan
Accrued as of December 31, 2017
$
22

Charges (credits)
12

Cash payments
(8
)
Accrued as of March 31, 2018
$
27



18


NOTE G – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions in our accompanying unaudited condensed consolidated balance sheets are as follows:

Cash, cash equivalents, restricted cash and restricted cash equivalents
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Cash and cash equivalents
 
$
287

 
$
188

Restricted cash included in Other current assets
 
850

 
803

Restricted cash included in Other long-term assets
 
31

 
26

Total cash, cash equivalents and restricted cash
 
$
1,168

 
$
1,017


Trade accounts receivable, net
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Accounts receivable
 
$
1,650

 
$
1,645

Allowance for doubtful accounts
 
(67
)
 
(68
)
Allowance for sales returns
 

 
(30
)
Other sales reserves
 
(3
)
 

 
 
$
1,580

 
$
1,548


Note: Due to the adoption of FASB ASC Topic 606 effective January 1, 2018, the allowance for sales returns has been prospectively reclassified from Trade accounts receivable, net to Other current liabilities within the unaudited condensed consolidated balance sheets. Prior period balances remain unchanged.

The following is a rollforward of our allowance for doubtful accounts:
 
 
Three Months Ended
March 31,
(in millions)
 
2018
 
2017
Beginning balance
 
$
68

 
$
73

Net charges to expenses
 
4

 
3

Utilization of allowances
 
(5
)
 
(1
)
Ending balance
 
$
67

 
$
75


Inventories
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Finished goods
 
$
717

 
$
685

Work-in-process
 
105

 
110

Raw materials
 
291

 
284

 
 
$
1,113

 
$
1,078



19


Property, plant and equipment, net
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Land
 
$
103

 
$
102

Buildings and improvements
 
1,132

 
1,120

Equipment, furniture and fixtures
 
3,246

 
3,183

Capital in progress
 
215

 
219

 
 
4,696

 
4,625

Accumulated depreciation
 
(2,996
)
 
(2,928
)
 
 
$
1,700

 
$
1,697


Depreciation expense was $68 million for the first quarter of 2018 and $63 million for the first quarter of 2017.

Accrued expenses
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Legal reserves
 
$
1,255

 
$
1,176

Payroll and related liabilities
 
488

 
591

Accrued contingent consideration
 
62

 
36

Other
 
643

 
653

 
 
$
2,447

 
$
2,456


Other long-term liabilities
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Accrued income taxes
 
$
1,119

 
$
1,275

Legal reserves
 
256

 
436

Accrued contingent consideration
 
92

 
133

Other
 
787

 
525

 
 
$
2,254

 
$
2,370


NOTE H – INCOME TAXES

Our effective tax rate from continuing operations is presented below:
 
 
Three Months Ended March 31,
 
2018
 
2017
Effective tax rate from continuing operations
 
8.0
%
 
4.9
%

The change in our reported tax rates for the first quarter of 2018, as compared to the same period in 2017, relates primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate, including intangible asset impairment charges, acquisition-related items, restructuring items, litigation-related items, as well as certain discrete tax items including impacts of the Tax Cuts and Jobs Act (TCJA), enacted on December 22, 2017.

As of March 31, 2018, we had $1.240 billion of gross unrecognized tax benefits, of which a net $1.157 billion, if recognized, would affect our effective tax rate. As of December 31, 2017, we had $1.238 billion of gross unrecognized tax benefits, of which a net $1.150 billion, if recognized, would affect our effective tax rate.

We have received Notices of Deficiency from the Internal Revenue Service (IRS) reflecting proposed audit adjustments for Guidant Corporation for its 2001 through 2006 tax years and for Boston Scientific Corporation for its 2006 and 2007 tax years. The total

20


incremental tax liability asserted by the IRS for the applicable periods is $1.162 billion plus interest. The primary issue in dispute for all years is the transfer pricing associated with the technology license agreements between domestic and foreign subsidiaries of Guidant. In addition, the IRS has proposed adjustments in connection with the financial terms of our Transaction Agreement with Abbott Laboratories pertaining to the sale of Guidant's vascular intervention business to Abbott Laboratories in April 2006. During 2014, we received a Revenue Agent Report from the IRS reflecting significant proposed audit adjustments to our 2008, 2009 and 2010 tax years based upon the same transfer pricing methodologies that the IRS applied to our 2001 through 2007 tax years.

We do not agree with the transfer pricing methodologies applied by the IRS or its resulting assessment. We have filed petitions with the U.S. Tax Court contesting the Notices of Deficiency for the 2001 through 2007 tax years in challenge and submitted a letter to the IRS Office of Appeals protesting the Revenue Agent Report for the 2008 through 2010 tax years and requesting an administrative appeal hearing. The issues in dispute were scheduled to be heard in U.S. Tax Court in July 2016. On July 19, 2016, we entered into a Stipulation of Settled Issues with the IRS intended to resolve all of the aforementioned transfer pricing issues, as well as the issues related to our transaction with Abbott Laboratories, for the 2001 through 2007 tax years. The Stipulation of Settled Issues was contingent upon the IRS Office of Appeals applying the same basis of settlement to all transfer pricing issues for the Company’s 2008, 2009 and 2010 tax years as well as review by the United States Congress Joint Committee on Taxation (JCT). In October 2016, we reached an agreement in principle with the IRS Office of Appeals as to the resolution of transfer pricing issues in 2008, 2009 and 2010 tax years, subject to additional calculations of tax as well as documentation to memorialize our agreement. The IRS has recalculated our final tax liabilities under this agreement for all of our tax years from 2001 through 2010 and the JCT has completed its review of the recalculations for the 2001 through 2010 tax years.

In the event that the conditions in the Stipulation of Settled Items are satisfied, we expect to make net tax payments of approximately $275 million, plus interest through the date of payment with respect to the settled issues. If finalized, payments related to the resolution are expected in the next six months. We believe that our income tax reserves associated with these matters are adequate as of March 31, 2018 and we do not expect to recognize any additional charges related to resolution of this controversy. However, the final resolution of these issues remains contingent and if the Stipulation of Settled Issues is not finalized, it could have a material impact on our financial condition, results of operations, or cash flows.

We recognize interest and penalties related to income taxes as a component of income tax expense. We had $675 million accrued for gross interest and penalties as of March 31, 2018 and $655 million as of December 31, 2017. We recognized net tax expense related to interest and penalties of $17 million during the first quarter of 2018 and $13 million in the first quarter of 2017.

It is reasonably possible that within the next 12 months we will resolve multiple issues including transfer pricing and transactional-related issues with foreign, federal and state taxing authorities, in which case we could record a reduction in our balance of unrecognized tax benefits of up to approximately $897 million.

There are a number of key provisions under the TCJA that impact us and we continue to monitor and analyze the ramification of the new law as the implementation is executed. The final impact of the TCJA may differ from the estimates reported due to, among other things, changes in interpretations and assumptions made by us, additional guidance that may be issued by the U.S. Department of the Treasury and actions that we may take as a result. The TCJA reduces the US Federal corporate income tax rate from 35 percent to 21 percent, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, and creates new taxes on certain foreign sourced earnings. Due to insufficient guidance, as well as the availability of information to accurately analyze the impact of the TCJA, we have made a reasonable estimate of the effects, as described below and in other cases we have not been able to make a reasonable estimate and continue to account for those items based on our existing accounting under FASB ASC Topic 740, Income Taxes and the provisions of the tax laws that were in effect immediately prior to enactment. In the first quarter of 2018, we recognized an additional tax benefit of $9 million, resulting in a total provisional estimate of $852 million related to the TCJA.

We are required to record deferred tax assets and liabilities based on the enacted tax rates at which they are expected to reverse in the future. Therefore, any U.S. related deferred taxes were re-measured from 35 percent down to 21 percent based on the recorded balances as of December 31, 2017. The analysis included a preliminary assessment on the deductibility of certain amounts for which deferred tax assets may have been recorded. However, we are still analyzing certain aspects of the TCJA and refining our calculations based on the available information, which could potentially affect the measurement of these balances or give rise to new deferred tax amounts. As of March 31, 2018, we have not adjusted our provisional estimate related to re-measurement of our deferred tax balances. As of December 31, 2017, we recorded an estimated tax benefit of approximately $99 million.

We are required to calculate a one-time transition tax based on our total post-1986 foreign earnings and profits (E&P) that we previously deferred from U.S. income taxes. In the first quarter of 2018, we recognized an additional tax benefit of $9 million, which results in a revised provisional amount of approximately $1.035 billion. We anticipate offsetting this liability against existing

21


tax attributes reducing the required payment to approximately $454 million which will be remitted over an eight year period. We have not yet completed our calculation of the total post-1986 E&P for these foreign subsidiaries and we continue to refine the analysis. Additionally, no income taxes have been provided for any remaining undistributed foreign earnings that are not subject to the transition tax or any additional outside basis difference inherent in these entities, as we expect these amounts will remain indefinitely reinvested in foreign operations. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings not subject to the transition tax and additional outside basis difference in these entities is not practicable.

We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. Additionally, we are required to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. As of March 31, 2018, we are still evaluating the effects of the GILTI provisions as guidance and interpretations continue to emerge. Therefore, we have not determined our accounting policy on the GILTI provisions. However, the standard requires that we reflect the impact of the GILTI provisions as a period expense until the accounting policy is finalized. Therefore, we have included the provisional estimate of GILTI related to current-year operations in our estimated annual effective tax rate only and will be updating the impact and accounting policy as the analysis related to the GILTI provisions is completed.

NOTE I – COMMITMENTS AND CONTINGENCIES

The medical device market in which we primarily participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding or in a series of related proceedings or litigate multiple features of a single class of devices. These forces frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters, however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In the normal course of business, product liability, securities and commercial claims are asserted against us. Similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.


22


Our accrual for legal matters that are probable and estimable was $1.511 billion as of March 31, 2018 and $1.612 billion as of December 31, 2017 and includes certain estimated costs of settlement, damages and defense. As of March 31, 2018 and December 31, 2017, a portion of our legal accrual is funded and included in our restricted cash balance as disclosed in Note G – Supplemental Balance Sheet Information. We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our debt covenants.

In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be estimated.

Patent Litigation

On November 9, 2015, Edwards Lifesciences, LLC filed an invalidity claim against one of our subsidiaries, Sadra Medical, Inc. (Sadra), in the High Court of Justice, Chancery Division Patents Court in the United Kingdom, alleging that a European patent owned by Sadra relating to a repositionable heart valve is invalid. On January 15, 2016, we filed our defense and counterclaim for a declaration that our European patent is valid and infringed by Edwards. On February 25, 2016, we amended our counterclaim to allege infringement of a second patent related to adaptive sealing technology. A trial was held from January 18 to January 27, 2017. On March 3, 2017, the court found one of our patents valid and infringed and some claims of the second patent invalid and the remaining claims not infringed. Both parties have filed an appeal. On March 28, 2018, the Court of Appeals affirmed the decision of the High Court.

On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation in the U.S. District Court for the District of Delaware for patent infringement. We allege that Edwards’ SAPIEN™ 3 Valve infringes a patent related to adaptive sealing technology. On June 9, 2016, Edwards filed a counterclaim alleging that our Lotus™ Valve System infringes three patents owned by Edwards. On October 12, 2016, Edwards filed a petition for inter partes review of our patent with the U.S. Patent and Trademark Office (USPTO), Patent Trial and Appeal Board. On March 29, 2017, the USPTO granted the inter partes review request. On April 18, 2017, Edwards filed a second petition for inter partes review of our patent with the USPTO. On March 23, 2018, the USPTO found the patent invalid. The Company plans to appeal that decision.

On April 26, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of Düsseldorf, Germany alleging a European patent (Spenser '550) owned by Edwards is infringed by our Lotus Transcatheter Heart Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we infringed the Spenser '550 patent. The Company filed an appeal. The appeal hearing is scheduled for May 17, 2018. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.

On December 22, 2016, Edwards Lifesciences PVT, Inc. and Edwards Lifesciences SA (AG) filed a plenary summons against Boston Scientific Limited and Boston Scientific Group Public Company in the High Court of Ireland alleging that a European patent (Spenser) owned by Edwards is infringed by our Lotus Valve System. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.

On November 20, 2017, The Board of Regents, University of Texas System (UT) and TissueGen. Inc. (TissueGen), served a lawsuit against us in the Western District of Texas. The complaint against us alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. On March 12, 2018, the court dismissed the action and transferred it to the United States District Court for the District of Delaware.


23


Product Liability Litigation

As of April 24, 2018, approximately 49,500 product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us. The pending cases are in various federal and state courts in the United States and include eight putative class actions. There were also approximately 20 cases in Canada, inclusive of one certified and three putative class actions and fewer than 25 claims in the United Kingdom. Generally, the plaintiffs allege personal injury associated with use of our transvaginal surgical mesh products. The plaintiffs assert design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. Over 3,100 of the cases have been specially assigned to one judge in state court in Massachusetts. On February 7, 2012, the Judicial Panel on Multi-District Litigation (MDL) established MDL-2326 in the United States District Court for the Southern District of West Virginia and transferred the federal court transvaginal surgical mesh cases to MDL-2326 for coordinated pretrial proceedings. During the fourth quarter of 2013, we received written discovery requests from certain state attorneys general offices regarding our transvaginal surgical mesh products. We have responded to those requests. As of April 24, 2018, we have entered into master settlement agreements in principle or are in final stages of entering one with certain plaintiffs' counsel to resolve an aggregate of approximately 47,500 cases and claims. These master settlement agreements provide that the settlement and distribution of settlement funds to participating claimants are conditional upon, among other things, achieving minimum required claimant participation thresholds. Of the approximately 47,500 cases and claims, approximately 21,000 have met the conditions of the settlement and are final. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing.

We have established a product liability accrual for known and estimated future cases and claims asserted against us as well as with respect to the actions that have resulted in verdicts against us and the costs of defense thereof associated with our transvaginal surgical mesh products. While we believe that our accrual associated with this matter is adequate, changes to this accrual may be required in the future as additional information becomes available. While we continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims and intend to vigorously contest the cases and claims asserted against us, that do not settle, the final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Initial trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

Other Proceedings

Refer to Note H – Income Taxes for information regarding our tax litigation.

NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING
 
 
Three Months Ended
March 31,
(in millions)
 
2018

2017
Weighted average shares outstanding - basic
 
1,376.5

 
1,365.4

Net effect of common stock equivalents
 
20.2

 
24.8

Weighted average shares outstanding - assuming dilution
 
1,396.8

 
1,390.2


The impact of stock options outstanding with exercise prices greater than the average fair market value of our common stock was immaterial for all periods presented.

We issued approximately six million shares of our common stock in the first quarter of 2018 and seven million shares of our common stock in the first quarter of 2017, following the exercise of underlying stock options, vesting of deferred stock units or purchases under our employee stock purchase plan. We did not repurchase any shares of our common stock during the first three months of 2018 or 2017.

NOTE K – SEGMENT REPORTING

We have three reportable segments comprised of MedSurg, Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments.
Each of our reportable segments generates revenues from the sale of medical devices. We measure and evaluate our reportable segments based on segment net sales and operating income, excluding intersegment profits. In 2017, we updated our presentation

24


of segment net sales and operating income to the impact of foreign currency fluctuations, since our chief operating decision maker (CODM) reviews operating results both including and excluding the impact of foreign currency fluctuations and the following presentation more closely aligns to our consolidated financial statements. We exclude from segment operating income certain corporate-related expenses and certain transactions or adjustments that our CODM considers to be non-operational, such as amounts related to amortization expense, intangible asset impairment charges, acquisition-related items, restructuring and restructuring-related items and litigation-related items. Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation below.

Effective January 1, 2018, following organizational changes to align the company's business and organization structure focused on active implantable devices, we revised our reportable segments, in accordance with FASB ASC Topic 280, Segment Reporting. The revision reflects a reclassification of our Neuromodulation business from our Medical Surgical (MedSurg) segment to our newly created Rhythm and Neuro segment. We have revised prior year amounts to conform to the current year’s presentation (as denoted with an asterisk throughout *). There was no revision to operating segments or reporting units as a result of the organizational change.

A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows:
 
 
Three Months Ended
March 31,
(in millions)
 
2018
 
2017
 
 
 
 
 
Net sales
 
 
 
 
MedSurg*
 
$
711

 
$
641

Rhythm and Neuro*
 
736

 
668

Cardiovascular
 
933

 
851

 
 
$
2,379

 
$
2,160

 
 
 
 
 
Income (loss) before income taxes
 
 
 
 
MedSurg*
 
$
259

 
$
215

Rhythm and Neuro*
 
153

 
109

Cardiovascular
 
290

 
233

Operating income allocated to reportable segments
 
703

 
557

Corporate expenses, including hedging activities
 
(100
)
 
(61
)
Intangible asset impairment charges, acquisition-related, restructuring- and restructuring-related and litigation-related net credits (charges)
 
(54
)
 
11

Amortization expense
 
(141
)
 
(143
)
Operating income (loss)
 
407

 
364

Other expense, net
 
(84
)
 
(59
)
Income (loss) before income taxes
 
$
323

 
$
305


 
 
Three Months Ended
March 31,
Operating income as a percentage of segment net sales
 
2018
 
2017
MedSurg*
 
36.4
%
 
33.5
%
Rhythm and Neuro*
 
20.8
%
 
16.3
%
Cardiovascular
 
31.1
%
 
27.3
%

NOTE L – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes in our unaudited condensed consolidated statements of operations. The following tables disaggregate our revenue from contracts with customers by business and geographic region:

25


 
 
Three Months Ended March 31,
Businesses (in millions)
 
2018
 
2017
Endoscopy
 
 
 
 
U.S.
 
$
231

 
$
215

International
 
187

 
164

Worldwide
 
418

 
379

 
 
 
 
 
Urology and Pelvic Health
 
 
 
 
U.S.
 
197

 
183

International
 
96

 
79

Worldwide
 
293

 
262

 
 
 
 
 
Cardiac Rhythm Management
 
 
 
 
U.S.
 
290

 
283

International
 
203

 
180

Worldwide
 
493

 
463

 
 
 
 
 
Electrophysiology
 
 
 
 
U.S.
 
35

 
32

International
 
39

 
32

Worldwide
 
75

 
64

 
 
 
 
 
Neuromodulation
 
 
 
 
U.S.
 
131

 
116

International
 
38

 
25

Worldwide
 
169

 
141

 
 
 
 
 
Interventional Cardiology
 
 
 
 
U.S.
 
281

 
278

International
 
364

 
312

Worldwide
 
645

 
590

 
 
 
 
 
Peripheral Interventions
 
 
 
 
U.S.
 
145

 
142

International
 
142

 
119

Worldwide
 
288

 
261

 
 
 
 
 
Total Company
 
 
 
 
U.S.
 
1,310

 
1,249

International
 
1,069

 
911

Net Sales
 
$
2,379

 
$
2,160



26


 
 
Three Months Ended March 31,
Geographic Regions (in millions)
 
2018
 
2017
U.S.
 
$
1,310

 
$
1,249

EMEA (Europe, Middle East and Africa)
 
563

 
454

APAC (Asia-Pacific)
 
415

 
371

LACA (Latin America and Canada)
 
91

 
84

 
 
$
2,379

 
$
2,160

 
 
 
 
 
Emerging Markets (1)
 
$
255

 
$
208

(1) Emerging Markets is defined as certain countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Currently, we include 20 countries in our definition of Emerging Markets.

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors. We consider revenue to be earned when all of the following criteria are met: we have a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount we expect to receive, is determinable and we have transferred control of the promised items to the customer. Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S., but may be longer in international markets.

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Contract liabilities are classified as other current liabilities and other long-term liabilities on the balance sheet. Our deferred revenue balance as of March 31, 2018 was $393 million and $411 million as of January 1, 2018. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. During the first quarter of 2018, we recognized $26 million of revenue that was included in the above January 1, 2018 contract liability balance. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next­ generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next­-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to estimate the expected rebates reasonably, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations

27


to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.

Capitalized Contract Costs

We capitalize commission fees related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE Remote Monitoring Service. These fulfillment costs are amortized over the average service period. Our total capitalized contract costs are immaterial to our consolidated financial statements.

NOTE M – CHANGES IN OTHER COMPREHENSIVE INCOME

The following table provides the reclassifications out of other comprehensive income, net of tax.
Three Months Ended March 31, 2018
 
 
 
 
 
 
 
 
 
 
(in millions)
 
Foreign Currency Translation Adjustments
 
Unrealized Gains/Losses on Derivative Financial Instruments
 
Unrealized Gains/Losses on Available-for-Sale Securities
 
Defined Benefit Pension Items/Other
 
Total
Balance as of December 31, 2017
 
$
(32
)
 
$
1

 
$
(1
)
 
$
(27
)
 
$
(59
)
Other comprehensive income (loss) before reclassifications
 
10

 
(91
)
 

 

 
(81
)
(Income) loss amounts reclassified from accumulated other comprehensive income
 

 
12

 
1

 

 
13

Net current-period other comprehensive income (loss)
 
10

 
(80
)
 

 

 
(69
)
Balance as of March 31, 2018
 
$
(22
)
 
$
(79
)
 
$

 
$
(27
)
 
$
(128
)

Three Months Ended March 31, 2017
 
 
 
 
 
 
 
 
 
 
(in millions)
 
Foreign Currency Translation Adjustments
 
Unrealized Gains/Losses on Derivative Financial Instruments
 
Unrealized Gains/Losses on Available-for-Sale Securities
 
Defined Benefit Pension Items/Other
 
Total
Balance as of December 31, 2016
 
$
(79
)
 
$
107

 
$
(6
)
 
$
(21
)
 
$
1

Other comprehensive income (loss) before reclassifications
 
8

 
(37
)
 

 
(3
)
 
(32
)
(Income) loss amounts reclassified from accumulated other comprehensive income
 

 
(18
)
 

 
3

 
(15
)
Net current-period other comprehensive income (loss)
 
8

 
(55
)
 

 

 
(47
)
Balance as of March 31, 2017
 
$
(71
)
 
$
52

 
$
(6
)
 
$
(21
)
 
$
(46
)

Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on the reclassifications related to derivatives.

We adopted Update No. 2016-01 in the first quarter of 2018, as a result of adopting the standard, we recorded a cumulative effect adjustment to retained earnings for unrealized gains and losses for available-for-sale securities previously recorded to accumulated other comprehensive income.

The gains and losses on defined benefit and pension related items before reclassifications and gains and losses on defined benefit and pension items reclassified from accumulated other comprehensive income were reduced by immaterial income tax impacts in the first three months of 2018 and 2017.


28


NOTE N – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our unaudited condensed consolidated financial statements.

Standards to be Implemented

ASC Update No. 2016-02

In February 2016, the FASB issued ASC Update No. 2016-02, Leases (Topic 842). The purpose of Update No. 2016-02 is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. Update No. 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted and a modified retrospective approach is required for adoption. While we are still in the process of determining the effect that the new standard will have on our financial position and results of operations, we expect to recognize additional assets and corresponding liabilities on our consolidated balance sheets, as a result of our operating lease portfolio as it exists at the date we adopt the new standard. Please refer to Note F - Lease and Other Purchase Obligations in our most recent Annual Report on Form 10-K for information regarding our most current lease activity. Additionally, we are in the process of implementing a new lease administration and lease accounting system, and updating our controls and procedures for maintaining and accounting for our lease portfolio under the new standard. As a result, we anticipate adopting the new standard on January 1, 2019.

ASC Update No. 2016-13

In June 2016, the FASB issued ASC Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted for annual periods beginning after December 15, 2018. We are in the process of determining the effect that the adoption will have on our financial position and results of operations.

No other new accounting pronouncements, issued or effective, during the period had, or are expected to have, a material impact on our condensed consolidated financial statements.

29


ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. Our products and technologies are used to diagnose or treat a wide range of medical conditions, including cardiovascular, digestive, respiratory, urological, pelvic health and neurological conditions. We continue to innovate in these areas and are intent on extending our innovations into new geographies and high-growth adjacency markets. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries.

Financial Summary

Three Months Ended March 31, 2018

Our net sales for the first quarter of 2018 were $2.379 billion, as compared to net sales of $2.160 billion for the first quarter of 2017, an increase of $219 million, or 10.1 percent. Our operational net sales, which exclude a 390 basis point impact of foreign currency fluctuations, increased $136 million, or 6.2 percent as compared to the same period in the prior year.1 This increase in the first quarter of 2018 included operational net sales of $21 million, with no prior year period related net sales, due to the acquisition of Symetis SA (Symetis) during the second quarter of 2017. Refer to Quarterly Results and Business Overview for a discussion of our net sales by global business.

Our reported net income for the first quarter of 2018 was $298 million, or $0.21 per share. Our reported results for the first quarter of 2018 included certain charges and/or credits totaling $157 million (after-tax), or $0.11 per share. Adjusted net income, which excludes these items, for the first quarter of 2018, was $455 million, or $0.33 per share.1  

Our reported net income for the first quarter of 2017 was $290 million, or $0.21 per share. Our reported results for the first quarter of 2017 included certain charges and/or credits totaling $107 million (after-tax), or $0.08 per share. Excluding these items, net income for the first quarter of 2017, was $397 million, or $0.29 per share.1 
























1Operational net sales, which exclude the impact of foreign currency fluctuations, and adjusted net income and adjusted net income per share, which exclude certain items required by generally accepted accounting principles in the United States (U.S. GAAP), are not prepared in accordance with U.S. GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of these non-GAAP financial measures.

30


The following is a reconciliation of our results of operations prepared in accordance with U.S. GAAP to those adjusted results considered by management. Refer to Quarterly Results and Business Overview for a discussion of each reconciling item:
 

Three Months Ended March 31, 2018
in millions, except per share data

Net income (loss)
 
Impact per share
GAAP net income (loss)

$
298

 
$
0.21

Non-GAAP adjustments:

 
 
 
Amortization expense
 
119

 
0.08

Intangible asset impairment charges

1

 
0.00

Acquisition-related net charges (credits)

20

 
0.01

Restructuring and restructuring-related net charges (credits)

22

 
0.02

Investment impairment charges
 
5

 
0.00

Tax Cuts and Jobs Act net charges
 
(9
)
 
(0.01
)
Adjusted net income

$
455

 
$
0.33

 
 
 
 
 

 
 
Three Months Ended March 31, 2017
in millions, except per share data
 
Net income (loss)
 
Impact per share
GAAP net income (loss)
 
$
290

 
$
0.21

Non-GAAP adjustments:
 
 
 
 
Amortization expense
 
122

 
0.09

Acquisition-related net charges (credits)
 
(32
)
 
(0.02
)
Restructuring and restructuring-related net charges (credits)
 
15

 
0.01

Litigation-related net charges (credits)
 
2

 
0.00

Adjusted net income
 
$
397

 
$
0.29

 
 
 
 
 

Cash provided by operating activities was $193 million for the first three months of 2018. As of March 31, 2018, we had total debt of $5.765 billion, cash and cash equivalents of $287 million and a working capital deficit of $908 million. Refer to Liquidity and Capital Resources for further discussion.













31


Quarterly Results and Business Overview

The following section describes an overview of our product offerings and results of operations by business unit. For additional information on our businesses and their product offerings, see Item 1. Business of our most recent Annual Report on Form 10-K.

Net Sales

The following table provides our net sales by business and the relative change in growth on a reported basis and operational basis.
 
Three Months Ended March 31, 2018
 
Change
 
 
Reported
Basis
 
Less: Impact of Foreign Currency
 
Operational
Basis
(in millions)
2018
2017
 
 
 
Endoscopy
$
418

$
379

 
10.2
%
 
4.0
%
 
6.2
%
Urology and Pelvic Health
293

262

 
11.8
%
 
2.6
%
 
9.2
%
MedSurg*
711

641

 
10.9
%
 
3.5
%
 
7.4
%
Cardiac Rhythm Management
493

463

 
6.5
%
 
4.1
%
 
2.4
%
Electrophysiology
75

64

 
17.2
%
 
5.7
%
 
11.5
%
Neuromodulation
169

141

 
19.3
%
 
2.1
%
 
17.2
%
Rhythm and Neuro*
736

668

 
10.2
%
 
3.8
%
 
6.4
%
Interventional Cardiology
645

590

 
9.3
%
 
4.5
%
 
4.8
%
Peripheral Interventions
288

261

 
10.1
%
 
4.1
%
 
6.0
%
Cardiovascular
933

851

 
9.5
%
 
4.3
%
 
5.2
%
 
 
 
 
 
 
 
 
 
 
 
 
Net Sales
$
2,379

$
2,160

 
10.1
%
 
3.9
%
 
6.2
%

Effective January 1, 2018, following organizational changes to align the company's business and organization structure focused on active implantable devices, we revised our reportable segments, in accordance with FASB ASC Topic 280, Segment Reporting. The revision reflects a reclassification of our Neuromodulation business from our Medical Surgical (MedSurg) segment to our newly created Rhythm and Neuro segment. We have revised prior year amounts to conform to the current year’s presentation (as denoted with an asterisk throughout *). There was no revision to operating segments or reporting units as a result of the organizational change.

MedSurg

Endoscopy

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with innovative, less invasive technologies.

Our net sales of Endoscopy products of $418 million represented approximately 18 percent of our consolidated net sales for the first quarter of 2018. Our Endoscopy net sales increased $39 million, or 10.2 percent, in the first quarter of 2018, as compared to the same period in the prior year. Our operational net sales, which exclude a 400 basis point impact of foreign currency fluctuations, increased 6.2 percent as compared to the same period in the prior year. This year-over-year increase was primarily driven by growth across several of our key product franchises, including our hemostasis franchise featuring our Resolution 360™ Clips, our biliary franchise with our SpyGlass™ DS Direct Visualization System and AXIOS™ Stent and Delivery System for endoscopic ultrasound-guided transluminal drainage of symptomatic pancreatic pseudocysts, as well as our infection prevention products and pathology services.

Urology and Pelvic Health

Our Urology and Pelvic Health business develops and manufactures devices to treat various urological and pelvic conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, erectile dysfunction, male incontinence, pelvic floor disorders, abnormal uterine bleeding and uterine fibroids and polyps.

Our net sales of Urology and Pelvic Health products of $293 million represented approximately 12 percent of our consolidated net sales for the first quarter of 2018. Urology and Pelvic Health net sales increased $31 million, or 11.8 percent in the first quarter

32


of 2018, as compared to the same period in the prior year. Our operational net sales, which exclude a 260 basis point impact of foreign currency fluctuations, increased 9.2 percent as compared to the same period in the prior year. This year-over-year increase was primarily attributable to growth in sales of our kidney stone products, including our LithoVue™ Digital Flexible Ureteroscope, our benign prostatic hyperplasia (BPH) business, and our men's health products, as well as growth across all of our franchises internationally.

Rhythm and Neuro

Cardiac Rhythm Management

Our Cardiac Rhythm Management (CRM) business develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.

Our net sales of CRM products of $493 million represented approximately 21 percent of our consolidated net sales for the first quarter of 2018. Our net sales of CRM products increased $30 million, or 6.5 percent, in the first quarter of 2018, as compared to the same period in the prior year. Our operational net sales, which exclude a 410 basis point impact of foreign currency fluctuations, increased 2.4 percent as compared to the same period in the prior year. This year-over-year increase was driven by continued EMBLEM™ Subcutaneous Implantable Cardiac Defibrillator (S-ICD) market penetration, the ongoing launch of our RESONATE™ family of implantable cardioverter defibrillators (ICD) and implantable cardiac resynchronization therapy defibrillators (CRT-D) in the U.S. and Europe, as well as the favorable impact from U.S. magnetic resonance imaging (MRI) safe conditional labeling, which was approved by the FDA in September 2017. Our defibrillator growth was partially offset by softness in pacemaker sales.

Electrophysiology

Our Electrophysiology business develops and manufactures less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart, including a broad portfolio of therapeutic and diagnostic catheters and variety of capital equipment used in the electrophysiology lab.

Our net sales of Electrophysiology products of $75 million represented approximately three percent of our consolidated net sales for the first quarter of 2018. Our Electrophysiology net sales increased $11 million, or 17.2 percent, in the first quarter of 2018, as compared to the same period in the prior year. Our operational net sales, which exclude a 570 basis point impact of foreign currency fluctuations, increased 11.5 percent as compared to the same period in the prior year. This year-over-year increase was primarily driven by increased sales of our next generation Rhythmia™ Mapping System, Rhythmia HDx™ Mapping System, related therapeutic and diagnostic catheters, and accessories.

Neuromodulation

Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain.

Our net sales of Neuromodulation products of $169 million represented approximately seven percent of our consolidated net sales for the first quarter of 2018. Neuromodulation net sales increased $27 million, or 19.3 percent, in the first quarter of 2018, as compared to the same period in the prior year. Our operational net sales, which exclude a 210 basis point impact of foreign currency fluctuations, increased 17.2 percent as compared to the same period in the prior year. This year-over-year increase was primarily driven by continued adoption of our Precision Montage™ Spinal Cord Stimulator and the launch of Spectra Wavewriter TM Technology SCS System and our Vercise™ Deep Brain Stimulation System in the U.S. combined with an increase in international sales.

Cardiovascular

Interventional Cardiology

Our Interventional Cardiology business develops and manufactures technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. Our broad, innovative product offerings have enabled us to become a leader in the global interventional cardiology market.

Our net sales of Interventional Cardiology products of $645 million represented approximately 27 percent of our consolidated net sales for the first quarter of 2018. Our Interventional Cardiology net sales increased $55 million, or 9.3 percent, in the first quarter

33


of 2018, as compared to the same period in the prior year. Our operational net sales, which exclude a 450 basis point impact of foreign currency fluctuations, increased 4.8 percent as compared to the same period in the prior year. This year-over-year increase was primarily related to sales of our complex percutaneous coronary interventions (PCI) product offerings driven by new launches, our structural heart product offerings including the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device and the ACURATE™ Transcatheter Aortic Valve, which was part of our Symetis acquisition in May 2017. Growth was partially offset by price challenges within the global drug-eluting coronary stent (DES) market, coupled with a strong prior period comparison for global DES.

Peripheral Interventions

Our Peripheral Interventions business develops and manufactures products used to diagnose and treat peripheral arterial diseases, including a broad line of medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular diseases, as well as products to diagnose, treat and ease various forms of cancer.

Our net sales of Peripheral Interventions products of $288 million represented approximately 12 percent of our consolidated net sales for the first quarter of 2018. Our Peripheral Interventions net sales increased $26 million, or 10.1 percent, in the first quarter of 2018, as compared to the same period in the prior year. Our operational net sales, which exclude a 410 basis point impact of foreign currency fluctuations, increased 6.0 percent as compared to the same period in the prior year. This year-over-year increase was primarily driven by growth in our core franchises, particularly our stent portfolio, our drug-eluting product franchise and our atherectomy systems.

Emerging Markets

As part of our strategic imperatives to drive global expansion, we are seeking to grow net sales and market share by expanding our global presence, including in Emerging Markets. We define Emerging Markets as including 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. We have increased our investment in infrastructure in these countries in order to maximize opportunities. Our Emerging Markets net sales represented 10.7 percent of our consolidated net sales in the first quarter of 2018 and 9.6 percent in the first quarter of 2017. In the first quarter of 2018, our Emerging Market net sales grew 22.6 percent on a reported basis and excluding a 540 basis point impact of foreign currency fluctuations, grew 17.2 percent on an operational basis, both as compared to the same period in the prior year.

Gross Profit

Our gross profit was $1.707 billion for the first quarter of 2018 and $1.510 billion for the first quarter of 2017. The following is a reconciliation of our gross profit margins and a description of the drivers of the change from period to period:

Three Months
Gross profit margin - period ended March 31, 2017
69.9
 %
Manufacturing cost reductions
1.7

Sales pricing and mix
0.5

Net impact of foreign currency
(1.9
)
All other, including inventory changes and other period expense
1.5

Gross profit margin - period ended March 31, 2018
71.7
 %

The primary factors contributing to the increase in our gross profit margins during the first quarter, as compared to the same period in 2017, were the positive impacts of cost reductions resulting from our process improvement programs and restructuring programs, along with the 180 basis point impact in the first quarter of 2017 primarily associated with the voluntary removal of Lotus™ Valve Devices from global, commercial and clinical sites. Partially offsetting these factors was the net negative impact of foreign currency fluctuations.


34


Operating Expenses

The following table provides a summary of certain of our operating expenses:
 
 
Three Months Ended March 31,
 
 
2018
 
2017
 
 
 
% of Net
 
 
% of Net
(in millions)
 
$
Sales
 
$
Sales
Selling, general and administrative expenses
 
860

36.1
%
 
794

36.8
%
Research and development expenses
 
261

11.0
%
 
235

10.9
%
Royalty expense
 
18

0.7
%
 
17

0.8
%

Selling, General and Administrative (SG&A) Expenses

In the first quarter of 2018, our SG&A expenses increased $66 million, or eight percent, as compared to the first quarter of 2017 and were 70 basis points lower as a percentage of net sales. The decrease in SG&A as a percentage of sales was primarily driven by the benefit of our targeted initiatives focused on reducing SG&A, including end-to-end business process streamlining and automation, expansion of global shared services, and leveraging global sourcing.

Research and Development (R&D) Expenses

We remain committed to advancing medical technologies and investing in meaningful R&D projects across our businesses. In the first quarter of 2018, our R&D expenses increased $26 million, as compared to the first quarter of 2017 and were relatively flat at approximately 11 percent of net sales for both periods as a result of investments across our businesses in order to maintain a healthy pipeline of new products that we believe will contribute to profitable sales growth.

Royalty Expense

Our royalty expense was $18 million in the first quarter of 2018, as compared to $17 million in the first quarter of 2017, remaining relatively flat at approximately one percent of net sales for both periods.

Amortization Expense

Our amortization expense was $141 million in the first quarter of 2018, as compared to $143 million in the first quarter of 2017. Amortization expense is excluded by management for purposes of evaluating operating performance.

Contingent Consideration Expense

We recorded a net expense of $5 million during the first quarter of 2018 and a net benefit of $50 million during the first quarter of 2017 related to the change in fair value of our contingent consideration liabilities. Refer to Note B – Acquisitions and Strategic Investments to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for additional details related to our contingent consideration expenses. Contingent consideration expense is excluded by management for purposes of evaluating operating performance.

Restructuring Charges and Restructuring-related Activities

The following table provides a summary of our restructuring and restructuring-related charges and cash payments:
 
 
Three Months Ended March 31,
(in millions)
 
2018
 
2017
Total restructuring charges
 
$
13

 
$
4

Total restructuring-related charges
 
$
15

 
$
15

 
 
 
 
 
Total cash payments
 
$
25

 
$
16


Restructuring and restructuring-related costs are excluded by management for purposes of evaluating operating performance.

35



The 2016 Restructuring Plan is expected to result in total pre-tax charges of approximately $275 million to $325 million and reduce gross annual expenses by approximately $165 million to $175 million by the end of 2020 as plan benefits are realized. A substantial portion of these savings will be reinvested in strategic growth initiatives.

Refer to Note F – Restructuring-related Activities to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for additional details related to our restructuring plans.

Litigation-related charges and credits

Litigation-related net charges were immaterial in the first quarter of 2018 and 2017. Litigation-related charges (credits) are excluded by management for purposes of evaluating operating performance. Refer to Note I – Commitments and Contingencies to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for discussion of our material legal proceedings.

Interest Expense
The following table provides a summary of our interest expense and average borrowing rate:
(in millions)
 
Three Months Ended March 31,
 
2018
 
2017
Interest expense
 
$
(61
)
 
$
(57
)
 
 
 
 
 
Average borrowing rate
 
4.1
%
 
4.0
%

Refer to Liquidity and Capital Resources and Note D – Hedging Activities and Fair Value Measurements and Note E – Borrowings and Credit Arrangements to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for information regarding our debt obligations and related derivative instruments and hedging activities.

Other, net

The following are the components of Other, net:
 
 
Three Months Ended March 31,
(in millions)
 
2018
 
2017
Interest income
 
$
1

 
$
1

Net foreign currency gain (loss)
 
(8
)
 

Net gains (losses) on investments
 
(13
)
 

Other income (expense), net
 
(3
)
 
(3
)
 
 
$
(23
)
 
$
(2
)

Tax Rates

Our effective tax rate from continuing operations is presented below:
 
 
Three Months Ended March 31,
 
 
2018
 
2017
Effective tax rate from continuing operations
 
8.0
%
 
4.9
%

The change in our reported tax rates for the first quarter of 2018, as compared to the same period in 2017, relates primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate, including intangible asset impairment charges, acquisition-related items, restructuring items, litigation-related items, as well as certain discrete tax items including impacts of the Tax Cuts and Jobs Act (TCJA), enacted on December 22, 2017.

We are contesting in U.S. Tax Court significant proposed adjustments from the Internal Revenue Service (IRS) related to its audit of our transfer pricing methodologies for the 2001 through 2007 tax years. The IRS also proposed similar transfer pricing

36


adjustments for the 2008 through 2010 tax years. We disagree with the transfer pricing methodologies being applied by the IRS and we were scheduled to go to trial in the U.S. Tax Court in late July 2016. On July 19, 2016, we entered a Stipulation of Settled Issues with the IRS intended to resolve all of the aforementioned transfer pricing issues, as well as issues related to our transaction with Abbott Laboratories, for the 2001 through 2007 tax years. The Stipulation of Settled Issues is contingent upon the IRS Office of Appeals applying the same basis of settlement to all transfer pricing issues for the Company’s 2008, 2009 and 2010 tax years as well as review by the United States Congress Joint Committee on Taxation (JCT). In October 2016, we reached an agreement in principle with the IRS Office of Appeals as to the resolution of the transfer pricing issues in 2008, 2009 and 2010 tax years, subject to additional calculations of tax as well as documentation to memorialize our agreement. The IRS has recalculated our final tax liabilities under this agreement for all of our tax years from 2001 through 2010 and the JCT has completed its review of the recalculations for the 2001 through 2010 tax years.

In the event that the conditions in the Stipulation of Settled Items are satisfied, we expect to make net tax payments of approximately $275 million, plus interest through the date of payment with respect to the settled issues. If finalized, payments related to the resolution are expected in the next six months. We believe that our income tax reserves associated with these matters are adequate as of March 31, 2018 and we do not expect to recognize any additional charges related to resolution of this controversy. However, the final resolution of these issues remains contingent and if the Stipulation of Settled Issues is not finalized, it could have a material impact on our financial condition, results of operations, or cash flows.

Refer to Note H – Income Taxes to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for information regarding our tax litigation.

Critical Accounting Policies and Estimates
Our financial results are affected by the selection and application of accounting policies and methods. In the three months ended March 31, 2018, there were changes to the application of critical accounting policies previously disclosed in our most recent Annual Report on Form 10-K related to the adoption of FASB ASC Topic 606, Revenue from Contracts with Customers on January 1, 2018, as described below.
Revenue Recognition
Post Implant Services
We provide non-contractual services to customers to ensure the safe and effective use of certain implanted devices. These promises are immaterial in the context of the contract.  In accordance with FASB ASC Topic 606, because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to selling, general and administrative expenses. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost.  Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost. Refer to Note L – Revenue for further information on our adoption of FASB ASC Topic 606.

Liquidity and Capital Resources

Based on our current business plan, we believe our existing balance of cash and cash equivalents, future cash generated from operations, access to capital markets and existing credit facilities will be sufficient to fund our operations, invest in our infrastructure, pay our legal-related liabilities, pay taxes due, fund possible mergers and/or acquisitions and service and repay our existing debt for the next twelve months.

As of March 31, 2018, we had $287 million of cash and cash equivalents on hand, comprised of $42 million invested in money market and government funds and $245 million in interest bearing and non-interest bearing bank accounts. We invest excess cash on hand in short-term financial instruments that earn market interest rates while mitigating principal risk through instrument and counterparty diversification, as well as what we believe to be prudent instrument selection. We limit our direct exposure to securities in any one industry or issuer. We also have full access to our $2.250 billion commercial paper program, which is backed by our 2017 revolving credit facility described below. As of March 31, 2018, we had $886 million in commercial paper debt outstanding resulting in an additional $1.364 billion of available liquidity and $70 million outstanding resulting in an additional $330 million of available liquidity under our credit facility secured by our U.S. trade receivables both described below.


37


The following provides a summary and description of our net cash inflows (outflows):
 
 
Three Months Ended
March 31,
(in millions)
 
2018
 
2017
 
 
 
 
(restated)
Cash provided by (used for) operating activities
 
$
193

 
$
(7
)
Cash provided by (used for) investing activities
 
(173
)
 
(140
)
Cash provided by (used for) financing activities
 
130

 
(15
)
Certain prior year balances related to restricted cash have been reclassified to reflect our adoption of FASB ASC Update No. 2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash in the fourth quarter of 2017. Please refer to our most recent annual report on Form 10-K for additional details.

Operating Activities

During the first three months of 2018, cash provided by operating activities was $193 million, as compared to cash used for operating activities of $7 million during the first three months of 2017, an increase of $200 million. The increase was primarily due to a reduction in litigation-related payments primarily associated with the transvaginal surgical mesh product liability cases and changes in working capital.

Investing Activities

During the first three months of 2018, cash used for investing activities primarily relates to purchases of property, plant and equipment of $60 million and payments related to strategic investments and acquisitions of certain technologies of $103 million, primarily related to our $90 million investment in Millipede, Inc. During the first three months of 2017, cash used for investing activities primarily included purchases of property, plant and equipment of $112 million and payments related to strategic investments and issuances of notes receivable of $28 million.

Financing Activities

Our cash flows for financing activities reflect issuances and repayments of debt, along with cash used to net share settle employee equity awards and stock issuances related to our equity incentive programs. Additionally, our financing activities included $18 million of contingent payments in the first three months of 2017.


38


Debt

We had total debt of $5.765 billion as of March 31, 2018 and $5.616 billion as of December 31, 2017. The debt maturity schedule for the significant components of our long-term debt obligations is presented below:
(in millions, except interest rates)
Issuance Date
Maturity Date
As of
 
Semi-annual Coupon Rate
March 31, 2018
 
December 31, 2017
 
October 2018 Notes
August 2013
October 2018

 
 
2.650
%
January 2020 Notes
December 2009
January 2020
850

 
850

 
6.000
%
May 2020 Notes
May 2015
May 2020
600

 
600

 
2.850
%
May 2022 Notes
May 2015
May 2022
500

 
500

 
3.375
%
October 2023 Notes
August 2013
October 2023
450

 
450

 
4.125
%
May 2025 Notes
May 2015
May 2025
750

 
750

 
3.850
%
March 2028 Notes
February 2018
March 2028
1,000

 

 
4.000
%
November 2035 Notes
November 2005
November 2035
350

 
350

 
7.000
%
January 2040 Notes
December 2009
January 2040
300

 
300

 
7.375
%
Unamortized Debt Issuance Discount
 
2020 - 2040
(14
)
 
(6
)
 
 
Unamortized Deferred Financing Costs
 
2020 - 2040
(19
)
 
(18
)
 
 
Unamortized Gain on Fair Value Hedges
 
2020 - 2023
35

 
38

 
 
Capital Lease Obligation
 
Various
1

 
1

 
 
Long-term debt
 
 
$
4,803

 
$
3,815

 
 
As of December 31, 2017, $600 million under the October 2018 Notes was outstanding and classified as short-term debt.
Note:
The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.

Revolving Credit Facility
As of March 31, 2018 and December 31, 2017, we maintained a $2.250 billion revolving credit facility (the 2017 Facility) with a global syndicate of commercial banks that matures on August 4, 2022. This facility provides backing for the commercial paper program described below. There were no amounts borrowed under our revolving credit facility as of March 31, 2018 and December 31, 2017.

The 2017 Facility requires that we maintain certain financial covenants, as follows:
 
Covenant Requirement
 
Actual
 
as of March 31, 2018
 
as of March 31, 2018
Maximum leverage ratio (1)
3.5 times
 
2.2 times

(1)
Ratio of total debt to consolidated EBITDA, as defined by the credit agreement, for the preceding four consecutive fiscal quarters.

The 2017 Facility provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of March 31, 2018, we had $415 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the 2017 Facility, are excluded from the calculation of consolidated EBITDA, as defined in the 2017 Facility, provided that the sum of any excluded net cash litigation payments does not exceed $2.624 billion in the aggregate. As of March 31, 2018, we had $1.690 billion of the legal exclusion remaining.

Any inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facility or seek waivers from compliance with these covenants, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all credit facility commitments would terminate and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our credit facility may negatively impact the credit ratings assigned to our commercial paper program which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

39


Commercial Paper
As of March 31, 2018, we had $886 million of commercial paper outstanding and $1.197 billion outstanding as of December 31, 2017. Our commercial paper program is backed by the 2017 Facility, which allows us to have a maximum of $2.250 billion in commercial paper outstanding. Outstanding commercial paper directly reduces borrowing capacity available under the 2017 Facility. As of March 31, 2018, the commercial paper issued and outstanding had a weighted average maturity of 22 days and a weighted average yield of 2.46 percent. As of December 31, 2017, the commercial paper issued and outstanding had a weighted average maturity of 38 days and a weighted average yield of 1.85 percent.

Senior Notes

We had senior notes outstanding of $4.800 billion as of March 31, 2018 and $4.400 billion as of December 31, 2017.

In February 2018, we completed an offering of $1.000 billion in aggregate principal amount of 4.000% senior notes, due March 2028. We used a portion of the net proceeds from the offering to repay the $600 million plus accrued interest of our 2.650% senior notes due in October 2018. The remaining proceeds were used to repay a portion of our outstanding commercial paper.

Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to borrowings under our credit and security facility, and to the extent borrowed by our subsidiaries, to liabilities of our subsidiaries (see Other Arrangements below).

Other Arrangements

As of March 31, 2018 and December 31, 2017, we maintained a $400 million credit and security facility secured by our U.S. trade receivables maturing in February 2019. We had outstanding borrowings of $70 million as of March 31, 2018 and no outstanding borrowings as of December 31, 2017 under our credit and security facility.

We have accounts receivable factoring programs in certain European countries that we account for as sales under FASB ASC Topic 860, Transfers and Servicing. These agreements provide for the sale of accounts receivable to third parties, of up to approximately $463 million as of March 31, 2018. We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. We de-recognized $178 million of receivables as of March 31, 2018 at an average interest rate of 2.1 percent and $171 million as of December 31, 2017 at an average interest rate of 1.8 percent.

In March 2018, we entered into a factoring agreement with a commercial Japanese bank. The agreement provides for the sale of accounts receivable and promissory notes of up to 30.000 billion Japanese yen (approximately $282 million as of March 31, 2018). We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. We de-recognized $95 million of receivables as of March 31, 2018 at an average interest rate of 0.5 percent.

In addition, we have uncommitted credit facilities with a commercial Japanese bank that provide for accounts receivable factoring and promissory notes discounting of up to 22.000 billion Japanese yen (approximately $207 million as of March 31, 2018). We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. We de-recognized $124 million of notes receivable as of March 31, 2018 at an average interest rate of 1.5 percent and $157 million of notes receivable as of December 31, 2017 at an average interest rate of 1.3 percent. De-recognized accounts and notes receivable are excluded from trade accounts receivable, net in the accompanying unaudited condensed consolidated balance sheets.

As of and through March 31, 2018, we were in compliance with all the required covenants related to our debt obligations.
Equity
We received $38 million during the first three months of 2018 and $33 million during the first three months of 2017 in proceeds from stock issuances related to our stock option and employee stock purchase plans. Proceeds from the exercise of employee stock options and employee stock purchases vary from period to period based upon, among other factors, fluctuations in the trading price of our common stock and in the exercise and stock purchase patterns of our employees.

40


We did not repurchase any shares of our common stock during the first three months of 2018 and 2017. As of March 31, 2018, the remaining authorization to repurchase shares under our 2013 share repurchase program was $535 million.
Stock-based compensation expense related to our stock ownership plans was approximately $36 million for the first quarter of 2018 and $30 million for the first quarter of 2017.
Contractual Obligations and Commitments

Certain of our acquisitions involve the payment of contingent consideration. See Note B – Acquisitions and Strategic Investments to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for further details regarding the estimated potential amount of future contingent consideration we could be required to pay associated with our acquisitions. There have been no other material changes to our contractual obligations and commitments as reported in our most recent Annual Report filed on Form 10-K.
Legal Matters
For a discussion of our material legal proceedings see Note I – Commitments and Contingencies to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q and Note J – Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.
Recent Accounting Pronouncements
Information regarding new accounting pronouncements implemented since December 31, 2017 is included in Note A – Basis of Presentation and information regarding new accounting pronouncements to be implemented is included in Note N – New Accounting Pronouncements to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q.

Additional Information

Use of Non-GAAP Financial Measures

To supplement our unaudited condensed consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (earnings) and adjusted net income (earnings) per share that exclude certain amounts and operational net sales growth that exclude the impact of foreign currency fluctuations. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (earnings) and adjusted net income (earnings) per share we exclude certain charges (credits) from GAAP net income, including amortization expense, intangible asset impairment charges, acquisition-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), certain investment impairment charges and certain discrete tax items, including net income tax charges resulting from the enactment of the TCJA. Amounts are tax effected at the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB ASC section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." Please refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K filed with the Securities and Exchange Commission for an explanation of each of these adjustments and the reasons for excluding each item.

The GAAP financial measures most directly comparable to adjusted net income and adjusted net income per share is GAAP net income and GAAP net income per share.

To calculate operational net sales, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. The GAAP financial measure most directly comparable to operational net sales is net sales on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included elsewhere in this Quarterly Report on Form 10-Q.


41


Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors, and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments’ measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income, adjusted net income per share that exclude certain amounts and operational net sales growth that exclude the impact of changes in foreign currency exchange rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

Safe Harbor for Forward-Looking Statements

Certain statements that we may make from time to time, including statements contained in this Quarterly Report on Form 10-Q and information incorporated by reference herein, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “may,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Except as required by law, we do not intend to update any forward-looking statements even if new information becomes available or other events occur in the future.

The forward-looking statements in this Quarterly Report on Form 10-Q are based on certain risks and uncertainties, including the risk factors described in “Part I, Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K and the specific risk factors discussed below and in connection with forward-looking statements throughout this Quarterly Report on Form 10-Q, which could cause actual results to vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the forward-looking statements. These additional factors include, among other things, future political, economic, competitive, reimbursement and regulatory conditions, new product introductions, demographic trends, intellectual property, litigation and governmental investigations, financial market conditions and future business decisions made by us and our competitors, all of which are difficult or impossible to predict accurately and many of which are beyond our control. We caution each reader of this Quarterly Report on Form 10-Q to consider carefully these factors.

The following are some of the important risk factors that could cause our actual results to differ materially from our expectations in any forward-looking statements. For further discussion of these and other risk factors, see “Part I, Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K.

Our Businesses
 
Our ability to increase net sales, expand the market, capture market share and adapt to market volatility,

The ongoing impact on our business of physician alignment to hospitals, governmental investigations and audits of hospitals and other market and economic conditions on the overall number of procedures performed,

Competitive offerings and related declines in average selling prices for our products,

The performance of and physician and patient confidence in, our products and technologies or those of our competitors,

The impact and outcome of ongoing and future clinical trials and market studies undertaken by us, our competitors or other third parties or perceived product performance of our or our competitors' products,
 

42


Variations in clinical results, reliability or product performance of our and our competitor's products,

Our ability to acquire or develop, launch and supply new or next-generation products and technologies worldwide and in line with our commercialization strategies in a timely and successful manner and with respect to our recent acquisitions,

The effect of consolidation and competition in the markets in which we do business or plan to do business,

Disruption in the manufacture or supply of certain components, materials or products or the failure to secure in a timely manner alternative manufacturing or additional or replacement components, materials or products,

Our ability to retain and attract key personnel,

The impact of enhanced requirements to obtain regulatory approval in the U.S. and around the world, including the associated timing and cost of product approval, and
 
The impact of increased pressure on the availability and rate of third-party reimbursement for our products and procedures in the U.S. and around the world, including with respect to the timing and costs of creating and expanding markets for new products and technologies.

Regulatory Compliance, Litigation and Data Protection

The impact of healthcare policy changes and legislative or regulatory efforts in the U.S. and around the world to modify product approval or reimbursement processes, including a trend toward demonstrating clinical outcomes, comparative effectiveness and cost efficiency, as well as the impact of other healthcare reform legislation,

Risks associated with our regulatory compliance and quality systems and activities in the U.S. and around the world, including meeting regulatory standards applicable to manufacturing and quality processes,

Our ability to minimize or avoid future field actions or FDA warning letters relating to our products and processes and the ongoing inherent risk of potential physician advisories related to medical devices,

The impact of increased scrutiny of and heightened global regulatory enforcement facing the medical device industry arising from political and regulatory changes, economic pressures or otherwise, including under U.S. Anti-Kickback Statute, U.S. False Claims Act and similar laws in other jurisdictions, U.S. Foreign Corrupt Practices Act (FCPA) and similar laws in other jurisdictions, and U.S. and foreign export control, trade embargo and customs laws,

Costs and risks associated with litigation,

The effect of our litigation and risk management practices, including self-insurance and compliance activities on our loss contingencies, legal provision and cash flows,
 
The impact of, diversion of management attention as a result of and costs to cooperate with, litigate and/or resolve governmental investigations and our class action, product liability, contract and other legal proceedings,

The possibility of failure to protect our intellectual property rights and the outcome of patent litigation, and

Our ability to properly operate our information systems that support our business operations and protect our data integrity and products from a cyber-attack or other breach that has a material adverse effect on our business, reputation or results of operations.

Innovation and Certain Growth Initiatives

The timing, size and nature of our strategic growth initiatives and market opportunities, including with respect to our internal research and development platforms and externally available research and development platforms and technologies and the ultimate cost and success of those initiatives and opportunities,

Our ability to complete planned clinical trials successfully, obtain regulatory approvals and launch new and next generation products in a timely manner consistent with cost estimates, including the successful completion of projects from in-process research and development,

43



Our ability to identify and prioritize our internal research and development project portfolio and our external investment portfolio on profitable revenue growth opportunities as well as to keep them in line with the estimated timing and costs of such projects and expected revenue levels for the resulting products and technologies,

Our ability to successfully develop, manufacture and market new products and technologies in a timely manner and the ability of our competitors and other third parties to develop products or technologies that render our products or technologies noncompetitive or obsolete,

The impact of our failure to succeed at our decision to discontinue, write-down or reduce the funding of any of our research and development projects, including in-process projects from in-process research and development, in our growth adjacencies or otherwise,

Dependence on acquisitions, alliances or investments to introduce new products or technologies and to enter new or adjacent growth markets and our ability to fund them or to fund contingent payments with respect to those acquisitions, alliances and investments, and

The failure to successfully integrate and realize the expected benefits from the strategic acquisitions, alliances and investments we have consummated or may consummate in the future.

International Markets

Our dependency on international net sales to achieve growth, including in emerging markets,

The impact of changes in our international structure and leadership,

The timing and collectability of customer payments, political and economic conditions (including the impact of the United Kingdom's exit from the EU, often referred to as "Brexit"), protection of our intellectual property, compliance with established and developing U.S. and foreign legal and regulatory requirements, including FCPA and similar laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws, as well as changes in reimbursement practices and policies,

Our ability to maintain or expand our worldwide market positions in the various markets in which we compete or seek to compete, including through investments in product diversification and emerging markets such as Brazil, Russia, India and China,

Our ability to execute and realize anticipated benefits from our investments in emerging markets, and

The potential effect of foreign currency fluctuations and interest rate fluctuations on our net sales, expenses and resulting margins.

Liquidity

Our ability to generate sufficient cash flow to fund operations, capital expenditures, global expansion initiatives, any litigation settlements and judgments, share repurchases and strategic investments and acquisitions as well as maintaining our investment grade ratings and managing our debt levels and covenant compliance,

Our ability to access the public and private capital markets when desired and to issue debt or equity securities on terms reasonably acceptable to us,

The unfavorable resolution of open tax matters, exposure to additional tax liabilities and the impact of changes in U.S. and international tax laws,

The impact of examinations and assessments by domestic and international taxing authorities on our tax provision, financial condition or results of operations,

The possibility of counterparty default on our derivative financial instruments,

The impact of goodwill and other intangible asset impairment charges, including on our results of operations, and

44



Our ability to collect outstanding and future receivables and/or sell receivables under our factoring programs.

Cost Reduction and Optimization Initiatives

Risks associated with significant changes made or expected to be made to our organizational and operational structure, pursuant to our 2016 Restructuring Plan as well as any further restructuring or optimization plans we may undertake in the future and our ability to recognize benefits and cost reductions from such programs and

Business disruption and employee distraction as we execute our global compliance program, restructuring and optimization plans and divestitures of assets or businesses and implement our other strategic and cost reduction initiatives.

Rule 10b5-1 Trading Plans by Executive Officers

Periodically, certain of our executive officers adopt written stock trading plans in accordance with Rule 10b5-1 under the Exchange Act and our own Stock Trading Policy. A Rule 10b5-1 Trading Plan is a written document that pre-establishes the amount, prices and dates (or formulas for determining the amounts, prices and dates) of future purchases or sales of our stock, including shares issued upon exercise of stock options or vesting of deferred stock units. These plans are entered into at a time when the person is not in possession of material non-public information about our company. We disclose details regarding individual Rule 10b5-1 Trading Plans on the Investor Relations section of our website.


45


ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We develop, manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates. We address these risks through a risk management program that includes the use of derivative financial instruments. We operate the program pursuant to documented corporate risk management policies. We do not enter derivative transactions for speculative purposes. Gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures. Furthermore, we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions.
Our currency risk consists primarily of foreign currency denominated firm commitments, forecasted foreign currency denominated intercompany and third-party transactions and net investments in certain subsidiaries. We use both nonderivative (primarily European manufacturing operations) and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates. We had currency derivative instruments outstanding in the contract amount of $6.161 billion as of March 31, 2018 and $5.923 billion as of December 31, 2017. A ten percent appreciation in the U.S. dollar’s value relative to the hedged currencies would increase the derivative instruments’ fair value by $350 million as of March 31, 2018 as compared to $321 million as of December 31, 2017. A ten percent depreciation in the U.S. dollar’s value relative to the hedged currencies would decrease the derivative instruments’ fair value by $428 million as of March 31, 2018 as compared to $421 million as of December 31, 2017. Any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset, liability or forecasted transaction, resulting in minimal impact on our consolidated statements of operations.
Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. We had no interest rate derivative instruments outstanding as of March 31, 2018 and December 31, 2017. As of March 31, 2018, $4.800 billion of our outstanding debt obligations were at fixed interest rates, representing approximately 84 percent of our total debt.
Refer to Note D – Hedging Activities and Fair Value Measurements to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for further information regarding our derivative financial instruments.


46


ITEM 4.
CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer (CEO) and our Chief Financial Officer (CFO), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2018 pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act). Disclosure controls and procedures are designed to ensure that material information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such material information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Based on their evaluation, our CEO and CFO concluded that, as of March 31, 2018, our disclosure controls and procedures were effective.
Changes in Internal Control Over Financial Reporting
During the three month period ended March 31, 2018, we implemented certain controls related to the adoption of FASB ASC Topic 606, effective January 1, 2018. These controls were designed and implemented to ensure the completeness and accuracy over financial reporting. With the exception of the controls implemented for FASB ASC Topic 606, there were no changes in our internal control over financial reporting during the three month period ended March 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

47


PART II
OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note H – Income Taxes and Note I – Commitments and Contingencies to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

ITEM 1A. RISK FACTORS

In addition to the information set forth below and other information contained elsewhere in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” in our most recent Annual Report filed on Form 10-K, which could materially affect our business, financial condition or future results.

ITEM 6. EXHIBITS (* documents filed or furnished with this report, # compensatory plans or arrangements)
4.1
 
 
 
 
4.2
 
 
 
 
10.1*
 
 
 
 
10.2*
 
 
 
 
10.3*
 
 
 
 
10.4*
 
 
 
 
10.5*
 
 
 
 
10.6*
 
 
 
 
10.7*
 
 
 
 
10.8*
 
 
 
 
10.9*
 
 
 
 
10.10
 
 
 
 
31.1*
 
 
 
 
31.2*
 

48


 
 
 
32.1*
 
 
 
 
32.2*
 
 
 
 
101*
 
Interactive Data Files Pursuant to Rule 405 of Regulation S-T: (i) the Condensed Consolidated Statements of Operations for the three months ended March 31, 2018 and 2017, (ii) the Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2018 and 2017, (iii) the Condensed Consolidated Balance Sheets as of March 31, 2018 and December 31, 2017, (iv) the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2018 and 2017 and (v) the notes to the Condensed Consolidated Financial Statements.

49


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on May 1, 2018.

 
BOSTON SCIENTIFIC CORPORATION
 
 
By:
/s/ Daniel J. Brennan
 
 
 
 
 
 
Name:
Daniel J. Brennan
 
 
Title:
Executive Vice President and
Chief Financial Officer 


50
EX-10.1 2 exhibit101-formofnqsoagree.htm EXHIBIT 10.1 Exhibit
EXHIBIT 10.1










Boston Scientific Corporation 2011 Long-Term Incentive Plan

Global Non-Qualified Stock Option Agreement

%%OPTION_DATE,’Month DD, YYYY’%-%




%%FIRST_NAME%-% %%LAST_NAME%-%
(“Optionee”)























EMPLOYEE COPY
PLEASE RETAIN FOR YOUR RECORDS


-Rev 1.2018


EXHIBIT 10.1


Boston Scientific Corporation 2011 Long-Term Incentive Plan
Global Non-Qualified Stock Option Agreement

This Global Non-Qualified Stock Option Agreement (the “Agreement”), dated %%OPTION_DATE,’Month DD, YYYY’%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the Non-Qualified Stock Option Award granted to you by the Company. This Agreement sets forth the terms and conditions relating to your Stock Option pursuant to the Boston Scientific Corporation 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan. The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.

1.    Grant of Stock Option. The Committee hereby grants you a Stock Option to purchase that number of shares of Stock set forth on herein (the “Option Shares”) at the price set forth herein (the “Grant Price”). The Grant Price is equal to the Fair Market Value of the Company’s Stock on the Grant Date.

2.    Term and Vesting of Stock Option. Except as otherwise provided in Section 4 below, your Stock Option shall have a term of ten (10) years from %%OPTION_DATE,’Month DD, YYYY’%-% until %%EXPIRE_DATE_PERIOD1,’Month DD, YYYY’%-% (the “Expiration Date”) and shall vest in accordance with the vesting schedule. If the Expiration Date falls on a date on which the New York Stock Exchange is closed for trading, the Expiration Date shall be the trading day immediately prior to the Expiration Date.

3.    Exercise of Stock Option. While this Stock Option remains exercisable, you may exercise any vested portion of the Option Shares by delivering to the Company or its designee, in the form and at the location specified by the Company, notice stating your intent to exercise a specified number of Option Shares and payment of the full Grant Price for the specified number of Option Shares. Payment in full for the Option Shares being exercised may be paid in such manner as the Committee may specify from time to time, in its sole discretion, including, but not limited to the following: (a) in cash, (b) by certified check or bank draft payable in U.S. dollars (US$) to the order of the Company, (c) in whole or in part in shares of Stock owned by you, valued at Fair Market Value, or (d) if available to you, via cashless exercise, by which you deliver to your securities broker instructions to sell a sufficient number of shares of Stock to cover the Grant Price for the Option Shares, any applicable tax obligations and the brokerage fees and expenses associated therewith. Notwithstanding the foregoing, if you reside in a country where the local laws and/or regulations preclude the remittance of currency out of the country for purposes of paying the Grant Price for the Option Shares being exercised, require the Company, its Affiliates and/or you to secure any legal or regulatory approvals or complete any legal or regulatory filings, or undertake any additional steps for remitting currency out of the country, the Company may restrict the method of exercise to a form of cashless exercise (either a cashless “sell all” exercise and/or a cashless “sell to cover” exercise) as it shall determine in its sole discretion.

    


-Rev 1.2018


EXHIBIT 10.1


The exercise date applicable to your exercise of the specified number of Option Shares pursuant to this Section 3 will be deemed to be the date on which the Company receives your irrevocable commitment to exercise the Option Shares in writing, subject to your payment in full of the Option Shares to be exercised within 10 (ten) days of the notice of exercise of the Option Shares to be exercised. The notice and payment in full of the Option Shares being exercised, must be received by the Company or its designee on or prior to the last day of the Stock Option term, as set forth in Section 2 above, except as provided in Section 4 below.

Upon the Company’s determination that there has been a valid exercise of the Option Shares, the Company shall issue certificates in accordance with the terms of this Agreement or cause the Company’s transfer agent to make the necessary book entries for the shares of Stock subject to the exercised Option Shares. However, the Company shall not be liable to you, your personal representative or your successor(s)-in-interest for damages relating to any delays in issuing the certificates or in making book entries, any loss of the certificates, or any mistakes or errors in the issuance of the certificates or in making book entries, or in the certificates themselves.

4.    Termination of Employment.

a.    In the event that your employment terminates due to death or Disability (as such term is defined in the Plan or determined under local law, as applicable), all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you or your appointed representative, as the case may be, until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option.

b.    Provided that you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date, in the event your employment terminates due to Retirement, all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option. 

c.    In the event that your employment terminates due to Retirement prior to the first anniversary of the Grant Date, the Option Shares shall immediately be forfeited in their entirety.

d.    Upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, you shall have the shorter of (i) one (1) year from the date of termination and (ii) the remaining term of the Stock Option to exercise all vested Option Shares. Immediately upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, all unvested Option Shares shall be forfeited; provided, however, that the Committee, in its sole discretion, may extend the exercise period and/or accelerate vesting of any unvested Option Shares (provided that such exercise period does not extend beyond the original term of the Stock Option). Your termination date shall be the last day of your active service with the Company or an Affiliate (if applicable).


-Rev 1.2018


EXHIBIT 10.1


e.    Immediately upon notice of termination of your employment for Cause, all unexercised Option Shares, whether vested or unvested, shall be forfeited.

f.    The Option Shares, to the extent unexercised on the date following the end of any period described above or the term of the Stock Option set forth above in Section 2, shall thereupon be forfeited.

g.    Notwithstanding anything to the contrary in the Plan or the Agreement, and for purposes of clarity, any termination of employment shall be effective as of the date your active employment ceases and shall not be extended by any statutory or common law notice of termination period.

h.    Any one of your permitted transferee(s) (pursuant to Section 7 below) shall receive the rights herein granted subject to the terms and conditions of this Agreement and any applicable Addendum. No transfer of this Stock Option shall be approved and effected by the Administrator unless (i) the Administrator shall have been timely furnished with written notice of such transfer and any copies of such notice as the Committee may deem, in its sole discretion, necessary to establish the validity of the transfer; (ii) the transferee or transferees shall have agreed in writing to be bound by the terms and conditions of this Agreement and any applicable Addendum; and (iii) such transfer complies with applicable laws and regulations.

i.    If you are a resident or employed in a country that is a member of the European Union, the grant of the Stock Option and this Agreement are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Stock Option is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

j.    If you reside or work in a country where the local foreign exchange rules and regulations require the repatriation of sale proceeds, the Company may require you to sell any Option Shares you acquire under the Plan immediately or within a specified period following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).

5.    Change in Control. To the extent that you have not entered into a Change in Control Agreement with the Company and except as the Administrator (as defined in the Plan) may otherwise determine, immediately prior to a Change in Control (as defined in the Plan), any unvested portion of the Stock Option shall vest and become exercisable. In addition, the Stock Option shall terminate immediately prior to the Change in Control unless the Stock Option is exercised coincident therewith or assumed in accordance with the immediately following sentence. If there is a surviving or acquiring entity, the Administrator may provide for a substitution or assumption of the Stock Option by the acquiring or surviving entity or an affiliate thereof, on such terms as the Administrator determines. If there is no surviving or acquiring entity, or if the Administrator does not provide for a substitution or assumption of the Stock Option, any unvested portion of the Stock Option shall

-Rev 1.2018


EXHIBIT 10.1


vest and become exercisable on a basis that gives you a reasonable opportunity to participate as a stockholder in the Change in Control. If you have entered into a Change in Control agreement with the Company, the Stock Option will vest according to the provisions of the Change in Control agreement.

6.    Recoupment Policy.

(a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

(i)    Definitions. The following terms, when used in this Section 6, shall have the meaning set forth below:

(1)    “Current Executive Officer” means any individual currently designated as an “officer” by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

(2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

(3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “officer” by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

(4)    “Recovery” means the forfeiture or cancellation of unexercised Stock Options, whether vested or unvested.

(b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

7.    Restrictions on Shares; Legend on Certificate. Shares of Stock issued to you in certificate form or to your book entry account upon exercise of the Stock Option may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.




-Rev 1.2018


EXHIBIT 10.1


8.    Transferability. Except as required by law, you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of the Stock Option granted under this Agreement other than by will or the laws of descent and distribution or without payment of consideration to your Family Members or to trusts or other entities for the benefit of your Family Members. During your lifetime, the Stock Option is exercisable only by you, subject to Section 4 above.

9.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Stock Option, including the grant of the Stock Option, the vesting of the Stock Option, the exercise of the Stock Option, the subsequent sale of any shares of Stock acquired upon exercise of the Stock Option and the receipt of any dividends, and (b) do not commit to structure the terms of the grant or any aspect of the Stock Option to reduce or eliminate your liability for Tax-Related Items.

Prior to the delivery of shares of Stock upon exercise of the Stock Option, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may withhold a sufficient whole number of shares of Stock otherwise issuable upon exercise of the Stock Option that has an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, withhold shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the Stock Option, you expressly consent to the withholding of shares of Stock as provided for hereunder.

Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon exercise resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the exercised Stock Option.





-Rev 1.2018


EXHIBIT 10.1


All other Tax-Related Items related to the Stock Option and any shares of Stock delivered in payment thereof are your sole responsibility. In no event, shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

The Stock Option is intended to be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

10.    Repatriation and Legal/Tax Compliance Requirements. If you are a resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Stock Option) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).

11.    Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Stock Option grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Stock Options awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.





-Rev 1.2018


EXHIBIT 10.1


You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.
You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon exercise of the Stock Option. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consent herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Stock Options or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

Finally, upon request of the Company or the Employer, you agree to provide an executed data privacy consent form (or any other agreements or consents that may be required by the Company and/or the Employer) to the Company and/or the Employer that the Company and/or the Employer may deem necessary to obtain from you for the purpose of administering your participation in the Plan in compliance with the data privacy laws in your country, either now or in the future. You understand and agree that you will not be able to participate in the Plan if you fail to provide any such consent or agreement requested by the Company and/or the Employer.

12.    Nature of Grant. By participating in the Plan, you acknowledge, understand and agree that:
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;



-Rev 1.2018


EXHIBIT 10.1


(b)the grant of the Stock Option is voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Stock Options, even if Stock Options have been granted in the past;

(c)all decisions with respect to future grants of Stock Options, if any, will be at the sole discretion of the Administrator;

(d)the Stock Option grant and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Stock Option is not intended to replace any pension rights or compensation;

(g)the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments;

(h)the future value of the shares of Stock subject to the Stock Option is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Stock Option resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;
 
(k)for purposes of the Stock Option, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, the period (if any) during which you may exercise the Option will commence as of such date and will not be extended by any notice period mandated under employment laws in the

-Rev 1.2018


EXHIBIT 10.1


jurisdiction where you are employed or the terms of your employment agreement, if any; the Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Stock Option or of any amount due to you pursuant to the exercise of the Stock Option or the subsequent sale of any Shares acquired upon exercise.

13.    Securities Laws. Upon the acquisition of any shares of Stock pursuant to the exercise of the Stock Option, you will make or enter into such written representations, warranties and agreements as the Company may reasonably request in order to comply with applicable securities laws or with the Plan.

14.    Not a Public Offering. Neither the grant of the Stock Option under the Plan nor the issuance of the underlying shares of Stock upon exercise of the Stock Option is intended to be a public offering of securities in your country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law.

15.    No Advice Regarding Grant. No Employee of the Company is permitted to advise you regarding whether you should purchase shares of Stock under the Plan. Investment in shares of Stock involves a degree of risk. Before deciding to purchase shares of Stock pursuant to the Stock Option, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Stock Option and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

16.    Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Stock Options) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your

-Rev 1.2018


EXHIBIT 10.1


responsibility to comply with any restrictions and are advised to speak to a personal advisor on this matter.

17.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Stock Option and participation in the Plan, or future grants of Stock Options that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.

18.    Language. If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Stock Option, be drawn up in English. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Stock Option translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

19.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Stock Option shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the “Addendum”). Further, if you transfer your residence and/or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Addendum shall constitute part of this Agreement.

20.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Stock Option, any shares of Stock acquired pursuant to the Stock Option and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

21.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal executive office of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.


-Rev 1.2018


EXHIBIT 10.1


22.    Choice of Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflicts of laws principles) and applicable federal laws.
For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston or the federal courts for the United States for the District of Massachusetts, and no other courts where the grant of the Stock Option is made and/or to be performed.

23.    Award Subject to Plan; Conflicts.    The Stock Option granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Committee specifically for the grant described herein. Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Stock Option granted under this Agreement as the Committee may determine are in the best interests of the Company. You hereby accept the Stock Option subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.

24.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

25.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable

26.     Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

27.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.











-Rev 1.2018


EXHIBIT 10.1


SIGNATURE PAGE
    
IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Optionee have executed and delivered this Agreement effective as of the date and year first above written.

Option Shares of Stock: %%TOTAL_SHARES_GRANTED%-%

Grant Price: %%OPTION_PRICE,’$999,999,999.99’%-%

Vesting Schedule:

Percent of
Stock Option
Date Vested
25%
%%VEST_DATE_PERIOD1%-%



25%
%%VEST_DATE_PERIOD2%-%

25%
%%VEST_DATE_PERIOD3%-%

25%
%%VEST_DATE_PERIOD4%-%




BOSTON SCIENTIFIC CORPORATION        
                    mma02.gif
Michael F. Mahoney
President and Chief Executive Officer


OPTIONEE



By: SIGNED BY ELECTRONIC SIGNATURE


By electronically accepting the Award, you agree that (i) such acceptance constitutes your electronic signature in execution of this Agreement; (ii) you agree to be bound by the provisions of the Plan, the Agreement and the Addendum; (iii) you have reviewed the Plan, the Agreement and the Addendum in their entirety, have had an opportunity to obtain the advice of counsel prior to accepting the Award and fully understand all of the provisions of the Plan, the Agreement and the Addendum; (iv) you have been provided with a copy or electronic access to a copy of the U.S. prospectus for the Plan and the tax supplement to the U.S. prospectus for your country, if applicable; and (v) you hereby agree to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Agreement and the Addendum.

-Rev 1.2018


EXHIBIT 10.1


BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO NON-QUALIFIED STOCK OPTIONS GRANTED
PURSUANT TO THE 2011 LONG-TERM INCENTIVE PLAN

In addition to the terms of the Plan and the Agreement, the Stock Option is subject to the following additional terms and conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 19 of the Agreement, if you transfer your residence and/or employment to another country reflected in an Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).

ARGENTINA

Type of Offering. Neither the grant of the Stock Option, nor the issuance of shares of Stock subject to the grant, constitutes a public offering. The offering of the Plan is a private placement and is not subject to the supervision of any Argentine governmental authority.

AUSTRALIA

1.    Limitations on Exercisability Following Termination of Employment. Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your vested Stock Option will no longer be exercisable after the earlier of: (i) thirty (30) days from the date of termination of employment; and (ii) the Expiration Date specified in Section 2 of the Agreement.

2.    Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.

AUSTRIA

No country-specific provisions.

BELGIUM

1.    Acceptance of Stock Option. In order for the Stock Option to be subject to taxation at the time of grant, you must affirmatively accept the Stock Option in writing within 60 days after the offer date by signing below and returning this original executed Addendum to:


-Rev 1.2018


EXHIBIT 10.1


Boston Scientific
Green Square,
Lambroekstraat 5D
1831 Diegem
Belgium
Attn.: Carine Depret

I hereby accept ________ (number) Option Shares underlying the Stock Option granted to me by the Company on the Grant Date.

The undersigned acknowledges that he/she has been encouraged to discuss this matter with a financial and/or tax advisor and that this decision is made in full knowledge.

Employee Signature:        _______________________________

Employee Printed Name:    _______________________________

Date of Acceptance:        _______________________________

If you fail to affirmatively accept the Stock Option in writing within 60 days after the offer date, the Stock Option will not be subject to taxation at the time of grant but instead will be subject to taxation on the date you exercise the Stock Option (or such other treatment as may apply under Belgian tax law at the time of exercise).

2.    Undertaking for Qualifying Option. If you are accepting the Stock Option in writing within 60 days after the offer date and wish to have the Stock Option subject to a lower valuation for Belgium tax purposes pursuant to the article 43, §6 of the Belgian law of 26 March 1999, you may agree and undertake to (a) not exercise the Stock Option before the end of the third calendar year following the calendar year in which the offer date falls, and (b) not transfer the Stock Option under any circumstances (except upon on rights your heir might have in the Stock Option upon your death). If you wish to make this undertaking, you must sign below and return this executed Addendum to the address listed above.
Employee Signature:        _______________________________

Employee Printed Name:    _______________________________
    
BRAZIL

1.    Compliance with Law. By accepting the Stock Option, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the Stock Option, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.





-Rev 1.2018


EXHIBIT 10.1


2.    Labor Law Policy and Acknowledgement. This provision supplements Section 12 of the Agreement:

By accepting the Stock Option, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment; and (iii) the income from the Stock Option, if any, is not part of your remuneration from employment.

CANADA

1.    Use of Previously Owned Shares. Notwithstanding any provision in Section 3 of the Agreement or the Plan to the contrary, if you are resident in Canada, you may not use previously-owned shares of Stock to pay the Grant Price or any Tax-Related Items in connection with the Stock Option.

2.    Personal Data. This provision supplements Section 11 of the Agreement:

You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors. You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.

3.    Securities Law Information. You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares are listed (i.e., the New York Stock Exchange).

4.    Language Consent. The following provision will apply if you are a resident of Quebec:

The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Les parties reconnaissent avoir exigé la rédaction en anglais de la présente convention, ainsi que de tous documents, avis et procédures judiciaires, exécutés, donnés ou intentés en vertu de, ou liés directement ou indirectement à, la présente convention.



-Rev 1.2018


EXHIBIT 10.1


CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

1.    Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

2.     Limitations on Exercisability Following Termination of Employment. Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your Stock Option will no longer be exercisable after the earlier of: (i) the period set forth in Section 4 of the Agreement; (ii) the last day of the 90 day period beginning on the date of termination of employment (or such earlier date as may be required by China State Administration of Foreign Exchange (“SAFE”)); and (iii) the Expiration Date specified in Section 2 of the Agreement.

3.    Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may need to be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company and its Affiliates in the future in order to facilitate compliance with exchange control requirements in China.

4.    Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.





-Rev 1.2018


EXHIBIT 10.1


The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

COLOMBIA

Nature of Grant. This provision supplements Section 12 of the Agreement:
You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.

COSTA RICA

No country-specific provisions.

CZECH REPUBLIC

No country-specific provisions.

DENMARK

Treatment of Stock Option Upon Termination of Employment. Notwithstanding any provisions in the Agreement to the contrary, if you are determined to be an “Employee” as defined in Section 2 of the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the “Stock Option Act”), the treatment of the Stock Option upon your termination of employment shall be governed by Section 4 and 5 of the Stock Option Act. However, if the provisions in the Agreement or the Plan governing the treatment of the Stock Option upon a termination are more favorable, the provisions of the Agreement or the Plan will govern. You acknowledge having received an “Employer Information Statement” in Danish.

FINLAND

No country-specific provisions.

FRANCE

1.    Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-177-1 and seq. of the French commercial code.



-Rev 1.2018


EXHIBIT 10.1


2.    Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

GERMANY

No country-specific provisions.

GREECE

No country-specific provisions.

HONG KONG

1.    Lapse of Restrictions. If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.

2.    IMPORTANT NOTICE/WARNING. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Stock Option and shares of Stock issued upon exercise do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong. The Units are intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.

3.    Wages. The Stock Option and shares of Stock subject to the Stock Option do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

4.    Nature of Scheme. You understand that the Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”).


-Rev 1.2018


EXHIBIT 10.1





INDIA

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

INDONESIA

No country-specific provisions.

IRELAND

No country-specific provisions.

ITALY

1.    Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

2.    Plan. This provision supplements Section 12 of the Agreement: You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement: Grant of Stock Option, Exercise of Stock Option, Termination of Employment, Recoupment Policy, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.
JAPAN

No country-specific provisions.

LEBANON

Securities Law Information. The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.

MALAYSIA

1.    Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board. You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board. (You may contact your Employer to request a form letter for this purpose.) You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.

-Rev 1.2018


EXHIBIT 10.1



2.    Consent to Collection, Processing and Transfer of Personal Data. This provision replaces Section 11 of the Agreement in its entirety:

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.

You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the
Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian Opsyen saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan.
Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua Opsyen saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (“Data”). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan

-Rev 1.2018


EXHIBIT 10.1


United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com. You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon exercise of the Stock Option may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Stock Options or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in

pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com. Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad Opsyen mungkin didepositkan. Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan


-Rev 1.2018


EXHIBIT 10.1


the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.
Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.

dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan Opsyen saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.










-Rev 1.2018


EXHIBIT 10.1


MEXICO

1.    Acknowledgement of the Agreement. By accepting the Stock Option, you acknowledge that have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed. You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum. You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in Section 12 of the Agreement, which clearly provide as follows:
(1)
Your participation in the Plan does not constitute an acquired right;
(2)
The Plan and your participation in it are offered by the Company on a wholly discretionary basis;
(3)
Your participation in the Plan is voluntary; and
(4)
The Company and its Affiliates are not responsible for any decrease in the value of any shares of Common Stock acquired at exercise of the Stock Option.
Reconocimiento del Contrato. Al aceptar la Opción, Usted reconoce que ha recibido una copia del Plan y del contrato, incluyendo este Apéndice, mismos que ha revisado. Usted reconoce, además, que acepta todas las disposiciones del Plan, y del contrato, incluyendo este Apéndice. También reconoce que ha leído y aprueba de forma expresa los términos y condiciones establecidos en la sección doce 12 del contrato que claramente dispone lo siguiente:
(1)
Su participación en el Plan no constituye un derecho adquirido;
(2)
El Plan su participación en el mismo son ofrecidos por la Compañía de forma totalmente discrecional;
(3)
Su participación en el Plan es voluntaria; y
(4)
La Compañía y sus afiliados no son responsables por cualquier disminución en el valor de las Acciones adquiridas al momento de tener derecho conforme a la Opción.
2.    Labor Law Acknowledgement and Policy Statement. By accepting the Stock Option, you acknowledge that Boston Scientific Corporation, with registered offices at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, United States of America, is solely responsible for the administration of the Plan. You further acknowledge your participation in the Plan, the grant of the Stock Option and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (“Boston Scientific-Mexico”). Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and/or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its

-Rev 1.2018


EXHIBIT 10.1


termination shall not constitute a change or impairment of the terms and conditions of your employment.
You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and/or discontinue your participation in the Plan at any time, without any liability to you.
Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise.
Reconocimiento de Ley Laboral y Declaración de la Política. Al aceptar el Otorgamiento de la Opción, Usted reconoce que Boston Scientific Corporation, con oficinas registradas en 300 Boston Scientific Way, Marlborough, Massachusetts 01752, Estados Unidos de América, es únicamente responsable de la administración del Plan. Usted además reconoce que su participación en el Plan, la concesión de Opción y cualquier adquisición de acciones de conformidad con el Plan no constituyen una relación de trabajo entre Usted y Boston Scientific Corporation, ya que Usted está participando en el Plan sobre una base totalmente comercial y su único patrón es una sociedad mercantil Mexicana (“Boston Scientific-México”). Derivado de lo anterior, Usted expresamente reconoce que el Plan y los beneficios que pueden derivarle de la participación en el Plan no establecen ningún derecho entre Usted y su Patrón, Boston Scientific-México, y no forman parte de las condiciones de trabajo y/o prestaciones otorgadas por Boston Scientific-México, y cualquier modificación al Plan o su terminación no constituirá un cambio o perjuicio de los términos y condiciones de su trabajo.
Usted además entiende que su participación en el Plan es resultado de una decisión unilateral y discrecional de Boston Scientific Corporation, por lo tanto Boston Scientific Corporation se reserva el derecho absoluto de modificar el Plan y/o discontinuar su participación en el Plan en cualquier momento, sin responsabilidad alguna para hacia Usted.
Finalmente, Usted declara que no se reserva acción o derecho alguno para presentar una reclamación o demanda en contra de Boston Scientific Corporation por cualquier compensación o daño o perjuicio en relación con cualquier disposición del Plan o los beneficios derivados del Plan y, por lo tanto, otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliados, afiliadas, sucursales, oficinas de representación, accionistas, directores, funcionarios, agentes y representantes con respecto a cualquier reclamación o demanda que pudiera surgir.

-Rev 1.2018


EXHIBIT 10.1




NETHERLANDS

Waiver of Termination Rights. By accepting the Stock Option, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with Boston Scientific Corporation and the Employer for any reason whatsoever, insofar as those rights result or may result from (i) the loss or diminution in value of such rights or entitlements under the Plan, or (ii) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.

NEW ZEALAND

Securities Law Notice

Warning

This is an offer of a Stock Option which, upon exercise and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.

If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid. You may lose some or all of your investment.

New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.

Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the exercise and settlement of the Stock Option, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock.
No interest in any Stock Option may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The shares of Stock are quoted on the New York Stock Exchange. This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you invested. The price will depend on the demand for the shares.


-Rev 1.2018


EXHIBIT 10.1


You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below:
1.
Boston Scientific Corporation’s most recent Annual Report (Form 10-K):
https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.
Boston Scientific Corporation’s most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

3.
The Boston Scientific Corporation 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.
Boston Scientific Corporation Non-Qualified Stock Option Grant and 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

A copy of the above documents will be sent to you free of charge on written request being mailed to: Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

NORWAY

No country-specific provisions.

PHILIPPINES

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

POLAND

No country-specific provisions.


-Rev 1.2018


EXHIBIT 10.1







PORTUGAL

Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.
Conhecimento da Lingua. Por meio do presente, eu declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano e no Acordo.

PUERTO RICO

No country-specific provisions.

RUSSIA

1.    U.S. Transaction. You understand that the Stock Option shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States. Upon exercise of the Stock Option, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States. In no event will shares of Stock be delivered to you in Russia; instead, all shares of Stock acquired upon exercise of the Stock Option will be maintained on your behalf in the United States. You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.
2.    Cashless Exercise Provision. Notwithstanding anything to the contrary in the Agreement, depending on the development of local regulatory requirements, the Company reserves the right to restrict exercise of your Stock Option to a cashless exercise through a licensed securities broker acceptable to the Company, such that all shares of Stock subject to the exercised Stock Option will be sold immediately upon exercise and the proceeds of sale, less the Grant Price, any Tax-Related Items and broker’s fees or commissions, will be remitted to you in accordance with any applicable exchange control laws and regulations.

3.    Repatriation Requirements. You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations. Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.


-Rev 1.2018


EXHIBIT 10.1


SINGAPORE

Private Placement. The grant of the Stock Option under the Plan is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Stock Option is subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the Stock Option in Singapore, unless such sale or offer in is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the SFA.

SOUTH AFRICA

1.    Responsibility for Taxes. This provision supplements Section 9 of the Agreement:
You are responsible for immediately notifying the Employer of the amount of any gain realized at exercise of the Stock Option. If you fail to advise the Employer of such gain, you may be liable for a fine.

2.    Securities Law Notice. In compliance with South African securities law, the documents listed below are available for review on the Company’s external and internal sites at the web addresses listed below:
a.
Boston Scientific Corporation’s most recent Annual Report (Form 10-K):
https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

b.
The Boston Scientific Corporation 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
c.
Boston Scientific Corporation Non-Qualified Stock Option Grant and 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn: Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.

-Rev 1.2018


EXHIBIT 10.1



SOUTH KOREA

Consent to Collection, Processing and Transfer of Personal Data. By electronically accepting this Agreement:

1.
You agree to the collection, use, processing and transfer of Data as described in Section 11 of the Agreement; and

2.
You agree to the processing of your unique identifying information (resident registration number) as described in Section 11 of the Agreement.

SPAIN

Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement.

In accepting the Stock Option grant, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.

You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Stock Options under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis. Consequently, you understand that the Stock Option is granted on the assumption and condition that the Stock Option and the shares of Stock acquired upon exercise of the Stock Option shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the Stock Option grant shall be null and void.

You understand and agree that, as a condition of the Stock Option grant, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Stock Option to the extent the Stock Option has not vested as of date you cease active employment. In particular, you understand and agree that any unvested Stock Option as of the date you cease active employment and any vested portion of the Stock Option not exercised within the post-termination exercise period set out in the Agreement will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’

-Rev 1.2018


EXHIBIT 10.1


Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985. You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Stock Option.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

SWEDEN

No country-specific provisions.

SWITZERLAND

Securities Law Information. The offer of the Stock Option is considered a private offering in Switzerland and is therefore not subject to registration in Switzerland. Neither this document nor any other materials relating to the Stock Option constitutes a prospectus as such term is understood pursuant to article 652a of the Swiss Code of Obligations, and neither this document nor any other materials relating to the Stock Option may be publicly distributed nor otherwise made publicly available in Switzerland.

TAIWAN

Securities Law Information. This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees. The Award is not a public offer of securities by a Taiwanese company.

THAILAND

No country-specific provisions.

TURKEY

Securities Law Information. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.

UNITED ARAB EMIRATES

Securities Law Information. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should

-Rev 1.2018


EXHIBIT 10.1


conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of the Agreement or the Plan, you should consult an authorized financial advisor.

UNITED KINGDOM

1.     Income Tax and Social Insurance Contribution Withholding. The following provision shall supplement Section 9 of the Agreement:
Without limitation Section 9 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

2.    Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.

-Rev 1.2018

EX-10.2 3 exhibit102-formofdsuagreem.htm EXHIBIT 10.2 Exhibit
EXHIBIT 10.2




Boston Scientific Corporation 2011 Long-Term Incentive Plan

Global Deferred Stock Unit Award Agreement

%%OPTION_DATE,’Month DD, YYYY’%-%




%%FIRST_NAME%-% %%LAST_NAME%-%
(“Participant”)






















EMPLOYEE COPY
PLEASE RETAIN FOR YOUR RECORDS






-Rev 1.2018


EXHIBIT 10.2


Boston Scientific Corporation 2011 Long-Term Incentive Plan
Global Deferred Stock Unit Award Agreement

This Global Deferred Stock Unit Award Agreement (the “Agreement”), dated %%OPTION_DATE,’Month DD, YYYY’%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the Award of Deferred Stock Units by the Committee under the Boston Scientific Corporation 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan. The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.

1.    Grant of Units. The Committee hereby grants you that number of Deferred Stock Units as set forth in this Agreement (the “Units”). Each Unit represents the Company’s commitment to issue to you one share of Stock subject to the conditions set forth in this Agreement. This Award is granted pursuant to and is subject to the provisions of the Plan and the terms and conditions of this Agreement and any applicable Addendum.

2.    Vesting. The Units shall vest and shares of Stock will be issued to you according to the vesting schedule set forth in this Agreement. Except as otherwise provided in Sections 4, 5, 6, 7 and 8 below, the Units will vest, subject to the conditions described in Section 7 below, in approximately equal annual installments on each of the five (5) consecutive anniversaries of the Grant Date, beginning on the first anniversary of the Grant Date. Shares of Stock for Units that vest in accordance with this Section 2 will be delivered to you within fifteen (15) days after the applicable vesting date but in no event later than the last day of the calendar year that includes the applicable vesting date. No shares of Stock shall otherwise be issued to you prior to the date on which the Units vest. Notwithstanding anything in the Agreement to the contrary, the Company may, in its sole discretion, settle the Units in the form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company and/or any of its Affiliates to obtain the approval of or complete any legal or regulatory filing with any governmental and/or regulatory body in your country of residence (or country of employment, if different). Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require you to sell such Stock immediately or within a specified time following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).

3.    Participant’s Rights in Stock. The shares of Stock, if and when issued to you pursuant to this Agreement, shall be registered in your name and evidenced in a manner as determined by the Company, in its sole discretion. Under no circumstance will you be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested with respect to such shares of Stock and the shares of Stock have been issued to you.



-Rev 1.2018


EXHIBIT 10.2


4.    Death. In the event you terminate employment by reason of death, any Units that have not vested prior to the date of your death shall immediately vest and shares of Stock shall be issued in accordance with your will or the laws of descent and distribution. Shares of Stock for Units which vest under this Section 4 will be delivered within sixty (60) days after your employment termination date.

5.    Retirement. If you terminate employment by reason of your Retirement, any Units that have not vested prior to the date of your Retirement shall immediately vest and shares of Stock shall be issued to you, provided you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date. In the event that your Retirement occurs prior to the first anniversary of the Grant Date, all unvested Units shall immediately terminate and be forfeited in their entirety. Shares of Stock for Units which vest under this Section 5 will be delivered within thirty (30) days after your employment termination date.

In this regard, if you are a local national of and employed in a country that is a member of the European Union, the grant of the Units and the terms and conditions governing the Units are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Units is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

6.     Disability. If you terminate employment by reason of your Disability (as the term is defined in the Plan or determined under local law), any Units that have not vested prior to the date of your termination by reason of Disability shall immediately vest and shares of Stock shall be issued to you. Shares of Stock for Units which vest under this Section 6 will be delivered within thirty (30) days after your employment termination date.

7.    Other Termination of Employment; Certain Vesting Conditions. If your employment terminates for any reason other than death, Retirement or Disability, any Units that have not vested prior to the date of your termination shall terminate and be forfeited on the effective date of such termination, except if your employment terminates for Cause, in which case, all unvested Units shall be forfeited upon notice to you of your termination for Cause. Subject to Sections 4, 5 and 6 of this Agreement, the issuance of shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the applicable anniversary of the Grant Date as set forth in Section 2 above. For purposes of the vesting conditions set forth in this Agreement, the effective date of your termination shall be deemed to be the last day of your active service with the Company or an Affiliate (if applicable). Notwithstanding anything to the contrary in the Plan or this Agreement, and for purposes of clarity, the date of your termination of employment shall not be extended by any statutory or common law notice of termination period.

-Rev 1.2018


EXHIBIT 10.2





8.    Change in Control of the Company. In the event you are employed by the Company or an Affiliate at the time of a Change in Control, any Units that have not vested prior to the Change in Control shall immediately vest and shares of Stock will be issued to you immediately prior to the Change in Control; provided, however, that if you have entered into a Change in Control agreement with the Company, the Units will vest according to the provisions of the Change in Control agreement. In the event you have terminated employment with the Company or an Affiliate prior to a Change in Control as a result of death, Disability, or Retirement occurring on or after the first anniversary of the Grant Date, and the Change in Control occurs following your termination of employment, shares of Stock for any Units that have vested under Section 4, 5 or 6 but which have not yet been issued will be issued immediately prior to the Change in Control. Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of a Change in Control on outstanding Awards which is in effect as of the Change in Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii); provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.

9.    Recoupment Policy.

(a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

(i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

(1)    “Current Executive Officer” means any individual currently designated as an “officer” by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

(2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.


-Rev 1.2018


EXHIBIT 10.2


(3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “officer” by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

(4)    “Recovery” means the forfeiture or cancellation of unvested Units.

(b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

10.    Consideration for Stock. The shares of Stock subject to the Units are intended to be issued for no cash consideration.

11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (a) all federal, state and local laws and regulations, as the Company may deem applicable, have been complied with; (b) the shares have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (c) all other legal matters in connection with the issuance and delivery of the shares have been approved by the Company’s legal department.

12.    Transferability; Restrictions on Shares; Legend on Certificate. Until the vesting conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Committee, the Units awarded under this Agreement are not transferable and you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.


-Rev 1.2018


EXHIBIT 10.2


13.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

The Units are intended to comply with or be exempt from the requirements of Code Section 409A. The Plan and this Agreement shall be administered and interpreted in a manner consistent

-Rev 1.2018


EXHIBIT 10.2


with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of Stock, shall be based on the value of the Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

14.    Repatriation and Legal/Tax Compliance Requirements. If you are resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Units) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).
    
15.    Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or

-Rev 1.2018


EXHIBIT 10.2


directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.

You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

Finally, upon request of the Company or the Employer, you agree to provide an executed data privacy consent form (or any other agreements or consents that may be required by the Company and/or the Employer) to the Company and/or the Employer that the Company and/or the Employer may deem necessary to obtain from you for the purpose of administering your participation in the Plan in compliance with the data privacy laws in your country, either now or in the future. You understand and agree that you will not be able to participate in the Plan if you fail to provide any such consent or agreement requested by the Company and/or the Employer.





-Rev 1.2018


EXHIBIT 10.2


16.    Nature of Grant. By participating in the Plan, you acknowledge, understand and agree that:

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying Shares, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;





-Rev 1.2018


EXHIBIT 10.2


(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

17.    Not a Public Offering. The grant of the Units under the Plan is not intended to be a public offering of securities in your country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law, and the grant of the Units is not subject to the supervision of the local securities authorities.

18.    No Advice Regarding Grant. No Employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock subject to the Units. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Units and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

19.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

20.    Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations

-Rev 1.2018


EXHIBIT 10.2


in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.

21.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.
    
22.    Language. If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

23.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the “Addendum”). Further, if you transfer your residence and/or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Addendum shall constitute part of this Agreement.

24.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.




-Rev 1.2018


EXHIBIT 10.2


25.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

26.    Award Subject to the Plan; Conflicts. The Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Committee specifically for the grant described herein. Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Units granted pursuant to this Agreement as the Committee may determine are in the best interests of the Company. You hereby accept the Units subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.

27.    Governing Law and Venue The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston, or the federal courts for the United States for the District of Massachusetts and no other courts where the grant of the Units is made and/or to be performed.

28.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

29.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

30.     Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

31.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be the one and the same instrument.

-Rev 1.2018


EXHIBIT 10.2


SIGNATURE PAGE

IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Participant have executed and delivered this Agreement as a sealed instrument as of the date and year first above written.


Number of Deferred Stock Units: %%TOTAL_SHARES_GRANTED%-%

Vesting Schedule
20%
%%VEST_DATE_PERIOD1%-%
20%
%%VEST_DATE_PERIOD2%-%
20%
%%VEST_DATE_PERIOD3%-%
20%
%%VEST_DATE_PERIOD4%-%
20%
%%VEST_DATE_PERIOD5%-%



BOSTON SCIENTIFIC CORPORATION        
mma01.gif
Michael F. Mahoney
President and Chief Executive Officer


PARTICIPANT



By: SIGNED BY ELECTRONIC SIGNATURE


By electronically accepting the Award, you agree that (i) such acceptance constitutes your electronic signature in execution of this Agreement; (ii) you agree to be bound by the provisions of the Plan, the Agreement and the Addendum; (iii) you have reviewed the Plan, the Agreement and the Addendum in their entirety, have had an opportunity to obtain the advice of counsel prior to accepting the Award and fully understand all of the provisions of the Plan, the Agreement and the Addendum; (iv) you have been provided with a copy or electronic access to a copy of the U.S. prospectus for the Plan and the tax supplement to the U.S. prospectus for your country, if applicable; and (v) you hereby agree to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Agreement and the Addendum.

-Rev 1.2018


EXHIBIT 10.2



BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO DEFERRED STOCK UNITS GRANTED
PURSUANT TO THE 2011 LONG-TERM INCENTIVE PLAN

In addition to the terms of the Plan and the Agreement, the Units are subject to the following additional terms and conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 23 of the Agreement, if you transfer your residence and/or employment to another country reflected in the Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).

ARGENTINA

Type of Offering. Neither the grant of the Units, nor the issuance of shares of Stock subject to the grant, constitutes a public offering. The offering of the Plan is a private placement and is not subject to the supervision of any Argentine governmental authority.

AUSTRALIA

1.    Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.

2.    Tax Information. The Plan is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the “Act”) applies (subject to the conditions in that Act).

AUSTRIA

No country-specific provisions.

BELGIUM

No country-specific provisions.


-Rev 1.2018


EXHIBIT 10.2



BRAZIL

1.    Compliance with Law. By accepting the Units, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the vesting of the Units, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.

2.    Labor Law Policy and Acknowledgement. This provision supplements Section 16 of the Agreement:

By accepting the Units, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment; and (iii) the income from the Units, if any, is not part of your remuneration from employment.

CANADA

1.    Settlement in Shares. Notwithstanding anything to the contrary in the Agreement or the Plan, all Units shall be settled only in shares of Stock (and shall not be settled in cash).

2.    Personal Data. This provision supplements Section 15 of the Agreement:

You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors. You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.

3.    Securities Law Information. You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares are listed (i.e., the New York Stock Exchange).

4.    Language Consent. The following provision will apply if you are a resident of Quebec:

The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Les parties reconnaissent avoir exigé la rédaction en anglais de la présente convention, ainsi que de tous documents, avis et procédures judiciaires, exécutés, donnés ou intentés en vertu de, ou liés directement ou indirectement à, la présente convention.


-Rev 1.2018


EXHIBIT 10.2


CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

1.    Shares of Stock Must Be Held with Designated Broker. All shares of Stock issued upon settlement of your Units will be deposited into a personal brokerage account established with the Company’s designated broker, E*TRADE (or any successor broker designated by the Company), on your behalf. You understand that you may sell the shares of Stock at any time after they are deposited in such account, however, you may not transfer the shares of Stock out of the brokerage account.

2.    Mandatory Sale of Shares Following Termination of Employment. You are required to sell all shares of Stock acquired upon vesting of the Units no later than 90 days following your termination of employment with the Company and its Affiliates (or such earlier date as may be required by the China State Administration of Foreign Exchange (“SAFE”)), in which case, this Addendum shall give the Company the authority to issue sales instructions on your behalf). If any shares remain outstanding on the 90th day following your employment termination date (or such earlier date as may be required by SAFE), you hereby direct, instruct and authorize the Company to issue sale instructions on your behalf.

You agree to sign any additional agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds and other exchange control matters noted below) and shall otherwise cooperate with the Company with respect to such matters. You acknowledge that neither the Company nor the designated brokerage firm is under any obligation to arrange for such sale of shares of Stock at any particular price (it being understood that the sale will occur in the market) and that broker’s fees and similar expenses may be incurred in any such sale. In any event, when the shares of Stock are sold, the sale proceeds, less any tax withholding, any broker’s fees or commissions, and any similar expenses of the sale will be remitted to you in accordance with applicable exchange control laws and regulations.

3.    Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays

-Rev 1.2018


EXHIBIT 10.2


in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.

4.    Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

COLOMBIA

Nature of Grant. This provision supplements Section 16 of the Agreement:
You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.

COSTA RICA

No country-specific provisions.

CZECH REPUBLIC

No country-specific provisions.

DENMARK

Treatment of Units upon Termination of Service. Notwithstanding any provisions in the Agreement to the contrary, if you are determined to be an “Employee” as defined in section 2 of the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the “Stock Option Act”), the treatment of the Units upon your termination of employment shall be governed by Section 4 and 5 of the Stock Option Act. However, if the provisions in the Agreement or the Plan governing the treatment of the Units upon a termination are more favorable, the provisions

-Rev 1.2018


EXHIBIT 10.2


of the Agreement or the Plan will govern. You acknowledge having received an “Employer Information Statement” in Danish.

FINLAND

No country-specific provisions.

FRANCE

1.    Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. of the French commercial code.

2.    Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

GERMANY

No country-specific provisions.

GREECE

No country-specific provisions.

HONG KONG

1.    Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Plan, the Units shall be settled only in shares of Stock (and may not be settled in cash).

2.    Lapse of Restrictions. If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.

3.    IMPORTANT NOTICE/WARNING. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Units and shares of Stock issued at vesting do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong. The Units

-Rev 1.2018


EXHIBIT 10.2


are intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.

4.    Wages. The Units and shares of Stock subject to the Units do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

5.    Nature of the Program. The Company specifically intends that the Plan will not be treated as an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”). To the extent any court, tribunal or legal/regulatory body in Hong Kong determines that the Plan constitutes an occupational retirement scheme for the purposes of ORSO, the grant of the Units shall be null and void.

INDIA

No country-specific provisions.

INDONESIA

No country-specific provisions.

IRELAND

No country-specific provisions.

ISRAEL

1.    Immediate Sale Restriction. Pursuant to Section 2 of the Agreement, when the Units vest, you understand and agree that all shares of Stock issued upon vesting immediately must be sold. You acknowledge and agree that the Company is authorized to issue sales instructions to the Company’s designated broker on your behalf pursuant to this authorization, and you expressly authorize the broker to complete the sale. You also agree to sign any agreements, forms and/or consents that may be reasonably requested by the Company or the Company’s designated broker to effectuate the sale of the shares of Stock and to cooperate with the Company and the Company’s designated broker with respect to such matters. When the shares of Stock are sold, a portion of the resulting sale proceeds will be used to cover any Tax-Related Items required to be withheld and any brokerage fees and expenses associated with the sale. The remaining proceeds will be paid to you as soon as practicable.

You acknowledge that neither the Company nor the Company’s designated broker is under any obligation to arrange for the sale of the shares of Stock at any particular price (it being understood that the sale will occur in the open market) and that brokerage fees and similar expenses may be incurred in any such sale. Due to fluctuations in the Stock price and/or applicable exchange rates between the date the Units vest and (if later) the date on which the shares of Stock are sold, the amount of proceeds ultimately may be more or less than the market value of the shares of Stock on the date the Units vest. You understand and agree that the Company assumes no liability for any

-Rev 1.2018


EXHIBIT 10.2


fluctuations in the Stock price and/or any applicable exchange rate.

2.    Securities Law Information.  The grant of Units under the Plan does not constitute a public offering under the Securities Law, 1968.

ITALY

Plan. This provision supplements Section 16 of the Agreement:
You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement: Vesting, Other Termination of Employment, Certain Vesting Conditions, Recoupment Policy, Issuance of Stock, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.
JAPAN

No country-specific provisions.

LEBANON

Securities Law Information. The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.

MALAYSIA

1.    Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board. You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board. (You may contact your Employer to request a form letter for this purpose.) You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.













-Rev 1.2018


EXHIBIT 10.2




2.    Consent to Collection, Processing and Transfer of Personal Data. This provision replaces Section 15 of the Agreement in its entirety:

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.
You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.
You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request
Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian unit saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan.
Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua unit saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (“Data”). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika

-Rev 1.2018


EXHIBIT 10.2


a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com. You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon vesting of the Units may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you

Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad unit mungkin didepositkan. Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan


-Rev 1.2018


EXHIBIT 10.2


understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.
Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.

pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan unit saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.


-Rev 1.2018


EXHIBIT 10.2






MEXICO

1.    Acknowledgement of the Agreement. By accepting the Units, you acknowledge that you have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed. You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum. You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in the “Nature of Grant” section of the Agreement, which clearly provide as follows:
(1)
Your participation in the Plan does not constitute an acquired right;
(2)
The Plan and your participation in it are offered by the Company on a wholly discretionary basis;
(3)
Your participation in the Plan is voluntary; and
(4)
The Company and its Affiliates are not responsible for any decrease in the value of any Shares acquired at vesting of the Units.
Reconocimiento del Contrato. Al aceptar los Unidades, usted reconoce que ha recibido una copia del Plan y del Contrato con inclusión de este Apéndice, que le ha examinado. Usted reconoce, además, que usted acepta todas las disposiciones del Plan y del Contrato. Usted también reconoce que ha leído y, concretamente, y aprobar de forma expresa los términos y condiciones establecidos en la “Naturaleza del Otorgamiento” que claramente dispone lo siguiente:
(1)
Su participación en el Plan no constituye un derecho adquirido;
(2)
El Plan y su participación en el Plan se ofrecen por Boston Scientific Corporation en su totalidad sobre una base discrecional;
(3)
Su participación en el Plan es voluntaria; y
(4)
Boston Scientific Corporation y sus afiliadas no son responsables de ninguna disminución en el valor de las acciones adquiridas en la adquisición de los Unidades.
2.    Labor Law Acknowledgement and Policy Statement. By accepting the Units, you acknowledge that Boston Scientific Corporation, with registered offices at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, United States of America, is solely responsible for the administration of the Plan. You further acknowledge that your participation in the Plan, the grant of Units and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the

-Rev 1.2018


EXHIBIT 10.2


Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (“Boston Scientific-Mexico”). Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and the Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and/or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and/or discontinue your participation in the Plan at any time, without any liability to you.
Finally, you hereby declare that you do not reserve to you any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation, its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise.
Reconocimiento de Ausencia de Relación Laboral y Declaración de la Política. Al aceptar los Unidades, usted reconoce que Boston Scientific Corporation, con oficians registradas on 300 Boston Scientific Way, Marlborough, Massachusetts 01752, Estados Unidos de América, es el único responsable de la administración del Plan. Además, usted acepta que su participación en el Plan, la concesión de los Unidades y cualquier adquisición de acciones en el marco del Plan no constituyen una relación laboral entre usted y Boston Scientific Corporation porque usted está participando en el Plan en su totalidad sobre una base comercial y su único empleador es una sociedad mercantil Mexicana (“Boston Scientific-Mexico”). Derivado de lo anterior, usted expresamente reconoce que el Plan y los beneficios que pueden derivarse de la participación en el Plan no establece ningún derecho entre usted y su Empleador, Boston Scientific-Mexico, y que no forman parte de las condiciones de empleo y / o prestaciones previstas por Boston Scientific-Mexico, y cualquier modificación del Plan o la terminación de su contrato no constituirá un cambio o deterioro de los términos y condiciones de su empleo.
Además, usted entiende que su participación en el Plan es causada por una decisión discrecional y unilateral de Boston Scientific Corporation, por lo que Boston Scientific Corporation se reserva el derecho absoluto a modificar y/o suspender su participación en el Plan en cualquier momento, sin responsabilidad alguna para con usted.
Finalmente, usted manifiesta que no se reserva ninguna acción o derecho que origine una demanda en contra de Boston Scientific Corporation, por cualquier compensación o daño en relación con cualquier disposición del Plan o de los beneficios derivados del mismo, y en consecuencia usted otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliadas, sucursales, oficinas de representación, sus accionistas, directores, agentes y representantes legales con respecto a cualquier demanda que pudiera surgir.

-Rev 1.2018


EXHIBIT 10.2


NETHERLANDS

Waiver of Termination Rights. By accepting the Units, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with the Company and the Employer for any reason whatsoever, insofar as those rights result or may result from (a) the loss or diminution in value of such rights or entitlements under the Plan, or (b) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.

NEW ZEALAND

Securities Law Notice.

Warning

This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.

If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid. You may lose some or all of your investment.

New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.

Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock.
No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The shares of Stock are quoted on the New York Stock Exchange. This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you invested. The price will depend on the demand for the shares of Stock.

You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below:

-Rev 1.2018


EXHIBIT 10.2


1.
Boston Scientific Corporation’s most recent Annual Report (Form 10-K):
https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.
Boston Scientific Corporation’s most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

3.
The Boston Scientific Corporation 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.
Boston Scientific Corporation Deferred Stock Unit Award and 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

A copy of the above documents will be sent to you free of charge on written request being mailed to: Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

NORWAY

No country-specific provisions.

PHILIPPINES

Settlement in Cash. Pursuant Section 2 of the Agreement, the Company shall settle your Units in the form of a cash payment unless, at the time of vesting, share settlement does not trigger the need for any approval from and/or filing with the Philippines Securities and Exchange Commission.

POLAND

No country-specific provisions.

PORTUGAL

Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.
Conhecimento da Lingua. Por meio do presente, eu declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano e no Acordo.


-Rev 1.2018


EXHIBIT 10.2


PUERTO RICO

No country-specific provisions.

RUSSIA
1.    U.S. Transaction. You understand that the Units shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States. Upon vesting of the Units, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States. In no event will shares of Stock be delivered to you in Russia; instead, all shares of Stock acquired upon vesting of the Units will be maintained on your behalf in the United States. You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.
2.    Repatriation Requirements. You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations. Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.
Depending on the development of local regulatory requirements, the Company reserves the right to settle the Units in cash and/or to pay any proceeds related to the Units to you through local payroll.
SINGAPORE

Private Placement. The grant of the Units is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Units are subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the grant in Singapore, unless such sale or offer is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.

SOUTH AFRICA

1.    Responsibility for Taxes. This provision supplements Section 13 of the Agreement:
You are responsible for immediately notifying the Employer of the amount of any gain realized at vesting of the Units. If you fail to advise the Employer of such gain, you may be liable for a fine.


-Rev 1.2018


EXHIBIT 10.2


2.    Securities Law Notice. In compliance with South African securities law, the documents listed below are available for review on the Company’s external and internal sites at the web addresses listed below:
a.
Boston Scientific Corporation’s most recent Annual Report (Form 10-K):
https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

b.
The Boston Scientific Corporation 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
c.
Boston Scientific Corporation Deferred Stock Unit Award and 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn: Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.

SOUTH KOREA

Consent to Collection, Processing and Transfer of Personal Data. By electronically accepting this Agreement:

1.
You agree to the collection, use, processing and transfer of Data as described in Section 15 of the Agreement; and

2.
You agree to the processing of your unique identifying information (resident registration number) as described in Section 15 of the Agreement.

SPAIN

Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement.





-Rev 1.2018


EXHIBIT 10.2


In accepting the grant of Units, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.

You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis. Consequently, you understand that the Units are granted on the assumption and condition that the Units and the shares of Stock acquired upon vesting of the Units shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the grant of the Units shall be null and void.

You understand and agree that, as a condition of the grant of the Units, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Units to the extent the Units have not vested as of date that you cease active employment. In particular, you understand and agree that any unvested Units as of the date you cease active employment will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985. You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Award.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

SWEDEN

No country-specific provisions.


-Rev 1.2018


EXHIBIT 10.2






SWITZERLAND

Securities Law Information. The offer of the Units is considered a private offering in Switzerland and is therefore not subject to registration in Switzerland. Neither this document nor any other materials relating to the Units constitutes a prospectus as such term is understood pursuant to article 652a of the Swiss Code of Obligations, and neither this document nor any other materials relating to the Unit may be publicly distributed nor otherwise made publicly available in Switzerland.

TAIWAN

Securities Law Information. This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees. The Award is not a public offer of securities by a Taiwanese company.

THAILAND

No country-specific provisions.

TURKEY

Securities Law Information. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.

UNITED ARAB EMIRATES

Securities Law Information. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of the Agreement or the Plan, you should consult an authorized financial advisor.


-Rev 1.2018


EXHIBIT 10.2


UNITED KINGDOM

1.     Income Tax and Social Insurance Contribution Withholding. The following provision shall supplement Section 13 of the Agreement:

Without limitation Section 13 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

2.     Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.


-Rev 1.2018

EX-10.3 4 exhibit103-2018_tsrpsuxawa.htm EXHIBIT 10.3 Exhibit
EXHIBIT 10.3




Boston Scientific Corporation
 
 
Participant: %%FIRST_NAME%-% %%LAST_NAME%-%
Employee ID: %%EMPLOYEE_IDENTIFIER%-%
Award Type: Performance Share Unit Award Agreement
Plan Name: TSR PERFORMANCE SHARE PROGRAM -
 
 
 
Award Date: %%OPTION_DATE,’Month DD, YYYY’%-%
 
 
Total Granted: %%TOTAL_SHARES_GRANTED%-%





BOSTON SCIENTIFIC

INTENT TO GRANT

PERFORMANCE SHARE UNIT AWARD AGREEMENT


This Agreement, dated as of the %%OPTION_DATE,’Month DD, YYYY’%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation (the “Company”), in connection with the Award of Performance Share Units by the Company under the Boston Scientific Corporation 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the Plan or in the Total Shareholder Return Performance Share Program (the “Program”) for the period beginning January 1, 2018 and ending on December 31, 2020 (the “Performance Period”).
 
1.    Grant and Acceptance of Award. The Company hereby indicates its award to you that number of Performance Share Units (the “Units”) set forth herein this Agreement (the “Award”). Each Unit represents the Company’s commitment to issue to you shares of the Company’s common stock, par value $.01 per share (“Stock”), subject to certain eligibility, performance and other conditions set forth herein. The Award is intended to be granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan and the Program.


-Rev. 1.2018                                            TSR Program


EXHIBIT 10.3


2.    Eligibility Conditions upon Award of the Units. You hereby acknowledge the intent of the Company to award the Units subject to certain eligibility, performance and other conditions set forth herein.

3.    Satisfaction of Performance-Based Conditions. Subject to the eligibility conditions described in Section 7 of this Agreement, except as otherwise provided in Section 8 of this Agreement and Appendix B, and the satisfaction of the performance conditions set forth on Appendix A to this Agreement during the Performance Period, the Company intends to award shares of Stock hereunder to you at the end of the Performance Period. Shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period. Except as set forth in Section 8 of this Agreement, no shares of Stock in settlement of the Units shall be issued to you prior to the end of the Performance Period.

4.    Participant’s Rights in Stock. The shares of Stock, if and when issued hereunder, shall be registered in your name and evidenced in the manner as the Company may determine. During the period prior to the issuance of shares of Stock, you will have no rights of a stockholder of the Company with respect to the shares of Stock, including no right to receive dividends or vote the shares of Stock underlying each Award.

5.    Death or Disability. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability (as the term is defined in the Plan or determined under local law), prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period.

6.    Retirement. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement after December 31, 2018, but prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period on a prorated basis based on actual performance as determined at the first Committee meeting following the Performance Period. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months that you worked during the Performance Period (rounded up to the nearest whole month) divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with the terms of the Program. In the event that you terminate your employment due to Retirement prior to January 1, 2019, the Award shall be forfeited in its entirety.

7.    Other Termination of Employment -- Eligibility Conditions. If your employment with the Company and its Affiliates or subsidiaries is terminated or you separate from the Company and its Affiliates or subsidiaries for any reason other than death, Retirement or Disability, any Units that remain subject to eligibility conditions shall be void and no shares of Stock shall be issued. Except as set forth in Sections 5, 6 and 8, eligibility to be issued shares of Stock is conditioned on

-Rev. 1.2018                                            TSR Program


EXHIBIT 10.3


your continuous employment with the Company or an Affiliate through and on the last day of the Performance Period.

8.    Change in Control of the Company. Subject to the terms of any separate Change in Control or similar agreement to which you are bound, in the event you are employed by the Company or an Affiliate at the time of a Change in Control after December 31, 2018, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2020, as determined by the Committee immediately prior to the consummation of the Change in Control. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months during the Performance Period (rounded up to the nearest whole month) prior to the consummation of the Change in Control divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount as calculated in accordance with the terms of the Program. In the event that a Change in Control occurs prior to January 1, 2019, the Award shall be forfeited in its entirety.

In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability prior to a Change in Control and a Change in Control occurs after December 31, 2018, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2020, as determined by the Committee immediately prior to the consummation of the Change in Control.

In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement prior to a Change in Control after December 31, 2018 and a Change in Control occurs after December 31, 2018, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis as determined under Section 6 based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2020, as determined by the Committee immediately prior to the consummation of the Change in Control.

9.    Recoupment Policy.

(a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and if, in the judgment of the Board, you commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.


-Rev. 1.2018                                            TSR Program


EXHIBIT 10.3


(i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

(1)    “Current Executive Officer” means any individual currently designated as an “officer” by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

(2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

(3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “officer” by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

(4)    “Recovery” means the forfeiture or cancellation of unvested Units.

(b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

10.    Consideration for Stock. The shares of Stock are intended to be issued for no cash consideration.

11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (i) all federal, state and local laws and regulations as the Company may deem applicable have been complied with; (ii) the shares have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (iii) all other legal matters in connection with the issuance and delivery of the shares have been approved by the Company’s legal department.

12.    Tax Withholding. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back

-Rev. 1.2018                                            TSR Program


EXHIBIT 10.3


from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

The Units are intended to comply with or be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence,

-Rev. 1.2018                                            TSR Program


EXHIBIT 10.3


which is (i) in whole or in part, settled in cash and (ii) based on the value of shares of Stock, shall be based on the value of the shares of Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

13.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

14.    Limits on Transferability; Restrictions on Shares; Legend on Certificate. Until the eligibility conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement or by action of the Committee, the Units awarded hereunder are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by you. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

15.    Award Subject to the Plan and the Program. The Award to be made pursuant to this Agreement is made subject to the Plan and the Program. The terms and provisions of the Plan and the Program, as each may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan or the Program, the applicable terms and conditions of the Plan or Program will govern and prevail. However, no amendment of the Plan or the Program after the date hereof may adversely alter or impair the issuance of the shares of Stock to be made pursuant to this Agreement.

16.    No Rights to Continued Employment. The Company’s intent to issue the shares of Stock hereunder shall not confer upon you any right to continued employment or other association with the Company or any of its Affiliates or subsidiaries; and this Agreement shall not be construed in any way to limit the right of the Company or any of its subsidiaries or Affiliates to terminate your employment or other association with the Company or to change the terms of such employment or association at any time.





-Rev. 1.2018                                            TSR Program


EXHIBIT 10.3


17.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

18.    Appendix. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable appendix to the Agreement (the “Appendix”). Further, if you transfer your residence and/or employment to another country reflected in the Appendices to these Agreements, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Appendix shall constitute part of this Agreement.

    19.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the Commonwealth of Massachusetts, or the federal courts for the United States for the District of Massachusetts, and no other courts, where this Award is made and/or to be performed.

20.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

21.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

22.    Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.    

23.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]





-Rev. 1.2018                                            TSR Program


EXHIBIT 10.3


APPENDIX A

PLAN: 2011 LONG-TERM INCENTIVE PLAN


The Performance Share Units will pay out in shares of Stock in a range of 0% to 200% of the number of Performance Share Units as follows:

TSR Performance
Percentile Rank
Performance Share Units as a Percent of Target
90th Percentile or above
200%
80th Percentile
150%
50th Percentile
100%
30th Percentile
40%
Below 30th Percentile
0%




































-Rev. 1.2018                                            TSR Program


EXHIBIT 10.3


APPENDIX B

This Appendix B contains supplemental terms and conditions for awards of Units granted under the Boston Scientific Corporation 2011 Long-Term Incentive Plan (the “Plan”) to Participants who reside outside the United States or who are otherwise subject to the laws of a country other than the United States. Capitalized terms used but not defined herein shall have the same meanings ascribed to them in the Agreement.

Section I of this Appendix B contains special terms and conditions that govern the Units outside of the United States. Section II of this Appendix B includes special terms and conditions in the specific countries listed therein.

This Appendix B may also include information regarding exchange controls, taxation of awards and certain other issues of which you should be aware with respect to participation in the Plan. The information is based on the securities, exchange control, tax and other laws concerning the Units in effect as of January 2018. Such laws are often complex and change frequently; the information may be out of date at the time you vest in the Units or sell shares of Stock acquired under the Plan. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan.

In addition, this Appendix B is general in nature, does not discuss all of the various laws, rules and regulations which may apply to your particular situation and the Company does not assure you of any particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country apply to your specific situation.

Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transferred employment after the Award was granted or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner. In addition, the Company shall, in its sole discretion, determine to what extent the terms and conditions contained herein will apply under these circumstances (or the Company may establish alternative terms and conditions as may be necessary or advisable).

Section I.     All Countries Outside the United States

Nature of Grant. In accepting the grant, you acknowledge that:

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

-Rev. 1.2018                                            TSR Program


EXHIBIT 10.3



(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

-Rev. 1.2018                                            TSR Program


EXHIBIT 10.3



(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.
 
Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Unit grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.

You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your

-Rev. 1.2018                                            TSR Program


EXHIBIT 10.3


consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

Finally, upon request of the Company or the Employer, you agree to provide an executed data privacy consent form (or any other agreements or consents that may be required by the Company and/or the Employer) to the Company and/or the Employer that the Company and/or the Employer may deem necessary to obtain from you for the purpose of administering your participation in the Plan in compliance with the data privacy laws in your country, either now or in the future. You understand and agree that you will not be able to participate in the Plan if you fail to provide any such consent or agreement requested by the Company and/or the Employer.

Electronic Delivery of Documents. The Company may, in its sole discretion, decide to deliver any documents related to the Units granted under and participation in the Plan or future Units that may be granted under the Plan by electronic means or to request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.


-Rev. 1.2018                                            TSR Program


EXHIBIT 10.3


Section II.     Country-Specific Terms and Conditions

CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

1.    Shares of Stock Must Be Held with Designated Broker. All shares of Stock issued upon settlement of your Units will be deposited into a personal brokerage account established with the Company’s designated broker, E*TRADE (or any successor broker designated by the Company), on your behalf. You understand that you may sell the shares of Stock at any time after they are deposited in such account, however, you may not transfer the shares of Stock out of the brokerage account.

2.    Termination of Employment. Unless otherwise determined by the Committee in its sole discretion, in the event that the Units remain outstanding as of the 90th day following your termination of employment with the Company and its Affiliates, all such Units shall be cancelled on the 90th day following your termination of employment. Further, you are required to sell all shares of Stock acquired upon settlement of the Units no later than 90 days following your termination of employment with the Company and its Affiliates (or such earlier date as may be required by the China State Administration of Foreign Exchange (“SAFE”)), in which case, this Addendum shall give the Company the authority to issue sales instructions on your behalf). If any shares remain outstanding on the 90th day following your employment termination date (or such earlier date as may be required by SAFE), you hereby direct, instruct and authorize the Company to issue sale instructions on your behalf.

You agree to sign any additional agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds and other exchange control matters noted below) and shall otherwise cooperate with the Company with respect to such matters. You acknowledge that neither the Company nor the designated brokerage firm is under any obligation to arrange for such sale of shares of Stock at any particular price (it being understood that the sale will occur in the market) and that broker’s fees and similar expenses may be incurred in any such sale. In any event, when the shares of Stock are sold, the sale proceeds, less any tax withholding, any broker’s fees or commissions, and any similar expenses of the sale will be remitted to you in accordance with applicable exchange control laws and regulations.

3.    Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The

-Rev. 1.2018                                            TSR Program


EXHIBIT 10.3


proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.

4.    Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

FRANCE

1.    Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. of the French commercial code.

2.    Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

SINGAPORE

Private Placement. The grant of the Units is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Units are subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in

-Rev. 1.2018                                            TSR Program


EXHIBIT 10.3


Singapore, or any offer of such subsequent sale of the shares of Stock subject to the grant in Singapore, unless such sale or offer is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.
 

*    *    *    *    *
6678399-v6\GESDMS


-Rev. 1.2018                                            TSR Program

EX-10.4 5 exhibit104-2018_fcfpsuxawa.htm EXHIBIT 10.4 Exhibit
EXHIBIT 10.4




Boston Scientific Corporation
 
 
Participant: %%FIRST_NAME%-% %%LAST_NAME%-%
Employee ID: %%EMPLOYEE_IDENTIFIER%-%
Award Type: Performance Share Unit Award Agreement
Plan Name: FCF PERFORMANCE SHARE PROGRAM
 
 
Award Date: %%OPTION_DATE,’Month DD, YYYY’%-%
 
 
Total Granted: %%TOTAL_SHARES_GRANTED%-%



BOSTON SCIENTIFIC

INTENT TO GRANT

PERFORMANCE SHARE UNIT AWARD AGREEMENT


This Agreement, dated as of the %%OPTION_DATE,’Month DD, YYYY’%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation (the “Company”), in connection with the Award of Performance Share Units by the Company under the Boston Scientific Corporation 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the Plan or in the Free Cash Flow Performance Share Program (the “Program”) for the performance period beginning January 1, 2018 and ending on December 31, 2018 (the “Performance Period”) and the three-year service period beginning on January 1, 2018 and ending on December 31, 2020 (the “Service Period”).
 
1.    Grant and Acceptance of Award. The Company hereby indicates its award to you that number of Performance Share Units (the “Units”) set forth herein this Agreement (the “Award”). Each Unit represents the Company’s commitment to issue to you shares of the Company’s common stock, par value $.01 per share (“Stock”), subject to certain eligibility, performance and other conditions set forth herein. The Award is intended to be granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan and the Program.

2.    Eligibility Conditions upon Award of the Units. You hereby acknowledge the intent of the Company to award the Units subject to certain eligibility, performance and other conditions set forth herein.


-Rev. 1.2018                                            FCF Program


EXHIBIT 10.4


3.    Satisfaction of Performance-Based Conditions and Service Period. Subject to the eligibility conditions described in Section 7 of this Agreement, except as otherwise provided in Sections 5, 6 and 8 of this Agreement and Appendix B, and the satisfaction of the performance conditions set forth on Appendix A to this Agreement during the Performance Period, the Company intends to award shares of Stock hereunder to you at the end of the Service Period (December 31, 2020). Shares of Stock shall be issued within thirty (30) days following the end of the Service Period based on actual performance during the Performance Period as determined at the first Committee meeting following the end of the Performance Period. Except as set forth in Sections 5, 6 and 8 of this Agreement, no shares of Stock in settlement of the Units shall be issued to you prior to the end of the Service Period.

4.    Participant’s Rights in Stock. The shares of Stock, if and when issued hereunder, shall be registered in your name and evidenced in the manner as the Company may determine. During the period prior to the issuance of shares of Stock, you will have no rights of a stockholder of the Company with respect to the shares of Stock, including no right to receive dividends or vote the shares of Stock underlying each Award.

5.    Death or Disability. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability (as the term is defined in the Plan or determined under local law) on or before the end of the Performance Period, shares of Stock shall be issued during the period January 1, 2019 to March 15, 2019, based on actual performance as determined at the first Committee meeting following the Performance Period. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability after the end of the Performance Period, shares of Stock shall be issued within seventy (70) days following your termination of employment based on actual performance during the Performance Period.

6.    Retirement. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement after December 31, 2018, but prior to the end of the Service Period, shares of Stock shall be issued to you within seventy (70) days following your Retirement on a prorated basis based on actual performance. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of the Units set forth herein multiplied by (ii) the quotient of the number of full and partial months that you worked during the Service Period (rounded up to the nearest whole month) divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with the terms of the Program. In the event that you terminate your employment due to Retirement prior to January 1, 2019, the Award shall be forfeited in its entirety.

7.    Other Termination of Employment -- Eligibility Conditions. If your employment with the Company and its Affiliates or subsidiaries is terminated or you separate from the Company and its Affiliates or subsidiaries for any reason other than death, Retirement or Disability, any Units that remain subject to eligibility conditions shall be void and no shares of Stock shall be issued. Except as set forth in Sections 5, 6 and 8, eligibility to be issued shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the last day of the Service Period as set forth in Section 3 above.

-Rev. 1.2018                                            FCF Program


EXHIBIT 10.4



8.    Change in Control of the Company. Subject to the terms of any separate Change in Control or similar agreement to which you are bound, in the event you are employed by the Company or an Affiliate at the time of a Change in Control after December 31, 2018, but prior to the end of the Service Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis based on actual performance as determined by the Committee immediately prior to the consummation of the Change in Control. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months during the Service Period (rounded up to the nearest whole month) prior to the consummation of the Change in Control divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with terms of the Program. In the event that a Change in Control occurs prior to January 1, 2019, the Award shall be forfeited in its entirety. In the event that your employment with the Company or an Affiliate terminates prior to a Change in Control as a result of death, Disability, or Retirement occurring after December 31, 2018, and a Change in Control occurs after December 31, 2018, then shares of Stock for any Units that have vested under Section 5 or 6 but which have not yet been issued will be issued immediately prior to the Change in Control.

Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of a Change of Control on outstanding Awards which is in effect as of the Change of Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii); provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.

9.    Recoupment Policy.

(a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

(i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:



-Rev. 1.2018                                            FCF Program


EXHIBIT 10.4


(1)    “Current Executive Officer” means any individual currently designated as an “officer” by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

(2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

(3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “officer” by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

(4)    “Recovery” means the forfeiture or cancellation of unvested Units.

(b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

10.    Consideration for Stock. The shares of Stock are intended to be issued for no cash consideration.

11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (i) all federal, state and local laws and regulations as the Company may deem applicable have been complied with; (ii) the shares have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (iii) all other legal matters in connection with the issuance and delivery of the shares have been approved by the Company’s legal department.

12.    Tax Withholding. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent

-Rev. 1.2018                                            FCF Program


EXHIBIT 10.4


it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

The Units are intended to comply with or be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of shares of Stock, shall be based on the value of the shares of Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not

-Rev. 1.2018                                            FCF Program


EXHIBIT 10.4


otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

13.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

14.    Limits on Transferability; Restrictions on Shares; Legend on Certificate. Until the eligibility conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement or by action of the Committee, the Units awarded hereunder are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by you. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

15.    Award Subject to the Plan and the Program. The Award to be made pursuant to this Agreement is made subject to the Plan and the Program. The terms and provisions of the Plan and the Program, as each may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan or the Program, the applicable terms and conditions of the Plan or Program will govern and prevail. However, no amendment of the Plan or the Program after the date hereof may adversely alter or impair the issuance of the shares of Stock to be made pursuant to this Agreement.

16.    No Rights to Continued Employment. The Company’s intent to issue the shares of Stock hereunder shall not confer upon you any right to continued employment or other association with the Company or any of its Affiliates or subsidiaries; and this Agreement shall not be construed in any way to limit the right of the Company or any of its subsidiaries or Affiliates to terminate your employment or other association with the Company or to change the terms of such employment or association at any time.

17.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.


-Rev. 1.2018                                            FCF Program


EXHIBIT 10.4


18.    Appendix. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable appendix to the Agreement (the “Appendix”). Further, if you transfer your residence and/or employment to another country reflected in the Appendices to these Agreements, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Appendix shall constitute part of this Agreement.

19.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the Commonwealth of Massachusetts, or the federal courts for the United States for the District of Massachusetts, and no other courts, where this Award is made and/or to be performed.

20.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

21.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

22.    Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

23.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]







-Rev. 1.2018                                            FCF Program


EXHIBIT 10.4


APPENDIX A

PLAN: 2011 LONG-TERM INCENTIVE PLAN



The Performance Share Units will pay out in shares of Stock in a range of 0% to 150% of the number of Performance Share Units as follows:

Performance
Percent to Plan
Units Vesting
125% or above
150%
110%
120%
100%
100%
90%
80%
50%
25%
Less than 50%
0%










































-Rev. 1.2018                                            FCF Program


EXHIBIT 10.4


APPENDIX B
This Appendix B contains supplemental terms and conditions for awards of Units granted under the Boston Scientific Corporation 2011 Long-Term Incentive Plan (the “Plan”) to Participants who reside outside the United States or who are otherwise subject to the laws of a country other than the United States. Capitalized terms used but not defined herein shall have the same meanings ascribed to them in the Agreement.
Section I of this Appendix B contains special terms and conditions that govern the Units outside of the United States. Section II of this Appendix B includes special terms and conditions in the specific countries listed therein.
This Appendix B may also include information regarding exchange controls, taxation of awards and certain other issues of which you should be aware with respect to participation in the Plan. The information is based on the securities, exchange control, tax and other laws concerning the Units in effect as of January 2018. Such laws are often complex and change frequently; the information may be out of date at the time you vest in the Units or sell shares of Stock acquired under the Plan. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan.
In addition, this Appendix B is general in nature, does not discuss all of the various laws, rules and regulations which may apply to your particular situation and the Company does not assure you of any particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country apply to your specific situation.
Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transferred employment after the Award was granted or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner. In addition, the Company shall, in its sole discretion, determine to what extent the terms and conditions contained herein will apply under these circumstances (or the Company may establish alternative terms and conditions as may be necessary or advisable).
Section I.     All Countries Outside the United States
Nature of Grant. In accepting the grant, you acknowledge that:
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;


-Rev. 1.2018                                            FCF Program


EXHIBIT 10.4


(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and


-Rev. 1.2018                                            FCF Program


EXHIBIT 10.4


(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Unit grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.
You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.
You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.
You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the

-Rev. 1.2018                                            FCF Program


EXHIBIT 10.4


only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.
Finally, upon request of the Company or the Employer, you agree to provide an executed data privacy consent form (or any other agreements or consents that may be required by the Company and/or the Employer) to the Company and/or the Employer that the Company and/or the Employer may deem necessary to obtain from you for the purpose of administering your participation in the Plan in compliance with the data privacy laws in your country, either now or in the future. You understand and agree that you will not be able to participate in the Plan if you fail to provide any such consent or agreement requested by the Company and/or the Employer.

Electronic Delivery of Documents. The Company may, in its sole discretion, decide to deliver any documents related to the Units granted under and participation in the Plan or future Units that may be granted under the Plan by electronic means or to request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.
Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.

-Rev. 1.2018                                            FCF Program


EXHIBIT 10.4



Section II.     Country-Specific Terms and Conditions
CHINA
The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

1.    Shares of Stock Must Be Held with Designated Broker. All shares of Stock issued upon settlement of your Units will be deposited into a personal brokerage account established with the Company’s designated broker, E*TRADE (or any successor broker designated by the Company), on your behalf. You understand that you may sell the shares of Stock at any time after they are deposited in such account, however, you may not transfer the shares of Stock out of the brokerage account.

2.    Termination of Employment. Unless otherwise determined by the Committee in its sole discretion, in the event that the Units remain outstanding as of the 90th day following your termination of employment with the Company and its Affiliates, all such Units shall be cancelled on the 90th day following your termination of employment. Further, you are required to sell all shares of Stock acquired upon settlement of the Units no later than 90 days following your termination of employment with the Company and its Affiliates (or such earlier date as may be required by the China State Administration of Foreign Exchange (“SAFE”)), in which case, this Addendum shall give the Company the authority to issue sales instructions on your behalf). If any shares remain outstanding on the 90th day following your employment termination date (or such earlier date as may be required by SAFE), you hereby direct, instruct and authorize the Company to issue sale instructions on your behalf.

You agree to sign any additional agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds and other exchange control matters noted below) and shall otherwise cooperate with the Company with respect to such matters. You acknowledge that neither the Company nor the designated brokerage firm is under any obligation to arrange for such sale of shares of Stock at any particular price (it being understood that the sale will occur in the market) and that broker’s fees and similar expenses may be incurred in any such sale. In any event, when the shares of Stock are sold, the sale proceeds, less any tax withholding, any broker’s fees or commissions, and any similar expenses of the sale will be remitted to you in accordance with applicable exchange control laws and regulations.

3.    Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired

-Rev. 1.2018                                            FCF Program


EXHIBIT 10.4


under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.

4.    Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

FRANCE
1.    Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. of the French commercial code.
2.    Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.
SINGAPORE
Private Placement. The grant of the Units is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation

-Rev. 1.2018                                            FCF Program


EXHIBIT 10.4


to the content of prospectuses would not apply. You should note that the Units are subject to section 257 of the SFA and you will not be able to make any subsequent sale of shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the grant in Singapore, unless such sale or offer is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.

*    *    *    *    *
6678407-v6\GESDMS


-Rev. 1.2018                                            FCF Program

EX-10.5 6 exhibit105-acquisitionxrel.htm EXHIBIT 10.5 Exhibit
EXHIBIT 10.5










Boston Scientific Corporation 2011 Long-Term Incentive Plan

Global Non-Qualified Stock Option Agreement

%%OPTION_DATE,’Month DD, YYYY’%-%




%%FIRST_NAME%-% %%LAST_NAME%-%
(“Optionee”)























EMPLOYEE COPY
PLEASE RETAIN FOR YOUR RECORDS



-Rev 1.2018                                                AQ


EXHIBIT 10.5


Boston Scientific Corporation 2011 Long-Term Incentive Plan
Global Non-Qualified Stock Option Agreement

This Global Non-Qualified Stock Option Agreement (the “Agreement”), dated %%OPTION_DATE,’Month DD, YYYY%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the Non-Qualified Stock Option Award granted to you by the Company. This Agreement sets forth the terms and conditions relating to your Stock Option pursuant to the Boston Scientific Corporation 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan. The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.

1.    Grant of Stock Option. The Committee hereby grants you a Stock Option to purchase that number of shares of Stock set forth on herein (the “Option Shares”) at the price set forth herein (the “Grant Price”). The Grant Price is equal to the Fair Market Value of the Company’s Stock on the Grant Date.

2.    Term and Vesting of Stock Option. Except as otherwise provided in Section 4 below, your Stock Option shall have a term of ten (10) years from %%OPTION_DATE,’Month DD, YYYY%-% until %%EXPIRE_DATE_PERIOD1,’Month DD, YYYY%-% (the “Expiration Date”) and shall vest in accordance with the vesting schedule. If the Expiration Date falls on a date on which the New York Stock Exchange is closed for trading, the Expiration Date shall be the trading day immediately prior to the Expiration Date.

3.    Exercise of Stock Option. While this Stock Option remains exercisable, you may exercise any vested portion of the Option Shares by delivering to the Company or its designee, in the form and at the location specified by the Company, notice stating your intent to exercise a specified number of Option Shares and payment of the full Grant Price for the specified number of Option Shares. Payment in full for the Option Shares being exercised may be paid in such manner as the Committee may specify from time to time, in its sole discretion, including, but not limited to the following: (a) in cash, (b) by certified check or bank draft payable in U.S. dollars (US$) to the order of the Company, (c) in whole or in part in shares of Stock owned by you, valued at Fair Market Value, or (d) if available to you, via cashless exercise, by which you deliver to your securities broker instructions to sell a sufficient number of shares of Stock to cover the Grant Price for the Option Shares, any applicable tax obligations and the brokerage fees and expenses associated therewith. Notwithstanding the foregoing, if you reside in a country where the local laws and/or regulations preclude the remittance of currency out of the country for purposes of paying the Grant Price for the Option Shares being exercised, require the Company, its Affiliates and/or you to secure any legal or regulatory approvals or complete any legal or regulatory filings, or undertake any additional steps for remitting currency out of the country, the Company may restrict the method of exercise to a form of cashless exercise (either a cashless “sell all” exercise and/or a cashless “sell to cover” exercise) as it shall determine in its sole discretion.




-Rev 1.2018                                                AQ


EXHIBIT 10.5


The exercise date applicable to your exercise of the specified number of Option Shares pursuant to this Section 3 will be deemed to be the date on which the Company receives your irrevocable commitment to exercise the Option Shares in writing, subject to your payment in full of the Option Shares to be exercised within 10 (ten) days of the notice of exercise of the Option Shares to be exercised. The notice and payment in full of the Option Shares being exercised, must be received by the Company or its designee on or prior to the last day of the Stock Option term, as set forth in Section 2 above, except as provided in Section 4 below.

Upon the Company’s determination that there has been a valid exercise of the Option Shares, the Company shall issue certificates in accordance with the terms of this Agreement or cause the Company’s transfer agent to make the necessary book entries for the shares of Stock subject to the exercised Option Shares. However, the Company shall not be liable to you, your personal representative or your successor(s)-in-interest for damages relating to any delays in issuing the certificates or in making book entries, any loss of the certificates, or any mistakes or errors in the issuance of the certificates or in making book entries, or in the certificates themselves.

4.    Termination of Employment.

a.    In the event that your employment terminates due to death or Disability (as such term is defined in the Plan or determined under local law, as applicable), all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you or your appointed representative, as the case may be, until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option. 

b.    Upon termination of your employment for reasons other than for Cause, death or Disability, you shall have the shorter of (i) one (1) year from the date of termination and (ii) the remaining term of the Stock Option to exercise all vested Option Shares. Immediately upon termination of your employment for reasons other than for Cause, death or Disability (including your termination by reason of Retirement (as such term is defined in the Plan or determined under local law), notwithstanding Section 4.a.(4)(B) of the Plan), all unvested Option Shares shall be forfeited; provided, however, that the Committee, in its sole discretion, may extend the exercise period and/or accelerate vesting of any unvested Option Shares (provided that such exercise period does not extend beyond the original term of the Stock Option). Your termination date shall be the last day of your active service with the Company or an Affiliate (if applicable).

e.    Immediately upon notice of termination of your employment for Cause, all unexercised Option Shares, whether vested or unvested, shall be forfeited.

f.    The Option Shares, to the extent unexercised on the date following the end of any period described above or the term of the Stock Option set forth above in Section 2, shall thereupon be forfeited.

g.    Notwithstanding anything to the contrary in the Plan or the Agreement, and for purposes of clarity, any termination of employment shall be effective as of the date your active

-Rev 1.2018                                                AQ


EXHIBIT 10.5


employment ceases and shall not be extended by any statutory or common law notice of termination period.

h.    Any one of your permitted transferee(s) (pursuant to Section 8 below) shall receive the rights herein granted subject to the terms and conditions of this Agreement and any applicable Addendum. No transfer of this Stock Option shall be approved and effected by the Administrator unless (i) the Administrator shall have been timely furnished with written notice of such transfer and any copies of such notice as the Committee may deem, in its sole discretion, necessary to establish the validity of the transfer; (ii) the transferee or transferees shall have agreed in writing to be bound by the terms and conditions of this Agreement and any applicable Addendum; and (iii) such transfer complies with applicable laws and regulations.

i.    If you reside or work in a country where the local foreign exchange rules and regulations require the repatriation of sale proceeds, the Company may require you to sell any Option Shares you acquire under the Plan immediately or within a specified period following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).

5.    Change in Control. To the extent that you have not entered into a Change in Control Agreement with the Company and except as the Administrator (as defined in the Plan) may otherwise determine, immediately prior to a Change in Control (as defined in the Plan), any unvested portion of the Stock Option shall vest and become exercisable. In addition, the Stock Option shall terminate immediately prior to the Change in Control unless the Stock Option is exercised coincident therewith or assumed in accordance with the immediately following sentence. If there is a surviving or acquiring entity, the Administrator may provide for a substitution or assumption of the Stock Option by the acquiring or surviving entity or an affiliate thereof, on such terms as the Administrator determines. If there is no surviving or acquiring entity, or if the Administrator does not provide for a substitution or assumption of the Stock Option, any unvested portion of the Stock Option shall vest and become exercisable on a basis that gives you a reasonable opportunity to participate as a stockholder in the Change in Control. If you have entered into a Change in Control agreement with the Company, the Stock Option will vest according to the provisions of the Change in Control agreement.

6.    Recoupment Policy.

(a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

(i)    Definitions. The following terms, when used in this Section 6, shall have the meaning set forth below:


-Rev 1.2018                                                AQ


EXHIBIT 10.5


(1)    “Current Executive Officer” means any individual currently designated as an “officer” by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

(2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

(3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “officer” by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

(4)    “Recovery” means the forfeiture or cancellation of unexercised Stock Options, whether vested or unvested.

(b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

7.    Restrictions on Shares; Legend on Certificate. Shares of Stock issued to you in certificate form or to your book entry account upon exercise of the Stock Option may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

8.    Transferability. Except as required by law, you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of the Stock Option granted under this Agreement other than by will or the laws of descent and distribution or without payment of consideration to your Family Members or to trusts or other entities for the benefit of your Family Members. During your lifetime, the Stock Option is exercisable only by you, subject to Section 4 above.

9.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Stock Option, including the grant of the Stock Option, the vesting of the Stock Option, the exercise of the Stock Option, the subsequent sale of any shares of Stock acquired upon exercise of the Stock Option and the receipt of any dividends, and (b) do not commit to structure the terms of the grant or any aspect of the Stock Option to reduce or eliminate your liability for Tax-Related Items.


-Rev 1.2018                                                AQ


EXHIBIT 10.5


Prior to the delivery of shares of Stock upon exercise of the Stock Option, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may withhold a sufficient whole number of shares of Stock otherwise issuable upon exercise of the Stock Option that has an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, withhold shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the Stock Option, you expressly consent to the withholding of shares of Stock as provided for hereunder.

Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon exercise resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the exercised Stock Option.

All other Tax-Related Items related to the Stock Option and any shares of Stock delivered in payment thereof are your sole responsibility. In no event, shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

The Stock Option is intended to be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

10.    Repatriation and Legal/Tax Compliance Requirements. If you are a resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Stock Option) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent

-Rev 1.2018                                                AQ


EXHIBIT 10.5


to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).

11.    Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Stock Option grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Stock Options awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.
You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon exercise of the Stock Option. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consent herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Stock Options or other equity awards or administer or

-Rev 1.2018                                                AQ


EXHIBIT 10.5


maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

Finally, upon request of the Company or the Employer, you agree to provide an executed data privacy consent form (or any other agreements or consents that may be required by the Company and/or the Employer) to the Company and/or the Employer that the Company and/or the Employer may deem necessary to obtain from you for the purpose of administering your participation in the Plan in compliance with the data privacy laws in your country, either now or in the future.  You understand and agree that you will not be able to participate in the Plan if you fail to provide any such consent or agreement requested by the Company and/or the Employer.

12.    Nature of Grant. By participating in the Plan, you acknowledge, understand and agree that:
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Stock Option is voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Stock Options, even if Stock Options have been granted in the past;

(c)all decisions with respect to future grants of Stock Options, if any, will be at the sole discretion of the Administrator;

(d)the Stock Option grant and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Stock Option is not intended to replace any pension rights or compensation;

(g)the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments;

(h)the future value of the shares of Stock subject to the Stock Option is unknown, indeterminable and cannot be predicted with certainty;





-Rev 1.2018                                                AQ


EXHIBIT 10.5


(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Stock Option resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;
 
(k)for purposes of the Stock Option, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, the period (if any) during which you may exercise the Option will commence as of such date and will not be extended by any notice period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any; the Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on an approved leave of absence); and
(l)the following provisions apply only if you are providing services outside the United States: (A) the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Stock Option or of any amount due to you pursuant to the exercise of the Stock Option or the subsequent sale of any Shares acquired upon exercise.

13.    Securities Laws. Upon the acquisition of any shares of Stock pursuant to the exercise of the Stock Option, you will make or enter into such written representations, warranties and agreements as the Company may reasonably request in order to comply with applicable securities laws or with the Plan.

14.    Not a Public Offering. Neither the grant of the Stock Option under the Plan nor the issuance of the underlying shares of Stock upon exercise of the Stock Option is intended to be a public offering of securities in your country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law.

15.    No Advice Regarding Grant. No Employee of the Company is permitted to advise you regarding whether you should purchase shares of Stock under the Plan. Investment in shares of Stock involves a degree of risk. Before deciding to purchase shares of Stock pursuant to the Stock Option, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Stock Option

-Rev 1.2018                                                AQ


EXHIBIT 10.5


and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

16.    Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Stock Options) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to a personal advisor on this matter.

17.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Stock Option and participation in the Plan, or future grants of Stock Options that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.

18.    Language. If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Stock Option, be drawn up in English. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Stock Option translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

19.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Stock Option shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the “Addendum”). Further, if you transfer your residence and/or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Addendum shall constitute part of this Agreement.


-Rev 1.2018                                                AQ


EXHIBIT 10.5


20.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Stock Option, any shares of Stock acquired pursuant to the Stock Option and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

21.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal executive office of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

22.    Choice of Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflicts of laws principles) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston or the federal courts for the United States for the District of Massachusetts, and no other courts where the grant of the Stock Option is made and/or to be performed.

23.    Award Subject to Plan; Conflicts. The Stock Option granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Committee specifically for the grant described herein. Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Stock Option granted under this Agreement as the Committee may determine are in the best interests of the Company. You hereby accept the Stock Option subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.

24.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

25.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.




-Rev 1.2018                                                AQ


EXHIBIT 10.5


26.     Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

27.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.


-Rev 1.2018                                                AQ


EXHIBIT 10.5


IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Optionee have executed and delivered this Agreement effective as of the date and year first above written.

Option Shares of Stock: %%TOTAL_SHARES_GRANTED%-%

Grant Price: %%OPTION_PRICE,’$999,999,999.99’%-%

Vesting Schedule:

Percent of
Stock Option
Date Vested
25%
%%VEST_DATE_PERIOD1%-%
25%
%%VEST_DATE_PERIOD2%-%
25%
%%VEST_DATE_PERIOD3%-%
25%
%%VEST_DATE_PERIOD4%-%



BOSTON SCIENTIFIC CORPORATION        
                
                    mma03.gif
Michael F. Mahoney
President and Chief Executive Officer


OPTIONEE



By: SIGNED BY ELECTRONIC SIGNATURE


By electronically accepting the Award, you agree that (i) such acceptance constitutes your electronic signature in execution of this Agreement; (ii) you agree to be bound by the provisions of the Plan, the Agreement and the Addendum; (iii) you have reviewed the Plan, the Agreement and the Addendum in their entirety, have had an opportunity to obtain the advice of counsel prior to accepting the Award and fully understand all of the provisions of the Plan, the Agreement and the Addendum; (iv) you have been provided with a copy or electronic access to a copy of the U.S. prospectus for the Plan and the tax supplement to the U.S. prospectus for your country, if applicable; and (v) you hereby agree to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Agreement and the Addendum.


-Rev 1.2018                                                AQ


EXHIBIT 10.5


BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO NON-QUALIFIED STOCK OPTIONS GRANTED
PURSUANT TO THE 2011 LONG-TERM INCENTIVE PLAN

In addition to the terms of the Plan and the Agreement, the Stock Option is subject to the following additional terms and conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 19 of the Agreement, if you transfer your residence and/or employment to another country reflected in an Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).

ARGENTINA

Type of Offering. Neither the grant of the Stock Option, nor the issuance of shares of Stock subject to the grant, constitutes a public offering. The offering of the Plan is a private placement and is not subject to the supervision of any Argentine governmental authority.

AUSTRALIA

1.    Limitations on Exercisability Following Termination of Employment. Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your vested Stock Option will no longer be exercisable after the earlier of: (i) thirty (30) days from the date of termination of employment; and (ii) the Expiration Date specified in Section 2 of the Agreement.

2.    Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.

AUSTRIA

No country-specific provisions.

BELGIUM

1.    Acceptance of Stock Option. In order for the Stock Option to be subject to taxation at the time of grant, you must affirmatively accept the Stock Option in writing within 60 days after the offer date by signing below and returning this original executed Addendum to:


-Rev 1.2018                                                AQ


EXHIBIT 10.5


Boston Scientific
Green Square,
Lambroekstraat 5D
1831 Diegem
Belgium
Attn.: Carine Depret

I hereby accept ________ (number) Option Shares underlying the Stock Option granted to me by the Company on the Grant Date.

The undersigned acknowledges that he/she has been encouraged to discuss this matter with a financial and/or tax advisor and that this decision is made in full knowledge.

Employee Signature:        _______________________________

Employee Printed Name:    _______________________________

Date of Acceptance:        _______________________________

If you fail to affirmatively accept the Stock Option in writing within 60 days after the offer date, the Stock Option will not be subject to taxation at the time of grant but instead will be subject to taxation on the date you exercise the Stock Option (or such other treatment as may apply under Belgian tax law at the time of exercise).

2.    Undertaking for Qualifying Option. If you are accepting the Stock Option in writing within 60 days after the offer date and wish to have the Stock Option subject to a lower valuation for Belgium tax purposes pursuant to the article 43, §6 of the Belgian law of 26 March 1999, you may agree and undertake to (a) not exercise the Stock Option before the end of the third calendar year following the calendar year in which the offer date falls, and (b) not transfer the Stock Option under any circumstances (except upon on rights your heir might have in the Stock Option upon your death). If you wish to make this undertaking, you must sign below and return this executed Addendum to the address listed above.
Employee Signature:        _______________________________

Employee Printed Name:    _______________________________
    
BRAZIL

1.    Compliance with Law. By accepting the Stock Option, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the Stock Option, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.





-Rev 1.2018                                                AQ


EXHIBIT 10.5


2.    Labor Law Policy and Acknowledgement. This provision supplements Section 12 of the Agreement:

By accepting the Stock Option, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment; and (iii) the income from the Stock Option, if any, is not part of your remuneration from employment.

CANADA

1.    Use of Previously Owned Shares. Notwithstanding any provision in Section 3 of the Agreement or the Plan to the contrary, if you are resident in Canada, you may not use previously-owned shares of Stock to pay the Grant Price or any Tax-Related Items in connection with the Stock Option.

2.    Personal Data. This provision supplements Section 11 of the Agreement:

You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors. You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.

3.    Securities Law Information. You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares are listed (i.e., the New York Stock Exchange).

4.    Language Consent. The following provision will apply if you are a resident of Quebec:

The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Les parties reconnaissent avoir exigé la rédaction en anglais de la présente convention, ainsi que de tous documents, avis et procédures judiciaires, exécutés, donnés ou intentés en vertu de, ou liés directement ou indirectement à, la présente convention.


-Rev 1.2018                                                AQ


EXHIBIT 10.5



CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

1.    Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

2.     Limitations on Exercisability Following Termination of Employment. Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your Stock Option will no longer be exercisable after the earlier of: (i) the period set forth in Section 4 of the Agreement; (ii) the last day of the 90 day period beginning on the date of termination of employment (or such earlier date as may be required by China State Administration of Foreign Exchange (“SAFE”)); and (iii) the Expiration Date specified in Section 2 of the Agreement.

3.    Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may need to be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company and its Affiliates in the future in order to facilitate compliance with exchange control requirements in China.

4.    Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.


-Rev 1.2018                                                AQ


EXHIBIT 10.5


BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

COLOMBIA

Nature of Grant. This provision supplements Section 12 of the Agreement:
You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.

COSTA RICA

No country-specific provisions.

CZECH REPUBLIC

No country-specific provisions.

DENMARK

Treatment of Stock Option Upon Termination of Employment. Notwithstanding any provisions in the Agreement to the contrary, if you are determined to be an “Employee” as defined in Section 2 of the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the “Stock Option Act”), the treatment of the Stock Option upon your termination of employment shall be governed by Section 4 and 5 of the Stock Option Act. However, if the provisions in the Agreement or the Plan governing the treatment of the Stock Option upon a termination are more favorable, the provisions of the Agreement or the Plan will govern. You acknowledge having received an “Employer Information Statement” in Danish.

FINLAND

No country-specific provisions.

FRANCE

1.    Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-177-1 and seq. of the French commercial code.






-Rev 1.2018                                                AQ


EXHIBIT 10.5


2.    Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

GERMANY

No country-specific provisions.

GREECE

No country-specific provisions.

HONG KONG

1.    Lapse of Restrictions. If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.

2.    IMPORTANT NOTICE/WARNING. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Stock Option and shares of Stock issued upon exercise do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong. The Units are intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.

3.    Wages. The Stock Option and shares of Stock subject to the Stock Option do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

4.    Nature of Scheme. You understand that the Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”).


-Rev 1.2018                                                AQ


EXHIBIT 10.5



INDIA

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

INDONESIA

No country-specific provisions.

IRELAND

No country-specific provisions.

ITALY

1.    Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

2.    Plan. This provision supplements Section 12 of the Agreement: You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement: Grant of Stock Option, Exercise of Stock Option, Termination of Employment, Recoupment Policy, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.
JAPAN

No country-specific provisions.

LEBANON

Securities Law Information. The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.

MALAYSIA

1.    Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board. You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board. (You may contact your Employer to request a form letter for this purpose.) You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.


-Rev 1.2018                                                AQ


EXHIBIT 10.5


2.    Consent to Collection, Processing and Transfer of Personal Data. This provision replaces Section 11 of the Agreement in its entirety:

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.

You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human

Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian Opsyen saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan.
Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua Opsyen saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (“Data”). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau


-Rev 1.2018                                                AQ


EXHIBIT 10.5


resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com. You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon exercise of the Stock Option may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Stock Options or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources

mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com. Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad Opsyen mungkin didepositkan. Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi



-Rev 1.2018                                                AQ


EXHIBIT 10.5


representative.
Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.

secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan Opsyen saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.










-Rev 1.2018                                                AQ


EXHIBIT 10.5



MEXICO

1.    Acknowledgement of the Agreement. By accepting the Stock Option, you acknowledge that have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed. You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum. You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in Section 12 of the Agreement, which clearly provide as follows:
(1)
Your participation in the Plan does not constitute an acquired right;
(2)
The Plan and your participation in it are offered by the Company on a wholly discretionary basis;
(3)
Your participation in the Plan is voluntary; and
(4)
The Company and its Affiliates are not responsible for any decrease in the value of any shares of Common Stock acquired at exercise of the Stock Option.
Reconocimiento del Contrato. Al aceptar la Opción, Usted reconoce que ha recibido una copia del Plan y del contrato, incluyendo este Apéndice, mismos que ha revisado. Usted reconoce, además, que acepta todas las disposiciones del Plan, y del contrato, incluyendo este Apéndice. También reconoce que ha leído y aprueba de forma expresa los términos y condiciones establecidos en la sección doce 12 del contrato que claramente dispone lo siguiente:
(1)
Su participación en el Plan no constituye un derecho adquirido;
(2)
El Plan su participación en el mismo son ofrecidos por la Compañía de forma totalmente discrecional;
(3)
Su participación en el Plan es voluntaria; y
(4)
La Compañía y sus afiliados no son responsables por cualquier disminución en el valor de las Acciones adquiridas al momento de tener derecho conforme a la Opción.
2.    Labor Law Acknowledgement and Policy Statement. By accepting the Stock Option, you acknowledge that Boston Scientific Corporation, with registered offices at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, United States of America, is solely responsible for the administration of the Plan. You further acknowledge your participation in the Plan, the grant of the Stock Option and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (“Boston Scientific-Mexico”). Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and/or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its

-Rev 1.2018                                                AQ


EXHIBIT 10.5


termination shall not constitute a change or impairment of the terms and conditions of your employment.
You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and/or discontinue your participation in the Plan at any time, without any liability to you.
Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise.
Reconocimiento de Ley Laboral y Declaración de la Política. Al aceptar el Otorgamiento de la Opción, Usted reconoce que Boston Scientific Corporation, con oficinas registradas en 300 Boston Scientific Way, Marlborough, Massachusetts 01752, Estados Unidos de América, es únicamente responsable de la administración del Plan. Usted además reconoce que su participación en el Plan, la concesión de Opción y cualquier adquisición de acciones de conformidad con el Plan no constituyen una relación de trabajo entre Usted y Boston Scientific Corporation, ya que Usted está participando en el Plan sobre una base totalmente comercial y su único patrón es una sociedad mercantil Mexicana (“Boston Scientific-México”). Derivado de lo anterior, Usted expresamente reconoce que el Plan y los beneficios que pueden derivarle de la participación en el Plan no establecen ningún derecho entre Usted y su Patrón, Boston Scientific-México, y no forman parte de las condiciones de trabajo y/o prestaciones otorgadas por Boston Scientific-México, y cualquier modificación al Plan o su terminación no constituirá un cambio o perjuicio de los términos y condiciones de su trabajo.
Usted además entiende que su participación en el Plan es resultado de una decisión unilateral y discrecional de Boston Scientific Corporation, por lo tanto Boston Scientific Corporation se reserva el derecho absoluto de modificar el Plan y/o discontinuar su participación en el Plan en cualquier momento, sin responsabilidad alguna para hacia Usted.
Finalmente, Usted declara que no se reserva acción o derecho alguno para presentar una reclamación o demanda en contra de Boston Scientific Corporation por cualquier compensación o daño o perjuicio en relación con cualquier disposición del Plan o los beneficios derivados del Plan y, por lo tanto, otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliados, afiliadas, sucursales, oficinas de representación, accionistas, directores, funcionarios, agentes y representantes con respecto a cualquier reclamación o demanda que pudiera surgir.

-Rev 1.2018                                                AQ


EXHIBIT 10.5




NETHERLANDS

Waiver of Termination Rights. By accepting the Stock Option, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with Boston Scientific Corporation and the Employer for any reason whatsoever, insofar as those rights result or may result from (i) the loss or diminution in value of such rights or entitlements under the Plan, or (ii) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.

NEW ZEALAND

Securities Law Notice

Warning

This is an offer of a Stock Option which, upon exercise and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.

If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid. You may lose some or all of your investment.

New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.

Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the exercise and settlement of the Stock Option, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock.
No interest in any Stock Option may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The shares of Stock are quoted on the New York Stock Exchange. This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you invested. The price will depend on the demand for the shares.


-Rev 1.2018                                                AQ


EXHIBIT 10.5


You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below:
1.
Boston Scientific Corporation’s most recent Annual Report (Form 10-K):
https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.
Boston Scientific Corporation’s most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

3.
The Boston Scientific Corporation 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.
Boston Scientific Corporation Non-Qualified Stock Option Grant and 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

A copy of the above documents will be sent to you free of charge on written request being mailed to: Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

NORWAY

No country-specific provisions.

PHILIPPINES

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

POLAND

No country-specific provisions.

PORTUGAL

Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.


-Rev 1.2018                                                AQ


EXHIBIT 10.5


Conhecimento da Lingua. Por meio do presente, eu declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano e no Acordo.

PUERTO RICO

No country-specific provisions.

RUSSIA

1.    U.S. Transaction. You understand that the Stock Option shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States. Upon exercise of the Stock Option, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States. In no event will shares of Stock be delivered to you in Russia; instead, all shares of Stock acquired upon exercise of the Stock Option will be maintained on your behalf in the United States. You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.
2.    Cashless Exercise Provision. Notwithstanding anything to the contrary in the Agreement, depending on the development of local regulatory requirements, the Company reserves the right to restrict exercise of your Stock Option to a cashless exercise through a licensed securities broker acceptable to the Company, such that all shares of Stock subject to the exercised Stock Option will be sold immediately upon exercise and the proceeds of sale, less the Grant Price, any Tax-Related Items and broker’s fees or commissions, will be remitted to you in accordance with any applicable exchange control laws and regulations.

3.    Repatriation Requirements. You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations. Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.

SINGAPORE

Private Placement. The grant of the Stock Option under the Plan is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Stock Option is subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the Stock Option in Singapore, unless such sale or offer in is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the SFA.


-Rev 1.2018                                                AQ


EXHIBIT 10.5


SOUTH AFRICA

1.    Responsibility for Taxes. This provision supplements Section 9 of the Agreement:
You are responsible for immediately notifying the Employer of the amount of any gain realized at exercise of the Stock Option. If you fail to advise the Employer of such gain, you may be liable for a fine.

2.    Securities Law Notice. In compliance with South African securities law, the documents listed below are available for review on the Company’s external and internal sites at the web addresses listed below:
a.
Boston Scientific Corporation’s most recent Annual Report (Form 10-K):
https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

b.
The Boston Scientific Corporation 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
c.
Boston Scientific Corporation Non-Qualified Stock Option Grant and 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn: Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.

SOUTH KOREA

Consent to Collection, Processing and Transfer of Personal Data. By electronically accepting this Agreement:

1.
You agree to the collection, use, processing and transfer of Data as described in Section 11 of the Agreement; and

2.
You agree to the processing of your unique identifying information (resident registration number) as described in Section 11 of the Agreement.


-Rev 1.2018                                                AQ


EXHIBIT 10.5


SPAIN

Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement.

In accepting the Stock Option grant, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.

You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Stock Options under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis. Consequently, you understand that the Stock Option is granted on the assumption and condition that the Stock Option and the shares of Stock acquired upon exercise of the Stock Option shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the Stock Option grant shall be null and void.

You understand and agree that, as a condition of the Stock Option grant, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Stock Option to the extent the Stock Option has not vested as of date you cease active employment. In particular, you understand and agree that any unvested Stock Option as of the date you cease active employment and any vested portion of the Stock Option not exercised within the post-termination exercise period set out in the Agreement will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985. You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Stock Option.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.


-Rev 1.2018                                                AQ


EXHIBIT 10.5



SWEDEN

No country-specific provisions.

SWITZERLAND

Securities Law Information. The offer of the Stock Option is considered a private offering in Switzerland and is therefore not subject to registration in Switzerland. Neither this document nor any other materials relating to the Stock Option constitutes a prospectus as such term is understood pursuant to article 652a of the Swiss Code of Obligations, and neither this document nor any other materials relating to the Stock Option may be publicly distributed nor otherwise made publicly available in Switzerland.

TAIWAN

Securities Law Information. This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees. The Award is not a public offer of securities by a Taiwanese company.

THAILAND

No country-specific provisions.

TURKEY

Securities Law Information. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.

UNITED ARAB EMIRATES

Securities Law Information. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of the Agreement or the Plan, you should consult an authorized financial advisor.

-Rev 1.2018                                                AQ


EXHIBIT 10.5



UNITED KINGDOM

1.     Income Tax and Social Insurance Contribution Withholding. The following provision shall supplement Section 9 of the Agreement:

Without limitation Section 9 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

2.    Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.

6677789-v4\GESDMS


-Rev 1.2018                                                AQ

EX-10.6 7 exhibit106-acquisitionxrel.htm EXHIBIT 10.6 Exhibit
EXHIBIT 10.6



Boston Scientific Corporation 2011 Long-Term Incentive Plan

Global Deferred Stock Unit Award Agreement

%%OPTION_DATE,’Month DD, YYYY’%-%




%%FIRST_NAME%-% %%LAST_NAME%-%
(“Participant”)









 












EMPLOYEE COPY
PLEASE RETAIN FOR YOUR RECORDS


-Rev 1.2018                                                 AQ


EXHIBIT 10.6


Boston Scientific Corporation 2011 Long-Term Incentive Plan
Global Deferred Stock Unit Award Agreement

This Global Deferred Stock Unit Award Agreement (the “Agreement”), dated %%OPTION_DATE,’Month DD, YYYY%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the Award of Deferred Stock Units by the Committee under the Boston Scientific Corporation 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan. The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.
 
1.    Grant of Units. The Committee hereby grants you that number of Deferred Stock Units as set forth in this Agreement (the “Units”). Each Unit represents the Company’s commitment to issue to you one share of Stock subject to the conditions set forth in this Agreement. This Award is granted pursuant to and is subject to the provisions of the Plan and the terms and conditions of this Agreement and any applicable Addendum.

2.    Vesting. The Units shall vest and shares of Stock will be issued to you according to the vesting schedule set forth in this Agreement. Except as otherwise provided in Sections 4, 5, 6, 7 and 8 below, the Units will vest, subject to the conditions described in Section 7 below, in approximately equal annual installments on each of the five (5) consecutive anniversaries of the Grant Date, beginning on the first anniversary of the Grant Date. Shares of Stock for Units that vest in accordance with this Section 2 will be delivered to you within fifteen (15) days after the applicable vesting date but in no event later than the last day of the calendar year that includes the applicable vesting date. No shares of Stock shall otherwise be issued to you prior to the date on which the Units vest. Notwithstanding anything in the Agreement to the contrary, the Company may, in its sole discretion, settle the Units in the form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company and/or any of its Affiliates to obtain the approval of or complete any legal or regulatory filing with any governmental and/or regulatory body in your country of residence (or country of employment, if different). Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require you to sell such Stock immediately or within a specified time following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).

3.    Participant’s Rights in Stock. The shares of Stock, if and when issued to you pursuant to this Agreement, shall be registered in your name and evidenced in a manner as determined by the Company, in its sole discretion. Under no circumstance will you be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested with respect to such shares of Stock and the shares of Stock have been issued to you.




-Rev 1.2018                                                 AQ


EXHIBIT 10.6


4.    Death. In the event you terminate employment by reason of death, any Units that have not vested prior to the date of your death shall immediately vest and shares of Stock shall be issued in accordance with your will or the laws of descent and distribution. Shares of Stock for Units which vest under this Section 4 will be delivered within sixty (60) days after your employment termination date.

5.    Retirement. Notwithstanding Section 4.a.(4)(B) of the Plan, if you terminate employment by reason of your Retirement (as the term is defined in the Plan or determined under local law), any Units that have not vested prior to the date of your Retirement shall immediately terminate and be forfeited in their entirety.

6.     Disability. If you terminate employment by reason of your Disability (as the term is defined in the Plan or determined under local law), any Units that have not vested prior to the date of your termination by reason of Disability shall immediately vest and shares of Stock shall be issued to you. Shares of Stock for Units which vest under this Section 6 will be delivered within thirty (30) days after your employment termination date.

7.    Other Termination of Employment; Certain Vesting Conditions. If your employment terminates for any reason other than death or Disability, any Units that have not vested prior to the date of your termination shall terminate and be forfeited on the effective date of such termination, except if your employment terminates for Cause, in which case, all unvested Units shall be forfeited upon notice to you of your termination for Cause. Subject to Sections 4 and 6 of this Agreement, the issuance of shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the applicable anniversary of the Grant Date as set forth in Section 2 above. For purposes of the vesting conditions set forth in this Agreement, the effective date of your termination shall be deemed to be the last day of your active service with the Company or an Affiliate (if applicable). Notwithstanding anything to the contrary in the Plan or this Agreement, and for purposes of clarity, the date of your termination of employment shall not be extended by any statutory or common law notice of termination period.

8.    Change in Control of the Company. In the event you are employed by the Company or an Affiliate at the time of a Change in Control, any Units that have not vested prior to the Change in Control shall immediately vest and shares of Stock will be issued to you immediately prior to the Change in Control; provided, however, that if you have entered into a Change in Control agreement with the Company, the Units will vest according to the provisions of the Change in Control agreement. In the event you have terminated employment with the Company or an Affiliate prior to a Change in Control as a result of death or Disability and the Change in Control occurs following your termination of employment, shares of Stock for any Units that have vested under Section 4 or 6 but which have not yet been issued will be issued immediately prior to the Change in Control. Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of a Change in Control on outstanding Awards which is in effect as of the Change in Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership

-Rev 1.2018                                                 AQ


EXHIBIT 10.6


of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii); provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.

9.    Recoupment Policy.

(a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

(i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

(1)    “Current Executive Officer” means any individual currently designated as an “officer” by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

(2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

(3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “officer” by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

(4)    “Recovery” means the forfeiture or cancellation of unvested Units.

(b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

10.    Consideration for Stock. The shares of Stock subject to the Units are intended to be issued for no cash consideration.







-Rev 1.2018                                                 AQ


EXHIBIT 10.6


11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (a) all federal, state and local laws and regulations, as the Company may deem applicable, have been complied with; (b) the shares have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (c) all other legal matters in connection with the issuance and delivery of the shares have been approved by the Company’s legal department.

12.    Transferability; Restrictions on Shares; Legend on Certificate. Until the vesting conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Committee, the Units awarded under this Agreement are not transferable and you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

13.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.





-Rev 1.2018                                                 AQ


EXHIBIT 10.6


Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

The Units are intended to comply with or be exempt from the requirements of Code Section 409A. The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of Stock, shall be based on the value of the Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.


-Rev 1.2018                                                 AQ


EXHIBIT 10.6


14.    Repatriation and Legal/Tax Compliance Requirements. If you are resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Units) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).
    
15.    Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.


-Rev 1.2018                                                 AQ


EXHIBIT 10.6


You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

Finally, upon request of the Company or the Employer, you agree to provide an executed data privacy consent form (or any other agreements or consents that may be required by the Company and/or the Employer) to the Company and/or the Employer that the Company and/or the Employer may deem necessary to obtain from you for the purpose of administering your participation in the Plan in compliance with the data privacy laws in your country, either now or in the future.  You understand and agree that you will not be able to participate in the Plan if you fail to provide any such consent or agreement requested by the Company and/or the Employer.


16.    Nature of Grant. By participating in the Plan, you acknowledge, understand and agree that:

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;




-Rev 1.2018                                                 AQ


EXHIBIT 10.6


(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying Shares, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and





-Rev 1.2018                                                 AQ


EXHIBIT 10.6


(l)    the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

17.    Not a Public Offering. The grant of the Units under the Plan is not intended to be a public offering of securities in your country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law, and the grant of the Units is not subject to the supervision of the local securities authorities.

18.    No Advice Regarding Grant. No Employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock subject to the Units. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Units and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

19.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

20.    Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.







-Rev 1.2018                                                 AQ


EXHIBIT 10.6


21.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.
    
22.    Language. If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

23.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the “Addendum”). Further, if you transfer your residence and/or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Addendum shall constitute part of this Agreement.

24.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

25.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

26.    Award Subject to the Plan; Conflicts. The Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Committee specifically for the grant described herein. Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the

-Rev 1.2018                                                 AQ


EXHIBIT 10.6


Committee retains the right to alter or modify the Units granted pursuant to this Agreement as the Committee may determine are in the best interests of the Company. You hereby accept the Units subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.

27.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston, or the federal courts for the United States for the District of Massachusetts and no other courts where the grant of the Units is made and/or to be performed.

28.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

29.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

30.     Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

31.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be the one and the same instrument.

-Rev 1.2018                                                 AQ


EXHIBIT 10.6


SIGNATURE PAGE

IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Participant have executed and delivered this Agreement as a sealed instrument as of the date and year first above written.


Number of Deferred Stock Units: %%TOTAL_SHARES_GRANTED%-%

Vesting Schedule
20%
%%VEST_DATE_PERIOD1%-%
20%
%%VEST_DATE_PERIOD2%-%
20%
%%VEST_DATE_PERIOD3%-%
20%
%%VEST_DATE_PERIOD4%-%
20%
%%VEST_DATE_PERIOD5%-%



                    BOSTON SCIENTIFIC CORPORATION        
                
                    mma04.gif
Michael F. Mahoney
President and Chief Executive Officer


PARTICIPANT



By: SIGNED BY ELECTRONIC SIGNATURE


By electronically accepting the Award, you agree that (i) such acceptance constitutes your electronic signature in execution of this Agreement; (ii) you agree to be bound by the provisions of the Plan, the Agreement and the Addendum; (iii) you have reviewed the Plan, the Agreement and the Addendum in their entirety, have had an opportunity to obtain the advice of counsel prior to accepting the Award and fully understand all of the provisions of the Plan, the Agreement and the Addendum; (iv) you have been provided with a copy or electronic access to a copy of the U.S. prospectus for the Plan and the tax supplement to the U.S. prospectus for your country, if applicable; and (v) you hereby agree to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Agreement and the Addendum.

-Rev 1.2018                                                 AQ


EXHIBIT 10.6


BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO DEFERRED STOCK UNITS GRANTED
PURSUANT TO THE 2011 LONG-TERM INCENTIVE PLAN

In addition to the terms of the Plan and the Agreement, the Units are subject to the following additional terms and conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 23 of the Agreement, if you transfer your residence and/or employment to another country reflected in the Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).

ARGENTINA

Type of Offering. Neither the grant of the Units, nor the issuance of shares of Stock subject to the grant, constitutes a public offering. The offering of the Plan is a private placement and is not subject to the supervision of any Argentine governmental authority.

AUSTRALIA

1.
Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.

2.
Tax Information. The Plan is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the “Act”) applies (subject to the conditions in that Act).

AUSTRIA

No country-specific provisions.

BELGIUM

No country-specific provisions.


-Rev 1.2018                                                 AQ


EXHIBIT 10.6






BRAZIL

1.
Compliance with Law. By accepting the Units, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the vesting of the Units, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.

2.
Labor Law Policy and Acknowledgement. This provision supplements Section 16 of the Agreement:

By accepting the Units, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment; and (iii) the income from the Units, if any, is not part of your remuneration from employment.

CANADA

1.    Settlement in Shares. Notwithstanding anything to the contrary in the Agreement or the Plan, all Units shall be settled only in shares of Stock (and shall not be settled in cash).

2.    Personal Data. This provision supplements Section 15 of the Agreement:

You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors. You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.

3.    Securities Law Information. You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares are listed (i.e., the New York Stock Exchange).

4.    Language Consent. The following provision will apply if you are a resident of Quebec:

The parties acknowledge that it is their express wish that the present Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Les parties reconnaissent avoir exigé la rédaction en anglais de la présente convention, ainsi que de tous documents, avis et procédures judiciaires, exécutés, donnés ou intentés en vertu de, ou liés directement ou indirectement à, la présente convention.


-Rev 1.2018                                                 AQ


EXHIBIT 10.6


CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

1.    Shares of Stock Must Be Held with Designated Broker. All shares of Stock issued upon settlement of your Units will be deposited into a personal brokerage account established with the Company’s designated broker, E*TRADE (or any successor broker designated by the Company), on your behalf. You understand that you may sell the shares of Stock at any time after they are deposited in such account, however, you may not transfer the shares of Stock out of the brokerage account.

2.    Mandatory Sale of Shares Following Termination of Employment. You are required to sell all shares of Stock acquired upon vesting of the Units no later than 90 days following your termination of employment with the Company and its Affiliates (or such earlier date as may be required by the China State Administration of Foreign Exchange (“SAFE”)), in which case, this Addendum shall give the Company the authority to issue sales instructions on your behalf). If any shares remain outstanding on the 90th day following your employment termination date (or such earlier date as may be required by SAFE), you hereby direct, instruct and authorize the Company to issue sale instructions on your behalf.

You agree to sign any additional agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds and other exchange control matters noted below) and shall otherwise cooperate with the Company with respect to such matters. You acknowledge that neither the Company nor the designated brokerage firm is under any obligation to arrange for such sale of shares of Stock at any particular price (it being understood that the sale will occur in the market) and that broker’s fees and similar expenses may be incurred in any such sale. In any event, when the shares of Stock are sold, the sale proceeds, less any tax withholding, any broker’s fees or commissions, and any similar expenses of the sale will be remitted to you in accordance with applicable exchange control laws and regulations.

3.    Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear

-Rev 1.2018                                                 AQ


EXHIBIT 10.6


any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.

4.    Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

COLOMBIA

Nature of Grant. This provision supplements Section 16 of the Agreement:
You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.

COSTA RICA

No country-specific provisions.

CZECH REPUBLIC

No country-specific provisions.

DENMARK

Treatment of Units upon Termination of Service. Notwithstanding any provisions in the Agreement to the contrary, if you are determined to be an “Employee” as defined in section 2 of the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the “Stock Option Act”), the treatment of the Units upon your termination of employment shall be governed by Section 4 and 5 of the Stock Option Act. However, if the provisions in the Agreement or the Plan governing the treatment of the Units upon a termination are more favorable, the provisions of the Agreement or the Plan will govern. You acknowledge having received an “Employer Information Statement” in Danish.


-Rev 1.2018                                                 AQ


EXHIBIT 10.6


FINLAND

No country-specific provisions.

FRANCE

1.    Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. of the French commercial code.

2.    Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

GERMANY

No country-specific provisions.

GREECE

No country-specific provisions.

HONG KONG

1.    Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Plan, the Units shall be settled only in shares of Stock (and may not be settled in cash).

2.    Lapse of Restrictions. If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.

3.    IMPORTANT NOTICE/WARNING. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Units and shares of Stock issued at vesting do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong. The Units are intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.


-Rev 1.2018                                                 AQ


EXHIBIT 10.6


4.    Wages. The Units and shares of Stock subject to the Units do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

5.    Nature of the Program. The Company specifically intends that the Plan will not be treated as an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”). To the extent any court, tribunal or legal/regulatory body in Hong Kong determines that the Plan constitutes an occupational retirement scheme for the purposes of ORSO, the grant of the Units shall be null and void.

INDIA

No country-specific provisions.

INDONESIA

No country-specific provisions.

IRELAND

No country-specific provisions.

ISRAEL

1.    Immediate Sale Restriction. Pursuant to Section 2 of the Agreement, when the Units vest, you understand and agree that all shares of Stock issued upon vesting immediately must be sold. You acknowledge and agree that the Company is authorized to issue sales instructions to the Company’s designated broker on your behalf pursuant to this authorization, and you expressly authorize the broker to complete the sale. You also agree to sign any agreements, forms and/or consents that may be reasonably requested by the Company or the Company’s designated broker to effectuate the sale of the shares of Stock and to cooperate with the Company and the Company’s designated broker with respect to such matters. When the shares of Stock are sold, a portion of the resulting sale proceeds will be used to cover any Tax-Related Items required to be withheld and any brokerage fees and expenses associated with the sale. The remaining proceeds will be paid to you as soon as practicable.

You acknowledge that neither the Company nor the Company’s designated broker is under any obligation to arrange for the sale of the shares of Stock at any particular price (it being understood that the sale will occur in the open market) and that brokerage fees and similar expenses may be incurred in any such sale. Due to fluctuations in the Stock price and/or applicable exchange rates between the date the Units vest and (if later) the date on which the shares of Stock are sold, the amount of proceeds ultimately may be more or less than the market value of the shares of Stock on the date the Units vest. You understand and agree that the Company assumes no liability for any fluctuations in the Stock price and/or any applicable exchange rate.



-Rev 1.2018                                                 AQ


EXHIBIT 10.6


2.    Securities Law Information.  The grant of Units under the Plan does not constitute a public offering under the Securities Law, 1968.

ITALY

Plan. This provision supplements Section 16 of the Agreement:
You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement: Vesting, Other Termination of Employment, Certain Vesting Conditions, Recoupment Policy, Issuance of Stock, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.
JAPAN

No country-specific provisions.

LEBANON

Securities Law Information. The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.

MALAYSIA

1.    Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board. You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board. (You may contact your Employer to request a form letter for this purpose.) You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.
















-Rev 1.2018                                                 AQ


EXHIBIT 10.6




2.    Consent to Collection, Processing and Transfer of Personal Data. This provision replaces Section 15 of the Agreement in its entirety:


You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.
You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.
You understand that Data will be transferred to the current stock plan service


Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian unit saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan.
Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua unit saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (“Data”). Data tersebut dibekalkan oleh Syarikat dan


-Rev 1.2018                                                 AQ


EXHIBIT 10.6


providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com. You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon vesting of the Units may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your

juga oleh anda berkenaan dengan Perjanjian dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com. Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad unit mungkin didepositkan.


-Rev 1.2018                                                 AQ


EXHIBIT 10.6


local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.
Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.

Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan unit saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda: Elly Kho, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8896; elly.kho@bsci.com.


-Rev 1.2018                                                 AQ


EXHIBIT 10.6


MEXICO

1.    Acknowledgement of the Agreement. By accepting the Units, you acknowledge that you have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed. You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum. You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in the “Nature of Grant” section of the Agreement, which clearly provide as follows:
(1)
Your participation in the Plan does not constitute an acquired right;
(2)
The Plan and your participation in it are offered by the Company on a wholly discretionary basis;
(3)
Your participation in the Plan is voluntary; and
(4)
The Company and its Affiliates are not responsible for any decrease in the value of any Shares acquired at vesting of the Units.
Reconocimiento del Contrato. Al aceptar los Unidades, usted reconoce que ha recibido una copia del Plan y del Contrato con inclusión de este Apéndice, que le ha examinado. Usted reconoce, además, que usted acepta todas las disposiciones del Plan y del Contrato. Usted también reconoce que ha leído y, concretamente, y aprobar de forma expresa los términos y condiciones establecidos en la “Naturaleza del Otorgamiento” que claramente dispone lo siguiente:
(1)
Su participación en el Plan no constituye un derecho adquirido;
(2)
El Plan y su participación en el Plan se ofrecen por Boston Scientific Corporation en su totalidad sobre una base discrecional;
(3)
Su participación en el Plan es voluntaria; y
(4)
Boston Scientific Corporation y sus afiliadas no son responsables de ninguna disminución en el valor de las acciones adquiridas en la adquisición de los Unidades.
2.    Labor Law Acknowledgement and Policy Statement. By accepting the Units, you acknowledge that Boston Scientific Corporation, with registered offices at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, United States of America, is solely responsible for the administration of the Plan. You further acknowledge that your participation in the Plan, the grant of Units and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (“Boston Scientific-Mexico”). Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and the Employer, Boston Scientific-Mexico, and do not form part of the employment conditions

-Rev 1.2018                                                 AQ


EXHIBIT 10.6


and/or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and/or discontinue your participation in the Plan at any time, without any liability to you.
Finally, you hereby declare that you do not reserve to you any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation, its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise.
Reconocimiento de Ausencia de Relación Laboral y Declaración de la Política. Al aceptar los Unidades, usted reconoce que Boston Scientific Corporation, con oficians registradas on 300 Boston Scientific Way, Marlborough, Massachusetts 01752, Estados Unidos de América, es el único responsable de la administración del Plan. Además, usted acepta que su participación en el Plan, la concesión de los Unidades y cualquier adquisición de acciones en el marco del Plan no constituyen una relación laboral entre usted y Boston Scientific Corporation porque usted está participando en el Plan en su totalidad sobre una base comercial y su único empleador es una sociedad mercantil Mexicana (“Boston Scientific-Mexico”). Derivado de lo anterior, usted expresamente reconoce que el Plan y los beneficios que pueden derivarse de la participación en el Plan no establece ningún derecho entre usted y su Empleador, Boston Scientific-Mexico, y que no forman parte de las condiciones de empleo y / o prestaciones previstas por Boston Scientific-Mexico, y cualquier modificación del Plan o la terminación de su contrato no constituirá un cambio o deterioro de los términos y condiciones de su empleo.
Además, usted entiende que su participación en el Plan es causada por una decisión discrecional y unilateral de Boston Scientific Corporation, por lo que Boston Scientific Corporation se reserva el derecho absoluto a modificar y/o suspender su participación en el Plan en cualquier momento, sin responsabilidad alguna para con usted.
Finalmente, usted manifiesta que no se reserva ninguna acción o derecho que origine una demanda en contra de Boston Scientific Corporation, por cualquier compensación o daño en relación con cualquier disposición del Plan o de los beneficios derivados del mismo, y en consecuencia usted otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliadas, sucursales, oficinas de representación, sus accionistas, directores, agentes y representantes legales con respecto a cualquier demanda que pudiera surgir.

-Rev 1.2018                                                 AQ


EXHIBIT 10.6




NETHERLANDS

Waiver of Termination Rights. By accepting the Units, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with the Company and the Employer for any reason whatsoever, insofar as those rights result or may result from (a) the loss or diminution in value of such rights or entitlements under the Plan, or (b) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.

NEW ZEALAND

Securities Law Notice.

Warning

This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.

If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid. You may lose some or all of your investment.

New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.

Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock.
No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The shares of Stock are quoted on the New York Stock Exchange. This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you invested. The price will depend on the demand for the shares of Stock.



-Rev 1.2018                                                 AQ


EXHIBIT 10.6


You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below:
1.
Boston Scientific Corporation’s most recent Annual Report (Form 10-K):
https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.
Boston Scientific Corporation’s most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

3.
The Boston Scientific Corporation 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.
Boston Scientific Corporation Deferred Stock Unit Award and 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

A copy of the above documents will be sent to you free of charge on written request being mailed to: Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

NORWAY

No country-specific provisions.

PHILIPPINES

Settlement in Cash. Pursuant Section 2 of the Agreement, the Company shall settle your Units in the form of a cash payment unless, at the time of vesting, share settlement does not trigger the need for any approval from and/or filing with the Philippines Securities and Exchange Commission.

POLAND

No country-specific provisions.

PORTUGAL

Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.

-Rev 1.2018                                                 AQ


EXHIBIT 10.6


Conhecimento da Lingua. Por meio do presente, eu declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano e no Acordo.

PUERTO RICO

No country-specific provisions.

RUSSIA
1.    U.S. Transaction. You understand that the Units shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States. Upon vesting of the Units, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States. In no event will shares of Stock be delivered to you in Russia; instead, all shares of Stock acquired upon vesting of the Units will be maintained on your behalf in the United States. You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.
2.    Repatriation Requirements. You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations. Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.
Depending on the development of local regulatory requirements, the Company reserves the right to settle the Units in cash and/or to pay any proceeds related to the Units to you through local payroll.
SINGAPORE

Private Placement. The grant of the Units is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Units are subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the grant in Singapore, unless such sale or offer is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.


-Rev 1.2018                                                 AQ


EXHIBIT 10.6




SOUTH AFRICA

1.    Responsibility for Taxes. This provision supplements Section 13 of the Agreement:
You are responsible for immediately notifying the Employer of the amount of any gain realized at vesting of the Units. If you fail to advise the Employer of such gain, you may be liable for a fine.
2.    Securities Law Notice. In compliance with South African securities law, the documents listed below are available for review on the Company’s external and internal sites at the web addresses listed below:
a.
Boston Scientific Corporation’s most recent Annual Report (Form 10-K):
https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

b.
The Boston Scientific Corporation 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
c.
Boston Scientific Corporation Deferred Stock Unit Award and 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn: Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.

SOUTH KOREA

Consent to Collection, Processing and Transfer of Personal Data. By electronically accepting this Agreement:

1.
You agree to the collection, use, processing and transfer of Data as described in Section 15 of the Agreement; and

2.
You agree to the processing of your unique identifying information (resident registration number) as described in Section 15 of the Agreement.


-Rev 1.2018                                                 AQ


EXHIBIT 10.6


SPAIN

Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement.

In accepting the grant of Units, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.

You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis. Consequently, you understand that the Units are granted on the assumption and condition that the Units and the shares of Stock acquired upon vesting of the Units shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the grant of the Units shall be null and void.

You understand and agree that, as a condition of the grant of the Units, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Units to the extent the Units have not vested as of date that you cease active employment. In particular, you understand and agree that any unvested Units as of the date you cease active employment will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985. You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Award.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

SWEDEN

No country-specific provisions.


-Rev 1.2018                                                 AQ


EXHIBIT 10.6


SWITZERLAND

Securities Law Information. The offer of the Units is considered a private offering in Switzerland and is therefore not subject to registration in Switzerland. Neither this document nor any other materials relating to the Units constitutes a prospectus as such term is understood pursuant to article 652a of the Swiss Code of Obligations, and neither this document nor any other materials relating to the Unit may be publicly distributed nor otherwise made publicly available in Switzerland.

TAIWAN

Securities Law Information. This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees. The Award is not a public offer of securities by a Taiwanese company.

THAILAND

No country-specific provisions.

TURKEY

Securities Law Information. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.

UNITED ARAB EMIRATES

Securities Law Information. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of the Agreement or the Plan, you should consult an authorized financial advisor.

-Rev 1.2018                                                 AQ


EXHIBIT 10.6





UNITED KINGDOM

1.     Income Tax and Social Insurance Contribution Withholding. The following provision shall supplement Section 13 of the Agreement:

Without limitation Section 13 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

2.     Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.
 

6677790-v4\GESDMS


-Rev 1.2018                                                 AQ

EX-10.7 8 exhibit107-2018_rsaxawardx.htm EXHIBIT 10.7 Exhibit
EXHIBIT 10.7


BOSTON SCIENTIFIC CORPORATION

RESTRICTED STOCK AWARD AGREEMENT
FOR NON-EMPLOYEE DIRECTORS


This Agreement, dated as of the %%OPTION_DATE,’Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company’s 2011 Long Term Incentive Plan, as amended from time to time (the “Plan”).

1.    Grant and Acceptance of Award. The Company hereby awards to the Participant that number of shares set forth on the Signature Page of this Agreement (the “Restricted Stock”) of the Company’s Stock, subject to the restrictions set forth below. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of the Restricted Stock.

2.    Restrictions on Shares of Stock. Shares of Restricted Stock awarded hereunder shall be subject to the forfeiture restrictions described in Section 5 hereof and the limits on transferability described in Section 12 below.

3.    Lapse of Restrictions. Except as otherwise provided in Section 5 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the “Director Deferred Compensation Plan”)) and Section 6 hereof (relating to a Change in Control of the Company), shares of Restricted Stock awarded hereunder shall become free of the forfeiture restrictions described in Section 5 hereof on the last day of the Participant’s current term as a non-employee director of the Company.

4.    Participant’s Rights in Restricted Stock. The shares of Restricted Stock awarded hereunder shall be evidenced in the manner as the Company may determine. Any shares issued shall be registered in the name of the Participant and any certificates representing those shares may be held by the Company and not be delivered to the Participant until the lapse of all forfeiture restrictions with respect to the shares. The Participant agrees to deliver a stock power, endorsed in blank, relating to the shares of Restricted Stock awarded hereunder, if so requested by the Company. During the period that shares of Restricted Stock are subject to forfeiture (subject, however, to Section 12 of this Agreement relating to limits on transferability), the Participant will have all the rights of a stockholder of the Company with respect to the shares, including the right to receive dividends and the right to vote the shares.


-Rev. 1.2018


EXHIBIT 10.7

5.    Separation From Service. If the Participant experiences a Separation From Service (as defined in the Director Deferred Compensation Plan) from the Company for any reason other than for cause (as defined in Section 4.a(4)(C) of the Plan) prior to the end of the Participant’s current term as a non-employee director of the Company, any shares of Restricted Stock awarded hereunder that remain subject to forfeiture shall be free of restrictions pro rata based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of such shares shall be immediately and automatically forfeited to the Company. If the Participant experiences a Separation From Service from the Company for cause (as defined in Section 4.a(4)(C) of the Plan), any shares of Restricted Stock awarded hereunder that have not been delivered to the Participant shall be immediately and automatically forfeited to the Company.

6.    Change in Control of the Company. In the event of a Change in Control of the Company, any shares of Restricted Stock awarded hereunder that remain subject to forfeiture shall immediately be free of restrictions.

7.    Consideration for Restricted Stock. The shares of Restricted Stock are being issued for no cash consideration.

8.    Legend on Certificate. The certificates representing the shares of Restricted Stock awarded hereunder, if delivered to the Participant prior to the lapse of the forfeiture restrictions, shall bear a legend substantially in the following form:

The transferability of this certificate and the shares of stock represented hereby are subject to the terms and conditions (including forfeiture) of a Boston Scientific Corporation Long-Term Incentive Plan and a Restricted Stock Award Agreement entered into between the registered owner and Boston Scientific Corporation. Copies of the Plan and Agreement are on file in the offices of Boston Scientific Corporation at 300 Boston Scientific Way, Marlborough, MA 01752, USA.

In addition, certificates representing shares of Restricted Stock shall also bear an Affiliate Legend.

9.    Delivery of Stock. The Company shall not be obligated to deliver any shares of Restricted Stock awarded hereunder until (i) all federal and state laws and regulations as the Company may deem applicable have been complied with, and (ii) all other legal matters in connection with the issuance and delivery of such shares have been approved by the Company’s legal department.






-Rev. 1.2018


EXHIBIT 10.7

10.    Responsibility for Taxes; Tax Withholding. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance or other taxes of any kind (“Tax-Related Items”) required by law to be paid with respect to the shares of Restricted Stock awarded hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. If the Participant elects pursuant to Code Section 83(b) to recognize taxable income in connection with the award of Restricted Stock pursuant to this Agreement, the Participant must notify the U.S. Internal Revenue Service (with a copy to the Company) of such election in writing within thirty (30) days of the Grant Date and must pay in cash to the Company the amount of withholding and other tax obligations associated with the election or make other arrangements satisfactory to the Company for the payment thereof. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Restricted Stock award, and (b) does not commit to structure the terms of the award to reduce or eliminate the Participant’s liability for Tax-Related Items.

The Company shall have the right and is hereby authorized to withhold Tax-Related Items required by law to be withheld with respect to the shares of Restricted Stock awarded hereunder from any compensation or other amount owing to the Participant, as may be necessary in the opinion of the Company to satisfy all such Tax-Related Items, requirements and withholding obligations. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

11.    Investment Intent. The Participant acknowledges that the acquisition of the Restricted Stock is for investment purposes without a view to distribution thereof.

12.    Limits on Transferability. Until the restrictions imposed upon the Restricted Stock by this Agreement lapse in accordance with the terms of this Agreement and any applicable Addendum or by action of the Administrator, the shares of Restricted Stock awarded and accepted hereby are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by the Participant. Transfers of shares of Stock by the Participant are subject to the Company’s Stock Trading Policy and any applicable laws, rules and regulations.

13.    Repatriation and Legal/Tax Compliance Requirements. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the shares of Restricted Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the award) in accordance with local foreign exchange rules and regulations in the Participant’s country of residence. In addition, the Participant agrees to take any and all actions, and consent to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant’s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant’s personal legal and tax obligations under local laws, rules and regulations in the Participant’s country of residence.


-Rev. 1.2018


EXHIBIT 10.7

14.    Data Privacy. The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant’s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant’s participation in the Plan.

The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant’s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all shares of Restricted Stock awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor (“Data”) for the purpose of implementing, managing and administering the Plan.

The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. The Participant understands the recipients of the Data may be located in the Participant’s country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than the Participant’s country. The Participant understands that the Participant may request a list with the names and addresses of any potential recipients of the Data by contacting the Company’s Vice President, Total Rewards.

The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant’s participation in the Plan. The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant’s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired under the Plan. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company’s Vice President, Total Rewards. Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant’s service with the Company will not be adversely affected; the only consequence of refusing or withdrawing the Participant’s consent is that the Company would not be able to grant the Participant shares of Restricted Stock or other equity awards or administer or maintain such awards. Therefore, the Participant understands that refusing or withdrawing the Participant’s consent may affect the Participant’s ability to participate in the Plan. For more information on the consequences of the Participant’s refusal

-Rev. 1.2018


EXHIBIT 10.7

to consent or withdrawal of consent, the Participant understands that he or she may contact the Company’s Vice President, Total Rewards.

Finally, upon request of the Company, the Participant agrees to provide an executed data privacy consent form (or any other agreements or consents that may be required by the Company) to the Company that the Company may deem necessary to obtain from the Participant for the purpose of administering the Participant’s participation in the Plan in compliance with the data privacy laws in the Participant’s country, either now or in the future. The Participant understands and agrees that the Participant will not be able to participate in the Plan if the Participant fails to provide any such consent or agreement requested by the Company.

15.    Nature of Grant. By participating in the Plan, the Participant acknowledges, understands and agrees that:

(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)    the grant of shares of Restricted Stock is voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of shares of Restricted Stock, even if shares of Restricted Stock have been granted in the past;

(c)    all decisions with respect to future grants of shares of Restricted Stock, if any, will be at the sole discretion of the Administrator;

(d)    the grant of the shares of Restricted Stock and the Participant’s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates; further, the award of shares of Restricted Stock hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law;

(e)    the Participant is voluntarily participating in the Plan;

(f)    the future value of the shares of Restricted Stock is unknown, indeterminable and cannot be predicted with certainty;

(g)    no claim or entitlement to compensation or damages shall arise from forfeiture of the shares of Restricted Stock resulting from the termination of the service relationship; and






-Rev. 1.2018


EXHIBIT 10.7

(h)    the following provisions apply only if the Participant is resident outside the United States: (A) the shares of Restricted Stock, and the income and value of same are not part of normal or expected compensation for any purpose; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant’s local currency and the U.S. dollar that may affect the value of the shares of Restricted Stock or of any amount due to the Participant upon lapse of restrictions on the Restricted Stock or the subsequent sale of any shares of Stock acquired.

16.    Not a Public Offering. If the Participant is resident outside the United States, the grant of Restricted Stock under the Plan is not intended to be a public offering of securities in the Participant’s country of residence. The Company has not submitted any registration statement, prospectus or other filings to securities authorities outside the United States unless otherwise required under local law, and the grant of Restricted Stock is not subject to the supervision of securities authorities outside the United States.

17.    Insider Trading Restrictions/Market Abuse Laws. The Participant acknowledges that, depending on the Participant’s or his or her broker’s country of residence or where the shares of Stock are listed, the Participant may be subject to insider trading restrictions and/or market abuse laws that may affect the Participant’s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock or rights linked to the value of shares (e.g., phantom awards, futures) during such times the Participant is considered to have “inside information” regarding the Company, as defined in the laws or regulations in the Participant’s country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Participant placed before the Participant possessed insider information. Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Participant acknowledges that it is the Participant’s responsibility to comply with any restrictions and is advised to speak to the Participant’s personal advisor on this matter.

18.    No Advice Regarding Grant. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant’s acquisition or sale of the shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Restricted Stock and the Plan. The Participant is hereby advised to consult with the Participant’s own personal tax, legal and financial advisors before taking any action related to the Plan.

19.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Restricted Stock and participation in the Plan or future grants of Restricted Stock that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.

-Rev. 1.2018


EXHIBIT 10.7

    
20.    Language. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant’s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Restricted Stock, be drawn up in English. If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Restricted Stock translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

21.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Restricted Stock shall be subject to any special terms and conditions for the Participant’s country of residence as are forth in an applicable addendum to the Agreement, if any (the “Addendum”). Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant’s transfer of residence). Any applicable Addendum shall constitute part of this Agreement.

22.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Restricted Stock, any shares of Stock acquired pursuant to the Restricted Stock and the Participant’s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Restricted Stock or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

23.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

24.    Award Subject to the Plan; Conflicts. The award of Restricted Stock granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the award of Restricted Stock granted pursuant to this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the award of Restricted Stock subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and

-Rev. 1.2018


EXHIBIT 10.7

interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant’s heirs and legal representatives.

25.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For the purpose of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.

26.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

27.    Severability. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

28.    Waiver. The Participant understands that the waiver by the Company with respect to the Participant’s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.

29.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]














-Rev. 1.2018


EXHIBIT 10.7



IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.



PLAN: 2011 LONG TERM INCENTIVE PLAN
Number of Shares: %%TOTAL_SHARES_GRANTED%-%

BOSTON SCIENTIFIC CORPORATION

                    mm.gif
Name: Michael F. Mahoney
Title: President and Chief Executive Officer


%%FIRST_NAME%-% %%LAST_NAME%-%
PARTICIPANT*


*Signed via electronic signature    

By electronically accepting the Award, THE PARTICIPANT agreeS that (i) such acceptance constitutes THE PARTICIPANT’S electronic signature in execution of this Agreement; (ii) THE PARTICIPANT agreeS to be bound by the provisions of the Plan, the Agreement and ANY Addendum; (iii) THE PARTICIPANT HAS reviewed the Plan, the Agreement and ANY Addendum in their entirety, haS had an opportunity to obtain the advice of counsel prior to accepting the Award and fully understandS all of the provisions of the Plan, the Agreement and ANY Addendum; (iv) THE PARTICIPANT HAS been provided with a copy or electronic access to a copy of the U.S. prospectus for the Plan; and (v) THE PARTICIPANT hereby agreeS to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Agreement and ANY Addendum.

6677167-v3\GESDMS


-Rev. 1.2018

EX-10.8 9 exhibit108-2018_dsuxawardx.htm EXHIBIT 10.8 Exhibit
EXHIBIT 10.8




BOSTON SCIENTIFIC CORPORATION


DEFERRED STOCK UNIT AWARD AGREEMENT
FOR NON-EMPLOYEE DIRECTORS



This Agreement, dated as of the %%OPTION_DATE,’Month DD, YYYY%-% (the “Grant Date”), is between Boston Scientific Corporation, a Delaware corporation (the “Company”), and the person whose name appears on the Signature Page of this Agreement (the “Participant”), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company’s 2011 Long Term Incentive Plan, as amended from time to time (the “Plan”).


1.    Grant and Acceptance of Award. The Company hereby awards to the Participant that number of Deferred Stock Units set forth on the Signature Page of this Agreement (the “Units”). Each Unit represents the Company’s commitment to issue to the Participant one share of Stock, subject to the conditions set forth in this Agreement. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of Units.


2.    Restrictions on Units. Units awarded hereunder shall be subject to the forfeiture restrictions described in Section 5 hereof and the limits on transferability described in Section 11 below.


3.    Vesting. Except as otherwise provided in Section 5 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the “Director Deferred Compensation Plan”)) and Section 6 hereof (relating to a Change in Control Event (as defined in the Director Deferred Compensation Plan)), the Units awarded hereunder shall vest in full on the last day of the Participant’s current term as a non-employee director of the Company.


4.    Participant’s Rights in Stock. The shares of Stock, if and when issued to the Participant pursuant to this Agreement, shall be registered in the Participant’s name and evidenced in a manner as determined by the Company, in its sole discretion. Under no circumstance will the Participant be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested and the underlying shares of Stock have been issued to the Participant.


-Rev. 1.2018


EXHIBIT 10.8


5.    Separation From Service. If the Participant experiences a Separation From Service (as defined in the Director Deferred Compensation Plan) from the Company for any reason other than for cause (as defined in Section 4.a(4)(C) of the Plan) prior to the end of the Participant’s current term as a non-employee director of the Company, any Units awarded hereunder that remain unvested shall vest pro rata based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of such Units shall be immediately and automatically forfeited. If the Participant experiences a Separation From Service from the Company for cause (as defined in Section 4.a(4)(C) of the Plan), any Units awarded hereunder that have not been settled shall be immediately and automatically forfeited.


6.    Change in Control Event. In the event of a Change in Control Event (as defined in the Director Deferred Compensation Plan), any unvested Units shall immediately vest in full.


7.    Consideration for Stock. The shares of Stock subject to the Units are intended to be issued for no cash consideration.


8.    Issuance of Stock. Shares of Stock will be issued in settlement of vested Units within sixty (60) days after the earlier of (i) a Change in Control Event or (ii) the Participant’s Separation From Service (as defined in the Director Deferred Compensation Plan). Notwithstanding the foregoing, in the event that a Participant is a Specified Employee (as defined in the Director Deferred Compensation Plan) at the time of his Separation From Service, then notwithstanding any other provision of the Plan, unless the Participant’s Separation From Service is by reason of the Participant’s death, then any Units that becomes payable under the Plan due to the Participant’s Separation From Service will be paid six (6) months and one (1) day after the date on which the Participant’s Separation From Service occurs.

The Company shall not be obligated to issue any shares of Stock until (a) all federal, state and local laws and regulations, as the Company may deem applicable, have been complied with; (b) the shares have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (c) all other legal matters in connection with the issuance and delivery of the shares have been approved by the Company’s legal department.

Further, notwithstanding anything in the Agreement to the contrary, if the Participant resides outside the United States, the Company may, in its sole discretion, settle the Units in the form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company to obtain the approval of or complete any legal or regulatory filing with any governmental and/or regulatory body in the Participant’s country of residence. Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require the Participant to sell such shares of Stock immediately or within a specified time following the Participant’s Separation From Service (in which case, this Agreement shall give the Company the authority to issue sales instructions on the Participant’s behalf).

-Rev. 1.2018


EXHIBIT 10.8



9.    Responsibility for Taxes; Tax Withholding. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance or other taxes of any kind (“Tax-Related Items”) required by law to be paid with respect to the grant, vesting and settlement of Units hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) does not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate the Participant’s liability for Tax-Related Items.

Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if the withholding of Tax-Related Items is required, the Company may hold back from the total number of shares of Stock to be delivered to the Participant, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the grant of Units, the Participant expressly consents to the withholding of shares of Stock and/or cash as provided for hereunder.

Alternatively, the Participant hereby authorizes the Company (on the Participant’s behalf and at the Participant’s direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. The Participant agrees to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from the Participant’s compensation or any other amounts payable to the Participant, with no withholding of shares of Stock or sale of shares of Stock, or may require the Participant to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.

All other Tax-Related Items related to the grant or vesting of Units and any shares of Stock delivered in settlement thereof are the Participant’s sole responsibility. In no event shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.


-Rev. 1.2018


EXHIBIT 10.8


The Units are intended to comply with or be exempt from the requirements of Code Section 409A. The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without the Participant’s consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A. Notwithstanding any action or inaction by the Administrator, the Participant is exclusively responsible for any tax consequences under Code Section 409A resulting from the award of Units.


10.    Investment Intent. The Participant acknowledges that the acquisition of the Units and underlying shares of Stock is for investment purposes without a view to distribution thereof.


11.    Transferability; Restrictions on Shares; Legend on Certificate. Until the vesting conditions of this award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Administrator, the Units awarded under this Agreement are not transferable and the Participant shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement. Transfers of shares of Stock by the Participant are subject to the Company’s Stock Trading Policy and applicable laws, rules and regulations. Shares of Stock issued to the Participant in certificate form or to the Participant’s book entry account upon settlement of the Units may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon the Participant’s book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.


12.    Repatriation and Legal/Tax Compliance Requirements. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the Units and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the award) in accordance with local foreign exchange rules and regulations in the Participant’s country of residence. In addition, the Participant agrees to take any and all actions, and consent to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant’s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant’s personal legal and tax obligations under local laws, rules and regulations in the Participant’s country of residence.









-Rev. 1.2018


EXHIBIT 10.8


13.    Data Privacy. The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant’s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant’s participation in the Plan.

The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant’s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor (“Data”) for the purpose of implementing, managing and administering the Plan.

The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. The Participant understands the recipients of the Data may be located in the Participant’s country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than the Participant’s country. The Participant understands that the Participant may request a list with the names and addresses of any potential recipients of the Data by contacting the Company’s Vice President, Total Rewards.

The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant’s participation in the Plan. The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant’s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired upon settlement of the Units. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company’s Vice President, Total Rewards. Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant’s service with the Company will not be adversely affected; the only consequence of refusing or withdrawing the Participant’s consent is that the Company would not be able to grant the Participant Units or other equity awards or administer or maintain such awards. Therefore, the Participant understands that refusing or withdrawing the Participant’s consent may affect the Participant’s ability to participate in the Plan. For more information on the consequences of the Participant’s refusal

-Rev. 1.2018


EXHIBIT 10.8


to consent or withdrawal of consent, the Participant understands that he or she may contact the Company’s Vice President, Total Rewards.

Finally, upon request of the Company, the Participant agrees to provide an executed data privacy consent form (or any other agreements or consents that may be required by the Company) to the Company that the Company may deem necessary to obtain from the Participant for the purpose of administering the Participant’s participation in the Plan in compliance with the data privacy laws in the Participant’s country, either now or in the future. The Participant understands and agrees that the Participant will not be able to participate in the Plan if the Participant fails to provide any such consent or agreement requested by the Company.

14.    Nature of Grant. By participating in the Plan, the Participant acknowledges, understands and agrees that:

(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)    the grant of the Units is voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)    all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)    the grant of the Units and the Participant’s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates; further, the award of Units hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law;

(e)    the Participant is voluntarily participating in the Plan;

(f)    the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(g)    no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of the service relationship; and

(h)    the following provisions apply only if the Participant is resident outside the United States: (A) the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for any purpose; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant’s local currency and the U.S. dollar that may affect the value of the Units or of any amount due to the Participant pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.


-Rev. 1.2018


EXHIBIT 10.8


15.    Not a Public Offering. If the Participant is resident outside the United States, the grant of Units under the Plan is not intended to be a public offering of securities in the Participant’s country of residence. The Company has not submitted any registration statement, prospectus or other filings to securities authorities outside the United States unless otherwise required under local law, and the grant of Units is not subject to the supervision of securities authorities outside the United States.

16.    No Advice Regarding Grant. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant’s acquisition or sale of the shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Units and the Plan. The Participant is hereby advised to consult with the Participant’s own personal tax, legal and financial advisors before taking any action related to the Plan.

17.    Insider Trading Restrictions/Market Abuse Laws. The Participant acknowledges that, depending on the Participant’s or his or her broker’s country of residence or where the shares of Stock are listed, the Participant may be subject to insider trading restrictions and/or market abuse laws that may affect the Participant’s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times the Participant is considered to have “inside information” regarding the Company, as defined in the laws or regulations in the Participant’s country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Participant placed before the Participant possessed insider information. Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. The Participant acknowledges that it is the Participant’s responsibility to comply with any restrictions and is advised to speak to the Participant’s personal advisor on this matter.

18.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.






    

-Rev. 1.2018


EXHIBIT 10.8


19.    Language. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant’s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

20.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for the Participant’s country of residence as are forth in an applicable addendum to the Agreement, if any (the “Addendum”). Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Units or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant’s transfer of residence). Any applicable Addendum shall constitute part of this Agreement.

21.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and the Participant’s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Units or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

22.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

23.    Award Subject to the Plan; Conflicts. The award of Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the award of Units granted pursuant to this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the Units subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant’s heirs and legal representatives.


-Rev. 1.2018


EXHIBIT 10.8


24.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For the purpose of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.

25.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

26.     Severability. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

27.    Waiver. The Participant understands that the waiver by the Company with respect to the Participant’s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.

28.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]

-Rev. 1.2018


EXHIBIT 10.8



IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.



PLAN: 2011 LONG TERM INCENTIVE PLAN
Number of Units: %%TOTAL_UNITS_GRANTED%-%

BOSTON SCIENTIFIC CORPORATION
    
                    mma05.gif
Name: Michael F. Mahoney
Title: President and Chief Executive Officer


%%FIRST_NAME%-% %%LAST_NAME%-%
PARTICIPANT*


*Signed via electronic signature    

By electronically accepting the Award, THE PARTICIPANT agreeS that (i) such acceptance constitutes THE PARTICIPANT’S electronic signature in execution of this Agreement; (ii) THE PARTICIPANT agreeS to be bound by the provisions of the Plan, the Agreement and ANY Addendum; (iii) THE PARTICIPANT HAS reviewed the Plan, the Agreement and ANY Addendum in their entirety, haS had an opportunity to obtain the advice of counsel prior to accepting the Award and fully understandS all of the provisions of the Plan, the Agreement and ANY Addendum; (iv) THE PARTICIPANT HAS been provided with a copy or electronic access to a copy of the U.S. prospectus for the Plan; and (v) THE PARTICIPANT hereby agreeS to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Agreement and ANY Addendum.

6677168-v4\GESDMS


-Rev. 1.2018

EX-10.9 10 exhibit109-2018_nqsoxaward.htm EXHIBIT 10.9 Exhibit
EXHIBIT 10.9



Boston Scientific Corporation

Non-Qualified Stock Option Award Agreement
for Non-Employee Directors


This Agreement, dated as of the %%OPTION_DATE,’Month DD, YYYY%-% (the "Grant Date"), is between Boston Scientific Corporation, a Delaware corporation (the "Company"), and the person whose name appears on the Signature Page of this Agreement (the "Participant"), a non-employee director of the Company. All capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in the Company's 2011 Long Term Incentive Plan, as amended from time to time (the "Plan").

1.    Grant and Acceptance of Award. The Company hereby awards to the Participant a Stock Option to purchase that number of shares of Stock set forth on the Signature Page of this Agreement at the price set forth herein (the "Grant Price"). The Grant Price is equal to the Fair Market Value of the Company’s Stock on the Grant Date. This award is granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan. The Participant hereby accepts the award of the Stock Option.

2.    Vesting and Term of Stock Option. Except as otherwise provided in Section 4 hereof (relating to a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the “Director Deferred Compensation Plan”)) and Section 5 hereof (relating to a Change in Control of the Company), the Stock Option awarded hereunder shall vest in full on the last day of the Participant’s current term as a non-employee director of the Company and have a term of ten (10) years from %%OPTION_DATE,’Month DD, YYYY%-% until %%EXPIRE_DATE_PERIOD1,’Month DD, YYYY%-% (the “Expiration Date”). If the Expiration Date falls on a date on which the New York Stock Exchange is closed for trading, the Expiration Date shall be the trading day immediately prior to the Expiration Date.

3.    Exercise of Stock Option. Once the Stock Option vests and while the Stock Option remains exercisable, the Participant may exercise the Stock Option by delivering to the Company or its designee, in the form and at the location specified by the Company, a notice stating the Participant’s intent to exercise the Stock Option to purchase a specified number of shares of Stock and pay the full Grant Price for such shares of Stock. Payment in full for the number of shares of Stock being acquired may be paid in such manner as the Administrator may specify from time to time, in its sole discretion, including, but not limited to the following: (a) in cash, (b) by certified check or bank draft payable in U.S. dollars ($US) to the order of the Company, (c) in whole or in part in shares of Stock owned by the Participant, valued at Fair Market Value, or (d) if available to the Participant, via cashless exercise, by which the Participant delivers to the Participant’s securities broker instructions to sell a sufficient number of shares of Stock acquired pursuant to the Stock Option to cover the Grant Price, any applicable tax obligations and the brokerage fees and expenses associated therewith. Notwithstanding the foregoing, if the Participant resides in a country where the local foreign exchange rules and regulations either preclude the remittance of currency out of

-Rev. 1.2018


EXHIBIT 10.9


the country for purposes of paying the Grant Price for the shares of Stock being acquired, or require the Company and/or the Participant to secure any legal or regulatory approvals, complete any legal or regulatory filings, or undertake any additional steps for remitting currency out of the country, the Company may restrict the method of exercise to a form of cashless exercise (either a cashless “sell all” exercise and/or a cashless “sell to cover” exercise) as it shall determine in its sole discretion.

The exercise date applicable to the Participant’s exercise of the Stock Option pursuant to this Section 3 will be deemed to be the date on which the Company receives the Participant’s irrevocable commitment to exercise the Stock Option in writing, subject to the Participant’s payment in full of the Grant Price for the shares of Stock to be acquired within 10 (ten) days of the notice of exercise of the Stock Option. The notice and payment in full of Grant Price for the shares of Stock being acquired must be received by the Company or its designee on or prior to the last day of the Stock Option term, as set forth in Section 2 above, except as provided in Sections 4 and 5 below.

Upon the Company’s determination that there has been a valid exercise of the Stock Option, the Company shall issue certificates in accordance with the terms of this Agreement or cause the Company’s transfer agent to make the necessary book entries for the shares of Stock subject to the exercised Stock Option. However, the Company shall not be liable to the Participant, the Participant’s personal representative or the Participant’s successor(s)-in-interest for damages relating to any delays in issuing the certificates or in making book entries, any loss of the certificates, or any mistakes or errors in the issuance of the certificates or in making book entries, or in the certificates themselves.

The Company shall not be obligated to issue any shares of Stock until (a) all federal, state and local laws and regulations, as the Company may deem applicable, have been complied with; (b) the shares have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (c) all other legal matters in connection with the issuance and delivery of the shares have been approved by the Company’s legal department.

4.    Separation From Service.

a.    If the Participant experiences a Separation From Service (as defined in the Boston Scientific Corporation Non-Employee Director Deferred Compensation Plan, as may be amended from time to time (the “Director Deferred Compensation Plan”)) from the Company for any reason other than for cause (as defined in Section 4.a(4)(C) of the Plan) prior to the end of the Participant’s current term as a non-employee director of the Company, the Stock Option shall vest with respect to a pro rata number of shares of Stock subject to the Stock Option based on the number of months of service completed by the Participant (rounded up to the nearest whole month) prior to such Separation From Service, and the remainder of the Stock Option shall be immediately and automatically forfeited. The vested portion of the Stock Option shall remain exercisable by the Participant or the Participant’s appointed representative until the Stock Option Expiration Date or such other term as the Administrator may determine at or after grant, provided that such exercise period does not extend beyond the original Expiration Date.


-Rev. 1.2018


EXHIBIT 10.9


b.    If the Participant experiences a Separation From Service from the Company for cause (as defined in Section 4.a(4)(C) of the Plan), the Stock Option, whether vested or unvested, shall be forfeited.

c.    The Stock Option, to the extent unexerciseable on the date following the end of any period described above or the term of the Stock Option set forth above in Section 2, shall thereupon be forfeited.

d.    Any one of the Participant’s permitted transferee(s) (pursuant to Section 7 below) shall receive the rights herein granted subject to the terms and conditions of this Agreement and any applicable Addendum. No transfer of this Stock Option shall be approved and effected by the Administrator unless (i) the Administrator shall have been timely furnished with written notice of such transfer and any copies of such notice as the Administrator may deem, in its sole discretion, necessary to establish the validity of the transfer; (ii) the transferee or transferees shall have agreed in writing to be bound by the terms and conditions of this Agreement and any applicable Addendum; and (iii) such transfer complies with applicable laws and regulations.

e.    If the Participant resides in a country where the local foreign exchange rules and regulations require the repatriation of sale proceeds, the Company may require the Participant to sell any shares of Stock acquired under the Plan within a specified period following the Participant’s Separation From Service (as defined in the Director Deferred Compensation Plan) (in which case, this Agreement shall give the Company the authority to issue sales instructions on the Participant’s behalf).

5.    Change in Control. Immediately prior to a Change in Control, any unvested portion of the Stock Option shall vest and become exercisable on a basis that gives the Participant a reasonable opportunity to participate as a stockholder in the Change in Control. In addition, the Stock Option shall terminate immediately prior to the Change in Control unless the Stock Option is exercised coincident therewith.

6.    Restrictions on Shares; Legend on Certificate. Shares of Stock issued to the Participant in certificate form or to the Participant’s book entry account upon exercise of the Stock Option may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon the Participant’s book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

7.    Transferability. Except as required by law, the Participant shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of the Stock Option granted under this Agreement other than by will or the laws of descent and distribution or without payment of consideration to the Participant’s Family Members or to trusts or other entities for the benefit of the Participant’s Family Members. During the Participant’s lifetime, the Stock Option is exercisable only by the Participant, subject to Section 4 above. Transfers of shares of Stock by the Participant are subject to the Company’s Stock Trading Policy and applicable laws, rules and regulations.

-Rev. 1.2018


EXHIBIT 10.9



8.    Responsibility for Taxes; Tax Withholding. The Participant shall be responsible for the payment of any and all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance or other taxes of any kind (“Tax-Related Items”) required by law to be paid with respect to the grant, vesting and exercise of the Stock Option hereunder, including, without limitation, the payment of any applicable withholding, Self-Employment Contributions Act of 1954, as amended, and similar taxes or obligations. The Company (a) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Stock Option, including the grant of the Stock Option, the vesting of the Stock Option, the exercise of the Stock Option, the subsequent sale of any shares of Stock acquired upon exercise of the Stock Option and the receipt of any dividends, and (b) does not commit to structure the terms of the grant or any aspect of the Stock Option to reduce or eliminate the Participant’s liability for Tax-Related Items.

Prior to the delivery of shares of Stock upon exercise of the Stock Option, if the Participant’s country of residence requires withholding of Tax-Related Items, the Company may withhold a sufficient whole number of shares of Stock otherwise issuable upon exercise of the Stock Option that has an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld or, to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion withhold shares of Stock based on a rate of up to the maximum applicable withholding rate. The cash equivalent of the shares of Stock withheld will be used to settle the obligation to withhold the Tax-Related Items. By accepting the Stock Option, the Participant expressly consents to the withholding of shares of Stock as provided for hereunder.

Alternatively, the Participant hereby authorizes the Company (on the Participant’s behalf and at the Participant’s direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon exercise resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. The Participant agrees to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from the Participant’s compensation or any other amounts payable to the Participant, with no withholding of shares of Stock or sale of shares of Stock, or may require the Participant to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Stock Option.

All other Tax-Related Items related to the Stock Option and any shares of Stock delivered in settlement of an exercised Stock Option are the Participant’s sole responsibility. In no event, shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. The Participant agrees to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.


-Rev. 1.2018


EXHIBIT 10.9


The Stock Option is intended to be exempt from the requirements of Section 409A of the Code. The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without the Participant’s consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

9.    Repatriation and Legal/Tax Compliance Requirements. If the Participant is resident outside of the United States, the Participant agrees to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of shares of Stock) in accordance with local foreign exchange rules and regulations in the Participant’s country of residence. In addition, the Participant agrees to take any and all actions, and consents to any and all actions taken by the Company, as may be required to allow the Company to comply with local laws, rules and regulations in the Participant’s country of residence. Finally, the Participant agrees to take any and all actions as may be required to comply with the Participant’s personal legal and tax obligations under local laws, rules and regulations in the Participant’s country of residence.

10.    Data Privacy. The Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant’s personal data as described in this Agreement and any other grant materials by the Company for the exclusive purpose of implementing, administering and managing the Participant’s participation in the Plan.

The Participant understands that the Company may hold certain personal information about the Participant, including (but not limited to) the Participant’s name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), nationality, job title, any shares of Stock or directorships held in the Company, and details of all Stock Options awarded to the Participant or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor (“Data”) for the purpose of implementing, managing and administering the Plan.

The Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. The Participant understands the recipients of the Data may be located in the Participant’s country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than the Participant’s country. The Participant understands that the Participant may request a list with the names and addresses of any potential recipients of the Data by contacting the Company’s Vice President, Total Rewards.

The Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing

-Rev. 1.2018


EXHIBIT 10.9


the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Participant’s participation in the Plan. The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant’s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any shares of Stock acquired upon exercise of the Stock Option. The Participant understands that the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Company’s Vice President, Total Rewards. Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later revokes his or her consent, the Participant’s service with the Company will not be adversely affected; the only consequence of refusing or withdrawing the Participant’s consent is that the Company would not be able to grant the Participant Stock Options or other equity awards or administer or maintain such awards. Therefore, the Participant understands that refusing or withdrawing the Participant’s consent may affect the Participant’s ability to participate in the Plan. For more information on the consequences of the Participant’s refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the Company’s Vice President, Total Rewards.

Finally, upon request of the Company, the Participant agrees to provide an executed data privacy consent form (or any other agreements or consents that may be required by the Company) to the Company that the Company may deem necessary to obtain from the Participant for the purpose of administering the Participant’s participation in the Plan in compliance with the data privacy laws in the Participant’s country, either now or in the future. The Participant understands and agrees that the Participant will not be able to participate in the Plan if the Participant fails to provide any such consent or agreement requested by the Company.

11.    Nature of Grant. By participating in the Plan, the Participant acknowledges, understands and agrees that:

(a)    the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)    the grant of the Stock Option is voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Stock Options, even if Stock Options have been granted in the past;

(c)    all decisions with respect to future grants of Stock Options, if any, will be at the sole discretion of the Administrator;

(d)    the Stock Option grant and the Participant’s participation in the Plan shall not be interpreted to form a contractual or other relationship with the Company or its Affiliates; further, the award of the Stock Option hereunder shall not confer upon the Participant any right to continued service as a director of the Company and this Agreement shall not be construed in any way to limit

-Rev. 1.2018


EXHIBIT 10.9


the rights of the Company or its shareholders pursuant to the organizational documents of the Company and applicable law;

(e)    the Participant is voluntarily participating in the Plan;

(f)    the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(g)    no claim or entitlement to compensation or damages shall arise from forfeiture of the Stock Option resulting from the termination of the service relationship; and

(h)    the following provisions apply only if the Participant is resident outside the United States: (A) the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not part of normal or expected compensation for any purpose; and (B) the Company shall not be liable for any foreign exchange rate fluctuation between the Participant’s local currency and the U.S. dollar that may affect the value of the Stock Option or of any amount due to the Participant pursuant to the exercise of the Stock Option or the subsequent sale of any shares of Stock acquired upon exercise.

12.    Securities Laws. Upon the acquisition of any shares of Stock pursuant to the exercise of the Stock Option, the Participant will make or enter into such written representations, warranties and agreements as the Company may reasonably request in order to comply with applicable securities laws or with the Plan.

13.    Not a Public Offering. If the Participant is resident outside the United States, neither the grant of the Stock Option under the Plan nor the issuance of the underlying shares of Stock upon exercise of the Stock Option is intended to be a public offering of securities in the Participant’s country of residence. The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law, and the grant of Stock Options is not subject to the supervision of securities authorities outside the United States.

14.    Insider Trading Restrictions/Market Abuse Laws. The Participant acknowledges that, depending on the Participant’s or his or her broker’s country of residence or where the shares of Stock are listed, the Participant may be subject to insider trading restrictions and/or market abuse laws that may affect the Participant’s ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Stock Options) or rights linked to the value of shares (e.g., phantom awards, futures) during such times the Participant is considered to have “inside information” regarding the Company, as defined in the laws or regulations in the Participant’s country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Participant placed before the Participant possessed insider information. Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading

-Rev. 1.2018


EXHIBIT 10.9


policy. The Participant acknowledges that it is the Participant’s responsibility to comply with any restrictions and is advised to speak to the Participant’s personal advisor on this matter.

15.    No Advice Regarding Grant. No Employee of the Company is permitted to advise the Participant regarding participation in the Plan or the Participant’s acquisition or sale of shares of Stock. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, the Participant should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and the Participant should carefully review all of the materials related to the Stock Option and the Plan. The Participant is hereby advised to consult with the Participant’s own personal tax, legal and financial advisors before taking any action related to the Plan.

16.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Stock Option and participation in the Plan, or future grants of Stock Options that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.

17.    Language. If the Participant is resident outside of the United States, the Participant hereby acknowledges and agrees that it is the Participant’s express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Stock Option, be drawn up in English. If the Participant has received this Agreement and any applicable Addendum, the Plan or any other documents related to the Stock Option translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

18.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Stock Option shall be subject to any special terms and conditions for the Participant’s country of residence as are forth in the applicable addendum to the Agreement, if any (the “Addendum”). Further, if the Participant transfers residence to another country reflected in an Addendum to the Agreement, the special terms and conditions for such country will apply to the Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Stock Option or the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant’s transfer of residence). Any applicable Addendum shall constitute part of this Agreement.

19.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Stock Option, any shares of Stock acquired pursuant to the Stock Option and the Participant’s participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws, rules and/or regulations or to facilitate the operation and administration of the Stock Option or the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

-Rev. 1.2018


EXHIBIT 10.9



20.       Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principal executive offices of the Company and to the Participant at the address appearing in the records of the Company for such Participant or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

21.    Award Subject to the Plan; Conflicts. The Stock Option granted by this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Administrator specifically for the grant described herein. Unless the Administrator has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Administrator retains the right to alter or modify the Stock Option granted under this Agreement as the Administrator may determine are in the best interests of the Company. The Participant hereby accepts the Stock Option subject to all the terms and provisions of the Plan and this Agreement and agrees that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon the Participant and the Participant’s heirs and legal representatives.

22.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflicts of laws principles) and applicable federal laws. For the purpose of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the District of Massachusetts.

23.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

24.    Severability. The Participant agrees that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

25.    Waiver. The Participant understands that the waiver by the Company with respect to the Participant’s compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of such party of a provision of this Agreement.

26.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.

[remainder of page intentionally left blank]

-Rev. 1.2018


EXHIBIT 10.9


IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed and delivered this Agreement as a sealed instrument as of the date and year first above written.


PLAN: 2011 LONG TERM INCENTIVE PLAN
Shares of Stock Subject to the Stock Option: %%TOTAL_SHARES_GRANTED%-%
Grant Price: %%OPTION_PRICE,’$999,999,999.99’%-%


BOSTON SCIENTIFIC CORPORATION
            
                    mma06.gif
Name: Michael F. Mahoney
Title: President and Chief Executive Officer


%%FIRST_NAME%-% %%LAST_NAME%-%
PARTICIPANT*


*Signed via electronic signature    

By electronically accepting the Award, THE PARTICIPANT agreeS that (i) such acceptance constitutes THE PARTICIPANT’S electronic signature in execution of this Agreement; (ii) THE PARTICIPANT agreeS to be bound by the provisions of the Plan, the Agreement and ANY Addendum; (iii) THE PARTICIPANT HAS reviewed the Plan, the Agreement and ANY Addendum in their entirety, haS had an opportunity to obtain the advice of counsel prior to accepting the Award and fully understandS all of the provisions of the Plan, the Agreement and ANY Addendum; (iv) THE PARTICIPANT HAS been provided with a copy or electronic access to a copy of the U.S. prospectus for the Plan; and (v) THE PARTICIPANT hereby agreeS to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Agreement and ANY Addendum.

6677169-v3\GESDMS


-Rev. 1.2018

EX-31.1 11 exhibit311-ceo302q12018.htm EXHIBIT 31.1 Exhibit


EXHIBIT 31.1
 
CERTIFICATIONS
 
I, Michael F. Mahoney, certify that:
 

1
I have reviewed this Quarterly Report on Form 10-Q of Boston Scientific Corporation;
 
 
2
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
 
3
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
 
4
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
 
 
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
 
 
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 
 
 
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 
 
 
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
 
 
5
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
 
 
 
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
 
 
 
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:
May 1, 2018
 
/s/ Michael F. Mahoney
 
 
Michael F. Mahoney
 
 
President and Chief Executive Officer



EX-31.2 12 exhibit312-cfo302q12018.htm EXHIBIT 31.2 Exhibit


EXHIBIT 31.2
 
CERTIFICATIONS
 
I, Daniel J. Brennan, certify that:


1
I have reviewed this Quarterly Report on Form 10-Q of Boston Scientific Corporation;
 
 
2
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
 
3
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
 
4
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
 
 
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
 
 
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 
 
 
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 
 
 
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
 
 
5
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
 
 
 
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
 
 
 
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:
May 1, 2018
 
/s/ Daniel J. Brennan
 
 
Daniel J. Brennan
 
 
Executive Vice President and Chief Financial Officer



EX-32.1 13 exhibit321-ceo906q12018.htm EXHIBIT 32.1 Exhibit


EXHIBIT 32.1
 
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Boston Scientific Corporation (the “Company”) for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Executive Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:

 
(1)   
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)   
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.

This certification shall not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 regardless of any general incorporation language in such filing.
 
 
 
By:
/s/ Michael F. Mahoney
 
Michael F. Mahoney
 
 
President and Chief Executive Officer
 
 
 
 
 
May 1, 2018
 
 



EX-32.2 14 exhibit322-cfo906q12018.htm EXHIBIT 32.2 Exhibit


EXHIBIT 32.2
 
 
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Boston Scientific Corporation (the “Company”) for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Financial Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:

 
(1)   
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)   
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.

This certification shall not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 regardless of any general incorporation language in such filing.

 
 
 
By:
/s/ Daniel J. Brennan
 
Daniel J. Brennan
 
 
 Executive Vice President and Chief Financial Officer
 
 
 
 
 
May 1, 2018
 



EX-101.INS 15 bsx-20180501.xml XBRL INSTANCE DOCUMENT 0000885725 2018-01-01 2018-03-31 0000885725 bsx:A2016RestructuringPlanMember 2018-01-01 2018-03-31 0000885725 2018-04-25 0000885725 2017-01-01 2017-03-31 0000885725 2017-12-31 0000885725 2018-03-31 0000885725 2017-03-31 0000885725 2016-12-31 0000885725 us-gaap:AccountingStandardsUpdate201409Member 2018-03-31 0000885725 us-gaap:AccountingStandardsUpdate201409Member us-gaap:OtherNoncurrentLiabilitiesMember 2018-01-01 2018-03-31 0000885725 us-gaap:AccountingStandardsUpdate201409Member us-gaap:OtherNoncurrentAssetsMember 2018-01-01 2018-03-31 0000885725 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DeferredIncomeTaxChargesMember 2018-01-01 2018-03-31 0000885725 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000885725 us-gaap:AccountingStandardsUpdate201409Member us-gaap:OtherCurrentLiabilitiesMember 2018-01-01 2018-03-31 0000885725 bsx:NxTheraMember us-gaap:SubsequentEventMember 2018-04-30 2018-04-30 0000885725 bsx:MilipedeMember 2018-01-24 0000885725 bsx:NVisionMember us-gaap:SubsequentEventMember 2018-04-16 0000885725 bsx:NVisionMember us-gaap:SubsequentEventMember 2018-04-16 2018-04-16 0000885725 bsx:NxTheraMember us-gaap:SubsequentEventMember 2018-04-30 0000885725 bsx:RDandCommercializationbasedMilestoneMember bsx:DiscountedCashFlowMember 2018-03-31 0000885725 bsx:RevenueBasedPaymentsMember bsx:DiscountedCashFlowMember 2018-03-31 0000885725 bsx:RevenueBasedPaymentsMember us-gaap:MaximumMember bsx:DiscountedCashFlowMember 2018-01-01 2018-03-31 0000885725 bsx:RDandCommercializationbasedMilestoneMember bsx:DiscountedCashFlowMember 2018-01-01 2018-03-31 0000885725 bsx:RDandCommercializationbasedMilestoneMember us-gaap:MaximumMember bsx:DiscountedCashFlowMember 2018-03-31 0000885725 bsx:RDandCommercializationbasedMilestoneMember us-gaap:MaximumMember bsx:DiscountedCashFlowMember 2018-01-01 2018-03-31 0000885725 bsx:RDandCommercializationbasedMilestoneMember us-gaap:MinimumMember bsx:DiscountedCashFlowMember 2018-01-01 2018-03-31 0000885725 bsx:RDandCommercializationbasedMilestoneMember us-gaap:MinimumMember bsx:DiscountedCashFlowMember 2018-03-31 0000885725 bsx:RevenueBasedPaymentsMember us-gaap:MinimumMember bsx:DiscountedCashFlowMember 2018-01-01 2018-03-31 0000885725 bsx:TechnologyRelatedMember 2018-03-31 0000885725 bsx:TechnologyRelatedMember 2017-12-31 0000885725 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2017-12-31 0000885725 bsx:PurchasedResearchAndDevelopmentMember 2017-12-31 0000885725 us-gaap:PatentsMember 2018-03-31 0000885725 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2018-03-31 0000885725 us-gaap:OtherIntangibleAssetsMember 2017-12-31 0000885725 bsx:TechnologyRelatedMember 2018-03-31 0000885725 us-gaap:PatentsMember 2017-12-31 0000885725 us-gaap:OtherIntangibleAssetsMember 2018-03-31 0000885725 bsx:TechnologyRelatedMember 2017-12-31 0000885725 bsx:PurchasedResearchAndDevelopmentMember 2018-03-31 0000885725 bsx:CardiovascularMember 2018-01-01 2018-03-31 0000885725 bsx:MedsurgMember 2018-01-01 2018-03-31 0000885725 bsx:RhythmandNeuroMember 2018-01-01 2018-03-31 0000885725 bsx:MedsurgMember 2018-03-31 0000885725 bsx:RhythmandNeuroMember 2018-03-31 0000885725 bsx:RhythmandNeuroMember 2017-12-31 0000885725 bsx:MedsurgMember 2017-12-31 0000885725 bsx:CardiovascularMember 2018-03-31 0000885725 bsx:CardiovascularMember 2017-12-31 0000885725 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-01-01 2018-03-31 0000885725 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2017-01-01 2017-03-31 0000885725 us-gaap:NondesignatedMember bsx:OtherNetMember 2017-01-01 2017-03-31 0000885725 us-gaap:NondesignatedMember bsx:OtherNetMember 2018-01-01 2018-03-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000885725 us-gaap:OtherCurrentAssetsMember us-gaap:NondesignatedMember 2017-12-31 0000885725 us-gaap:OtherCurrentAssetsMember us-gaap:NondesignatedMember 2018-03-31 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000885725 us-gaap:OtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-03-31 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2018-03-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-03-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-03-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:NondesignatedMember 2018-03-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-12-31 0000885725 us-gaap:OtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-03-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:NondesignatedMember 2017-12-31 0000885725 us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2018-03-31 0000885725 us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2018-03-31 0000885725 us-gaap:CashFlowHedgingMember us-gaap:CostOfGoodsProductLineMember 2018-03-31 0000885725 bsx:May2022NotesMember 2018-03-31 0000885725 bsx:January2040NotesMember 2018-03-31 0000885725 bsx:October2023NotesMember 2018-03-31 0000885725 bsx:May2020NotesMember 2017-12-31 0000885725 bsx:May2025NotesMember 2018-03-31 0000885725 bsx:PremiumsacceleratedamortizationofdebtissuancecostsinvestordiscountcostsMember 2017-12-31 0000885725 bsx:March2028NotesMember 2018-03-31 0000885725 bsx:May2020NotesMember 2018-03-31 0000885725 bsx:January2020NotesMember 2018-03-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2017-12-31 0000885725 us-gaap:SecuritiesFinancingTransactionCostMember 2017-12-31 0000885725 bsx:May2022NotesMember 2017-12-31 0000885725 bsx:November2035NotesMember 2017-12-31 0000885725 bsx:January2020NotesMember 2017-12-31 0000885725 bsx:November2035NotesMember 2018-03-31 0000885725 us-gaap:SecuritiesFinancingTransactionCostMember 2018-03-31 0000885725 us-gaap:InterestRateSwapMember 2017-12-31 0000885725 bsx:October2018NotesMember 2018-03-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2018-03-31 0000885725 bsx:May2025NotesMember 2017-12-31 0000885725 bsx:January2040NotesMember 2017-12-31 0000885725 us-gaap:InterestRateSwapMember 2018-03-31 0000885725 bsx:PremiumsacceleratedamortizationofdebtissuancecostsinvestordiscountcostsMember 2018-03-31 0000885725 bsx:October2023NotesMember 2017-12-31 0000885725 bsx:ActualCovenantMember 2018-03-31 0000885725 bsx:CurrentRequirementMember 2018-03-31 0000885725 us-gaap:LineOfCreditMember 2018-03-31 0000885725 bsx:NewJapaneseFactoringMarch2018ProgramMember 2018-03-31 0000885725 bsx:The2017FacilityMember 2017-08-04 0000885725 us-gaap:CommercialPaperMember 2018-03-31 0000885725 bsx:October2018NotesMember 2017-12-31 0000885725 bsx:UncommittedCreditFacilitiesWithTwoCommercialJapaneseBanksMember 2018-03-31 0000885725 bsx:The2017FacilityMember 2018-03-31 0000885725 2016-01-01 2016-12-31 0000885725 us-gaap:BorrowingsMember 2018-03-31 0000885725 us-gaap:CommercialPaperMember 2017-12-31 0000885725 us-gaap:SeniorNotesMember 2017-12-31 0000885725 bsx:March2028NotesMember 2018-02-26 0000885725 us-gaap:SeniorNotesMember 2018-03-31 0000885725 bsx:UncommittedCreditFacilitiesWithTwoCommercialJapaneseBanksMember 2017-12-31 0000885725 bsx:March2028NotesMember 2017-12-31 0000885725 us-gaap:MaximumMember bsx:A2016RestructuringPlanMember 2018-01-01 2018-03-31 0000885725 us-gaap:MinimumMember bsx:A2016RestructuringPlanMember 2018-01-01 2018-03-31 0000885725 us-gaap:CostOfSalesMember 2018-01-01 2018-03-31 0000885725 us-gaap:EmployeeSeveranceMember 2018-01-01 2018-03-31 0000885725 bsx:TransferCostsMember 2018-01-01 2018-03-31 0000885725 us-gaap:OtherRestructuringMember 2018-01-01 2018-03-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember bsx:TransferCostsMember 2018-01-01 2018-03-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2018-01-01 2018-03-31 0000885725 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2018-01-01 2018-03-31 0000885725 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember 2018-01-01 2018-03-31 0000885725 us-gaap:CostOfSalesMember bsx:TransferCostsMember 2018-01-01 2018-03-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-03-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2018-01-01 2018-03-31 0000885725 bsx:AcceleratedDepreciationMember 2017-01-01 2017-03-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2017-01-01 2017-03-31 0000885725 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2017-01-01 2017-03-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-03-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember bsx:TransferCostsMember 2017-01-01 2017-03-31 0000885725 us-gaap:OtherRestructuringMember 2017-01-01 2017-03-31 0000885725 us-gaap:EmployeeSeveranceMember 2017-01-01 2017-03-31 0000885725 bsx:TransferCostsMember 2017-01-01 2017-03-31 0000885725 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember 2017-01-01 2017-03-31 0000885725 us-gaap:CostOfSalesMember bsx:AcceleratedDepreciationMember 2017-01-01 2017-03-31 0000885725 us-gaap:CostOfSalesMember bsx:TransferCostsMember 2017-01-01 2017-03-31 0000885725 us-gaap:CostOfSalesMember 2017-01-01 2017-03-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember bsx:AcceleratedDepreciationMember 2017-01-01 2017-03-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2017-01-01 2017-03-31 0000885725 us-gaap:EmployeeSeveranceMember bsx:A2016RestructuringPlanMember 2018-03-31 0000885725 us-gaap:EmployeeSeveranceMember bsx:A2016RestructuringPlanMember 2017-12-31 0000885725 us-gaap:EmployeeSeveranceMember bsx:A2016RestructuringPlanMember 2018-01-01 2018-03-31 0000885725 us-gaap:EmployeeSeveranceMember bsx:A2016RestructuringPlanMember 2016-06-06 2018-03-31 0000885725 us-gaap:OtherRestructuringMember bsx:A2016RestructuringPlanMember 2018-01-01 2018-03-31 0000885725 us-gaap:OtherRestructuringMember bsx:A2016RestructuringPlanMember 2016-06-06 2018-03-31 0000885725 bsx:A2016RestructuringPlanMember 2016-06-06 2018-03-31 0000885725 bsx:TransferCostsMember bsx:A2016RestructuringPlanMember 2018-01-01 2018-03-31 0000885725 bsx:TransferCostsMember bsx:A2016RestructuringPlanMember 2016-06-06 2018-03-31 0000885725 bsx:A2016RestructuringPlanMember 2018-03-31 0000885725 bsx:AcceleratedDepreciationMember bsx:A2016RestructuringPlanMember 2016-06-06 2018-03-31 0000885725 bsx:RestructuringPlanMember us-gaap:MinimumMember us-gaap:OtherRestructuringMember bsx:A2016RestructuringPlanMember 2018-03-31 0000885725 bsx:RestructuringPlanMember us-gaap:MinimumMember us-gaap:EmployeeSeveranceMember bsx:A2016RestructuringPlanMember 2018-03-31 0000885725 bsx:RestructuringRelatedToPlanMember us-gaap:MaximumMember us-gaap:OtherRestructuringMember bsx:A2016RestructuringPlanMember 2018-03-31 0000885725 us-gaap:MaximumMember bsx:A2016RestructuringPlanMember 2018-03-31 0000885725 bsx:RestructuringPlanMember us-gaap:MaximumMember us-gaap:EmployeeSeveranceMember bsx:A2016RestructuringPlanMember 2018-03-31 0000885725 us-gaap:MinimumMember bsx:A2016RestructuringPlanMember 2018-03-31 0000885725 bsx:RestructuringPlanMember us-gaap:MaximumMember us-gaap:OtherRestructuringMember bsx:A2016RestructuringPlanMember 2018-03-31 0000885725 bsx:RestructuringRelatedToPlanMember us-gaap:MinimumMember us-gaap:OtherRestructuringMember bsx:A2016RestructuringPlanMember 2018-03-31 0000885725 us-gaap:OtherCurrentAssetsMember 2018-03-31 0000885725 us-gaap:OtherCurrentAssetsMember 2017-12-31 0000885725 bsx:OtherLongTermAssetsMember 2018-03-31 0000885725 bsx:OtherLongTermAssetsMember 2017-12-31 0000885725 2017-01-01 2017-12-31 0000885725 us-gaap:SubsequentEventMember 2017-10-01 2018-09-30 0000885725 us-gaap:SubsequentEventMember 2018-01-01 2018-12-31 0000885725 us-gaap:SubsequentEventMember 2018-04-30 2018-04-30 0000885725 us-gaap:SubsequentEventMember 2018-04-24 0000885725 us-gaap:SettledLitigationMember us-gaap:SubsequentEventMember 2018-04-24 0000885725 bsx:AssignedtoonejudgeinMAMember us-gaap:SubsequentEventMember 2018-04-24 0000885725 bsx:RhythmandNeuroMember 2017-01-01 2017-03-31 0000885725 bsx:MedsurgMember 2017-01-01 2017-03-31 0000885725 bsx:CardiovascularMember 2017-01-01 2017-03-31 0000885725 bsx:CorporateExpensesAndCurrencyExchangeMember 2018-01-01 2018-03-31 0000885725 bsx:SpecialChargesMember 2018-01-01 2018-03-31 0000885725 bsx:SpecialChargesMember 2017-01-01 2017-03-31 0000885725 bsx:CorporateExpensesAndCurrencyExchangeMember 2017-01-01 2017-03-31 0000885725 bsx:NeuromodulationMember country:US 2017-01-01 2017-03-31 0000885725 bsx:NeuromodulationMember us-gaap:NonUsMember 2017-01-01 2017-03-31 0000885725 bsx:InterventionalCardiologyMember 2017-01-01 2017-03-31 0000885725 bsx:EndoscopyMember 2017-01-01 2017-03-31 0000885725 bsx:EndoscopyMember us-gaap:NonUsMember 2018-01-01 2018-03-31 0000885725 bsx:EndoscopyMember country:US 2017-01-01 2017-03-31 0000885725 country:US 2018-01-01 2018-03-31 0000885725 bsx:PeripheralInterventionsMember us-gaap:NonUsMember 2018-01-01 2018-03-31 0000885725 country:US 2017-01-01 2017-03-31 0000885725 bsx:PeripheralInterventionsMember 2017-01-01 2017-03-31 0000885725 bsx:UrologyandPelvicHealthMember 2018-01-01 2018-03-31 0000885725 bsx:InterventionalCardiologyMember country:US 2018-01-01 2018-03-31 0000885725 bsx:ElectrophysiologyMember us-gaap:NonUsMember 2018-01-01 2018-03-31 0000885725 bsx:InterventionalCardiologyMember us-gaap:NonUsMember 2018-01-01 2018-03-31 0000885725 bsx:EndoscopyMember us-gaap:NonUsMember 2017-01-01 2017-03-31 0000885725 bsx:PeripheralInterventionsMember country:US 2018-01-01 2018-03-31 0000885725 bsx:CardiacRhythmManagementMember 2018-01-01 2018-03-31 0000885725 bsx:EndoscopyMember country:US 2018-01-01 2018-03-31 0000885725 bsx:ElectrophysiologyMember country:US 2017-01-01 2017-03-31 0000885725 bsx:EndoscopyMember 2018-01-01 2018-03-31 0000885725 bsx:InterventionalCardiologyMember 2018-01-01 2018-03-31 0000885725 bsx:NeuromodulationMember 2018-01-01 2018-03-31 0000885725 bsx:UrologyandPelvicHealthMember 2017-01-01 2017-03-31 0000885725 bsx:CardiacRhythmManagementMember 2017-01-01 2017-03-31 0000885725 bsx:ElectrophysiologyMember country:US 2018-01-01 2018-03-31 0000885725 bsx:CardiacRhythmManagementMember us-gaap:NonUsMember 2017-01-01 2017-03-31 0000885725 bsx:NeuromodulationMember 2017-01-01 2017-03-31 0000885725 bsx:NeuromodulationMember country:US 2018-01-01 2018-03-31 0000885725 bsx:ElectrophysiologyMember 2017-01-01 2017-03-31 0000885725 bsx:UrologyandPelvicHealthMember country:US 2017-01-01 2017-03-31 0000885725 bsx:InterventionalCardiologyMember country:US 2017-01-01 2017-03-31 0000885725 bsx:CardiacRhythmManagementMember us-gaap:NonUsMember 2018-01-01 2018-03-31 0000885725 bsx:ElectrophysiologyMember us-gaap:NonUsMember 2017-01-01 2017-03-31 0000885725 bsx:NeuromodulationMember us-gaap:NonUsMember 2018-01-01 2018-03-31 0000885725 bsx:UrologyandPelvicHealthMember us-gaap:NonUsMember 2017-01-01 2017-03-31 0000885725 bsx:ElectrophysiologyMember 2018-01-01 2018-03-31 0000885725 us-gaap:NonUsMember 2017-01-01 2017-03-31 0000885725 bsx:PeripheralInterventionsMember 2018-01-01 2018-03-31 0000885725 bsx:UrologyandPelvicHealthMember country:US 2018-01-01 2018-03-31 0000885725 bsx:UrologyandPelvicHealthMember us-gaap:NonUsMember 2018-01-01 2018-03-31 0000885725 bsx:CardiacRhythmManagementMember country:US 2017-01-01 2017-03-31 0000885725 us-gaap:NonUsMember 2018-01-01 2018-03-31 0000885725 bsx:PeripheralInterventionsMember us-gaap:NonUsMember 2017-01-01 2017-03-31 0000885725 bsx:InterventionalCardiologyMember us-gaap:NonUsMember 2017-01-01 2017-03-31 0000885725 bsx:CardiacRhythmManagementMember country:US 2018-01-01 2018-03-31 0000885725 bsx:PeripheralInterventionsMember country:US 2017-01-01 2017-03-31 0000885725 2018-01-01 0000885725 bsx:EmergingMarketsMember 2018-01-01 2018-03-31 0000885725 bsx:LatinAmericaandCanadaMember 2017-01-01 2017-03-31 0000885725 us-gaap:EMEAMember 2018-01-01 2018-03-31 0000885725 us-gaap:EMEAMember 2017-01-01 2017-03-31 0000885725 us-gaap:AsiaPacificMember 2018-01-01 2018-03-31 0000885725 bsx:LatinAmericaandCanadaMember 2018-01-01 2018-03-31 0000885725 us-gaap:AsiaPacificMember 2017-01-01 2017-03-31 0000885725 bsx:EmergingMarketsMember 2017-01-01 2017-03-31 xbrli:pure bsx:claims iso4217:USD bsx:reportablesegments iso4217:USD xbrli:shares iso4217:JPY xbrli:shares 0 0 169000000 169000000 0 0 152000000 152000000 107000000 52000000 1000000 -79000000 22000000 30000000 0 0.013 0.005 0.015 327000000 1168000000 -161000000 151000000 487000000 1017000000 1 325000000 1.00 0.17 2022 2018 2026 2018 99000000 3183000000 3246000000 500000000 1162000000 9900000000 9900000000 17295000000 17281000000 1690000000 2624000000 463000000 30000000000 282000000 207000000 22000000000 2.2 3.5 81000000 84000000 17000000 16000000 13000000 17000000 47000000 43000000 1035000000 454000000 557000000 233000000 215000000 109000000 703000000 290000000 259000000 153000000 61000000 -11000000 100000000 54000000 -15000000 13000000 -37000000 -91000000 -18000000 12000000 0 3000000 28000000 18000000 0 61000000 50000000 125000000 125000000 85000000 897000000 100000000 20 25 3100 47500 49500 15000000 15000000 0 0 15000000 12000000 12000000 0 0 12000000 3 8 61000000 16000000 77000000 415000000 300000000 250000000 9000000 68000000 15000000 92000000 15000000 12000000 0 12000000 0 0 3000000 2000000 0 0 1000000 2000000 12000000 0 1000000 7000000 7000000 0 0 8000000 0 0 8000000 7000000 0 8000000 15000000 0.273 0.335 0.163 0.311 0.364 0.208 852000000 21000 90000000 false --12-31 Q1 2018 2018-03-31 10-Q 0000885725 1379810502 Large Accelerated Filer BOSTON SCIENTIFIC CORPORATION 5923000000 6161000000 1548000000 1580000000 530000000 404000000 1645000000 1650000000 1275000000 1119000000 2456000000 2447000000 2928000000 2996000000 -6000000 -6000000 -1000000 0 -21000000 -21000000 -27000000 -27000000 -79000000 -71000000 -32000000 -22000000 1000000 -46000000 -59000000 -128000000 17161000000 17184000000 68000000 67000000 143000000 141000000 19042000000 19202000000 3822000000 4080000000 36000000 82000000 0 118000000 54000000 32000000 0 86000000 1120000000 1132000000 -50000000 5000000 1320000000 169000000 152000000 105000000 48000000 36000000 62000000 133000000 92000000 167000000 245000000 188000000 287000000 886000000 2250000000 0.01 0.01 2000000000 2000000000 1621062898 1627188009 1373496628 1379621739 16000000 16000000 243000000 228000000 219000000 215000000 650000000 672000000 55000000 177000000 8000000 10000000 5616000000 5765000000 1801000000 600000000 962000000 5945000000 6040000000 0.06 0.07375 0.04 0.0285 0.03375 0.0385 0.0700 0.0265 0.04125 0.06 0.07375 0.04 0.0285 0.03375 0.0385 0.07 0.0265 0.04125 0.04 393000000 411000000 26000000 66000000 50000000 191000000 128000000 63000000 68000000 171000000 157000000 178000000 95000000 124000000 82000000 32000000 18000000 -12000000 -12000000 37000000 91000000 91000000 28000000 15000000 15000000 7000000 57000000 64000000 3000000 15000000 17000000 37000000 33000000 69000000 54000000 69000000 123000000 58000000 118000000 118000000 18000000 15000000 -17000000 -23000000 21000000 31000000 90000000 154000000 0.21 0.22 0.21 0.21 1000000 1000000 0.049 0.08 0.21 0.35 591000000 488000000 335000000 209000000 304000000 0.03 0.15 0.11 6097000000 4880000000 838000000 379000000 6233000000 4984000000 868000000 381000000 11536000000 9386000000 1633000000 517000000 11549000000 9396000000 1636000000 517000000 -55000000 1000000 12000000 0 82000000 0 82000000 0 32000000 0 32000000 3252000000 0 90000000 0 90000000 3595000000 0 154000000 0 154000000 2671000000 2565000000 0 -8000000 6998000000 3704000000 2877000000 417000000 6984000000 3707000000 1503000000 1774000000 3000000 0 3000000 0 16898000000 16884000000 9900000000 9900000000 0 0 -1379000000 1379000000 -17000000 3000000 1000000 -22000000 1510000000 1707000000 0 1000000 305000000 323000000 15000000 26000000 278000000 120000000 278000000 120000000 5837000000 5713000000 57000000 61000000 685000000 717000000 1078000000 1113000000 284000000 291000000 110000000 105000000 353000000 442000000 102000000 103000000 19042000000 19202000000 5654000000 4988000000 0 90000000 169000000 259000000 0 154000000 152000000 306000000 70000000 400000000 2250000000 1176000000 1255000000 436000000 256000000 275000000 3000000 0 3815000000 850000000 300000000 600000000 500000000 750000000 350000000 450000000 6000000 1000000 38000000 18000000 4400000000 4803000000 850000000 300000000 1000000000 600000000 500000000 750000000 350000000 0 450000000 14000000 1000000 35000000 19000000 4800000000 1000000000 3815000000 4803000000 1612000000 1511000000 21000000 0 0 21000000 42000000 0 0 42000000 -15000000 130000000 -140000000 -173000000 -7000000 193000000 41 59 12 206 -59000000 -84000000 3 1146000000 1300000000 364000000 407000000 653000000 643000000 525000000 787000000 688000000 725000000 0 0 0 0 0 1000000 -32000000 -81000000 21000000 27000000 27000000 8000000 10000000 -47000000 -69000000 -3000000 0 0 0 10000000 -3000000 -3000000 3000000 0 -55000000 -80000000 867000000 1174000000 2370000000 2254000000 -2000000 -23000000 9000000 67000000 36000000 19000000 122000000 7000000 8000000 9000000 25000000 306000000 240000000 150000000 0 9000000 28000000 103000000 112000000 60000000 0.01 0.01 50000000 50000000 0 0 0 0 942000000 1048000000 33000000 38000000 0 990000000 1016000000 70000000 0 -316000000 290000000 298000000 4625000000 4696000000 1697000000 1700000000 0.018 0.021 250000000 602000000 735000000 0 235000000 261000000 26000000 803000000 31000000 850000000 169000000 110000000 50000000 100000000 25000000 165000000 150000000 325000000 275000000 19000000 2000000 12000000 3000000 2000000 7000000 12000000 8000000 28000000 4000000 0 0 3000000 1000000 0 12000000 1000000 13000000 12000000 22000000 27000000 -8390000000 -8326000000 17000000 18000000 2160000000 463000000 283000000 180000000 64000000 32000000 32000000 379000000 215000000 164000000 590000000 278000000 312000000 141000000 116000000 25000000 261000000 142000000 119000000 262000000 183000000 79000000 851000000 641000000 668000000 208000000 84000000 1249000000 371000000 454000000 911000000 493000000 290000000 203000000 75000000 35000000 39000000 418000000 231000000 187000000 645000000 281000000 364000000 169000000 131000000 38000000 288000000 145000000 142000000 293000000 197000000 96000000 255000000 91000000 1310000000 415000000 563000000 1069000000 2379000000 933000000 711000000 736000000 794000000 860000000 30000000 36000000 0.0185 0.0246 7000000 6000000 7012000000 7030000000 247566270 247566270 1717000000 1717000000 1238000000 1240000000 655000000 675000000 1150000000 1157000000 73000000 75000000 68000000 67000000 3000000 4000000 1000000 5000000 24800000 20200000 1390200000 1396800000 1365400000 1376500000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2014-09</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASC Update No. 2014-09,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue from Contracts with Customers </font><font style="font-family:inherit;font-size:10pt;">(Topic 606), which was subsequently updated. We adopted the standard as of January 1, 2018, using the modified retrospective method. Under this method, we applied FASB ASC Topic 606 to contracts that were not complete as of January 1, 2018 and recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings. Results for reporting periods beginning after January 1, 2018 are presented in accordance with FASB ASC Topic 606. Prior period amounts are not adjusted and are reported in accordance with legacy GAAP requirements in FASB ASC Topic 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the adoption of FASB ASC Topic 606, we recorded a net reduction to opening retained earnings of </font><font style="font-family:inherit;font-size:10pt;">$177 million</font><font style="font-family:inherit;font-size:10pt;"> on January 1, 2018, primarily related to cost of providing non-contractual post-implant support to certain customers, which we deemed immaterial in the context of the arrangement. Upon the adoption of FASB ASC Topic 606, when we sell a device with an implied non-contractual post-implant support obligation, we forward accrue the cost of the service within</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Selling, general and administrative expenses </font><font style="font-family:inherit;font-size:10pt;">and recognize it at the point in time the associated revenue is earned. We release the accrual over the related service period. These costs were previously expensed as incurred due to such service obligation being non-contractual. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The impact of adopting FASB ASC Topic 606 on our </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, resulted in an increase in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$59 million</font><font style="font-family:inherit;font-size:10pt;"> and an increase in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$206 million</font><font style="font-family:inherit;font-size:10pt;">, as a result of accruing for our post-implant support obligation. We also recorded deferred tax assets primarily related to post-implant support, resulting in an increase in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets </font><font style="font-family:inherit;font-size:10pt;">of </font><font style="font-family:inherit;font-size:10pt;">$12 million</font><font style="font-family:inherit;font-size:10pt;"> and a reduction in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred income taxes</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$41 million</font><font style="font-family:inherit;font-size:10pt;">. The remaining impact of adopting FASB ASC Topic 606 was not material to our financial position or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-01</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASC Update No. 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Overall </font><font style="font-family:inherit;font-size:10pt;">(Subtopic 825-10)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Recognition and Measurement of Financial Assets and Financial Liabilities. </font><font style="font-family:inherit;font-size:10pt;">The purpose of Update No. 2016-01 is to improve financial reporting for financial instruments by reducing the number of items recorded to other comprehensive income. We adopted Update No. 2016-01 in the first quarter of 2018, using both the modified retrospective and prospective methods. For publicly-held securities, we used the modified retrospective approach.&#160;Unrealized gains and losses previously recorded to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">other comprehensive income</font><font style="font-family:inherit;font-size:10pt;"> were reclassified to</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> retained earnings</font><font style="font-family:inherit;font-size:10pt;"> and all future fair value changes will be recorded to net income. For privately-held securities, we elected the measurement alternative approach which is applied prospectively upon adoption. This approach requires entities to measure their investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The adoption of the standard did not have a material impact on our financial position or results of operations.&#160;The actual impact to future periods resulting from fair value changes of our equity investments is difficult to predict as it will depend on their future performance.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-02</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASC Update No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases </font><font style="font-family:inherit;font-size:10pt;">(Topic 842)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> The purpose of Update No. 2016-02 is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. Update No. 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted and a modified retrospective approach is required for adoption. While we are still in the process of determining the effect that the new standard will have on our financial position and results of operations, we expect to recognize additional assets and corresponding liabilities on our consolidated balance sheets, as a result of our operating lease portfolio as it exists at the date we adopt the new standard. Please refer to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note F - Lease and Other Purchase Obligations</font><font style="font-family:inherit;font-size:10pt;"> in our most recent Annual Report on Form 10-K for information regarding our most current lease activity. Additionally, we are in the process of implementing a new lease administration and lease accounting system, and updating our controls and procedures for maintaining and accounting for our lease portfolio under the new standard. As a result, we anticipate adopting the new standard on January 1, 2019.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-13</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASC Update No. 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses </font><font style="font-family:inherit;font-size:10pt;">(Topic 326)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Measurement of Credit Losses on Financial Instruments</font><font style="font-family:inherit;font-size:10pt;">. The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted for annual periods beginning after December 15, 2018. We are in the process of determining the effect that the adoption will have on our financial position and results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2017-12</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASC Update No. 2017-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:inherit;font-size:10pt;"> (Topic 815)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Targeted Improvements to Accounting for Hedging Activities</font><font style="font-family:inherit;font-size:10pt;">. The purpose of Update No. 2017-12 is to simplify the application of hedge accounting and better align financial reporting of hedging relationships with risk management objectives. Update No. 2017-12 was effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. We early adopted Update No. 2017-12 in the first quarter of 2018. The adoption of the standard had no impact on our financial position or results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-16</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASC Update No. 2016-16,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes</font><font style="font-family:inherit;font-size:10pt;"> (Topic 740): </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intra-Entity Transfers of Assets Other Than Inventory</font><font style="font-family:inherit;font-size:10pt;">. The purpose of Update No. 2016-16 is to allow an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, as opposed to waiting until the asset is sold to a third party, or impaired. Update No. 2016-16 was effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. We adopted Update No. 2016-16 prospectively in the first quarter of 2018 and recognized a net reduction to opening retained earnings of </font><font style="font-family:inherit;font-size:10pt;">$55 million</font><font style="font-family:inherit;font-size:10pt;"> for income tax consequences not previously recognized for intra-entity transfers of assets other than inventories. All future income tax consequences of intra-entity transfers of assets other than inventories will be recognized through income tax expense.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> were made using cash generated from operations and are comprised of the following:</font></div><div style="line-height:120%;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016 Restructuring Plan</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfer costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Program to Date</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfer costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">122</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the reclassifications out of other comprehensive income, net of tax.</font></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Three Months Ended March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains/Losses on Derivative Financial Instruments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains/Losses on Available-for-Sale Securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Defined Benefit Pension Items/Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(91</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(81</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current-period other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of March 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(22</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(79</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(128</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Three Months Ended March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains/Losses on Derivative Financial Instruments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains/Losses on Available-for-Sale Securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Defined Benefit Pension Items/Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current-period other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of March 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(71</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">52</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(46</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div><div style="line-height:120%;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016 Restructuring Plan</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfer costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (2)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">92</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of our contingent consideration liabilities include the following significant unobservable inputs:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingent Consideration Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value as of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">R&amp;D and Commercialization-based Milestones</font></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$105 million</font></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount Rate</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Probability of Payment</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17% - 100%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Projected Year of Payment</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018 - 2022</font></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue-based Payments</font></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$48 million</font></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount Rate</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11% - 15%</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Projected Year of Payment</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018 - 2026</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables disaggregate our revenue from contracts with customers by business and geographic region:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Businesses</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Endoscopy</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">418</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">379</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Urology and Pelvic Health</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cardiac Rhythm Management</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">463</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Electrophysiology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Neuromodulation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interventional Cardiology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Peripheral Interventions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,249</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,069</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">911</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Geographic Regions </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,249</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EMEA (Europe, Middle East and Africa)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APAC (Asia-Pacific)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LACA (Latin America and Canada)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging Markets (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Location in </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unaudited Condensed Consolidated Statements of Operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gain (loss) on currency hedge contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gain (loss) on currency transaction exposures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net currency exchange gain (loss)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE L &#8211; REVENUE</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes in our </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;">. The following tables disaggregate our revenue from contracts with customers by business and geographic region:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Businesses</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Endoscopy</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">418</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">379</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Urology and Pelvic Health</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cardiac Rhythm Management</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">463</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Electrophysiology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Neuromodulation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interventional Cardiology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Peripheral Interventions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,249</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,069</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">911</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Geographic Regions </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,249</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EMEA (Europe, Middle East and Africa)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APAC (Asia-Pacific)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LACA (Latin America and Canada)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging Markets (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Emerging Markets is defined as certain countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Currently, we include </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> countries in our definition of Emerging Markets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors. We consider revenue to be earned when all of the following criteria are met: we have a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount we expect to receive, is determinable and we have transferred control of the promised items to the customer. Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S., but may be longer in international markets. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Deferred Revenue</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE&#8482; Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities are classified as other current liabilities and other long-term liabilities on the balance sheet. Our deferred revenue balance as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$393 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$411 million</font><font style="font-family:inherit;font-size:10pt;"> as of January 1, 2018. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE&#8482; Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. During the </font><font style="font-family:inherit;font-size:10pt;">first</font><font style="font-family:inherit;font-size:10pt;"> quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we recognized </font><font style="font-family:inherit;font-size:10pt;">$26 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue that was included in the above January 1, 2018 contract liability balance. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Variable Consideration</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next&#173; generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next&#173;-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to estimate the expected rebates reasonably, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Capitalized Contract Costs</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We capitalize commission fees related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE Remote Monitoring Service. These fulfillment costs are amortized over the average service period. Our total capitalized contract costs are immaterial to our consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning balance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net charges to expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Utilization of allowances</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">67</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">75</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the fair value of our contingent consideration liabilities were as follows (in millions):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts recorded related to prior acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">152</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a rollforward of the termination benefit liability associated with our 2016 Restructuring Plan, which is reported as a component of accrued expenses included in our accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016 Restructuring Plan</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accrued as of December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charges (credits)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accrued as of March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Covenant Requirement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Actual</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">as of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">as of March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maximum leverage ratio (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.5 times</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2 times</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-size:9pt;">Ratio of total debt to consolidated EBITDA, as defined by the credit agreement, for the preceding four consecutive fiscal quarters.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate carrying amount of our strategic investments were comprised of the following categories:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity method investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measurement alternative investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Publicly-held securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">353</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE B &#8211; ACQUISITIONS AND STRATEGIC INVESTMENTS</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We did not close any material acquisitions during the </font><font style="font-family:inherit;font-size:10pt;">first quarter</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 30, 2018, we announced the closing of our acquisition of NxThera, Inc. (NxThera), a privately-held company based in Maple Grove, Minnesota. NxThera developed the Rez&#251;m</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> System, a minimally invasive therapy in a growing category of treatment options for patients with benign prostatic hyperplasia (BPH). The transaction consists of an upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$306 million</font><font style="font-family:inherit;font-size:10pt;">, and up to an additional </font><font style="font-family:inherit;font-size:10pt;">$100 million</font><font style="font-family:inherit;font-size:10pt;"> in potential commercial milestone payments over the next four years.&#160;We have an existing minority investment in NxThera which is expected to result in a net upfront payment of approximately </font><font style="font-family:inherit;font-size:10pt;">$240 million</font><font style="font-family:inherit;font-size:10pt;"> upon closing, and milestone payments of up to </font><font style="font-family:inherit;font-size:10pt;">$85 million</font><font style="font-family:inherit;font-size:10pt;">. NxThera will be integrated into our Urology and Pelvic Health business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 16, 2018, we announced the closing of our acquisition of nVision Medical Corporation (nVision), a privately-held company focused on women&#8217;s health. nVision developed the first and only device cleared by the U.S. Food and Drug Administration (FDA) to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. The transaction consists of an upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$150 million</font><font style="font-family:inherit;font-size:10pt;">, and up to an additional </font><font style="font-family:inherit;font-size:10pt;">$125 million</font><font style="font-family:inherit;font-size:10pt;"> in potential clinical and commercial milestones over four years. nVision will be integrated into our Urology and Pelvic Health business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Contingent Consideration</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recorded a net expense related to the changes in fair value of our contingent consideration liabilities of </font><font style="font-family:inherit;font-size:10pt;">$5 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">first quarter</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and a net benefit related to the changes in fair value of our contingent consideration liabilities of </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">first quarter</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. We made </font><font style="font-family:inherit;font-size:10pt;">$28 million</font><font style="font-family:inherit;font-size:10pt;"> of contingent payments during the </font><font style="font-family:inherit;font-size:10pt;">first quarter</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the fair value of our contingent consideration liabilities were as follows (in millions):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts recorded related to prior acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">152</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the maximum amount of future contingent consideration (undiscounted)&#160;that we could be required to pay was approximately </font><font style="font-family:inherit;font-size:10pt;">$1.320 billion</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of our contingent consideration liabilities include the following significant unobservable inputs:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingent Consideration Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value as of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">R&amp;D and Commercialization-based Milestones</font></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$105 million</font></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount Rate</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Probability of Payment</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17% - 100%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Projected Year of Payment</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018 - 2022</font></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue-based Payments</font></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$48 million</font></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount Rate</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11% - 15%</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Projected Year of Payment</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018 - 2026</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Projected contingent payment amounts related to some of our R&amp;D, commercialization-based and revenue-based milestones are discounted back to the current period using a discounted cash flow (DCF) model. Projected revenues are based on our most recent internal operational budgets and long-range strategic plans. Increases in projected revenues and probabilities of payment may result in higher fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Strategic Investments</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 24, 2018, we closed an investment and entered into an acquisition option agreement with Millipede, Inc. (Millipede), a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation. Under the terms of the agreements, we have purchased a portion of the outstanding shares of Millipede along with newly issued shares of the company for a total consideration of </font><font style="font-family:inherit;font-size:10pt;">$90 million</font><font style="font-family:inherit;font-size:10pt;">. We also have the option to acquire the remaining shares of the company at any time prior to the completion of a first in human clinical study that meets certain parameters. Upon the completion of the clinical study, Millipede has the option to compel us to acquire the remaining shares of the company. Each company&#8217;s option period expires by the end of 2019. Completion of this acquisition would result in an additional </font><font style="font-family:inherit;font-size:10pt;">$325 million</font><font style="font-family:inherit;font-size:10pt;"> payment by us at closing with a further </font><font style="font-family:inherit;font-size:10pt;">$125 million</font><font style="font-family:inherit;font-size:10pt;"> becoming payable upon achievement of a commercial milestone.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate carrying amount of our strategic investments were comprised of the following categories:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity method investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measurement alternative investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Publicly-held securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">353</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These investments are classified as other long-term assets within our accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</font><font style="font-family:inherit;font-size:10pt;">, in accordance with U.S. GAAP and our accounting policies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the book value of our equity method investments exceeded our share of the book value of the investees&#8217; underlying net assets by approximately </font><font style="font-family:inherit;font-size:10pt;">$335 million</font><font style="font-family:inherit;font-size:10pt;">, which represents amortizable intangible assets and in-process research and development, corresponding deferred tax liabilities and goodwill.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE I &#8211; COMMITMENTS AND CONTINGENCIES</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The medical device market in which we primarily participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding or in a series of related proceedings or litigate multiple features of a single class of devices. These forces frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters, however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the normal course of business, product liability, securities and commercial claims are asserted against us. Similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our financial position, results of operations and/or liquidity.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with </font><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 450, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies</font><font style="font-family:inherit;font-size:10pt;">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our accrual for legal matters that are probable and estimable was </font><font style="font-family:inherit;font-size:10pt;">$1.511 billion</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.612 billion</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and includes certain estimated costs of settlement, damages and defense. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, a portion of our legal accrual is funded and included in our restricted cash balance as disclosed in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note G &#8211; Supplemental Balance Sheet Information</font><font style="font-family:inherit;font-size:10pt;">. We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our debt covenants.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be estimated.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Patent Litigation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 9, 2015, Edwards Lifesciences, LLC filed an invalidity claim against one of our subsidiaries, Sadra Medical, Inc. (Sadra), in the High Court of Justice, Chancery Division Patents Court in the United Kingdom, alleging that a European patent owned by Sadra relating to a repositionable heart valve is invalid. On January 15, 2016, we filed our defense and counterclaim for a declaration that our European patent is valid and infringed by Edwards. On February 25, 2016, we amended our counterclaim to allege infringement of a second patent related to adaptive sealing technology. A trial was held from January 18 to January 27, 2017. On March 3, 2017, the court found one of our patents valid and infringed and some claims of the second patent invalid and the remaining claims not infringed. Both parties have filed an appeal. On March 28, 2018, the Court of Appeals affirmed the decision of the High Court.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation in the U.S. District Court for the District of Delaware for patent infringement. We allege that Edwards&#8217; SAPIEN&#8482; 3 Valve infringes a patent related to adaptive sealing technology. On June 9, 2016, Edwards filed a counterclaim alleging that our Lotus&#8482; Valve System infringes three patents owned by Edwards. On October 12, 2016, Edwards filed a petition for inter partes review of our patent with the U.S. Patent and Trademark Office (USPTO), Patent Trial and Appeal Board. On March 29, 2017, the USPTO granted the inter partes review request. On April 18, 2017, Edwards filed a second petition for inter partes review of our patent with the USPTO. On March 23, 2018, the USPTO found the patent invalid. The Company plans to appeal that decision.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 26, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of D&#252;sseldorf, Germany alleging a European patent (Spenser '550) owned by Edwards is infringed by our Lotus Transcatheter Heart Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we infringed the Spenser '550 patent. The Company filed an appeal. The appeal hearing is scheduled for May 17, 2018. On April 13, 2018, the &#8216;550 patent was revoked by the European Patent Office.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2016, Edwards Lifesciences PVT, Inc. and Edwards Lifesciences SA (AG) filed a plenary summons against Boston Scientific Limited and Boston Scientific Group Public Company in the High Court of Ireland alleging that a European patent (Spenser) owned by Edwards is infringed by our Lotus Valve System. On April 13, 2018, the &#8216;550 patent was revoked by the European Patent Office.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 20, 2017, The Board of Regents, University of Texas System (UT) and TissueGen. Inc. (TissueGen), served a lawsuit against us in the Western District of Texas. The complaint against us alleges patent infringement of two U.S. patents owned by UT, relating to &#8220;Drug Releasing Biodegradable Fiber Implant&#8221; and &#8220;Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,&#8221; and affects the manufacture, use and sale of our Synergy&#8482; Stent System. On March 12, 2018, the court dismissed the action and transferred it to the United States District Court for the District of Delaware.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Liability Litigation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">April 24, 2018</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">49,500</font><font style="font-family:inherit;font-size:10pt;"> product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us. The pending cases are in various federal and state courts in the United States and include </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;"> putative class actions. There were also approximately </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> cases in Canada, inclusive of </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> certified and </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> putative class actions and fewer than </font><font style="font-family:inherit;font-size:10pt;">25</font><font style="font-family:inherit;font-size:10pt;"> claims in the United Kingdom. Generally, the plaintiffs allege personal injury associated with use of our transvaginal surgical mesh products. The plaintiffs assert design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. Over </font><font style="font-family:inherit;font-size:10pt;">3,100</font><font style="font-family:inherit;font-size:10pt;"> of the cases have been specially assigned to one judge in state court in Massachusetts. On February 7, 2012, the Judicial Panel on Multi-District Litigation (MDL) established MDL-2326 in the United States District Court for the Southern District of West Virginia and transferred the federal court transvaginal surgical mesh cases to MDL-2326 for coordinated pretrial proceedings. During the fourth quarter of 2013, we received written discovery requests from certain state attorneys general offices regarding our transvaginal surgical mesh products. We have responded to those requests. As of </font><font style="font-family:inherit;font-size:10pt;">April&#160;24, 2018</font><font style="font-family:inherit;font-size:10pt;">, we have entered into master settlement agreements in principle or are in final stages of entering one with certain plaintiffs' counsel to resolve an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">47,500</font><font style="font-family:inherit;font-size:10pt;"> cases and claims. These master settlement agreements provide that the settlement and distribution of settlement funds to participating claimants are conditional upon, among other things, achieving minimum required claimant participation thresholds. Of the approximately </font><font style="font-family:inherit;font-size:10pt;">47,500</font><font style="font-family:inherit;font-size:10pt;"> cases and claims, approximately </font><font style="font-family:inherit;font-size:10pt;">21,000</font><font style="font-family:inherit;font-size:10pt;"> have met the conditions of the settlement and are final. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have established a product liability accrual for known and estimated future cases and claims asserted against us as well as with respect to the actions that have resulted in verdicts against us and the costs of defense thereof associated with our transvaginal surgical mesh products. While we believe that our accrual associated with this matter is adequate, changes to this accrual may be required in the future as additional information becomes available. While we continue to engage in discussions with plaintiffs&#8217; counsel regarding potential resolution of pending cases and claims and intend to vigorously contest the cases and claims asserted against us, that do not settle, the final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Initial trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Proceedings</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note H &#8211; Income Taxes</font><font style="font-family:inherit;font-size:10pt;"> for information regarding our tax litigation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE M &#8211; CHANGES IN OTHER COMPREHENSIVE INCOME</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the reclassifications out of other comprehensive income, net of tax.</font></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Three Months Ended March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains/Losses on Derivative Financial Instruments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains/Losses on Available-for-Sale Securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Defined Benefit Pension Items/Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(91</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(81</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current-period other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of March 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(22</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(79</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(128</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Three Months Ended March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains/Losses on Derivative Financial Instruments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains/Losses on Available-for-Sale Securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Defined Benefit Pension Items/Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current-period other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of March 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(71</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">52</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(46</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note D &#8211; Hedging Activities and Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;"> for further detail on the reclassifications related to derivatives.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We adopted Update No. 2016-01 in the first quarter of 2018, as a result of adopting the standard, we recorded a cumulative effect adjustment to retained earnings for unrealized gains and losses for available-for-sale securities previously recorded to accumulated other comprehensive income.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The gains and losses on defined benefit and pension related items before reclassifications and gains and losses on defined benefit and pension items reclassified from accumulated other comprehensive income were reduced by immaterial income tax impacts in the </font><font style="font-family:inherit;font-size:10pt;">first three months of</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE E &#8211; BORROWINGS AND CREDIT ARRANGEMENTS</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had total debt of</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">$5.765 billion</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">and </font><font style="font-family:inherit;font-size:10pt;">$5.616 billion</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">The debt maturity schedule for the significant components of our long-term debt obligations is presented below:</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except interest rates)</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Issuance Date</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity Date</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Semi-annual Coupon Rate</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2018 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2020 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2009</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2020 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2022 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.375</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2023 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2025 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2025</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.850</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 2028 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 2028</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 2035 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 2005</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 2035</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2040 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2040</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized Debt Issuance Discount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020 - 2040</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized Deferred Financing Costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020 - 2040</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized Gain on Fair Value Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020 - 2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital Lease Obligation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8224;</sup></font><font style="font-family:inherit;font-size:9pt;">As of </font><font style="font-family:inherit;font-size:9pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:9pt;">, </font><font style="font-family:inherit;font-size:9pt;">$600 million</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:9pt;">under the October 2018 Notes was outstanding and classified as short-term debt.</font><font style="font-family:inherit;font-size:9pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:93%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revolving Credit Facility</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we maintained a </font><font style="font-family:inherit;font-size:10pt;">$2.250 billion</font><font style="font-family:inherit;font-size:10pt;"> revolving credit facility (the 2017 Facility) with a global syndicate of commercial banks that matures on August 4, 2022. This facility provides backing for the commercial paper program described below. There were no amounts borrowed under our revolving credit facility as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2017 Facility requires that we maintain certain financial covenants, as follows:</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Covenant Requirement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Actual</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">as of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">as of March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maximum leverage ratio (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.5 times</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2 times</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-size:9pt;">Ratio of total debt to consolidated EBITDA, as defined by the credit agreement, for the preceding four consecutive fiscal quarters.</font><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2017 Facility provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">$500 million</font><font style="font-family:inherit;font-size:10pt;"> in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$415 million</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the 2017 Facility, are excluded from the calculation of consolidated EBITDA, as defined in the 2017 Facility, provided that the sum of any excluded net cash litigation payments does not exceed</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">$2.624 billion</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$1.690 billion</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">of the legal exclusion remaining.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facility or seek waivers from compliance with these covenants, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all credit facility commitments would terminate and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our credit facility may negatively impact the credit ratings assigned to our commercial paper program which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commercial Paper</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$886 million</font><font style="font-family:inherit;font-size:10pt;"> of commercial paper outstanding and</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">$1.197 billion</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">Our commercial paper program is backed by the 2017 Facility, which allows us to have a maximum of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.250 billion</font><font style="font-family:inherit;font-size:10pt;"> in commercial paper outstanding. </font><font style="font-family:inherit;font-size:10pt;">Outstanding commercial paper directly reduces borrowing capacity available under the 2017 Facility</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">the commercial paper issued and outstanding had a weighted average maturity of </font><font style="font-family:inherit;font-size:10pt;">22</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">days and a weighted average yield of</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">2.46 percent</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">the commercial paper issued and outstanding had a weighted average maturity of </font><font style="font-family:inherit;font-size:10pt;">38</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">days and a weighted average yield of</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">1.85 percent</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Senior Notes</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had senior notes outstanding of </font><font style="font-family:inherit;font-size:10pt;">$4.800 billion</font><font style="font-family:inherit;font-size:10pt;"> as of</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">$4.400 billion</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">as of</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, we completed an offering of</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.000 billion</font><font style="font-family:inherit;font-size:10pt;"> in&#160;aggregate principal amount of</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4.000%</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">senior notes, due&#160;March 2028. We used a portion of the net proceeds from the offering to repay the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$600 million</font><font style="font-family:inherit;font-size:10pt;"> plus accrued interest of our</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">2.650%</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">senior notes due&#160;in October 2018. The remaining proceeds were used to repay a portion</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">of our outstanding commercial paper.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to borrowings under our credit and security facility, and to the extent borrowed by our subsidiaries, to liabilities of our subsidiaries (see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Arrangements</font><font style="font-family:inherit;font-size:10pt;"> below).</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Arrangements</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we maintained a </font><font style="font-family:inherit;font-size:10pt;">$400 million</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">credit and security facility secured by our U.S. trade receivables maturing in February 2019.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">We had outstanding borrowings of </font><font style="font-family:inherit;font-size:10pt;">$70 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">and no outstanding borrowings as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> under our credit and security facility.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have accounts receivable factoring programs in certain European countries that we account for as sales under </font><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 860, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Transfers and Servicing</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">These agreements provide for the sale of accounts receivable to third parties, of up to approximately </font><font style="font-family:inherit;font-size:10pt;">$463 million</font><font style="font-family:inherit;font-size:10pt;"> as of</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. We de-recognized </font><font style="font-family:inherit;font-size:10pt;">$178 million</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">of receivables as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">at an average interest rate of </font><font style="font-family:inherit;font-size:10pt;">2.1 percent</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">and</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">$171 million</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> at an average interest rate of </font><font style="font-family:inherit;font-size:10pt;">1.8 percent</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2018, we entered into a factoring agreement with a commercial Japanese bank. The agreement provides for the sale of accounts receivable and promissory notes of up to </font><font style="font-family:inherit;font-size:10pt;">30.000 billion</font><font style="font-family:inherit;font-size:10pt;"> Japanese yen (approximately </font><font style="font-family:inherit;font-size:10pt;">$282 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">). We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. We de-recognized </font><font style="font-family:inherit;font-size:10pt;">$95 million</font><font style="font-family:inherit;font-size:10pt;"> of receivables as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> at an average interest rate of </font><font style="font-family:inherit;font-size:10pt;">0.5 percent</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we have uncommitted credit facilities with a commercial Japanese bank that provide for accounts receivable factoring and promissory notes discounting of up to</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">22.000 billion</font><font style="font-family:inherit;font-size:10pt;"> Japanese yen (approximately</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">$207 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">). We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. We de-recognized</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">$124 million</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">of notes receivable as of</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">at an average interest rate of </font><font style="font-family:inherit;font-size:10pt;">1.5 percent</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">and</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">$157 million</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">of notes receivable as of</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">at an average interest rate of </font><font style="font-family:inherit;font-size:10pt;">1.3 percent</font><font style="font-family:inherit;font-size:10pt;">. De-recognized accounts and notes receivable are excluded from trade accounts receivable, net in the accompanying</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of and through </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">we were in compliance with all the required covenants related to our debt obligations. For additional information regarding the terms of our debt agreements, refer to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note E - Borrowings and Credit Arrangements </font><font style="font-family:inherit;font-size:10pt;">of the consolidated financial statements in our most recent Annual Report on Form 10-K.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our derivative instruments do not subject our earnings or cash flows to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE J &#8211; WEIGHTED AVERAGE SHARES OUTSTANDING</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding - basic</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,376.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,365.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net effect of common stock equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted average shares outstanding - assuming dilution</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,396.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,390.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The impact of stock options outstanding with exercise prices greater than the average fair market value of our common stock was immaterial for all periods presented.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We issued approximately </font><font style="font-family:inherit;font-size:10pt;">six million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock in the </font><font style="font-family:inherit;font-size:10pt;">first</font><font style="font-family:inherit;font-size:10pt;"> quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">seven million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock in the </font><font style="font-family:inherit;font-size:10pt;">first</font><font style="font-family:inherit;font-size:10pt;"> quarter of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, following the exercise of underlying stock options, vesting of deferred stock units or purchases under our employee stock purchase plan. We did not repurchase any shares of our common stock during the </font><font style="font-family:inherit;font-size:10pt;">first three months of</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following are the balances of our derivative assets and liabilities:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Location in </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unaudited Condensed Consolidated </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheets </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(1)</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative Assets:</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Designated Derivative Instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Designated Derivative Instruments</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Derivative Assets</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative Liabilities:</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Designated Derivative Instruments</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Designated Derivative Instruments</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Derivative Liabilities</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">154</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">We classify derivative assets and liabilities as current when the remaining term of the derivative contract is one year or less.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE D &#8211; HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings or cash flows to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecast intercompany and third-party transactions and net investments in certain subsidiaries. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in British pound sterling, Euro and Japanese yen. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our currency derivative instruments are designated as cash flow hedges under </font><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Derivatives and Hedging</font><font style="font-family:inherit;font-size:10pt;"> and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">other comprehensive income </font><font style="font-family:inherit;font-size:10pt;">(OCI) and is included in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss), net of tax </font><font style="font-family:inherit;font-size:10pt;">(AOCI) caption of our </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</font><font style="font-family:inherit;font-size:10pt;"> until the underlying third-party transaction occurs. When the related third-party transaction occurs we recognize the gain or loss to earnings within the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of products sold</font><font style="font-family:inherit;font-size:10pt;"> caption of our </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;">. In the event the hedging relationship is no longer effective, or if the hedged forecast transaction becomes no longer probable of occurring, we reclassify the amount of gains or losses on the derivative instrument designated as a cash flow hedge to earnings at that time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also use forward currency contracts that are not part of designated hedging relationships under </font><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</font><font style="font-family:inherit;font-size:10pt;"> as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings and reflected within the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other, net</font><font style="font-family:inherit;font-size:10pt;"> caption of our </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. Under these agreements we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges under </font><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in the fair value of interest rate derivatives designated as fair value hedges and the changes in the fair value of the underlying hedged debt instrument generally offset and are recorded within the</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Interest expense</font><font style="font-family:inherit;font-size:10pt;"> caption of our </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;">. We record the changes in the fair value of interest rate derivatives designated as cash flow hedges within OCI and is included within the AOCI</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">caption of our </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</font><font style="font-family:inherit;font-size:10pt;"> until the underlying hedged transaction occurs, at which time we recognize the gain or loss within </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</font><font style="font-family:inherit;font-size:10pt;">. In the event the hedging relationship is no longer effective, or if the hedged forecast transaction becomes no longer probable of occurring, we reclassify the amount of gains or losses on the interest rate derivative designated as a cash flow hedge to earnings at that time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are amortizing the realized gains or losses from interest rate derivative instruments previously designated as fair value or cash flow hedges into earnings as a component of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</font><font style="font-family:inherit;font-size:10pt;"> over the remaining term of the hedged item in accordance with </font><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</font><font style="font-family:inherit;font-size:10pt;">, so long as the hedge relationship remains effective. Prior to the adoption of ASC Update No. 2017-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:inherit;font-size:10pt;"> (Topic 815), the ineffective portion, if any, of our interest rate derivatives designated as either fair value or cash flow hedges was recognized in earnings in the period in which the hedging relationship exhibited ineffectiveness.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the contractual amounts of our derivative instruments outstanding:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FASB ASC Topic 815 Designation</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flow hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-designated</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,565</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,671</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Notional Outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,923</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The remaining time to maturity as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> is within </font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;">&#160;months for all designated forward currency contracts and generally less than one year for all non-designated forward currency contracts.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had no interest rate derivative instruments outstanding as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following presents the effect of our derivative instruments designated as cash flow hedges under </font><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</font><font style="font-family:inherit;font-size:10pt;"> on our accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Location in Unaudited Condensed Consolidated Statements of Operations</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Amounts Presented in Unaudited Condensed Consolidated Statements of Operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Recognized in OCI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Amount Reclassified from AOCI into Earnings</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Pre-Tax Gain (Loss)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax Benefit (Expense)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain (Loss) Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Pre-Tax (Gain) Loss</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax (Benefit) Expense</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Gain) Loss </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net of Tax</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Three Months Ended March 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forward currency contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cost of products sold</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(118</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(91</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Three Months Ended March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forward currency contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cost of products sold</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(58</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">21</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">10</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as currency hedge contracts under </font><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</font><font style="font-family:inherit;font-size:10pt;"> that may be reclassified to earnings within the next twelve months are presented below:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(in millions)</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Designated Derivative Instrument</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">FASB ASC Topic 815 Designation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Location in </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unaudited Condensed Consolidated Statements of Operations</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Amounts </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Presented in </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unaudited Condensed Consolidated </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Statements of Operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount of </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Pre-Tax </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gain (Loss) </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">that may be Reclassified to Earnings</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate derivative contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value hedge</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flow hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flow hedge</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of products sold</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Location in </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unaudited Condensed Consolidated Statements of Operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gain (loss) on currency hedge contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gain (loss) on currency transaction exposures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net currency exchange gain (loss)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</font><font style="font-family:inherit;font-size:10pt;"> requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by </font><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements and Disclosures</font><font style="font-family:inherit;font-size:10pt;">, by considering the estimated amount we would receive or pay to transfer these instruments at the reporting date when taking into account current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following are the balances of our derivative assets and liabilities:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Location in </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unaudited Condensed Consolidated </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheets </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(1)</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative Assets:</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Designated Derivative Instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Designated Derivative Instruments</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Derivative Assets</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative Liabilities:</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Designated Derivative Instruments</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Designated Derivative Instruments</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Derivative Liabilities</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">154</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">We classify derivative assets and liabilities as current when the remaining term of the derivative contract is one year or less.</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Recurring Fair Value Measurements</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. </font><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 820</font><font style="font-family:inherit;font-size:10pt;"> establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Inputs to the valuation methodology are unobservable inputs based on management&#8217;s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value on a recurring basis consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market and government funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Publicly-held securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">86</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">118</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">154</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">152</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">306</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">259</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our investments in money market and government funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as cash and cash equivalents within our accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</font><font style="font-family:inherit;font-size:10pt;">, in accordance with U.S. GAAP and our accounting policies. In addition to </font><font style="font-family:inherit;font-size:10pt;">$42 million</font><font style="font-family:inherit;font-size:10pt;"> invested in money market and government funds as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$245 million</font><font style="font-family:inherit;font-size:10pt;"> in interest bearing and non-interest bearing bank accounts. In addition to </font><font style="font-family:inherit;font-size:10pt;">$21 million</font><font style="font-family:inherit;font-size:10pt;"> invested in money market and government funds as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$167 million</font><font style="font-family:inherit;font-size:10pt;"> in interest bearing and non-interest bearing bank accounts.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our recurring fair value measurements using significant unobservable inputs (Level 3) relate solely to our contingent consideration liability. Refer to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note B &#8211; Acquisitions and Strategic Investments</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">for a discussion of the changes in the fair value of our contingent consideration liability.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Recurring Fair Value Measurements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods subsequent to initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note B &#8211; Acquisitions and Strategic Investments</font><font style="font-family:inherit;font-size:10pt;"> for a discussion of our strategic investments. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note C &#8211; Goodwill and Other Intangible Assets</font><font style="font-family:inherit;font-size:10pt;"> for a discussion of the fair values and annual impairment tests of goodwill and our indefinite lived intangible assets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of our outstanding debt obligations was </font><font style="font-family:inherit;font-size:10pt;">$6.040 billion</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5.945 billion</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, amortized cost for commercial paper and face value for term loans and credit facility borrowings outstanding. Refer to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note E &#8211; Borrowings and Credit Arrangements</font><font style="font-family:inherit;font-size:10pt;"> for a discussion of our debt obligations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</font><font style="font-family:inherit;font-size:10pt;"> requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by </font><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements and Disclosures</font><font style="font-family:inherit;font-size:10pt;">, </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE C &#8211; GOODWILL AND OTHER INTANGIBLE ASSETS</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated<br clear="none"/>Amortization/<br clear="none"/>Write-offs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated<br clear="none"/>Amortization/<br clear="none"/>Write-offs</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology-related</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,396</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,984</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,386</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,880</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(868</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,633</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(838</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,549</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,536</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6,097</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unamortizable intangible assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development (IPR&amp;D)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology-related</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">17,281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9,900</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">17,295</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9,900</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents our goodwill balance by global reportable segment:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MedSurg*</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rhythm and Neuro*</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cardiovascular</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of reportable segment revisions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,379</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of foreign currency fluctuations and other changes in carrying amount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,774</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,707</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We did not have any goodwill impairments in the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. We test our goodwill balances during the second quarter of each year for impairment, or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. We have seven reporting units: Endoscopy, Urology and Pelvic Health, Cardiac Rhythm Management, Electrophysiology, Neuromodulation, Interventional Cardiology and Peripheral Interventions. As such, the first quarter change in our reportable segments, where Neuromodulation was reclassified from our MedSurg segment to our newly created Rhythm and Neuro segment did not trigger a goodwill impairment assessment or impact our total goodwill carrying value.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE H &#8211; INCOME TAXES</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our effective tax rate from continuing operations is presented below:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective tax rate from continuing operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in our reported tax rates for the </font><font style="font-family:inherit;font-size:10pt;">first</font><font style="font-family:inherit;font-size:10pt;"> quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, as compared to the same period in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, relates primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate, including intangible asset impairment charges, acquisition-related items, restructuring items, litigation-related items, as well as certain discrete tax items including impacts of the Tax Cuts and Jobs Act (TCJA), enacted on December 22, 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$1.240 billion</font><font style="font-family:inherit;font-size:10pt;"> of gross unrecognized tax benefits, of which a net </font><font style="font-family:inherit;font-size:10pt;">$1.157 billion</font><font style="font-family:inherit;font-size:10pt;">, if recognized, would affect our effective tax rate. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$1.238 billion</font><font style="font-family:inherit;font-size:10pt;"> of gross unrecognized tax benefits, of which a net </font><font style="font-family:inherit;font-size:10pt;">$1.150 billion</font><font style="font-family:inherit;font-size:10pt;">, if recognized, would affect our effective tax rate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have received Notices of Deficiency from the Internal Revenue Service (IRS) reflecting proposed audit adjustments for Guidant Corporation for its 2001 through 2006 tax years and for Boston Scientific Corporation for its 2006 and 2007 tax years. The total incremental tax liability asserted by the IRS for the applicable periods is </font><font style="font-family:inherit;font-size:10pt;">$1.162 billion</font><font style="font-family:inherit;font-size:10pt;"> plus interest. The primary issue in dispute for all years is the transfer pricing associated with the technology license agreements between domestic and foreign subsidiaries of Guidant. In addition, the IRS has proposed adjustments in connection with the financial terms of our Transaction Agreement with Abbott Laboratories pertaining to the sale of Guidant's vascular intervention business to Abbott Laboratories in April 2006. During 2014, we received a Revenue Agent Report from the IRS reflecting significant proposed audit adjustments to our 2008, 2009 and 2010 tax years based upon the same transfer pricing methodologies that the IRS applied to our 2001 through 2007 tax years.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not agree with the transfer pricing methodologies applied by the IRS or its resulting assessment. We have filed petitions with the U.S. Tax Court contesting the Notices of Deficiency for the 2001 through 2007 tax years in challenge and submitted a letter to the IRS Office of Appeals protesting the Revenue Agent Report for the 2008 through 2010 tax years and requesting an administrative appeal hearing. The issues in dispute were scheduled to be heard in U.S. Tax Court in July 2016. On July 19, 2016, we entered into a Stipulation of Settled Issues with the IRS intended to resolve all of the aforementioned transfer pricing issues, as well as the issues related to our transaction with Abbott Laboratories, for the 2001 through 2007 tax years. The Stipulation of Settled Issues was contingent upon the IRS Office of Appeals applying the same basis of settlement to all transfer pricing issues for the Company&#8217;s 2008, 2009 and 2010 tax years as well as review by the United States Congress Joint Committee on Taxation (JCT). In October 2016, we reached an agreement in principle with the IRS Office of Appeals as to the resolution of transfer pricing issues in 2008, 2009 and 2010 tax years, subject to additional calculations of tax as well as documentation to memorialize our agreement. The IRS has recalculated our final tax liabilities under this agreement for all of our tax years from 2001 through 2010 and the JCT has completed its review of the recalculations for the 2001 through 2010 tax years.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event that the conditions in the Stipulation of Settled Items are satisfied, we expect to make net tax payments of approximately </font><font style="font-family:inherit;font-size:10pt;">$275 million</font><font style="font-family:inherit;font-size:10pt;">, plus interest through the date of payment with respect to the settled issues. If finalized, payments related to the resolution are expected in the next six months. We believe that our income tax reserves associated with these matters are adequate as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and we do not expect to recognize any additional charges related to resolution of this controversy. However, the final resolution of these issues remains contingent and if the Stipulation of Settled Issues is not finalized, it could have a material impact on our financial condition, results of operations, or cash flows.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize interest and penalties related to income taxes as a component of income tax expense. We had </font><font style="font-family:inherit;font-size:10pt;">$675 million</font><font style="font-family:inherit;font-size:10pt;"> accrued for gross interest and penalties as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$655 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. We recognized net tax expense related to interest and penalties of </font><font style="font-family:inherit;font-size:10pt;">$17 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">first</font><font style="font-family:inherit;font-size:10pt;"> quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$13 million</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;">first</font><font style="font-family:inherit;font-size:10pt;"> quarter of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is reasonably possible that within the next 12&#160;months we will resolve multiple issues including transfer pricing and transactional-related issues with foreign, federal and state taxing authorities, in which case we could record a reduction in our balance of unrecognized tax benefits of up to approximately </font><font style="font-family:inherit;font-size:10pt;">$897 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are a number of key provisions under the TCJA that impact us and we continue to monitor and analyze the ramification of the new law as the implementation is executed. The final impact of the TCJA may differ from the estimates reported due to, among other things, changes in interpretations and assumptions made by us, additional guidance that may be issued by the U.S. Department of the Treasury and actions that we may take as a result. The TCJA reduces the US Federal corporate income tax rate from </font><font style="font-family:inherit;font-size:10pt;">35 percent</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">21 percent</font><font style="font-family:inherit;font-size:10pt;">, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, and creates new taxes on certain foreign sourced earnings. Due to insufficient guidance, as well as the availability of information to accurately analyze the impact of the TCJA, we have made a reasonable estimate of the effects, as described below and in other cases we have not been able to make a reasonable estimate and continue to account for those items based on our existing accounting under FASB ASC Topic 740, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;"> and the provisions of the tax laws that were in effect immediately prior to enactment. In the </font><font style="font-family:inherit;font-size:10pt;">first</font><font style="font-family:inherit;font-size:10pt;"> quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we recognized an additional tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$9 million</font><font style="font-family:inherit;font-size:10pt;">, resulting in a total provisional estimate of </font><font style="font-family:inherit;font-size:10pt;">$852 million</font><font style="font-family:inherit;font-size:10pt;"> related to the TCJA. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are required to record deferred tax assets and liabilities based on the enacted tax rates at which they are expected to reverse in the future. Therefore, any U.S. related deferred taxes were re-measured from </font><font style="font-family:inherit;font-size:10pt;">35 percent</font><font style="font-family:inherit;font-size:10pt;"> down to </font><font style="font-family:inherit;font-size:10pt;">21 percent</font><font style="font-family:inherit;font-size:10pt;"> based on the recorded balances as of December 31, 2017. The analysis included a preliminary assessment on the deductibility of certain amounts for which deferred tax assets may have been recorded. However, we are still analyzing certain aspects of the TCJA and refining our calculations based on the available information, which could potentially affect the measurement of these balances or give rise to new deferred tax amounts. As of March 31, 2018, we have not adjusted our provisional estimate related to re-measurement of our deferred tax balances. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we recorded an estimated tax benefit of approximately </font><font style="font-family:inherit;font-size:10pt;">$99 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are required to calculate a one-time transition tax based on our total post-1986 foreign earnings and profits (E&amp;P) that we previously deferred from U.S. income taxes. In the </font><font style="font-family:inherit;font-size:10pt;">first</font><font style="font-family:inherit;font-size:10pt;"> quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we recognized an additional tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$9 million</font><font style="font-family:inherit;font-size:10pt;">, which results in a revised provisional amount of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.035 billion</font><font style="font-family:inherit;font-size:10pt;">. We anticipate offsetting this liability against existing tax attributes reducing the required payment to approximately </font><font style="font-family:inherit;font-size:10pt;">$454 million</font><font style="font-family:inherit;font-size:10pt;"> which will be remitted over an eight year period. We have not yet completed our calculation of the total post-1986 E&amp;P for these foreign subsidiaries and we continue to refine the analysis. Additionally, no income taxes have been provided for any remaining undistributed foreign earnings that are not subject to the transition tax or any additional outside basis difference inherent in these entities, as we expect these amounts will remain indefinitely reinvested in foreign operations. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings not subject to the transition tax and additional outside basis difference in these entities is not practicable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. Additionally, we are required to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. As of March 31, 2018, we are still evaluating the effects of the GILTI provisions as guidance and interpretations continue to emerge. Therefore, we have not determined our accounting policy on the GILTI provisions. However, the standard requires that we reflect the impact of the GILTI provisions as a period expense until the accounting policy is finalized. Therefore, we have included the provisional estimate of GILTI related to current-year operations in our estimated annual effective tax rate only and will be updating the impact and accounting policy as the analysis related to the GILTI provisions is completed.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,113</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,078</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with </font><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 450, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies</font><font style="font-family:inherit;font-size:10pt;">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE N &#8211; NEW ACCOUNTING PRONOUNCEMENTS</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our unaudited condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Standards to be Implemented</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-02</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASC Update No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases </font><font style="font-family:inherit;font-size:10pt;">(Topic 842)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> The purpose of Update No. 2016-02 is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. Update No. 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted and a modified retrospective approach is required for adoption. While we are still in the process of determining the effect that the new standard will have on our financial position and results of operations, we expect to recognize additional assets and corresponding liabilities on our consolidated balance sheets, as a result of our operating lease portfolio as it exists at the date we adopt the new standard. Please refer to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note F - Lease and Other Purchase Obligations</font><font style="font-family:inherit;font-size:10pt;"> in our most recent Annual Report on Form 10-K for information regarding our most current lease activity. Additionally, we are in the process of implementing a new lease administration and lease accounting system, and updating our controls and procedures for maintaining and accounting for our lease portfolio under the new standard. As a result, we anticipate adopting the new standard on January 1, 2019.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-13</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASC Update No. 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses </font><font style="font-family:inherit;font-size:10pt;">(Topic 326)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Measurement of Credit Losses on Financial Instruments</font><font style="font-family:inherit;font-size:10pt;">. The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted for annual periods beginning after December 15, 2018. We are in the process of determining the effect that the adoption will have on our financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No other new accounting pronouncements, issued or effective, during the period had, or are expected to have, a material impact on our condensed consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE A &#8211; BASIS OF PRESENTATION</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated financial statements</font><font style="font-family:inherit;font-size:10pt;"> of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-Q and Article&#160;10 of Regulation&#160;S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. For further information, refer to the consolidated financial statements and footnotes thereto included in Item&#160;8 of our most recent Annual Report on Form 10-K.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reported in millions within this report are computed based on the amounts in thousands.&#160;As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars. Prior year balances were subject to rounding.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revision of Reportable Segments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, following organizational changes to align the company's business and organization structure focused on active implantable devices, we revised our reportable segments, in accordance with FASB ASC Topic 280, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Reporting.</font><font style="font-family:inherit;font-size:10pt;"> The revision reflects a reclassification of our Neuromodulation business from our Medical Surgical (MedSurg) segment to our newly created Rhythm and Neuro segment. We have revised prior year amounts to conform to the current year&#8217;s presentation (as denoted with an asterisk throughout *). There was no revision to operating segments or reporting units as a result of the organizational change.</font><font style="font-family:inherit;font-size:10pt;"> See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note C &#8211; Goodwill and Other Intangible Assets</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note K &#8211; Segment Reporting</font><font style="font-family:inherit;font-size:10pt;"> for further details.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate events occurring after the date of our most recent accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</font><font style="font-family:inherit;font-size:10pt;"> for potential recognition or disclosure in our financial statements. We did not identify any material subsequent events requiring adjustment to our accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated financial statements</font><font style="font-family:inherit;font-size:10pt;"> (recognized subsequent events) for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. Those items requiring disclosure (unrecognized subsequent events) in the financial statements have been disclosed accordingly. Refer to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note B &#8211; Acquisitions and Strategic Investments</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note I &#8211; Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;"> for more information.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Standards Implemented Since December 31, 2017</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2014-09</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASC Update No. 2014-09,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue from Contracts with Customers </font><font style="font-family:inherit;font-size:10pt;">(Topic 606), which was subsequently updated. We adopted the standard as of January 1, 2018, using the modified retrospective method. Under this method, we applied FASB ASC Topic 606 to contracts that were not complete as of January 1, 2018 and recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings. Results for reporting periods beginning after January 1, 2018 are presented in accordance with FASB ASC Topic 606. Prior period amounts are not adjusted and are reported in accordance with legacy GAAP requirements in FASB ASC Topic 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the adoption of FASB ASC Topic 606, we recorded a net reduction to opening retained earnings of </font><font style="font-family:inherit;font-size:10pt;">$177 million</font><font style="font-family:inherit;font-size:10pt;"> on January 1, 2018, primarily related to cost of providing non-contractual post-implant support to certain customers, which we deemed immaterial in the context of the arrangement. Upon the adoption of FASB ASC Topic 606, when we sell a device with an implied non-contractual post-implant support obligation, we forward accrue the cost of the service within</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Selling, general and administrative expenses </font><font style="font-family:inherit;font-size:10pt;">and recognize it at the point in time the associated revenue is earned. We release the accrual over the related service period. These costs were previously expensed as incurred due to such service obligation being non-contractual. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The impact of adopting FASB ASC Topic 606 on our </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, resulted in an increase in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$59 million</font><font style="font-family:inherit;font-size:10pt;"> and an increase in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$206 million</font><font style="font-family:inherit;font-size:10pt;">, as a result of accruing for our post-implant support obligation. We also recorded deferred tax assets primarily related to post-implant support, resulting in an increase in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets </font><font style="font-family:inherit;font-size:10pt;">of </font><font style="font-family:inherit;font-size:10pt;">$12 million</font><font style="font-family:inherit;font-size:10pt;"> and a reduction in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred income taxes</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$41 million</font><font style="font-family:inherit;font-size:10pt;">. The remaining impact of adopting FASB ASC Topic 606 was not material to our financial position or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note L &#8211; Revenue</font><font style="font-family:inherit;font-size:10pt;"> for additional details.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-01</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASC Update No. 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Overall </font><font style="font-family:inherit;font-size:10pt;">(Subtopic 825-10)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Recognition and Measurement of Financial Assets and Financial Liabilities. </font><font style="font-family:inherit;font-size:10pt;">The purpose of Update No. 2016-01 is to improve financial reporting for financial instruments by reducing the number of items recorded to other comprehensive income. We adopted Update No. 2016-01 in the first quarter of 2018, using both the modified retrospective and prospective methods. For publicly-held securities, we used the modified retrospective approach.&#160;Unrealized gains and losses previously recorded to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">other comprehensive income</font><font style="font-family:inherit;font-size:10pt;"> were reclassified to</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> retained earnings</font><font style="font-family:inherit;font-size:10pt;"> and all future fair value changes will be recorded to net income. For privately-held securities, we elected the measurement alternative approach which is applied prospectively upon adoption. This approach requires entities to measure their investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The adoption of the standard did not have a material impact on our financial position or results of operations.&#160;The actual impact to future periods resulting from fair value changes of our equity investments is difficult to predict as it will depend on their future performance.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-16</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASC Update No. 2016-16,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes</font><font style="font-family:inherit;font-size:10pt;"> (Topic 740): </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intra-Entity Transfers of Assets Other Than Inventory</font><font style="font-family:inherit;font-size:10pt;">. The purpose of Update No. 2016-16 is to allow an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, as opposed to waiting until the asset is sold to a third party, or impaired. Update No. 2016-16 was effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. We adopted Update No. 2016-16 prospectively in the first quarter of 2018 and recognized a net reduction to opening retained earnings of </font><font style="font-family:inherit;font-size:10pt;">$55 million</font><font style="font-family:inherit;font-size:10pt;"> for income tax consequences not previously recognized for intra-entity transfers of assets other than inventories. All future income tax consequences of intra-entity transfers of assets other than inventories will be recognized through income tax expense.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2017-12</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASC Update No. 2017-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:inherit;font-size:10pt;"> (Topic 815)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Targeted Improvements to Accounting for Hedging Activities</font><font style="font-family:inherit;font-size:10pt;">. The purpose of Update No. 2017-12 is to simplify the application of hedge accounting and better align financial reporting of hedging relationships with risk management objectives. Update No. 2017-12 was effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. We early adopted Update No. 2017-12 in the first quarter of 2018. The adoption of the standard had no impact on our financial position or results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal reserves</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">787</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">525</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,254</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings and improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment, furniture and fixtures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,183</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital in progress</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated depreciation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,928</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,697</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE F &#8211; RESTRUCTURING-RELATED ACTIVITIES</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2016 Restructuring Plan </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 6, 2016, our Board of Directors approved and we committed to a restructuring initiative (the 2016 Restructuring Plan). The 2016 Restructuring Plan is intended to&#160;develop global commercialization, technology and manufacturing capabilities in key growth markets and build on our Plant Network Optimization (PNO) strategy, which is intended to simplify our manufacturing plant structure by transferring certain production lines among facilities and expanding operational efficiencies in support of our operating income margin goals. Key activities under the 2016 Restructuring Plan include strengthening global infrastructure through evolving global real estate assets and workplaces, developing global commercial and technical competencies, enhancing manufacturing and distribution expertise in certain regions and continuing implementation of our PNO strategy. These activities were initiated in the second quarter of 2016 and are expected to be substantially complete by the end of 2018. We revised the original estimate for the costs and savings associated with the program in the first quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, as approved by the Board of Directors.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of our estimates of costs associated with the 2016 Restructuring Plan by major type of cost:</font></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:42%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Type of cost</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Estimated Amount Expected to be Incurred</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$100 million to $110 million</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$25 million to $50 million</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$150 million to $165 million</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$275 million to $325 million</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Consists primarily of consulting fees and costs associated with contract cancellations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Comprised of other costs directly related to the 2016 Restructuring Plan, including program management, accelerated depreciation and costs to transfer product lines among facilities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Approximately </font><font style="font-family:inherit;font-size:10pt;">$250 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$300 million</font><font style="font-family:inherit;font-size:10pt;"> of these charges are estimated to result in cash outlays.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following presents these costs (credits) by major type and line item within our accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Three Months Ended March 31, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Termination</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Benefits</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Transfer</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of products sold</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Three Months Ended March 31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Termination</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Benefits</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accelerated</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Depreciation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Transfer</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of products sold</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents cumulative restructuring and restructuring-related charges as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, related to our 2016 Restructuring Plan by major type:</font></div><div style="line-height:120%;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016 Restructuring Plan</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfer costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (2)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">92</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Consists primarily of consulting fees and costs associated with contract cancellations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Comprised of other costs directly related to our Restructuring Plan, including program management, accelerated depreciation and costs to transfer product lines among facilities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash payments associated with our 2016 Restructuring Plan were made using cash generated from operations and are comprised of the following:</font></div><div style="line-height:120%;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016 Restructuring Plan</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfer costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Program to Date</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfer costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">122</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our restructuring liability is primarily comprised of accruals for termination benefits. The following is a rollforward of the termination benefit liability associated with our 2016 Restructuring Plan, which is reported as a component of accrued expenses included in our accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016 Restructuring Plan</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accrued as of December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charges (credits)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accrued as of March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(67</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(68</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for sales returns</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other sales reserves</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,580</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,548</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal reserves</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payroll and related liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">488</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">653</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,447</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as currency hedge contracts under </font><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</font><font style="font-family:inherit;font-size:10pt;"> that may be reclassified to earnings within the next twelve months are presented below:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(in millions)</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Designated Derivative Instrument</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">FASB ASC Topic 815 Designation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Location in </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unaudited Condensed Consolidated Statements of Operations</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Amounts </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Presented in </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unaudited Condensed Consolidated </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Statements of Operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount of </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Pre-Tax </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gain (Loss) </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">that may be Reclassified to Earnings</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate derivative contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value hedge</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flow hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flow hedge</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of products sold</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following presents the effect of our derivative instruments designated as cash flow hedges under </font><font style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</font><font style="font-family:inherit;font-size:10pt;"> on our accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Location in Unaudited Condensed Consolidated Statements of Operations</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Amounts Presented in Unaudited Condensed Consolidated Statements of Operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Recognized in OCI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Amount Reclassified from AOCI into Earnings</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Pre-Tax Gain (Loss)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax Benefit (Expense)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain (Loss) Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Pre-Tax (Gain) Loss</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax (Benefit) Expense</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Gain) Loss </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net of Tax</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Three Months Ended March 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forward currency contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cost of products sold</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(118</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(91</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;text-decoration:underline;">Three Months Ended March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forward currency contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cost of products sold</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(58</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">21</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">10</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the contractual amounts of our derivative instruments outstanding:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FASB ASC Topic 815 Designation</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flow hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-designated</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,565</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,671</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Notional Outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,923</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective tax rate from continuing operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value on a recurring basis consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market and government funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Publicly-held securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">86</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">36</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">118</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward currency contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">154</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">152</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">306</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">259</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents our goodwill balance by global reportable segment:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MedSurg*</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rhythm and Neuro*</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cardiovascular</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of reportable segment revisions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,379</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of foreign currency fluctuations and other changes in carrying amount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,503</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,774</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,707</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,984</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated<br clear="none"/>Amortization/<br clear="none"/>Write-offs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated<br clear="none"/>Amortization/<br clear="none"/>Write-offs</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology-related</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,396</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,984</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,386</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,880</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,636</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(868</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,633</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(838</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,549</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,536</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6,097</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unamortizable intangible assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development (IPR&amp;D)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology-related</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">17,281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9,900</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">17,295</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9,900</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except interest rates)</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Issuance Date</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity Date</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Semi-annual Coupon Rate</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2018 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2020 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2009</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2020 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2022 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.375</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2023 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2025 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2025</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.850</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 2028 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 2028</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 2035 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 2005</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 2035</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2040 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2040</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized Debt Issuance Discount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020 - 2040</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized Deferred Financing Costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020 - 2040</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized Gain on Fair Value Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020 - 2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital Lease Obligation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8224;</sup></font><font style="font-family:inherit;font-size:9pt;">As of </font><font style="font-family:inherit;font-size:9pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:9pt;">, </font><font style="font-family:inherit;font-size:9pt;">$600 million</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:9pt;">under the October 2018 Notes was outstanding and classified as short-term debt.</font><font style="font-family:inherit;font-size:9pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:93%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Cash, cash equivalents, restricted cash and restricted cash equivalents</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash included in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">803</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash included in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total cash, cash equivalents and restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of our estimates of costs associated with the 2016 Restructuring Plan by major type of cost:</font></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:42%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Type of cost</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Estimated Amount Expected to be Incurred</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Termination benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$100 million to $110 million</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$25 million to $50 million</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$150 million to $165 million</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$275 million to $325 million</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Consists primarily of consulting fees and costs associated with contract cancellations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Comprised of other costs directly related to the 2016 Restructuring Plan, including program management, accelerated depreciation and costs to transfer product lines among facilities.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following presents these costs (credits) by major type and line item within our accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Three Months Ended March 31, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Termination</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Benefits</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Transfer</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of products sold</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Three Months Ended March 31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Termination</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Benefits</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accelerated</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Depreciation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Transfer</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of products sold</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;"> is as follows: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MedSurg*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">711</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rhythm and Neuro*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">736</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">668</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cardiovascular</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Income (loss) before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MedSurg*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rhythm and Neuro*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cardiovascular</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income allocated to reportable segments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate expenses, including hedging activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset impairment charges, acquisition-related, restructuring- and restructuring-related and litigation-related net credits (charges)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(141</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">407</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expense, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income (loss) before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">323</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">305</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Operating income as a percentage of segment net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MedSurg*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rhythm and Neuro*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cardiovascular</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding - basic</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,376.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,365.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net effect of common stock equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted average shares outstanding - assuming dilution</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,396.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,390.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE K &#8211; SEGMENT REPORTING</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> reportable segments comprised of MedSurg, Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of our reportable segments generates revenues from the sale of medical devices. We measure and evaluate our reportable segments based on segment net sales and operating income, excluding intersegment profits. In 2017, we updated our presentation of segment net sales and operating income to the impact of foreign currency fluctuations, since our chief operating decision maker (CODM) reviews operating results both including and excluding the impact of foreign currency fluctuations and the following presentation more closely aligns to our consolidated financial statements. We exclude from segment operating income certain corporate-related expenses and certain transactions or adjustments that our CODM considers to be non-operational, such as amounts related to amortization expense, intangible asset impairment charges, acquisition-related items, restructuring and restructuring-related items and litigation-related items. Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation below. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, following organizational changes to align the company's business and organization structure focused on active implantable devices, we revised our reportable segments, in accordance with FASB ASC Topic 280, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Reporting.</font><font style="font-family:inherit;font-size:10pt;"> The revision reflects a reclassification of our Neuromodulation business from our Medical Surgical (MedSurg) segment to our newly created Rhythm and Neuro segment. We have revised prior year amounts to conform to the current year&#8217;s presentation (as denoted with an asterisk throughout *). There was no revision to operating segments or reporting units as a result of the organizational change.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;"> is as follows: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MedSurg*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">711</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rhythm and Neuro*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">736</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">668</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cardiovascular</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Income (loss) before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MedSurg*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rhythm and Neuro*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cardiovascular</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income allocated to reportable segments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate expenses, including hedging activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset impairment charges, acquisition-related, restructuring- and restructuring-related and litigation-related net credits (charges)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(141</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(143</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">407</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expense, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income (loss) before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">323</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">305</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Operating income as a percentage of segment net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MedSurg*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rhythm and Neuro*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cardiovascular</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Standards Implemented Since December 31, 2017</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2014-09</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASC Update No. 2014-09,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue from Contracts with Customers </font><font style="font-family:inherit;font-size:10pt;">(Topic 606), which was subsequently updated. We adopted the standard as of January 1, 2018, using the modified retrospective method. Under this method, we applied FASB ASC Topic 606 to contracts that were not complete as of January 1, 2018 and recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings. Results for reporting periods beginning after January 1, 2018 are presented in accordance with FASB ASC Topic 606. Prior period amounts are not adjusted and are reported in accordance with legacy GAAP requirements in FASB ASC Topic 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the adoption of FASB ASC Topic 606, we recorded a net reduction to opening retained earnings of </font><font style="font-family:inherit;font-size:10pt;">$177 million</font><font style="font-family:inherit;font-size:10pt;"> on January 1, 2018, primarily related to cost of providing non-contractual post-implant support to certain customers, which we deemed immaterial in the context of the arrangement. Upon the adoption of FASB ASC Topic 606, when we sell a device with an implied non-contractual post-implant support obligation, we forward accrue the cost of the service within</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Selling, general and administrative expenses </font><font style="font-family:inherit;font-size:10pt;">and recognize it at the point in time the associated revenue is earned. We release the accrual over the related service period. These costs were previously expensed as incurred due to such service obligation being non-contractual. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The impact of adopting FASB ASC Topic 606 on our </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, resulted in an increase in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$59 million</font><font style="font-family:inherit;font-size:10pt;"> and an increase in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$206 million</font><font style="font-family:inherit;font-size:10pt;">, as a result of accruing for our post-implant support obligation. We also recorded deferred tax assets primarily related to post-implant support, resulting in an increase in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets </font><font style="font-family:inherit;font-size:10pt;">of </font><font style="font-family:inherit;font-size:10pt;">$12 million</font><font style="font-family:inherit;font-size:10pt;"> and a reduction in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred income taxes</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$41 million</font><font style="font-family:inherit;font-size:10pt;">. The remaining impact of adopting FASB ASC Topic 606 was not material to our financial position or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note L &#8211; Revenue</font><font style="font-family:inherit;font-size:10pt;"> for additional details.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-01</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASC Update No. 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Overall </font><font style="font-family:inherit;font-size:10pt;">(Subtopic 825-10)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Recognition and Measurement of Financial Assets and Financial Liabilities. </font><font style="font-family:inherit;font-size:10pt;">The purpose of Update No. 2016-01 is to improve financial reporting for financial instruments by reducing the number of items recorded to other comprehensive income. We adopted Update No. 2016-01 in the first quarter of 2018, using both the modified retrospective and prospective methods. For publicly-held securities, we used the modified retrospective approach.&#160;Unrealized gains and losses previously recorded to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">other comprehensive income</font><font style="font-family:inherit;font-size:10pt;"> were reclassified to</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> retained earnings</font><font style="font-family:inherit;font-size:10pt;"> and all future fair value changes will be recorded to net income. For privately-held securities, we elected the measurement alternative approach which is applied prospectively upon adoption. This approach requires entities to measure their investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The adoption of the standard did not have a material impact on our financial position or results of operations.&#160;The actual impact to future periods resulting from fair value changes of our equity investments is difficult to predict as it will depend on their future performance.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-16</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASC Update No. 2016-16,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes</font><font style="font-family:inherit;font-size:10pt;"> (Topic 740): </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intra-Entity Transfers of Assets Other Than Inventory</font><font style="font-family:inherit;font-size:10pt;">. The purpose of Update No. 2016-16 is to allow an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, as opposed to waiting until the asset is sold to a third party, or impaired. Update No. 2016-16 was effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. We adopted Update No. 2016-16 prospectively in the first quarter of 2018 and recognized a net reduction to opening retained earnings of </font><font style="font-family:inherit;font-size:10pt;">$55 million</font><font style="font-family:inherit;font-size:10pt;"> for income tax consequences not previously recognized for intra-entity transfers of assets other than inventories. All future income tax consequences of intra-entity transfers of assets other than inventories will be recognized through income tax expense.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2017-12</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASC Update No. 2017-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:inherit;font-size:10pt;"> (Topic 815)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Targeted Improvements to Accounting for Hedging Activities</font><font style="font-family:inherit;font-size:10pt;">. The purpose of Update No. 2017-12 is to simplify the application of hedge accounting and better align financial reporting of hedging relationships with risk management objectives. Update No. 2017-12 was effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. We early adopted Update No. 2017-12 in the first quarter of 2018. The adoption of the standard had no impact on our financial position or results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate events occurring after the date of our most recent accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</font><font style="font-family:inherit;font-size:10pt;"> for potential recognition or disclosure in our financial statements. We did not identify any material subsequent events requiring adjustment to our accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated financial statements</font><font style="font-family:inherit;font-size:10pt;"> (recognized subsequent events) for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. Those items requiring disclosure (unrecognized subsequent events) in the financial statements have been disclosed accordingly. Refer to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note B &#8211; Acquisitions and Strategic Investments</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note I &#8211; Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;"> for more information.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE G &#8211; SUPPLEMENTAL BALANCE SHEET INFORMATION</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Components of selected captions in our accompanying </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Cash, cash equivalents, restricted cash and restricted cash equivalents</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash included in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">803</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash included in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total cash, cash equivalents and restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Trade accounts receivable, net</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(67</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(68</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for sales returns</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other sales reserves</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,580</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,548</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note:</font><font style="font-family:inherit;font-size:10pt;"> Due to the adoption of FASB ASC Topic 606 effective January 1, 2018, the allowance for sales returns has been prospectively reclassified from </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Trade accounts receivable, net</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</font><font style="font-family:inherit;font-size:10pt;"> within the </font><font style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</font><font style="font-family:inherit;font-size:10pt;">. Prior period balances remain unchanged.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a rollforward of our allowance for doubtful accounts:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning balance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net charges to expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Utilization of allowances</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">67</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">75</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Inventories</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,113</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,078</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Property, plant and equipment, net</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings and improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment, furniture and fixtures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,183</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital in progress</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated depreciation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,928</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,697</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense was </font><font style="font-family:inherit;font-size:10pt;">$68 million</font><font style="font-family:inherit;font-size:10pt;">&#160;for the </font><font style="font-family:inherit;font-size:10pt;">first</font><font style="font-family:inherit;font-size:10pt;"> quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$63 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">first</font><font style="font-family:inherit;font-size:10pt;"> quarter of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Accrued expenses</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal reserves</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payroll and related liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">488</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">653</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,447</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other long-term liabilities</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal reserves</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">787</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">525</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,254</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> EX-101.SCH 16 bsx-20180501.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2102100 - Disclosure - Acquisitions and Strategic Investments link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Acquisitions and Strategic Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Acquisitions and Strategic Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis of Presentation ASUs Implemented (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation Standards Implemented Since Dec 31 (Policies) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Borrowings and Credit Arrangements link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Borrowings and Credit Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Borrowings and Credit Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Changes in Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Changes in Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Changes in Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2210201 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Policies) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Fair Value Measurements Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2205201 - Disclosure - Fair Value Measurements Fair Value Measurements (Policies) link:presentationLink link:calculationLink link:definitionLink 2305302 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Policies) link:presentationLink link:calculationLink link:definitionLink 2304302 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - New Accounting Pronouncements New ASU impacts (Details) link:presentationLink link:calculationLink link:definitionLink 2215201 - Disclosure - New Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Restructuring Related Activities link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Restructuring Related Activities (Details) link:presentationLink link:calculationLink link:definitionLink 2207201 - Disclosure - Restructuring Related Activities Restructuring Related Activities (Policies) link:presentationLink link:calculationLink link:definitionLink 2307302 - Disclosure - Restructuring Related Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Revenue Revenue link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Revenue Revenue Disclosure (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Strategic Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Supplemental Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Supplemental Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Weighted Average Shares Outstanding link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Weighted Average Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Weighted Average Shares Outstanding (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 17 bsx-20180501_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 18 bsx-20180501_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 19 bsx-20180501_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Fair Value Disclosures [Abstract] Derivative [Table] Derivative [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Derivative [Line Items] Derivative [Line Items] Schedule of Derivative Instruments [Table Text Block] Schedule of Derivative Instruments [Table Text Block] Gains (losses) recognized in earnings for derivatives designed as hedging instruments Derivative Instruments, Gain (Loss) [Table Text Block] Net foreign currency gain (loss) [Table Text Block] Net foreign currency gain (loss) [Table Text Block] [Table Text Block] for Net foreign currency gain (loss) [Table] Classification of derivative assets and liabilities within level 2 Fair Value, by Balance Sheet Grouping [Table Text Block] Assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Restructuring and Related Activities [Abstract] Debt Disclosure [Abstract] Debt Instrument [Table] Schedule of Long-term Debt Instruments [Table] Covenant [Axis] Covenant [Axis] Covenant. Covenant [Domain] Covenant [Domain] Covenant. Current Requirement [Member] Current Requirement [Member] Current Requirement. Actual, Covenant [Member] Actual, Covenant [Member] Actual Covenant. Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] New Japanese Factoring March 2018 Program [Member] New Japanese Factoring March 2018 Program [Member] New Japanese Factoring March 2018 Program [Member] Uncommitted Credit Facilities With A Commercial Japanese Banks [Member] Uncommitted Credit Facilities With Two Commercial Japanese Banks [Member] Uncommitted credit facilities with two commercial Japanese banks. Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] the 2017 Facility [Member] the 2017 Facility [Member] the 2017 Facility [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Line of Credit [Member] Line of Credit [Member] Senior Notes [Member] Senior Notes [Member] Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Borrowings [Member] Commercial Paper [Member] Commercial Paper [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] October 2018 Notes [Member] October 2018 Notes [Member] October 2018 Notes [Member] January 2020 Notes [Member] January 2020 Notes [Member] January 2020 Notes [Member] May 2020 Notes [Member] May 2020 Notes [Member] May 2020 Notes [Member] May 2022 Notes [Member] May 2022 Notes [Member] May 2022 Notes [Member] May 2025 Notes [Member] May 2025 Notes [Member] May 2025 Notes [Member] October 2023 Notes [Member] October 2023 Notes [Member] October 2023 Notes [Member] November 2035 Notes [Member] November 2035 Notes [Member] November 2035 Notes [Member] January 2040 Notes [Member] January 2040 Notes [Member] January 2040 Notes [Member] March 2028 Notes [Member] March 2028 Notes [Member] March 2028 Notes [Member] Premiums, accelerated amortization of debt issuance costs & investor discount costs [Member] Premiums, accelerated amortization of debt issuance costs & investor discount costs [Member] Premiums, accelerated amortization of debt issuance costs & investor discount costs [Member] Securities Financing Transaction, Cost [Member] Securities Financing Transaction, Cost [Member] Interest Rate Swap [Member] Interest Rate Swap [Member] Capital Lease Obligations [Member] Capital Lease Obligations [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Maximum Leverage Ratio Maximum Leverage Ratio Maximum leverage ratio permitted by revolving credit facility agreement. Total debt Debt and Capital Lease Obligations Debt, Current Debt, Current Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Fair Value of Amount Outstanding Line of Credit Facility, Fair Value of Amount Outstanding Maximum amount of proceeds from sale of finance receivables Maximum Amount Of Proceeds From Sale Of Finance Receivables Maximum amount of proceeds from sale of finance receivables. Average interest rate of de-recognized receivables Receivable with Imputed Interest, Effective Yield (Interest Rate) De-recognized receivables Continuing Involvement with Derecognized Transferred Financial Assets, Amount Outstanding Average discounted rates of notes receivables Average Discount Rate Of Notes Receivable Average discount rate of notes receivable. Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Commercial Paper Commercial Paper Short-term Debt, Weighted Average Interest Rate Short-term Debt, Weighted Average Interest Rate Long-term Debt Long-term Debt Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA. Litigation and Debt Exclusion from EBITDA Litigation and Debt Exclusion from EBITDA Exclusion of litigation payments and any debt Issued to fund tax deficiency payments Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Income Statement [Abstract] Statement [Table] Statement [Table] Statement, Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Statement [Line Items] Statement [Line Items] Net sales Revenue, Net Cost of products sold Cost of Goods and Services Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Selling, general and administrative expenses Selling, General and Administrative Expense Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Royalty expense Royalty Expense Amortization expense Amortization of Intangible Assets Intangible asset impairment charges Impairment of Intangible Assets (Excluding Goodwill) Restructuring charges (credits) Restructuring Charges Contingent consideration expense (benefit) Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Litigation-related net charges (credits) Litigation Settlement, Expense Operating expenses Operating Expenses Operating income (loss) Operating Income (Loss) Other income (expense): Other Nonoperating Income (Expense) [Abstract] Interest expense Interest Expense Other, net Other Nonoperating Income (Expense) Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax expense (benefit) Income Tax Expense (Benefit) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income (loss) per common share — basic Earnings Per Share, Basic Net income (loss) per common share — assuming dilution Earnings Per Share, Diluted Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic Weighted Average Number of Shares Outstanding, Basic Assuming dilution Weighted Average Number of Shares Outstanding, Diluted Statement of Comprehensive Income [Abstract] Net income (loss) Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Net change in derivative financial instruments Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Intangible Assets [Axis] Intangible Assets [Axis] Intangible Assets [Axis] Intangible Assets [Domain] Intangible Assets [Domain] [Domain] for Intangible Assets [Axis] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Technology-related [Member] Technology-related [Member] Technology-related [Member] Patents [Member] Patents [Member] Other Intangible Assets [Member] Other Intangible Assets [Member] Indefinite-lived Intangible Assets by Major Class [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite Lived Intangible Assets Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Unclassified Indefinite-lived Intangible Assets [Member] Unclassified Indefinite-lived Intangible Assets [Member] In-process research and development [Member] Purchased research and development [Member] Purchased research and development. Statement, Business Segments [Axis] Segments [Axis] Segment [Domain] Segments [Domain] Cardiovascular [Member] Cardiovascular [Member] Cardiovascular [Member] Rhythm and Neuro [Member] Rhythm and Neuro [Member] Rhythm and Neuro [Member] MedSurg [Member] MedSurg [Member] MedSurg [Member] Goodwill [Line Items] Goodwill [Line Items] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Goodwill, Gross Goodwill, Gross Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-lived intangible assets, including goodwill Indefinite-lived intangible assets, including goodwill indefinite-lived intangible assets including goodwill Indefinite-lived intangible assets, accumulated write-offs Indefinite-lived intangible assets, accumulated write-offs Indefinite-lived intangible assets, accumulated write-offs Goodwill Goodwill Goodwill, Period Increase (Decrease) Goodwill, Period Increase (Decrease) Goodwill, Purchase Accounting Adjustments Goodwill, Translation and Purchase Accounting Adjustments Goodwill, Acquired During Period Goodwill, Acquired During Period Goodwill, Impaired, Accumulated Impairment Loss Goodwill, Impaired, Accumulated Impairment Loss Goodwill (Textuals) [Abstract] Goodwill (Textuals) [Abstract] Goodwill (Textuals) [Abstract] Fair Value Inputs, Discount Rate Fair Value Inputs, Discount Rate Segment Reporting [Abstract] Schedule Of Segment Reporting Information By Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Corporate expenses and currency exchange [Member] Corporate Expenses and Currency Exchange [Member] Corporate expenses and currency exchange. Special Charges [Member] Special Charges [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Segment Reporting (Textuals) [Abstract] Segment Reporting (Textuals) [Abstract] Segment Reporting. Number of reportable segments Number of Reportable Segments Net sales Revenue, Net [Abstract] Operating Income Allocated to Reportable Segments Operating Income Allocated to Reportable Segments Operating Income Allocated to Reportable Segments Operating (Loss) Income Unallocated to Segment Operating Income Unallocated to Segment Operating Income Unallocated to Segment Amortization expense Operating income (loss) Other expense, net Nonoperating Income (Expense) Segment operating income as percentage of net sales Segment operating income as percentage of net sales Segment operating income as percentage of net sales Earnings Per Share [Abstract] Weighted Average Number Of Shares Outstanding [Text Block] Earnings Per Share [Text Block] Income Tax Disclosure [Abstract] Income Tax Examination [Table] Income Tax Examination [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Income Tax Examination [Line Items] Income Tax Examination [Line Items] INCOME TAXES Income Tax Disclosure [Text Block] Changes in Other Comprehensive Income [Abstract] Changes in Other Comprehensive Income [Abstract] Changes in Other Comprehensive Income [Table Text Block] Changes in Other Comprehensive Income [Table Text Block] [Table Text Block] for Changes in Other Comprehensive Income [Table] Statement of Financial Position [Abstract] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Trade accounts receivable, net Accounts, Notes, Loans and Financing Receivable, Net, Current Inventories Inventory, Net Prepaid income taxes Deferred Tax Assets, Net of Valuation Allowance, Current Other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property, plant and equipment, net Property, Plant and Equipment, Net Goodwill Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Other long-term assets Other Assets, Noncurrent TOTAL ASSETS Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Current debt obligations Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Long-term debt Long-term Debt and Capital Lease Obligations Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Commitments and contingencies Commitments and Contingencies Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.01 par value - authorized 50,000,000 shares, none issued and outstanding Preferred Stock, Value, Issued Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,627,188,009 shares as of March 31, 2018 and 1,621,062,898 shares as of December 31, 2017 Common Stock, Value, Issued Treasury stock, at cost - 247,566,270 shares as of March 31, 2018 and December 31, 2017 Treasury Stock, Value Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive income (loss), net of tax Accumulated Other Comprehensive Income (Loss), Net of Tax Total stockholders’ equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity Revenue Recognition [Abstract] Revenue [Text Block] Revenue [Text Block] RESTRUCTURING-RELATED ACTIVITIES Restructuring and Related Activities Disclosure [Text Block] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Plan [Axis] Restructuring Plan [Domain] 2016 Restructuring Plan [Member] 2016 Restructuring Plan [Member] 2016 Restructuring Plan [Member] Restructuring and Related Cost [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring and related costs Restructuring and Related Costs [Table Text Block] Cumulative restructuring charges Cumulative Restructuring Charges [Text Block] Cumulative restructuring charges. Cash payments associated with restructuring initiatives Amount Of Cash Paid In Period To Fully Or Partially Settle Specified Type Of Restructuring Cost [Text Block] Amount of cash paid in the period to fully or partially settle a specified type of restructuring cost. Summary of accrued expenses within accompanying unaudited condensed consolidated balance sheets Summary Of Restructuring Accrued Expenses [Text Block] Summary of accrued expenses within accompanying unaudited condensed consolidated balance sheets. GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Accounting Policies [Abstract] Subsequent Events, Policy [Policy Text Block] Subsequent Events, Policy [Policy Text Block] ASC Topic 820, Fair Value Measurements and Disclosures Fair Value Measurement, Policy [Policy Text Block] ASC Topic 815, Derivatives and Hedging Derivatives, Policy [Policy Text Block] Legal Costs, Policy [Policy Text Block] Legal Costs, Policy [Policy Text Block] ASC Update No. 2016-02, Leases (Topic 842) [Policy Text Block] ASC Update No. 2016-02, Leases (Topic 842) [Policy Text Block] ASC Update No. 2016-02, Leases (Topic 842) [Policy Text Block] ASC Update No. 2016-13 [Policy Text Block] ASC Update No. 2016-13 [Policy Text Block] ASC Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments [Policy Text Block] ASU Update No. 2016-16, Income Taxes (Topic 740) [Policy Text Block] ASC Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities [Policy Text Block] ASC Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities [Policy Text Block] Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information. Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other Current Assets [Member] Other Current Assets [Member] Other Long Term Assets [Member] Other Long Term Assets [Member] Other Long Term Assets. Cash and cash equivalents Total cash, cash equivalents and restricted cash Cash, cash equivalents, restricted cash and restricted cash equivalents Cash, cash equivalents, restricted cash and restricted cash equivalents Restricted cash included in Other long-term assets Restricted Cash and Cash Equivalents Trade accounts receivable, net Accounts, Notes, Loans and Financing Receivable, Net, Current [Abstract] Accounts receivable Accounts Receivable, Gross, Current Less: allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Less: allowance for sales returns Allowance For Sales Returns Current Allowance for sales returns current. Other sales reserves Other sales reserves Other sales reserves Trade accounts receivable, net Allowance for doubtful accounts Movement in Valuation Allowances and Reserves [Roll Forward] Beginning balance Valuation Allowances and Reserves, Balance Charges to expenses Valuation Allowances and Reserves, Additions for Charges to Cost and Expense Utilization of allowances Valuation Allowances and Reserves, Deductions Ending balance Inventories Inventory, Net [Abstract] Finished goods Inventory, Finished Goods, Gross Work-in-process Inventory, Work in Process, Gross Raw materials Inventory, Raw Materials, Gross Inventories Property, plant and equipment, net Property, Plant and Equipment, Net [Abstract] Land Land Buildings and improvements Buildings and Improvements, Gross Equipment, furniture and fixtures Equipment, furniture and fixtures Gross Equipment, furniture and fixtures Gross. Capital in progress Construction in Progress, Gross Property, plant and equipment Property, Plant and Equipment, Gross Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Accrued expenses Accrued Liabilities, Current [Abstract] Legal reserves Estimated Litigation Liability, Current Payroll and related liabilities Employee-related Liabilities, Current Business Combination, Contingent Consideration, Liability, Current Business Combination, Contingent Consideration, Liability, Current Other Other Accrued Liabilities, Current Accrued expenses Other long-term liabilities Other Liabilities, Noncurrent [Abstract] Accrued income taxes Accrued Income Taxes, Noncurrent Legal reserves Estimated Litigation Liability, Noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Other Accrued Liabilities, Noncurrent Other Accrued Liabilities, Noncurrent Other long-term liabilities Supplemental Balance Sheet Information Supplemental Balance Sheet Information (Textuals) [Abstract] Supplemental Balance Sheet Information. Depreciation expense Depreciation cash, cash equivalents, restricted cash and restricted cash equivalents, beginning of period cash, cash equivalents, restricted cash and restricted cash equivalents, beginning of period cash, cash equivalents, restricted cash and restricted cash equivalents, beginning of period Commitments and Contingencies Disclosure [Abstract] Schedule of Restricted Cash and Cash Equivalents [Table Text Block] Schedule of Restricted Cash and Cash Equivalents [Table Text Block] Trade accounts receivable, net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Rollforward of allowances for doubtful accounts Rollforward Of Allowances For Doubtful Accounts [Text Block] An element designated to encapsulate the entire schedule of allowances for doubtful accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Inventory Disclosure [Text Block] Inventory Disclosure [Text Block] Property, plant and equipment, net Property, Plant and Equipment Disclosure [Text Block] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Other long-term liabilities Other Liabilities Disclosure [Text Block] BORROWINGS AND CREDIT ARRANGEMENTS Debt Disclosure [Text Block] Basis of Presentation [Abstract] Basis of Presentation [Abstract] New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Statement of Operations Caption [Axis] Statement of Operations Caption [Axis] Statement of Operations Caption [Axis] Statement of Operations Caption [Domain] Statement of Operations Caption [Domain] Statement of Operations Caption [Domain] Cost of Sales [Member] Cost of Sales [Member] Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] Restructuring and Related Cost, by Type of Restructuring Charge Expected [Axis] Restructuring and Related Cost, by Type of Restructuring Three [Axis] Restructuring and Related Cost, by Type of Restructuring Charge [Domain] Restructuring and Related Cost, by Type of Restructuring Three [Domain] Restructuring Plan [Member] Restructuring Plan [Member] Restructuring Related To Plan [Member] Restructuring Related To Plan [Member] Restructuring Type [Axis] Type of Restructuring [Domain] Termination Benefits [Member] Employee Severance [Member] Accelerated depreciation [Member] Accelerated Depreciation [Member] Accelerated depreciation [Member]. Transfer costs [Member] Transfer costs [Member] Transfer costs [Member]. Other [Member] Other Restructuring [Member] Restructuring Plan [Domain] Restructuring and Related Cost, Expected Cost Restructuring and Related Cost, Expected Cost Restructuring Reserve Restructuring Reserve Restructuring Charges Incurred to Date Restructuring Charges Incurred to Date Restructuring Charges Incurred to Date Restructuring-related Costs Incurred to Date Restructuring-related Costs Incurred to Date Restructuring-related Costs Incurred to Date Estimated costs of restructuring program by major type of cost Summary of expected total major Restructuring cost [Abstract] Summary of expected total major Restructuring cost [Abstract]. Restructuring and Related Cost, Cost Incurred to Date Restructuring and Related Cost, Cost Incurred to Date Restructuring plan estimated future cash outflow Restructuring plan estimated future cash outflow Restructuring plan estimated future cash outflow Payments for Restructuring Payments for Restructuring Restructuring Related Expenses Restructuring Related Expenses Restructuring related expenses. Restructuring and Related Cost, Incurred Cost Restructuring and Related Cost, Incurred Cost Restructuring Charges Fair Value Measurement, Policy [Policy Text Block] Derivatives, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Significant Accounting Policies [Text Block] ASC Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) [Policy Text Block] ASC Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) [Policy Text Block] ASC Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) [Policy Text Block] ASC Update No. 2016-01, Financial Instruments [Policy Text Block] ASC Update No. 2016-01, Financial Instruments [Policy Text Block] ASC Update No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities [Policy Text Block] ASU Update No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory [Policy Text Block] ASU Update No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory [Policy Text Block] ASU Update No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory [Policy Text Block] Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block] Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block] Summary of term loan and revolving credit facility agreement compliance with debt covenants. Schedule of debt maturities Schedule of Maturities of Long-term Debt [Table Text Block] Business Combinations [Abstract] Schedule Of Business Acquisitions By Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] NxThera [Member] NxThera [Member] NxThera [Member] nVision [Member] nVision [Member] nVision [Member] Finite-Lived Intangible Assets by Major Class [Axis] Technology-related [Member] Minimum [Member] Maximum [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] revenue-based payments [Member] revenue-based payments [Member] revenue-based payments [Member] R&D and Commercialization-based Milestone [Member] R&D and Commercialization-based Milestone [Member] R&D and Commercialization-based Milestone [Member] Valuation Technique [Axis] Valuation Technique [Axis] Valuation Technique [Domain] Valuation Technique [Domain] Discounted cash flow [Member] Discounted cash flow [Member] Discounted cash flow [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Adjustments to accrued contingent consideration Adjustments to accrued contingent consideration Adjustments to accrued contingent consideration Other Nonoperating Income (Expense) Business Combination, Contingent Consideration, Asset Business Combination, Contingent Consideration, Asset Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability contingent consideration liability, probability of payment contingent consideration liability, probability of payment contingent consideration liability, probability of payment Payments for acquisitions of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Potential payments based on acheiving certain milestones Potential payments based on acheiving certain milestones Potential payments based on acheiving certain milestones Payments to Acquire Businesses, Gross Payments to Acquire Businesses, Gross Potential payments based on certain milestones, gross Potential payments based on certain milestones, gross Potential payments based on certain milestones, gross contingent consideration liability, projected year of payment contingent consideration liability, projected year of payment contingent consideration liability, projected year of payment Payment of contingent consideration Payment of contingent consideration Payment of contingent consideration Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Description of unobservable inputs used in Level 3 fair value measurements [Table Text Block] Description of unobservable inputs used in Level 3 fair value measurements [Table Text Block] Description of unobservable inputs used in Level 3 fair value measurements [Table Text Block] Schedule of Goodwill [Table Text Block] Schedule of Goodwill [Table Text Block] Document and Entity Information [Abstract] Document and Company Information. Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Investments [Abstract] Schedule of Investments [Table] Schedule of Investments [Table] Impairment Charges [Axis] Impairment Charges [Axis] Impairment Charges [Axis] Impairment Charges [Domain] Impairment Charges [Domain] [Domain] for Impairment Charges [Axis] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Milipede [Member] Milipede [Member] Milipede [Member] Schedule of Investments [Line Items] Schedule of Investments [Line Items] Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Total consideration for share purchase Total consideration for share purchase Total consideration for share purchase Equity Method Investments Equity Method Investments Measurement Alternative Investments Measurement Alternative Investments Measurement Alternative Investments Publicly-held Securities publicly-held securities publicly-held securities Notes Receivable Notes Receivable From Portfolio Companies Notes Receivable From Portfolio Companies Strategic Investments Investments Closing payment Closing payment Closing payment disaggregated revenue [Table] disaggregated revenue [Table] disaggregated revenue [Table] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] disaggregated revenue [Line Items] disaggregated revenue [Line Items] [Line Items] for disaggregated revenue [Table] disaggregated revenue [Line Items] disaggregated revenue [Table Text Block] [Table Text Block] for disaggregated revenue [Table] Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges and Treasury Locks, Effect Net of Tax Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges and Treasury Locks, Effect Net of Tax Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease) Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease) Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Before Reclassifications, Net of Tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Before Reclassifications, Net of Tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Before Reclassifications, Net of Tax Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Reclassification Adjustments, Net of Tax Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Reclassification Adjustments, Net of Tax Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Reclassified from OCI, Net of Tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Reclassified from OCI, Net of Tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Reclassified from OCI, Net of Tax Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, Net of Tax Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, Net of Tax Other Comprehensive Income (Loss), Reclassifications out of OCI, Net of Tax Other Comprehensive Income (Loss), Reclassifications out of OCI, Net of Tax Other Comprehensive Income (Loss), Reclassification out of OCI, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Reclassification Adjustments and Tax Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Reclassification Adjustments and Tax Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax Other Comprehensive Income (Loss), Net of Tax COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Peripheral Interventions [Member] Peripheral Interventions [Member] Peripheral Interventions [Member] Urology and Pelvic Health [Member] Urology and Pelvic Health [Member] Urology and Pelvic Health [Member] Endoscopy [Member] Endoscopy [Member] Endoscopy [Member] Cardiac Rhythm Management [Member] Cardiac Rhythm Management [Member] Cardiac Rhythm Management [Member] Electrophysiology [Member] Electrophysiology [Member] Electrophysiology [Member] Neuromodulation [Member] Neuromodulation [Member] Neuromodulation [Member] Interventional Cardiology [Member] Interventional Cardiology [Member] Interventional Cardiology [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] UNITED STATES UNITED STATES EMEA [Member] EMEA [Member] Asia Pacific [Member] Asia Pacific [Member] Non-US [Member] Non-US [Member] Latin America and Canada [Member] Latin America and Canada [Member] Latin America and Canada [Member] Emerging Markets [Member] Emerging Markets [Member] Emerging Markets [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Weighted average shares outstanding - basic Weighted Average Number Diluted Shares Outstanding Adjustment Weighted Average Number Diluted Shares Outstanding Adjustment Weighted average shares outstanding - assuming dilution Stock Issued During Period, Shares, New Issues Stock Issued During Period, Shares, New Issues Schedule of Business Acquisitions, by Acquisition [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Investment [Table Text Block] Investment [Table Text Block] Rollforward of Fair Value of Contingent Consideration [Table Text Block] Rollforward of Fair Value of Contingent Consideration [Table Text Block] Rollforward of Fair Value of Contingent Consideration [Table Text Block] Statement of Cash Flows [Abstract] Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period Cash provided by (used for) operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Cash provided by (used for) operating activities Net Cash Provided by (Used in) Operating Activities Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Payments for acquisitions of businesses, net of cash acquired Payments for investments and acquisitions of certain technologies Payments to Acquire Investments Cash provided by (used for) investing activities Net Cash Provided by (Used in) Investing Activities Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Payments on long-term borrowings Repayments of Long-term Debt Proceeds from long-term borrowings, net of debt issuance and extinguishment costs Proceeds from Issuance of Long-term Debt and Capital Securities, Net Net increase (decrease) in commercial paper Proceeds from (Repayments of) Commercial Paper Payment of contingent consideration amounts previously established in purchase accounting Payment of contingent consideration in financing Payment of contingent consideration in financing Proceeds from borrowings on credit facilities Proceeds from Long-term Lines of Credit Payments on borrowings from credit facilities Repayments of Long-term Lines of Credit Cash used to net share settle employee equity awards Payment to net share settle employee equity awards Payment to net share settle employee equity awards Proceeds from issuances of shares of common stock Proceeds from Issuance of Common Stock Cash provided by (used for) financing activities Net Cash Provided by (Used in) Financing Activities Effect of foreign exchange rates on cash Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents Cash, cash equivalents, restricted cash and restricted cash equivalents, Period increase (decrease) Cash, cash equivalents, restricted cash and restricted cash equivalents, Period increase (decrease) Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period Supplemental Information Supplemental Cash Flow Information [Abstract] Stock-based compensation expense Share-based Compensation Schedule of Weighted Average Number of Shares [Table Text Block] Schedule of Weighted Average Number of Shares [Table Text Block] ACQUISITIONS AND STRATEGIC INVESTMENTS Business Combination Disclosure [Text Block] Accounting Changes and Error Corrections [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2014-09 [Member] Other Current Liabilities [Member] Other Current Liabilities [Member] Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Other Noncurrent Assets [Member] Other Noncurrent Assets [Member] Deferred Income Tax Charge [Member] Deferred Income Tax Charge [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Cumulative Effect of New Accounting Principle in Period of Adoption Cumulative Effect of New Accounting Principle in Period of Adoption New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted Supplemental Balance Sheet Disclosures Supplemental Balance Sheet Disclosures [Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Settled Litigation [Member] Settled Litigation [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Assigned to one judge in MA [Member] Assigned to one judge in MA [Member] Assigned to one judge in MA [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Litigation Settlement, Amount Litigation Settlement, Amount Commitments and Contingencies (Textuals) [Abstract] Commitments And Contingencies (Textuals) [Abstract] Commitments and Contingencies Textuals. Accrual for legal matters that are probable and estimable Loss Contingency Accrual Litigation Settlement, Expense Product liability cases or claims related to mesh product Product liability cases or claims related to mesh product - United States Product liability cases or claims asserted related to mesh products Putative class actions in the U.S., Mesh Putative class actions in the U.S., Mesh Putative class actions in the U.S., Mesh Product liability cases or claims related to mesh product - Canada Product liability cases or claims related to mesh product - Canada Product liability cases or claims related to mesh product - Canada Certified class actions in Canada, Mesh Certified class actions in Canada, Mesh Certified class actions in Canada, Mesh Putative class actions in Canada, Mesh Putative class actions in Canada, Mesh Putative class actions in Canada, Mesh Product liability cases or claims related to mesh product - United Kingdom Product liability cases or claims related to mesh product - United Kingdom Product liability cases or claims related to mesh product - United Kingdom Total Product liability cases and claims settled related to Mesh product Total Product liability cases and claims settled related to Mesh product Total Product liability cases and claims settled related to Mesh product Condensed Consolidated Balance Sheet (Parenthetical) [Abstract] Condensed Consolidated Balance Sheet (Parenthetical) [Abstract] Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Issued Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Preferred Stock, Par or Stated Value Per Share Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding Treasury Stock, Shares Treasury Stock, Shares New ASU impacts [Abstract] New ASU impacts [Abstract] Schedule of Income Tax Rate Reconciliation [Table] Schedule of Income Tax Rate Reconciliation [Table] Schedule of Income Tax Rate Reconciliation [Table] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Schedule of Income Tax Rate Reconciliation [Line Items] Schedule of Income Tax Rate Reconciliation [Line Items] [Line Items] for Schedule of Income Tax Rate Reconciliation [Table] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table] Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table] Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] Other Tax Expense (Benefit) Other Tax Expense (Benefit) Total Impact of TCJA TotalImpactofTCJA TotalImpactofTCJA One-time transaction tax post-1986 E&P One-time transaction tax post-1986 E&P One-time transaction tax post-1986 E&P Effective Income Tax Rate Reconciliation, Percent [Abstract] Unrecognized Tax Benefits Unrecognized Tax Benefits Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Incremental tax liability asserted by IRS Incremental tax liability asserted by IRS Incremental tax liability asserted by IRS. Reported tax rate Effective Income Tax Rate Reconciliation, Percent Net tax expense/benefits related to interest and penalties Net tax expense/benefits related to interest and penalties Net tax expense/benefits related to interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Potential Reduction In Unrecognized Tax Benefits Over Next Twelve Months As Result Of Concluding Certain Matters Potential Reduction In Unrecognized Tax Benefits Over Next Twelve Months As Result Of Concluding Certain Matters Potential reduction in unrecognized tax benefits over next 12 months as a result of concluding certain matters. Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Deferred tax asset TCJA remeasurement benefit Deferred tax asset TCJA remeasurement benefit Deferred tax asset TCJA remeasurement benefit One-time transaction tax post-1986 E&P - net payment One-time transaction tax post-1986 E&P - net payment One-time transaction tax post-1986 E&P - net payment New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Comprehensive Income (Loss) Note [Text Block] Comprehensive Income (Loss) Note [Text Block] Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Fair Value Hedging [Member] Fair Value Hedging [Member] Cash Flow Hedging [Member] Cash Flow Hedging [Member] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Designation [Axis] Hedging Designation [Domain] Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Interest Expense [Member] Interest Expense [Member] Other, net [Member] Other net [Member]. Cost of Goods, Product Line [Member] Cost of Goods, Product Line [Member] Prepaid And Other Current Assets [Member] Other Long Term Assets [Member] Other current liabilities [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Hedged Debt [Axis] Hedged Debt [Axis] Hedged Debt [Axis] Hedged Debt [Domain] Hedged Debt [Domain] [Domain] for Hedged Debt [Axis] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Cost of Goods and Services Sold Interest Expense Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Foreign Currency Derivative Instruments Not Designated as Hedging Instruments at Fair Value, Net Foreign Currency Derivative Instruments Not Designated as Hedging Instruments at Fair Value, Net Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Net gain (loss) from foreign currency transaction exposures Net gain (loss) from foreign currency transaction exposures Net gain (loss) from foreign currency transaction exposures Foreign Currency Transaction Gain (Loss), Realized Foreign Currency Transaction Gain (Loss), Realized Derivative Instruments in Hedges, Assets, at Fair Value Derivative Instruments in Hedges, Assets, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Derivative Assets Derivative Asset Derivative Instruments in Hedges, Liabilities, at Fair Value Derivative Instruments in Hedges, Liabilities, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Derivative Liabilities Derivative Liability Money Market Funds, at Carrying Value Money Market Funds, at Carrying Value Foreign Currency Contract, Asset, Fair Value Disclosure Foreign Currency Contract, Asset, Fair Value Disclosure Assets, Fair Value Disclosure Assets, Fair Value Disclosure Foreign Currency Contracts, Liability, Fair Value Disclosure Foreign Currency Contracts, Liability, Fair Value Disclosure Accrued Contingent Consideration Accrued Contingent Consideration Estimated discounted potential payments under contingent consideration arrangements. Liabilities, Fair Value Disclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure Cash Cash Debt Instrument, Fair Value Disclosure Debt Instrument, Fair Value Disclosure Derivative, Notional Amount Derivative, Notional Amount Revenue, Net Deferred Revenue Deferred Revenue Deferred Revenue, Revenue Recognized Deferred Revenue, Revenue Recognized Segment Reporting Information By Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] EX-101.PRE 20 bsx-20180501_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 21 mm.gif begin 644 mm.gif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end GRAPHIC 22 mma01.gif begin 644 mma01.gif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end GRAPHIC 23 mma02.gif begin 644 mma02.gif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end GRAPHIC 24 mma03.gif begin 644 mma03.gif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end GRAPHIC 25 mma04.gif begin 644 mma04.gif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end GRAPHIC 26 mma05.gif begin 644 mma05.gif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end GRAPHIC 27 mma06.gif begin 644 mma06.gif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end XML 28 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2018
Apr. 25, 2018
Document and Entity Information [Abstract]    
Entity Registrant Name BOSTON SCIENTIFIC CORPORATION  
Entity Central Index Key 0000885725  
Document Type 10-Q  
Document Period End Date Mar. 31, 2018  
Amendment Flag false  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q1  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   1,379,810,502
XML 29 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Net sales $ 2,379 $ 2,160
Cost of products sold 672 650
Gross profit 1,707 1,510
Operating expenses:    
Selling, general and administrative expenses 860 794
Research and development expenses 261 235
Royalty expense 18 17
Amortization expense 141 143
Intangible asset impairment charges 1 0
Restructuring charges (credits) 13 4
Contingent consideration expense (benefit) 5 (50)
Litigation-related net charges (credits) 0 3
Operating expenses 1,300 1,146
Operating income (loss) 407 364
Other income (expense):    
Interest expense (61) (57)
Other, net (23) (2)
Income (loss) before income taxes 323 305
Income tax expense (benefit) 26 15
Net income (loss) $ 298 $ 290
Net income (loss) per common share — basic $ 0.22 $ 0.21
Net income (loss) per common share — assuming dilution $ 0.21 $ 0.21
Weighted-average shares outstanding    
Basic 1,376.5 1,365.4
Assuming dilution 1,396.8 1,390.2
XML 30 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Net income (loss) $ 298 $ 290
Other comprehensive income (loss), net of tax:    
Foreign currency translation adjustment 10 8
Net change in derivative financial instruments (80) (55)
Total other comprehensive income (loss) (69) (47)
Total comprehensive income (loss) $ 228 $ 243
XML 31 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 287 $ 188
Trade accounts receivable, net 1,580 1,548
Inventories 1,113 1,078
Prepaid income taxes 50 66
Other current assets 1,048 942
Total current assets 4,080 3,822
Property, plant and equipment, net 1,700 1,697
Goodwill 6,984 6,998
Other intangible assets, net 5,713 5,837
Other long-term assets 725 688
TOTAL ASSETS 19,202 19,042
Current liabilities:    
Current debt obligations 962 1,801
Accounts payable 404 530
Accrued expenses 2,447 2,456
Other current liabilities 1,174 867
Total current liabilities 4,988 5,654
Long-term debt 4,803 3,815
Deferred income taxes 128 191
Other long-term liabilities 2,254 2,370
Commitments and contingencies
Stockholders’ equity    
Preferred stock, $0.01 par value - authorized 50,000,000 shares, none issued and outstanding
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,627,188,009 shares as of March 31, 2018 and 1,621,062,898 shares as of December 31, 2017 16 16
Treasury stock, at cost - 247,566,270 shares as of March 31, 2018 and December 31, 2017 (1,717) (1,717)
Additional paid-in capital 17,184 17,161
Accumulated deficit (8,326) (8,390)
Accumulated other comprehensive income (loss), net of tax (128) (59)
Total stockholders’ equity 7,030 7,012
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 19,202 $ 19,042
XML 32 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2018
Dec. 31, 2017
Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]    
Common Stock, Par or Stated Value Per Share $ 0.01 $ 0.01
Common Stock, Shares Authorized 2,000,000,000 2,000,000,000
Common Stock, Shares, Issued 1,627,188,009 1,621,062,898
Common Stock, Shares, Outstanding 1,379,621,739 1,373,496,628
Preferred Stock, Par or Stated Value Per Share $ 0.01 $ 0.01
Preferred Stock, Shares Authorized 50,000,000 50,000,000
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstanding 0 0
Treasury Stock, Shares 247,566,270 247,566,270
XML 33 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period $ 1,168 $ 327
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 1,017 487
Cash provided by (used for) operating activities    
Cash provided by (used for) operating activities 193 (7)
Investing activities:    
Purchases of property, plant and equipment (60) (112)
Payments for acquisitions of businesses, net of cash acquired (9) 0
Payments for investments and acquisitions of certain technologies (103) (28)
Cash provided by (used for) investing activities (173) (140)
Financing activities:    
Payments on long-term borrowings (602) (250)
Proceeds from long-term borrowings, net of debt issuance and extinguishment costs 990 0
Net increase (decrease) in commercial paper (316) 0
Payment of contingent consideration amounts previously established in purchase accounting 0 (18)
Proceeds from borrowings on credit facilities 70 1,016
Payments on borrowings from credit facilities 0 (735)
Cash used to net share settle employee equity awards (50) (61)
Proceeds from issuances of shares of common stock 38 33
Cash provided by (used for) financing activities 130 (15)
Effect of foreign exchange rates on cash 1 1
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents 151 (161)
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 188  
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period 287  
Supplemental Information    
Stock-based compensation expense $ 36 $ 30
XML 34 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Basis of Presentation
3 Months Ended
Mar. 31, 2018
Basis of Presentation [Abstract]  
New Accounting Pronouncements, Policy [Policy Text Block]
NOTE N – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our unaudited condensed consolidated financial statements.

Standards to be Implemented

ASC Update No. 2016-02

In February 2016, the FASB issued ASC Update No. 2016-02, Leases (Topic 842). The purpose of Update No. 2016-02 is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. Update No. 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted and a modified retrospective approach is required for adoption. While we are still in the process of determining the effect that the new standard will have on our financial position and results of operations, we expect to recognize additional assets and corresponding liabilities on our consolidated balance sheets, as a result of our operating lease portfolio as it exists at the date we adopt the new standard. Please refer to Note F - Lease and Other Purchase Obligations in our most recent Annual Report on Form 10-K for information regarding our most current lease activity. Additionally, we are in the process of implementing a new lease administration and lease accounting system, and updating our controls and procedures for maintaining and accounting for our lease portfolio under the new standard. As a result, we anticipate adopting the new standard on January 1, 2019.

ASC Update No. 2016-13

In June 2016, the FASB issued ASC Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted for annual periods beginning after December 15, 2018. We are in the process of determining the effect that the adoption will have on our financial position and results of operations.

No other new accounting pronouncements, issued or effective, during the period had, or are expected to have, a material impact on our condensed consolidated financial statements.
BASIS OF PRESENTATION
NOTE A – BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K.

Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars. Prior year balances were subject to rounding.

Revision of Reportable Segments

Effective January 1, 2018, following organizational changes to align the company's business and organization structure focused on active implantable devices, we revised our reportable segments, in accordance with FASB ASC Topic 280, Segment Reporting. The revision reflects a reclassification of our Neuromodulation business from our Medical Surgical (MedSurg) segment to our newly created Rhythm and Neuro segment. We have revised prior year amounts to conform to the current year’s presentation (as denoted with an asterisk throughout *). There was no revision to operating segments or reporting units as a result of the organizational change. See Note C – Goodwill and Other Intangible Assets and Note K – Segment Reporting for further details.

Subsequent Events

We evaluate events occurring after the date of our most recent accompanying unaudited condensed consolidated balance sheets for potential recognition or disclosure in our financial statements. We did not identify any material subsequent events requiring adjustment to our accompanying unaudited condensed consolidated financial statements (recognized subsequent events) for the three months ended March 31, 2018. Those items requiring disclosure (unrecognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions and Strategic Investments and Note I – Commitments and Contingencies for more information.

Accounting Standards Implemented Since December 31, 2017

ASC Update No. 2014-09

In May 2014, the FASB issued ASC Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), which was subsequently updated. We adopted the standard as of January 1, 2018, using the modified retrospective method. Under this method, we applied FASB ASC Topic 606 to contracts that were not complete as of January 1, 2018 and recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings. Results for reporting periods beginning after January 1, 2018 are presented in accordance with FASB ASC Topic 606. Prior period amounts are not adjusted and are reported in accordance with legacy GAAP requirements in FASB ASC Topic 605, Revenue Recognition.

Due to the adoption of FASB ASC Topic 606, we recorded a net reduction to opening retained earnings of $177 million on January 1, 2018, primarily related to cost of providing non-contractual post-implant support to certain customers, which we deemed immaterial in the context of the arrangement. Upon the adoption of FASB ASC Topic 606, when we sell a device with an implied non-contractual post-implant support obligation, we forward accrue the cost of the service within Selling, general and administrative expenses and recognize it at the point in time the associated revenue is earned. We release the accrual over the related service period. These costs were previously expensed as incurred due to such service obligation being non-contractual.

The impact of adopting FASB ASC Topic 606 on our unaudited condensed consolidated balance sheets as of March 31, 2018, resulted in an increase in Other current liabilities of $59 million and an increase in Other long-term liabilities of $206 million, as a result of accruing for our post-implant support obligation. We also recorded deferred tax assets primarily related to post-implant support, resulting in an increase in Other long-term assets of $12 million and a reduction in Deferred income taxes of $41 million. The remaining impact of adopting FASB ASC Topic 606 was not material to our financial position or results of operations.

Refer to Note L – Revenue for additional details.

ASC Update No. 2016-01

In January 2016, the FASB issued ASC Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The purpose of Update No. 2016-01 is to improve financial reporting for financial instruments by reducing the number of items recorded to other comprehensive income. We adopted Update No. 2016-01 in the first quarter of 2018, using both the modified retrospective and prospective methods. For publicly-held securities, we used the modified retrospective approach. Unrealized gains and losses previously recorded to other comprehensive income were reclassified to retained earnings and all future fair value changes will be recorded to net income. For privately-held securities, we elected the measurement alternative approach which is applied prospectively upon adoption. This approach requires entities to measure their investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The adoption of the standard did not have a material impact on our financial position or results of operations. The actual impact to future periods resulting from fair value changes of our equity investments is difficult to predict as it will depend on their future performance.

ASC Update No. 2016-16

In October 2016, the FASB issued ASC Update No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. The purpose of Update No. 2016-16 is to allow an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, as opposed to waiting until the asset is sold to a third party, or impaired. Update No. 2016-16 was effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. We adopted Update No. 2016-16 prospectively in the first quarter of 2018 and recognized a net reduction to opening retained earnings of $55 million for income tax consequences not previously recognized for intra-entity transfers of assets other than inventories. All future income tax consequences of intra-entity transfers of assets other than inventories will be recognized through income tax expense.

ASC Update No. 2017-12

In August 2017, the FASB issued ASC Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The purpose of Update No. 2017-12 is to simplify the application of hedge accounting and better align financial reporting of hedging relationships with risk management objectives. Update No. 2017-12 was effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. We early adopted Update No. 2017-12 in the first quarter of 2018. The adoption of the standard had no impact on our financial position or results of operations.
XML 35 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions and Strategic Investments
3 Months Ended
Mar. 31, 2018
Business Combinations [Abstract]  
ACQUISITIONS AND STRATEGIC INVESTMENTS
NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS

We did not close any material acquisitions during the first quarter of 2018 or 2017.

On April 30, 2018, we announced the closing of our acquisition of NxThera, Inc. (NxThera), a privately-held company based in Maple Grove, Minnesota. NxThera developed the Rezûm® System, a minimally invasive therapy in a growing category of treatment options for patients with benign prostatic hyperplasia (BPH). The transaction consists of an upfront cash payment of $306 million, and up to an additional $100 million in potential commercial milestone payments over the next four years. We have an existing minority investment in NxThera which is expected to result in a net upfront payment of approximately $240 million upon closing, and milestone payments of up to $85 million. NxThera will be integrated into our Urology and Pelvic Health business.

On April 16, 2018, we announced the closing of our acquisition of nVision Medical Corporation (nVision), a privately-held company focused on women’s health. nVision developed the first and only device cleared by the U.S. Food and Drug Administration (FDA) to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. The transaction consists of an upfront cash payment of $150 million, and up to an additional $125 million in potential clinical and commercial milestones over four years. nVision will be integrated into our Urology and Pelvic Health business.

Contingent Consideration

We recorded a net expense related to the changes in fair value of our contingent consideration liabilities of $5 million during the first quarter of 2018 and a net benefit related to the changes in fair value of our contingent consideration liabilities of $50 million during the first quarter of 2017. We made $28 million of contingent payments during the first quarter of 2017.

Changes in the fair value of our contingent consideration liabilities were as follows (in millions):
Balance as of December 31, 2017
$
169

Amounts recorded related to prior acquisitions
(22
)
Fair value adjustment
5

Balance as of March 31, 2018
$
152



As of March 31, 2018, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay was approximately $1.320 billion.

The recurring Level 3 fair value measurements of our contingent consideration liabilities include the following significant unobservable inputs:
Contingent Consideration Liabilities
Fair Value as of March 31, 2018
Valuation Technique
Unobservable Input
Range
R&D and Commercialization-based Milestones
$105 million
Discounted Cash Flow
Discount Rate
3%
Probability of Payment
17% - 100%
Projected Year of Payment
2018 - 2022
Revenue-based Payments
$48 million
Discounted Cash Flow
Discount Rate
11% - 15%
Projected Year of Payment
2018 - 2026


Projected contingent payment amounts related to some of our R&D, commercialization-based and revenue-based milestones are discounted back to the current period using a discounted cash flow (DCF) model. Projected revenues are based on our most recent internal operational budgets and long-range strategic plans. Increases in projected revenues and probabilities of payment may result in higher fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement.

Strategic Investments

On January 24, 2018, we closed an investment and entered into an acquisition option agreement with Millipede, Inc. (Millipede), a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation. Under the terms of the agreements, we have purchased a portion of the outstanding shares of Millipede along with newly issued shares of the company for a total consideration of $90 million. We also have the option to acquire the remaining shares of the company at any time prior to the completion of a first in human clinical study that meets certain parameters. Upon the completion of the clinical study, Millipede has the option to compel us to acquire the remaining shares of the company. Each company’s option period expires by the end of 2019. Completion of this acquisition would result in an additional $325 million payment by us at closing with a further $125 million becoming payable upon achievement of a commercial milestone.

The aggregate carrying amount of our strategic investments were comprised of the following categories:


 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Equity method investments
 
$
304

 
$
209

Measurement alternative investments
 
84

 
81

Publicly-held securities
 
12

 
15

Notes receivable
 
43

 
47

 
 
$
442

 
$
353



These investments are classified as other long-term assets within our accompanying unaudited condensed consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.

As of March 31, 2018, the book value of our equity method investments exceeded our share of the book value of the investees’ underlying net assets by approximately $335 million, which represents amortizable intangible assets and in-process research and development, corresponding deferred tax liabilities and goodwill.
XML 36 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and Other Intangible Assets
3 Months Ended
Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS
NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows:
 
As of March 31, 2018
 
As of December 31, 2017
(in millions)
Gross Carrying
Amount
 
Accumulated
Amortization/
Write-offs
 
Gross Carrying
Amount
 
Accumulated
Amortization/
Write-offs
Amortizable intangible assets
 
 
 
 
 
 
 
Technology-related
$
9,396

 
$
(4,984
)
 
$
9,386

 
$
(4,880
)
Patents
517

 
(381
)
 
517

 
(379
)
Other intangible assets
1,636

 
(868
)
 
1,633

 
(838
)
 
$
11,549

 
$
(6,233
)
 
$
11,536

 
$
(6,097
)
Unamortizable intangible assets
 
 
 
 
 
 
 
Goodwill
$
16,884

 
$
(9,900
)
 
$
16,898

 
$
(9,900
)
In-process research and development (IPR&D)
278

 

 
278

 

Technology-related
120

 

 
120

 

 
$
17,281

 
$
(9,900
)
 
$
17,295

 
$
(9,900
)


The following represents our goodwill balance by global reportable segment:
(in millions)
MedSurg*
 
Rhythm and Neuro*
 
Cardiovascular
 
Total
Balance as of December 31, 2017
$
2,877

 
$
417

 
$
3,704

 
$
6,998

Impact of reportable segment revisions
(1,379
)
 
1,379

 

 

Impact of foreign currency fluctuations and other changes in carrying amount
1

 
(22
)
 
3

 
(17
)
Goodwill acquired
3

 

 

 
3

Balance as of March 31, 2018
$
1,503

 
$
1,774

 
$
3,707

 
$
6,984



We did not have any goodwill impairments in the three months ended March 31, 2018 or 2017. We test our goodwill balances during the second quarter of each year for impairment, or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. We have seven reporting units: Endoscopy, Urology and Pelvic Health, Cardiac Rhythm Management, Electrophysiology, Neuromodulation, Interventional Cardiology and Peripheral Interventions. As such, the first quarter change in our reportable segments, where Neuromodulation was reclassified from our MedSurg segment to our newly created Rhythm and Neuro segment did not trigger a goodwill impairment assessment or impact our total goodwill carrying value.
XML 37 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2018
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS
NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings or cash flows to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.
Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecast intercompany and third-party transactions and net investments in certain subsidiaries. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in British pound sterling, Euro and Japanese yen. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in other comprehensive income (OCI) and is included in the Accumulated other comprehensive income (loss), net of tax (AOCI) caption of our unaudited condensed consolidated balance sheets until the underlying third-party transaction occurs. When the related third-party transaction occurs we recognize the gain or loss to earnings within the Cost of products sold caption of our unaudited condensed consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the hedged forecast transaction becomes no longer probable of occurring, we reclassify the amount of gains or losses on the derivative instrument designated as a cash flow hedge to earnings at that time.

We also use forward currency contracts that are not part of designated hedging relationships under FASB ASC Topic 815 as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings and reflected within the Other, net caption of our unaudited condensed consolidated statements of operations.

Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. Under these agreements we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges under FASB ASC Topic 815.

The changes in the fair value of interest rate derivatives designated as fair value hedges and the changes in the fair value of the underlying hedged debt instrument generally offset and are recorded within the Interest expense caption of our unaudited condensed consolidated statements of operations. We record the changes in the fair value of interest rate derivatives designated as cash flow hedges within OCI and is included within the AOCI caption of our unaudited condensed consolidated balance sheets until the underlying hedged transaction occurs, at which time we recognize the gain or loss within Interest expense. In the event the hedging relationship is no longer effective, or if the hedged forecast transaction becomes no longer probable of occurring, we reclassify the amount of gains or losses on the interest rate derivative designated as a cash flow hedge to earnings at that time.

We are amortizing the realized gains or losses from interest rate derivative instruments previously designated as fair value or cash flow hedges into earnings as a component of Interest expense over the remaining term of the hedged item in accordance with FASB ASC Topic 815, so long as the hedge relationship remains effective. Prior to the adoption of ASC Update No. 2017-12, Derivatives and Hedging (Topic 815), the ineffective portion, if any, of our interest rate derivatives designated as either fair value or cash flow hedges was recognized in earnings in the period in which the hedging relationship exhibited ineffectiveness.

The following table presents the contractual amounts of our derivative instruments outstanding:
(in millions)
FASB ASC Topic 815 Designation
As of
March 31, 2018
 
December 31, 2017
Forward currency contracts
Cash flow hedge
$
3,595

 
$
3,252

Forward currency contracts
Non-designated
2,565

 
2,671

Total Notional Outstanding
 
$
6,161

 
$
5,923



The remaining time to maturity as of March 31, 2018 is within 60 months for all designated forward currency contracts and generally less than one year for all non-designated forward currency contracts.

We had no interest rate derivative instruments outstanding as of March 31, 2018 and December 31, 2017.

The following presents the effect of our derivative instruments designated as cash flow hedges under FASB ASC Topic 815 on our accompanying unaudited condensed consolidated statements of operations:
(in millions)
 
Location in Unaudited Condensed Consolidated Statements of Operations
Total Amounts Presented in Unaudited Condensed Consolidated Statements of Operations
 
Effective Amount
Recognized in OCI
 
Effective Amount Reclassified from AOCI into Earnings
 
 
Pre-Tax Gain (Loss)
Tax Benefit (Expense)
Gain (Loss) Net of Tax
 
Pre-Tax (Gain) Loss
Tax (Benefit) Expense
(Gain) Loss
Net of Tax
Three Months Ended March 31, 2018
 
 
 
 
 
 
 
 
 
 
 
Forward currency contracts
 
Cost of products sold
$
672

 
$
(118
)
$
27

$
(91
)
 
$
15

$
(3
)
$
12

 
 
 
 
 
$
(118
)
$
27

$
(91
)
 
$
15

$
(3
)
$
12

Three Months Ended March 31, 2017
 
 
 
 
 
 
 
 
 
 
 
Forward currency contracts
 
Cost of products sold
$
650

 
$
(58
)
$
21

$
(37
)
 
$
(28
)
$
10

$
(18
)
 
 
 
 
 
$
(58
)
$
21

$
(37
)
 
$
(28
)
$
10

$
(18
)


As of March 31, 2018, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as currency hedge contracts under FASB ASC Topic 815 that may be reclassified to earnings within the next twelve months are presented below:
(in millions)
Designated Derivative Instrument
 
FASB ASC Topic 815 Designation
 
Location in
Unaudited Condensed Consolidated Statements of Operations
Total Amounts
Presented in
Unaudited Condensed Consolidated
Statements of Operations
 
Amount of
Pre-Tax
Gain (Loss)
that may be Reclassified to Earnings
 
 
 
Interest rate derivative contracts
 
Fair value hedge
 
Interest expense
$
(61
)
 
$
12

Interest rate derivative contracts
 
Cash flow hedge
 
Interest expense
(61
)
 
1

Forward currency contracts
 
Cash flow hedge
 
Cost of products sold

672

 
(55
)

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
 
 
Location in
Unaudited Condensed Consolidated Statements of Operations
 
 
 
 
 
 
 
Three Months Ended March 31,
(in millions)
 
 
2018
 
2017
Net gain (loss) on currency hedge contracts
 
Other, net
 
$
(23
)
 
$
(17
)
Net gain (loss) on currency transaction exposures
 
Other, net
 
16

 
17

Net currency exchange gain (loss)
 
 
 
$
(8
)
 
$



Fair Value Measurements

FASB ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures, by considering the estimated amount we would receive or pay to transfer these instruments at the reporting date when taking into account current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.

The following are the balances of our derivative assets and liabilities:
 
Location in
Unaudited Condensed Consolidated
Balance Sheets (1)
As of
 
March 31,
 
December 31,
(in millions)
2018
 
2017
Derivative Assets:
 
 
 
 
Designated Derivative Instruments
 
 
 
 
Forward currency contracts
Other current assets
$
3

 
$
7

Forward currency contracts
Other long-term assets
15

 
57

 
 
17

 
64

Non-Designated Derivative Instruments
 
 
 
 
Forward currency contracts
Other current assets
15

 
18

Total Derivative Assets
 
$
32

 
$
82

 
 
 
 
 
Derivative Liabilities:
 
 
 
 
Designated Derivative Instruments
 
 
 
Forward currency contracts
Other current liabilities
$
54

 
$
37

Forward currency contracts
Other long-term liabilities
69

 
33

 
 
123

 
69

Non-Designated Derivative Instruments
 
 
 
 
Forward currency contracts
Other current liabilities
31

 
21

Total Derivative Liabilities
 
$
154

 
$
90


(1)
We classify derivative assets and liabilities as current when the remaining term of the derivative contract is one year or less.
Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Assets and liabilities measured at fair value on a recurring basis consist of the following:
 
As of
 
March 31, 2018
 
December 31, 2017
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets
 
 
 

 
 
 
 
 
 
 
 

 
 
 
 
Money market and government funds
$
42

 
$

 
$

 
$
42

 
$
21

 
$

 
$

 
$
21

Publicly-held securities
12

 

 

 
12

 
15

 

 

 
15

Forward currency contracts

 
32

 

 
32

 

 
82

 

 
82

 
$
54

 
$
32

 
$

 
$
86

 
$
36

 
$
82

 
$

 
$
118

Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Forward currency contracts
$

 
$
154

 
$

 
$
154

 
$

 
$
90

 
$

 
$
90

Accrued contingent consideration

 

 
152

 
152

 

 

 
169

 
169

 
$

 
$
154

 
$
152

 
$
306

 
$

 
$
90

 
$
169

 
$
259



Our investments in money market and government funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as cash and cash equivalents within our accompanying unaudited condensed consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $42 million invested in money market and government funds as of March 31, 2018, we had $245 million in interest bearing and non-interest bearing bank accounts. In addition to $21 million invested in money market and government funds as of December 31, 2017, we had $167 million in interest bearing and non-interest bearing bank accounts.

Our recurring fair value measurements using significant unobservable inputs (Level 3) relate solely to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability.
Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods subsequent to initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments.

Refer to Note C – Goodwill and Other Intangible Assets for a discussion of the fair values and annual impairment tests of goodwill and our indefinite lived intangible assets.

The fair value of our outstanding debt obligations was $6.040 billion as of March 31, 2018 and $5.945 billion as of December 31, 2017. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, amortized cost for commercial paper and face value for term loans and credit facility borrowings outstanding. Refer to Note E – Borrowings and Credit Arrangements for a discussion of our debt obligations.
XML 38 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Borrowings and Credit Arrangements
3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
BORROWINGS AND CREDIT ARRANGEMENTS
NOTE E – BORROWINGS AND CREDIT ARRANGEMENTS

We had total debt of $5.765 billion as of March 31, 2018 and $5.616 billion as of December 31, 2017. The debt maturity schedule for the significant components of our long-term debt obligations is presented below:
(in millions, except interest rates)
Issuance Date
Maturity Date
As of
 
Semi-annual Coupon Rate
March 31, 2018
 
December 31, 2017
 
October 2018 Notes
August 2013
October 2018

 

 
2.650
%
January 2020 Notes
December 2009
January 2020
850

 
850

 
6.000
%
May 2020 Notes
May 2015
May 2020
600

 
600

 
2.850
%
May 2022 Notes
May 2015
May 2022
500

 
500

 
3.375
%
October 2023 Notes
August 2013
October 2023
450

 
450

 
4.125
%
May 2025 Notes
May 2015
May 2025
750

 
750

 
3.850
%
March 2028 Notes
February 2018
March 2028
1,000

 

 
4.000
%
November 2035 Notes
November 2005
November 2035
350

 
350

 
7.000
%
January 2040 Notes
December 2009
January 2040
300

 
300

 
7.375
%
Unamortized Debt Issuance Discount
 
2020 - 2040
(14
)
 
(6
)
 
 
Unamortized Deferred Financing Costs
 
2020 - 2040
(19
)
 
(18
)
 
 
Unamortized Gain on Fair Value Hedges
 
2020 - 2023
35

 
38

 
 
Capital Lease Obligation
 
Various
1

 
1

 
 
Long-term debt
 
 
$
4,803

 
$
3,815

 
 
As of December 31, 2017, $600 million under the October 2018 Notes was outstanding and classified as short-term debt.
Note:
The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.


Revolving Credit Facility
As of March 31, 2018 and December 31, 2017, we maintained a $2.250 billion revolving credit facility (the 2017 Facility) with a global syndicate of commercial banks that matures on August 4, 2022. This facility provides backing for the commercial paper program described below. There were no amounts borrowed under our revolving credit facility as of March 31, 2018 and December 31, 2017.
The 2017 Facility requires that we maintain certain financial covenants, as follows:
 
Covenant Requirement
 
Actual
 
as of March 31, 2018
 
as of March 31, 2018
Maximum leverage ratio (1)
3.5 times
 
2.2 times

(1)
Ratio of total debt to consolidated EBITDA, as defined by the credit agreement, for the preceding four consecutive fiscal quarters.

The 2017 Facility provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of March 31, 2018, we had $415 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the 2017 Facility, are excluded from the calculation of consolidated EBITDA, as defined in the 2017 Facility, provided that the sum of any excluded net cash litigation payments does not exceed $2.624 billion in the aggregate. As of March 31, 2018, we had $1.690 billion of the legal exclusion remaining.

Any inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facility or seek waivers from compliance with these covenants, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all credit facility commitments would terminate and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our credit facility may negatively impact the credit ratings assigned to our commercial paper program which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.
Commercial Paper
As of March 31, 2018, we had $886 million of commercial paper outstanding and $1.197 billion outstanding as of December 31, 2017. Our commercial paper program is backed by the 2017 Facility, which allows us to have a maximum of $2.250 billion in commercial paper outstanding. Outstanding commercial paper directly reduces borrowing capacity available under the 2017 Facility. As of March 31, 2018, the commercial paper issued and outstanding had a weighted average maturity of 22 days and a weighted average yield of 2.46 percent. As of December 31, 2017, the commercial paper issued and outstanding had a weighted average maturity of 38 days and a weighted average yield of 1.85 percent.

Senior Notes

We had senior notes outstanding of $4.800 billion as of March 31, 2018 and $4.400 billion as of December 31, 2017.

In February 2018, we completed an offering of $1.000 billion in aggregate principal amount of 4.000% senior notes, due March 2028. We used a portion of the net proceeds from the offering to repay the $600 million plus accrued interest of our 2.650% senior notes due in October 2018. The remaining proceeds were used to repay a portion of our outstanding commercial paper.

Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to borrowings under our credit and security facility, and to the extent borrowed by our subsidiaries, to liabilities of our subsidiaries (see Other Arrangements below).

Other Arrangements

As of March 31, 2018 and December 31, 2017, we maintained a $400 million credit and security facility secured by our U.S. trade receivables maturing in February 2019. We had outstanding borrowings of $70 million as of March 31, 2018 and no outstanding borrowings as of December 31, 2017 under our credit and security facility.

We have accounts receivable factoring programs in certain European countries that we account for as sales under FASB ASC Topic 860, Transfers and Servicing. These agreements provide for the sale of accounts receivable to third parties, of up to approximately $463 million as of March 31, 2018. We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. We de-recognized $178 million of receivables as of March 31, 2018 at an average interest rate of 2.1 percent and $171 million as of December 31, 2017 at an average interest rate of 1.8 percent.

In March 2018, we entered into a factoring agreement with a commercial Japanese bank. The agreement provides for the sale of accounts receivable and promissory notes of up to 30.000 billion Japanese yen (approximately $282 million as of March 31, 2018). We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. We de-recognized $95 million of receivables as of March 31, 2018 at an average interest rate of 0.5 percent.

In addition, we have uncommitted credit facilities with a commercial Japanese bank that provide for accounts receivable factoring and promissory notes discounting of up to 22.000 billion Japanese yen (approximately $207 million as of March 31, 2018). We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. We de-recognized $124 million of notes receivable as of March 31, 2018 at an average interest rate of 1.5 percent and $157 million of notes receivable as of December 31, 2017 at an average interest rate of 1.3 percent. De-recognized accounts and notes receivable are excluded from trade accounts receivable, net in the accompanying unaudited condensed consolidated balance sheets.

As of and through March 31, 2018, we were in compliance with all the required covenants related to our debt obligations. For additional information regarding the terms of our debt agreements, refer to Note E - Borrowings and Credit Arrangements of the consolidated financial statements in our most recent Annual Report on Form 10-K.
XML 39 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restructuring Related Activities
3 Months Ended
Mar. 31, 2018
Restructuring and Related Activities [Abstract]  
RESTRUCTURING-RELATED ACTIVITIES
NOTE F – RESTRUCTURING-RELATED ACTIVITIES

2016 Restructuring Plan

On June 6, 2016, our Board of Directors approved and we committed to a restructuring initiative (the 2016 Restructuring Plan). The 2016 Restructuring Plan is intended to develop global commercialization, technology and manufacturing capabilities in key growth markets and build on our Plant Network Optimization (PNO) strategy, which is intended to simplify our manufacturing plant structure by transferring certain production lines among facilities and expanding operational efficiencies in support of our operating income margin goals. Key activities under the 2016 Restructuring Plan include strengthening global infrastructure through evolving global real estate assets and workplaces, developing global commercial and technical competencies, enhancing manufacturing and distribution expertise in certain regions and continuing implementation of our PNO strategy. These activities were initiated in the second quarter of 2016 and are expected to be substantially complete by the end of 2018. We revised the original estimate for the costs and savings associated with the program in the first quarter of 2018, as approved by the Board of Directors.

The following table provides a summary of our estimates of costs associated with the 2016 Restructuring Plan by major type of cost:
Type of cost
Total Estimated Amount Expected to be Incurred
Restructuring charges:
 
Termination benefits
$100 million to $110 million
Other (1)
$25 million to $50 million
Restructuring-related expenses:
 
Other (2)
$150 million to $165 million
 
$275 million to $325 million

(1) Consists primarily of consulting fees and costs associated with contract cancellations.
(2) Comprised of other costs directly related to the 2016 Restructuring Plan, including program management, accelerated depreciation and costs to transfer product lines among facilities.

Approximately $250 million to $300 million of these charges are estimated to result in cash outlays.

The following presents these costs (credits) by major type and line item within our accompanying unaudited condensed consolidated statements of operations.
Three Months Ended March 31, 2018
 
 
 
 
 
 
 
(in millions)
Termination
Benefits
 
Transfer
Costs
 
Other
 
Total
Restructuring charges
$
12

 
$

 
$
1

 
$
13

Restructuring-related expenses:
 
 
 
 
 
 
 
Cost of products sold

 
7

 

 
7

Selling, general and administrative expenses

 

 
8

 
8

 

 
7

 
8

 
15

 
$
12

 
$
7

 
$
8

 
$
28

 
 
 
 
 
 
 
 

Three Months Ended March 31, 2017
 
 
 
 
 
 
 
 
 
(in millions)
Termination
Benefits
 
Accelerated
Depreciation
 
Transfer
Costs
 
Other
 
Total
Restructuring charges
$
3

 
$

 
$

 
$
1

 
$
4

Restructuring-related expenses:
 
 
 
 
 
 
 
 
 
Cost of products sold

 

 
12

 

 
12

Selling, general and administrative expenses

 
2

 

 
1

 
3

 

 
2

 
12

 
1

 
15

 
$
3

 
$
2

 
$
12

 
$
2

 
$
19



The following table presents cumulative restructuring and restructuring-related charges as of March 31, 2018, related to our 2016 Restructuring Plan by major type:
(in millions)
2016 Restructuring Plan
Termination benefits
$
61

Other (1)
16

Total restructuring charges
77

Accelerated depreciation
9

Transfer costs
68

Other (2)
15

Restructuring-related expenses
92

 
$
169


(1) Consists primarily of consulting fees and costs associated with contract cancellations.
(2) Comprised of other costs directly related to our Restructuring Plan, including program management, accelerated depreciation and costs to transfer product lines among facilities.

Cash payments associated with our 2016 Restructuring Plan were made using cash generated from operations and are comprised of the following:
(in millions)
2016 Restructuring Plan
Three Months Ended March 31, 2018
 
Termination benefits
$
8

Transfer costs
7

Other
9

 
$
25

 
 
Program to Date
 
Termination benefits
$
36

Transfer costs
67

Other
19

 
$
122



Our restructuring liability is primarily comprised of accruals for termination benefits. The following is a rollforward of the termination benefit liability associated with our 2016 Restructuring Plan, which is reported as a component of accrued expenses included in our accompanying unaudited condensed consolidated balance sheets:
(in millions)
2016 Restructuring Plan
Accrued as of December 31, 2017
$
22

Charges (credits)
12

Cash payments
(8
)
Accrued as of March 31, 2018
$
27

XML 40 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Supplemental Balance Sheet Information
3 Months Ended
Mar. 31, 2018
Supplemental Balance Sheet Information [Abstract]  
Supplemental Balance Sheet Disclosures
NOTE G – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions in our accompanying unaudited condensed consolidated balance sheets are as follows:

Cash, cash equivalents, restricted cash and restricted cash equivalents
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Cash and cash equivalents
 
$
287

 
$
188

Restricted cash included in Other current assets
 
850

 
803

Restricted cash included in Other long-term assets
 
31

 
26

Total cash, cash equivalents and restricted cash
 
$
1,168

 
$
1,017



Trade accounts receivable, net
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Accounts receivable
 
$
1,650

 
$
1,645

Allowance for doubtful accounts
 
(67
)
 
(68
)
Allowance for sales returns
 

 
(30
)
Other sales reserves
 
(3
)
 

 
 
$
1,580

 
$
1,548



Note: Due to the adoption of FASB ASC Topic 606 effective January 1, 2018, the allowance for sales returns has been prospectively reclassified from Trade accounts receivable, net to Other current liabilities within the unaudited condensed consolidated balance sheets. Prior period balances remain unchanged.

The following is a rollforward of our allowance for doubtful accounts:
 
 
Three Months Ended
March 31,
(in millions)
 
2018
 
2017
Beginning balance
 
$
68

 
$
73

Net charges to expenses
 
4

 
3

Utilization of allowances
 
(5
)
 
(1
)
Ending balance
 
$
67

 
$
75



Inventories
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Finished goods
 
$
717

 
$
685

Work-in-process
 
105

 
110

Raw materials
 
291

 
284

 
 
$
1,113

 
$
1,078



Property, plant and equipment, net
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Land
 
$
103

 
$
102

Buildings and improvements
 
1,132

 
1,120

Equipment, furniture and fixtures
 
3,246

 
3,183

Capital in progress
 
215

 
219

 
 
4,696

 
4,625

Accumulated depreciation
 
(2,996
)
 
(2,928
)
 
 
$
1,700

 
$
1,697



Depreciation expense was $68 million for the first quarter of 2018 and $63 million for the first quarter of 2017.

Accrued expenses
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Legal reserves
 
$
1,255

 
$
1,176

Payroll and related liabilities
 
488

 
591

Accrued contingent consideration
 
62

 
36

Other
 
643

 
653

 
 
$
2,447

 
$
2,456



Other long-term liabilities
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Accrued income taxes
 
$
1,119

 
$
1,275

Legal reserves
 
256

 
436

Accrued contingent consideration
 
92

 
133

Other
 
787

 
525

 
 
$
2,254

 
$
2,370

XML 41 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes
3 Months Ended
Mar. 31, 2018
Income Tax Examination [Line Items]  
INCOME TAXES
NOTE H – INCOME TAXES

Our effective tax rate from continuing operations is presented below:
 
 
Three Months Ended March 31,
 
2018
 
2017
Effective tax rate from continuing operations
 
8.0
%
 
4.9
%


The change in our reported tax rates for the first quarter of 2018, as compared to the same period in 2017, relates primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate, including intangible asset impairment charges, acquisition-related items, restructuring items, litigation-related items, as well as certain discrete tax items including impacts of the Tax Cuts and Jobs Act (TCJA), enacted on December 22, 2017.

As of March 31, 2018, we had $1.240 billion of gross unrecognized tax benefits, of which a net $1.157 billion, if recognized, would affect our effective tax rate. As of December 31, 2017, we had $1.238 billion of gross unrecognized tax benefits, of which a net $1.150 billion, if recognized, would affect our effective tax rate.

We have received Notices of Deficiency from the Internal Revenue Service (IRS) reflecting proposed audit adjustments for Guidant Corporation for its 2001 through 2006 tax years and for Boston Scientific Corporation for its 2006 and 2007 tax years. The total incremental tax liability asserted by the IRS for the applicable periods is $1.162 billion plus interest. The primary issue in dispute for all years is the transfer pricing associated with the technology license agreements between domestic and foreign subsidiaries of Guidant. In addition, the IRS has proposed adjustments in connection with the financial terms of our Transaction Agreement with Abbott Laboratories pertaining to the sale of Guidant's vascular intervention business to Abbott Laboratories in April 2006. During 2014, we received a Revenue Agent Report from the IRS reflecting significant proposed audit adjustments to our 2008, 2009 and 2010 tax years based upon the same transfer pricing methodologies that the IRS applied to our 2001 through 2007 tax years.

We do not agree with the transfer pricing methodologies applied by the IRS or its resulting assessment. We have filed petitions with the U.S. Tax Court contesting the Notices of Deficiency for the 2001 through 2007 tax years in challenge and submitted a letter to the IRS Office of Appeals protesting the Revenue Agent Report for the 2008 through 2010 tax years and requesting an administrative appeal hearing. The issues in dispute were scheduled to be heard in U.S. Tax Court in July 2016. On July 19, 2016, we entered into a Stipulation of Settled Issues with the IRS intended to resolve all of the aforementioned transfer pricing issues, as well as the issues related to our transaction with Abbott Laboratories, for the 2001 through 2007 tax years. The Stipulation of Settled Issues was contingent upon the IRS Office of Appeals applying the same basis of settlement to all transfer pricing issues for the Company’s 2008, 2009 and 2010 tax years as well as review by the United States Congress Joint Committee on Taxation (JCT). In October 2016, we reached an agreement in principle with the IRS Office of Appeals as to the resolution of transfer pricing issues in 2008, 2009 and 2010 tax years, subject to additional calculations of tax as well as documentation to memorialize our agreement. The IRS has recalculated our final tax liabilities under this agreement for all of our tax years from 2001 through 2010 and the JCT has completed its review of the recalculations for the 2001 through 2010 tax years.

In the event that the conditions in the Stipulation of Settled Items are satisfied, we expect to make net tax payments of approximately $275 million, plus interest through the date of payment with respect to the settled issues. If finalized, payments related to the resolution are expected in the next six months. We believe that our income tax reserves associated with these matters are adequate as of March 31, 2018 and we do not expect to recognize any additional charges related to resolution of this controversy. However, the final resolution of these issues remains contingent and if the Stipulation of Settled Issues is not finalized, it could have a material impact on our financial condition, results of operations, or cash flows.

We recognize interest and penalties related to income taxes as a component of income tax expense. We had $675 million accrued for gross interest and penalties as of March 31, 2018 and $655 million as of December 31, 2017. We recognized net tax expense related to interest and penalties of $17 million during the first quarter of 2018 and $13 million in the first quarter of 2017.

It is reasonably possible that within the next 12 months we will resolve multiple issues including transfer pricing and transactional-related issues with foreign, federal and state taxing authorities, in which case we could record a reduction in our balance of unrecognized tax benefits of up to approximately $897 million.

There are a number of key provisions under the TCJA that impact us and we continue to monitor and analyze the ramification of the new law as the implementation is executed. The final impact of the TCJA may differ from the estimates reported due to, among other things, changes in interpretations and assumptions made by us, additional guidance that may be issued by the U.S. Department of the Treasury and actions that we may take as a result. The TCJA reduces the US Federal corporate income tax rate from 35 percent to 21 percent, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, and creates new taxes on certain foreign sourced earnings. Due to insufficient guidance, as well as the availability of information to accurately analyze the impact of the TCJA, we have made a reasonable estimate of the effects, as described below and in other cases we have not been able to make a reasonable estimate and continue to account for those items based on our existing accounting under FASB ASC Topic 740, Income Taxes and the provisions of the tax laws that were in effect immediately prior to enactment. In the first quarter of 2018, we recognized an additional tax benefit of $9 million, resulting in a total provisional estimate of $852 million related to the TCJA.

We are required to record deferred tax assets and liabilities based on the enacted tax rates at which they are expected to reverse in the future. Therefore, any U.S. related deferred taxes were re-measured from 35 percent down to 21 percent based on the recorded balances as of December 31, 2017. The analysis included a preliminary assessment on the deductibility of certain amounts for which deferred tax assets may have been recorded. However, we are still analyzing certain aspects of the TCJA and refining our calculations based on the available information, which could potentially affect the measurement of these balances or give rise to new deferred tax amounts. As of March 31, 2018, we have not adjusted our provisional estimate related to re-measurement of our deferred tax balances. As of December 31, 2017, we recorded an estimated tax benefit of approximately $99 million.

We are required to calculate a one-time transition tax based on our total post-1986 foreign earnings and profits (E&P) that we previously deferred from U.S. income taxes. In the first quarter of 2018, we recognized an additional tax benefit of $9 million, which results in a revised provisional amount of approximately $1.035 billion. We anticipate offsetting this liability against existing tax attributes reducing the required payment to approximately $454 million which will be remitted over an eight year period. We have not yet completed our calculation of the total post-1986 E&P for these foreign subsidiaries and we continue to refine the analysis. Additionally, no income taxes have been provided for any remaining undistributed foreign earnings that are not subject to the transition tax or any additional outside basis difference inherent in these entities, as we expect these amounts will remain indefinitely reinvested in foreign operations. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings not subject to the transition tax and additional outside basis difference in these entities is not practicable.

We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. Additionally, we are required to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. As of March 31, 2018, we are still evaluating the effects of the GILTI provisions as guidance and interpretations continue to emerge. Therefore, we have not determined our accounting policy on the GILTI provisions. However, the standard requires that we reflect the impact of the GILTI provisions as a period expense until the accounting policy is finalized. Therefore, we have included the provisional estimate of GILTI related to current-year operations in our estimated annual effective tax rate only and will be updating the impact and accounting policy as the analysis related to the GILTI provisions is completed.
XML 42 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE I – COMMITMENTS AND CONTINGENCIES

The medical device market in which we primarily participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding or in a series of related proceedings or litigate multiple features of a single class of devices. These forces frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters, however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In the normal course of business, product liability, securities and commercial claims are asserted against us. Similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.

Our accrual for legal matters that are probable and estimable was $1.511 billion as of March 31, 2018 and $1.612 billion as of December 31, 2017 and includes certain estimated costs of settlement, damages and defense. As of March 31, 2018 and December 31, 2017, a portion of our legal accrual is funded and included in our restricted cash balance as disclosed in Note G – Supplemental Balance Sheet Information. We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our debt covenants.

In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be estimated.

Patent Litigation

On November 9, 2015, Edwards Lifesciences, LLC filed an invalidity claim against one of our subsidiaries, Sadra Medical, Inc. (Sadra), in the High Court of Justice, Chancery Division Patents Court in the United Kingdom, alleging that a European patent owned by Sadra relating to a repositionable heart valve is invalid. On January 15, 2016, we filed our defense and counterclaim for a declaration that our European patent is valid and infringed by Edwards. On February 25, 2016, we amended our counterclaim to allege infringement of a second patent related to adaptive sealing technology. A trial was held from January 18 to January 27, 2017. On March 3, 2017, the court found one of our patents valid and infringed and some claims of the second patent invalid and the remaining claims not infringed. Both parties have filed an appeal. On March 28, 2018, the Court of Appeals affirmed the decision of the High Court.

On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation in the U.S. District Court for the District of Delaware for patent infringement. We allege that Edwards’ SAPIEN™ 3 Valve infringes a patent related to adaptive sealing technology. On June 9, 2016, Edwards filed a counterclaim alleging that our Lotus™ Valve System infringes three patents owned by Edwards. On October 12, 2016, Edwards filed a petition for inter partes review of our patent with the U.S. Patent and Trademark Office (USPTO), Patent Trial and Appeal Board. On March 29, 2017, the USPTO granted the inter partes review request. On April 18, 2017, Edwards filed a second petition for inter partes review of our patent with the USPTO. On March 23, 2018, the USPTO found the patent invalid. The Company plans to appeal that decision.

On April 26, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of Düsseldorf, Germany alleging a European patent (Spenser '550) owned by Edwards is infringed by our Lotus Transcatheter Heart Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we infringed the Spenser '550 patent. The Company filed an appeal. The appeal hearing is scheduled for May 17, 2018. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.

On December 22, 2016, Edwards Lifesciences PVT, Inc. and Edwards Lifesciences SA (AG) filed a plenary summons against Boston Scientific Limited and Boston Scientific Group Public Company in the High Court of Ireland alleging that a European patent (Spenser) owned by Edwards is infringed by our Lotus Valve System. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.

On November 20, 2017, The Board of Regents, University of Texas System (UT) and TissueGen. Inc. (TissueGen), served a lawsuit against us in the Western District of Texas. The complaint against us alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. On March 12, 2018, the court dismissed the action and transferred it to the United States District Court for the District of Delaware.

Product Liability Litigation

As of April 24, 2018, approximately 49,500 product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us. The pending cases are in various federal and state courts in the United States and include eight putative class actions. There were also approximately 20 cases in Canada, inclusive of one certified and three putative class actions and fewer than 25 claims in the United Kingdom. Generally, the plaintiffs allege personal injury associated with use of our transvaginal surgical mesh products. The plaintiffs assert design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. Over 3,100 of the cases have been specially assigned to one judge in state court in Massachusetts. On February 7, 2012, the Judicial Panel on Multi-District Litigation (MDL) established MDL-2326 in the United States District Court for the Southern District of West Virginia and transferred the federal court transvaginal surgical mesh cases to MDL-2326 for coordinated pretrial proceedings. During the fourth quarter of 2013, we received written discovery requests from certain state attorneys general offices regarding our transvaginal surgical mesh products. We have responded to those requests. As of April 24, 2018, we have entered into master settlement agreements in principle or are in final stages of entering one with certain plaintiffs' counsel to resolve an aggregate of approximately 47,500 cases and claims. These master settlement agreements provide that the settlement and distribution of settlement funds to participating claimants are conditional upon, among other things, achieving minimum required claimant participation thresholds. Of the approximately 47,500 cases and claims, approximately 21,000 have met the conditions of the settlement and are final. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing.

We have established a product liability accrual for known and estimated future cases and claims asserted against us as well as with respect to the actions that have resulted in verdicts against us and the costs of defense thereof associated with our transvaginal surgical mesh products. While we believe that our accrual associated with this matter is adequate, changes to this accrual may be required in the future as additional information becomes available. While we continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims and intend to vigorously contest the cases and claims asserted against us, that do not settle, the final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Initial trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

Other Proceedings

Refer to Note H – Income Taxes for information regarding our tax litigation.
XML 43 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Weighted Average Shares Outstanding
3 Months Ended
Mar. 31, 2018
Earnings Per Share [Abstract]  
Weighted Average Number Of Shares Outstanding [Text Block]
NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING
 
 
Three Months Ended
March 31,
(in millions)
 
2018

2017
Weighted average shares outstanding - basic
 
1,376.5

 
1,365.4

Net effect of common stock equivalents
 
20.2

 
24.8

Weighted average shares outstanding - assuming dilution
 
1,396.8

 
1,390.2


The impact of stock options outstanding with exercise prices greater than the average fair market value of our common stock was immaterial for all periods presented.

We issued approximately six million shares of our common stock in the first quarter of 2018 and seven million shares of our common stock in the first quarter of 2017, following the exercise of underlying stock options, vesting of deferred stock units or purchases under our employee stock purchase plan. We did not repurchase any shares of our common stock during the first three months of 2018 or 2017.
XML 44 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Reporting
3 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
SEGMENT REPORTING
NOTE K – SEGMENT REPORTING

We have three reportable segments comprised of MedSurg, Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments.
Each of our reportable segments generates revenues from the sale of medical devices. We measure and evaluate our reportable segments based on segment net sales and operating income, excluding intersegment profits. In 2017, we updated our presentation of segment net sales and operating income to the impact of foreign currency fluctuations, since our chief operating decision maker (CODM) reviews operating results both including and excluding the impact of foreign currency fluctuations and the following presentation more closely aligns to our consolidated financial statements. We exclude from segment operating income certain corporate-related expenses and certain transactions or adjustments that our CODM considers to be non-operational, such as amounts related to amortization expense, intangible asset impairment charges, acquisition-related items, restructuring and restructuring-related items and litigation-related items. Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation below.

Effective January 1, 2018, following organizational changes to align the company's business and organization structure focused on active implantable devices, we revised our reportable segments, in accordance with FASB ASC Topic 280, Segment Reporting. The revision reflects a reclassification of our Neuromodulation business from our Medical Surgical (MedSurg) segment to our newly created Rhythm and Neuro segment. We have revised prior year amounts to conform to the current year’s presentation (as denoted with an asterisk throughout *). There was no revision to operating segments or reporting units as a result of the organizational change.

A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows:
 
 
Three Months Ended
March 31,
(in millions)
 
2018
 
2017
 
 
 
 
 
Net sales
 
 
 
 
MedSurg*
 
$
711

 
$
641

Rhythm and Neuro*
 
736

 
668

Cardiovascular
 
933

 
851

 
 
$
2,379

 
$
2,160

 
 
 
 
 
Income (loss) before income taxes
 
 
 
 
MedSurg*
 
$
259

 
$
215

Rhythm and Neuro*
 
153

 
109

Cardiovascular
 
290

 
233

Operating income allocated to reportable segments
 
703

 
557

Corporate expenses, including hedging activities
 
(100
)
 
(61
)
Intangible asset impairment charges, acquisition-related, restructuring- and restructuring-related and litigation-related net credits (charges)
 
(54
)
 
11

Amortization expense
 
(141
)
 
(143
)
Operating income (loss)
 
407

 
364

Other expense, net
 
(84
)
 
(59
)
Income (loss) before income taxes
 
$
323

 
$
305


 
 
Three Months Ended
March 31,
Operating income as a percentage of segment net sales
 
2018
 
2017
MedSurg*
 
36.4
%
 
33.5
%
Rhythm and Neuro*
 
20.8
%
 
16.3
%
Cardiovascular
 
31.1
%
 
27.3
%
XML 45 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Revenue Revenue
3 Months Ended
Mar. 31, 2018
Revenue Recognition [Abstract]  
Revenue [Text Block]
NOTE L – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes in our unaudited condensed consolidated statements of operations. The following tables disaggregate our revenue from contracts with customers by business and geographic region:
 
 
Three Months Ended March 31,
Businesses (in millions)
 
2018
 
2017
Endoscopy
 
 
 
 
U.S.
 
$
231

 
$
215

International
 
187

 
164

Worldwide
 
418

 
379

 
 
 
 
 
Urology and Pelvic Health
 
 
 
 
U.S.
 
197

 
183

International
 
96

 
79

Worldwide
 
293

 
262

 
 
 
 
 
Cardiac Rhythm Management
 
 
 
 
U.S.
 
290

 
283

International
 
203

 
180

Worldwide
 
493

 
463

 
 
 
 
 
Electrophysiology
 
 
 
 
U.S.
 
35

 
32

International
 
39

 
32

Worldwide
 
75

 
64

 
 
 
 
 
Neuromodulation
 
 
 
 
U.S.
 
131

 
116

International
 
38

 
25

Worldwide
 
169

 
141

 
 
 
 
 
Interventional Cardiology
 
 
 
 
U.S.
 
281

 
278

International
 
364

 
312

Worldwide
 
645

 
590

 
 
 
 
 
Peripheral Interventions
 
 
 
 
U.S.
 
145

 
142

International
 
142

 
119

Worldwide
 
288

 
261

 
 
 
 
 
Total Company
 
 
 
 
U.S.
 
1,310

 
1,249

International
 
1,069

 
911

Net Sales
 
$
2,379

 
$
2,160


 
 
Three Months Ended March 31,
Geographic Regions (in millions)
 
2018
 
2017
U.S.
 
$
1,310

 
$
1,249

EMEA (Europe, Middle East and Africa)
 
563

 
454

APAC (Asia-Pacific)
 
415

 
371

LACA (Latin America and Canada)
 
91

 
84

 
 
$
2,379

 
$
2,160

 
 
 
 
 
Emerging Markets (1)
 
$
255

 
$
208


(1) Emerging Markets is defined as certain countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Currently, we include 20 countries in our definition of Emerging Markets.

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors. We consider revenue to be earned when all of the following criteria are met: we have a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount we expect to receive, is determinable and we have transferred control of the promised items to the customer. Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S., but may be longer in international markets.

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management (CRM) product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Contract liabilities are classified as other current liabilities and other long-term liabilities on the balance sheet. Our deferred revenue balance as of March 31, 2018 was $393 million and $411 million as of January 1, 2018. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. During the first quarter of 2018, we recognized $26 million of revenue that was included in the above January 1, 2018 contract liability balance. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next­ generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next­-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to estimate the expected rebates reasonably, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.

Capitalized Contract Costs

We capitalize commission fees related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE Remote Monitoring Service. These fulfillment costs are amortized over the average service period. Our total capitalized contract costs are immaterial to our consolidated financial statements.
XML 46 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Changes in Other Comprehensive Income
3 Months Ended
Mar. 31, 2018
Changes in Other Comprehensive Income [Abstract]  
Comprehensive Income (Loss) Note [Text Block]
NOTE M – CHANGES IN OTHER COMPREHENSIVE INCOME

The following table provides the reclassifications out of other comprehensive income, net of tax.
Three Months Ended March 31, 2018
 
 
 
 
 
 
 
 
 
 
(in millions)
 
Foreign Currency Translation Adjustments
 
Unrealized Gains/Losses on Derivative Financial Instruments
 
Unrealized Gains/Losses on Available-for-Sale Securities
 
Defined Benefit Pension Items/Other
 
Total
Balance as of December 31, 2017
 
$
(32
)
 
$
1

 
$
(1
)
 
$
(27
)
 
$
(59
)
Other comprehensive income (loss) before reclassifications
 
10

 
(91
)
 

 

 
(81
)
(Income) loss amounts reclassified from accumulated other comprehensive income
 

 
12

 
1

 

 
13

Net current-period other comprehensive income (loss)
 
10

 
(80
)
 

 

 
(69
)
Balance as of March 31, 2018
 
$
(22
)
 
$
(79
)
 
$

 
$
(27
)
 
$
(128
)


Three Months Ended March 31, 2017
 
 
 
 
 
 
 
 
 
 
(in millions)
 
Foreign Currency Translation Adjustments
 
Unrealized Gains/Losses on Derivative Financial Instruments
 
Unrealized Gains/Losses on Available-for-Sale Securities
 
Defined Benefit Pension Items/Other
 
Total
Balance as of December 31, 2016
 
$
(79
)
 
$
107

 
$
(6
)
 
$
(21
)
 
$
1

Other comprehensive income (loss) before reclassifications
 
8

 
(37
)
 

 
(3
)
 
(32
)
(Income) loss amounts reclassified from accumulated other comprehensive income
 

 
(18
)
 

 
3

 
(15
)
Net current-period other comprehensive income (loss)
 
8

 
(55
)
 

 

 
(47
)
Balance as of March 31, 2017
 
$
(71
)
 
$
52

 
$
(6
)
 
$
(21
)
 
$
(46
)

Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on the reclassifications related to derivatives.

We adopted Update No. 2016-01 in the first quarter of 2018, as a result of adopting the standard, we recorded a cumulative effect adjustment to retained earnings for unrealized gains and losses for available-for-sale securities previously recorded to accumulated other comprehensive income.

The gains and losses on defined benefit and pension related items before reclassifications and gains and losses on defined benefit and pension items reclassified from accumulated other comprehensive income were reduced by immaterial income tax impacts in the first three months of 2018 and 2017.
XML 47 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
New Accounting Pronouncements
3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]
NOTE N – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our unaudited condensed consolidated financial statements.

Standards to be Implemented

ASC Update No. 2016-02

In February 2016, the FASB issued ASC Update No. 2016-02, Leases (Topic 842). The purpose of Update No. 2016-02 is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. Update No. 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted and a modified retrospective approach is required for adoption. While we are still in the process of determining the effect that the new standard will have on our financial position and results of operations, we expect to recognize additional assets and corresponding liabilities on our consolidated balance sheets, as a result of our operating lease portfolio as it exists at the date we adopt the new standard. Please refer to Note F - Lease and Other Purchase Obligations in our most recent Annual Report on Form 10-K for information regarding our most current lease activity. Additionally, we are in the process of implementing a new lease administration and lease accounting system, and updating our controls and procedures for maintaining and accounting for our lease portfolio under the new standard. As a result, we anticipate adopting the new standard on January 1, 2019.

ASC Update No. 2016-13

In June 2016, the FASB issued ASC Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted for annual periods beginning after December 15, 2018. We are in the process of determining the effect that the adoption will have on our financial position and results of operations.

No other new accounting pronouncements, issued or effective, during the period had, or are expected to have, a material impact on our condensed consolidated financial statements.
XML 48 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Basis of Presentation Standards Implemented Since Dec 31 (Policies)
3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
New Accounting Pronouncements, Policy [Policy Text Block]
Accounting Standards Implemented Since December 31, 2017

ASC Update No. 2014-09

In May 2014, the FASB issued ASC Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), which was subsequently updated. We adopted the standard as of January 1, 2018, using the modified retrospective method. Under this method, we applied FASB ASC Topic 606 to contracts that were not complete as of January 1, 2018 and recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings. Results for reporting periods beginning after January 1, 2018 are presented in accordance with FASB ASC Topic 606. Prior period amounts are not adjusted and are reported in accordance with legacy GAAP requirements in FASB ASC Topic 605, Revenue Recognition.

Due to the adoption of FASB ASC Topic 606, we recorded a net reduction to opening retained earnings of $177 million on January 1, 2018, primarily related to cost of providing non-contractual post-implant support to certain customers, which we deemed immaterial in the context of the arrangement. Upon the adoption of FASB ASC Topic 606, when we sell a device with an implied non-contractual post-implant support obligation, we forward accrue the cost of the service within Selling, general and administrative expenses and recognize it at the point in time the associated revenue is earned. We release the accrual over the related service period. These costs were previously expensed as incurred due to such service obligation being non-contractual.

The impact of adopting FASB ASC Topic 606 on our unaudited condensed consolidated balance sheets as of March 31, 2018, resulted in an increase in Other current liabilities of $59 million and an increase in Other long-term liabilities of $206 million, as a result of accruing for our post-implant support obligation. We also recorded deferred tax assets primarily related to post-implant support, resulting in an increase in Other long-term assets of $12 million and a reduction in Deferred income taxes of $41 million. The remaining impact of adopting FASB ASC Topic 606 was not material to our financial position or results of operations.

Refer to Note L – Revenue for additional details.

ASC Update No. 2016-01

In January 2016, the FASB issued ASC Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The purpose of Update No. 2016-01 is to improve financial reporting for financial instruments by reducing the number of items recorded to other comprehensive income. We adopted Update No. 2016-01 in the first quarter of 2018, using both the modified retrospective and prospective methods. For publicly-held securities, we used the modified retrospective approach. Unrealized gains and losses previously recorded to other comprehensive income were reclassified to retained earnings and all future fair value changes will be recorded to net income. For privately-held securities, we elected the measurement alternative approach which is applied prospectively upon adoption. This approach requires entities to measure their investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The adoption of the standard did not have a material impact on our financial position or results of operations. The actual impact to future periods resulting from fair value changes of our equity investments is difficult to predict as it will depend on their future performance.

ASC Update No. 2016-16

In October 2016, the FASB issued ASC Update No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. The purpose of Update No. 2016-16 is to allow an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, as opposed to waiting until the asset is sold to a third party, or impaired. Update No. 2016-16 was effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. We adopted Update No. 2016-16 prospectively in the first quarter of 2018 and recognized a net reduction to opening retained earnings of $55 million for income tax consequences not previously recognized for intra-entity transfers of assets other than inventories. All future income tax consequences of intra-entity transfers of assets other than inventories will be recognized through income tax expense.

ASC Update No. 2017-12

In August 2017, the FASB issued ASC Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The purpose of Update No. 2017-12 is to simplify the application of hedge accounting and better align financial reporting of hedging relationships with risk management objectives. Update No. 2017-12 was effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. We early adopted Update No. 2017-12 in the first quarter of 2018. The adoption of the standard had no impact on our financial position or results of operations.
ASC Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) [Policy Text Block]
ASC Update No. 2014-09

In May 2014, the FASB issued ASC Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), which was subsequently updated. We adopted the standard as of January 1, 2018, using the modified retrospective method. Under this method, we applied FASB ASC Topic 606 to contracts that were not complete as of January 1, 2018 and recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings. Results for reporting periods beginning after January 1, 2018 are presented in accordance with FASB ASC Topic 606. Prior period amounts are not adjusted and are reported in accordance with legacy GAAP requirements in FASB ASC Topic 605, Revenue Recognition.

Due to the adoption of FASB ASC Topic 606, we recorded a net reduction to opening retained earnings of $177 million on January 1, 2018, primarily related to cost of providing non-contractual post-implant support to certain customers, which we deemed immaterial in the context of the arrangement. Upon the adoption of FASB ASC Topic 606, when we sell a device with an implied non-contractual post-implant support obligation, we forward accrue the cost of the service within Selling, general and administrative expenses and recognize it at the point in time the associated revenue is earned. We release the accrual over the related service period. These costs were previously expensed as incurred due to such service obligation being non-contractual.

The impact of adopting FASB ASC Topic 606 on our unaudited condensed consolidated balance sheets as of March 31, 2018, resulted in an increase in Other current liabilities of $59 million and an increase in Other long-term liabilities of $206 million, as a result of accruing for our post-implant support obligation. We also recorded deferred tax assets primarily related to post-implant support, resulting in an increase in Other long-term assets of $12 million and a reduction in Deferred income taxes of $41 million. The remaining impact of adopting FASB ASC Topic 606 was not material to our financial position or results of operations.

ASC Update No. 2016-01, Financial Instruments [Policy Text Block]
ASC Update No. 2016-01

In January 2016, the FASB issued ASC Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The purpose of Update No. 2016-01 is to improve financial reporting for financial instruments by reducing the number of items recorded to other comprehensive income. We adopted Update No. 2016-01 in the first quarter of 2018, using both the modified retrospective and prospective methods. For publicly-held securities, we used the modified retrospective approach. Unrealized gains and losses previously recorded to other comprehensive income were reclassified to retained earnings and all future fair value changes will be recorded to net income. For privately-held securities, we elected the measurement alternative approach which is applied prospectively upon adoption. This approach requires entities to measure their investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The adoption of the standard did not have a material impact on our financial position or results of operations. The actual impact to future periods resulting from fair value changes of our equity investments is difficult to predict as it will depend on their future performance.

ASU Update No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory [Policy Text Block]
ASC Update No. 2016-16

In October 2016, the FASB issued ASC Update No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. The purpose of Update No. 2016-16 is to allow an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, as opposed to waiting until the asset is sold to a third party, or impaired. Update No. 2016-16 was effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. We adopted Update No. 2016-16 prospectively in the first quarter of 2018 and recognized a net reduction to opening retained earnings of $55 million for income tax consequences not previously recognized for intra-entity transfers of assets other than inventories. All future income tax consequences of intra-entity transfers of assets other than inventories will be recognized through income tax expense.
XML 49 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements Fair Value Measurements (Policies)
3 Months Ended
Mar. 31, 2018
Fair Value Disclosures [Abstract]  
Fair Value Measurement, Policy [Policy Text Block]
FASB ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures,
Derivatives, Policy [Policy Text Block]
Our derivative instruments do not subject our earnings or cash flows to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.
XML 50 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies Commitments and Contingencies (Policies)
3 Months Ended
Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
Legal Costs, Policy [Policy Text Block]
In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.
XML 51 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
New Accounting Pronouncements (Policies)
3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
Subsequent Events, Policy [Policy Text Block]
Subsequent Events

We evaluate events occurring after the date of our most recent accompanying unaudited condensed consolidated balance sheets for potential recognition or disclosure in our financial statements. We did not identify any material subsequent events requiring adjustment to our accompanying unaudited condensed consolidated financial statements (recognized subsequent events) for the three months ended March 31, 2018. Those items requiring disclosure (unrecognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions and Strategic Investments and Note I – Commitments and Contingencies for more information.
ASC Topic 820, Fair Value Measurements and Disclosures
FASB ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures,
ASC Topic 815, Derivatives and Hedging
Our derivative instruments do not subject our earnings or cash flows to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.
Legal Costs, Policy [Policy Text Block]
In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.
ASC Update No. 2016-02, Leases (Topic 842) [Policy Text Block]
ASC Update No. 2016-02

In February 2016, the FASB issued ASC Update No. 2016-02, Leases (Topic 842). The purpose of Update No. 2016-02 is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. Update No. 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted and a modified retrospective approach is required for adoption. While we are still in the process of determining the effect that the new standard will have on our financial position and results of operations, we expect to recognize additional assets and corresponding liabilities on our consolidated balance sheets, as a result of our operating lease portfolio as it exists at the date we adopt the new standard. Please refer to Note F - Lease and Other Purchase Obligations in our most recent Annual Report on Form 10-K for information regarding our most current lease activity. Additionally, we are in the process of implementing a new lease administration and lease accounting system, and updating our controls and procedures for maintaining and accounting for our lease portfolio under the new standard. As a result, we anticipate adopting the new standard on January 1, 2019.
ASC Update No. 2016-13 [Policy Text Block]
ASC Update No. 2016-13

In June 2016, the FASB issued ASC Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted for annual periods beginning after December 15, 2018. We are in the process of determining the effect that the adoption will have on our financial position and results of operations.
ASU Update No. 2016-16, Income Taxes (Topic 740) [Policy Text Block]
ASC Update No. 2017-12

In August 2017, the FASB issued ASC Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The purpose of Update No. 2017-12 is to simplify the application of hedge accounting and better align financial reporting of hedging relationships with risk management objectives. Update No. 2017-12 was effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. We early adopted Update No. 2017-12 in the first quarter of 2018. The adoption of the standard had no impact on our financial position or results of operations.
XML 52 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions and Strategic Investments (Tables)
3 Months Ended
Mar. 31, 2018
Business Acquisition [Line Items]  
Investment [Table Text Block]
The aggregate carrying amount of our strategic investments were comprised of the following categories:


 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Equity method investments
 
$
304

 
$
209

Measurement alternative investments
 
84

 
81

Publicly-held securities
 
12

 
15

Notes receivable
 
43

 
47

 
 
$
442

 
$
353

Rollforward of Fair Value of Contingent Consideration [Table Text Block]
Changes in the fair value of our contingent consideration liabilities were as follows (in millions):
Balance as of December 31, 2017
$
169

Amounts recorded related to prior acquisitions
(22
)
Fair value adjustment
5

Balance as of March 31, 2018
$
152

Description of unobservable inputs used in Level 3 fair value measurements [Table Text Block]
The recurring Level 3 fair value measurements of our contingent consideration liabilities include the following significant unobservable inputs:
Contingent Consideration Liabilities
Fair Value as of March 31, 2018
Valuation Technique
Unobservable Input
Range
R&D and Commercialization-based Milestones
$105 million
Discounted Cash Flow
Discount Rate
3%
Probability of Payment
17% - 100%
Projected Year of Payment
2018 - 2022
Revenue-based Payments
$48 million
Discounted Cash Flow
Discount Rate
11% - 15%
Projected Year of Payment
2018 - 2026
XML 53 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and Other Intangible Assets Goodwill (Tables)
3 Months Ended
Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Description of unobservable inputs used in Level 3 fair value measurements [Table Text Block]
The recurring Level 3 fair value measurements of our contingent consideration liabilities include the following significant unobservable inputs:
Contingent Consideration Liabilities
Fair Value as of March 31, 2018
Valuation Technique
Unobservable Input
Range
R&D and Commercialization-based Milestones
$105 million
Discounted Cash Flow
Discount Rate
3%
Probability of Payment
17% - 100%
Projected Year of Payment
2018 - 2022
Revenue-based Payments
$48 million
Discounted Cash Flow
Discount Rate
11% - 15%
Projected Year of Payment
2018 - 2026
Schedule of Goodwill [Table Text Block]
The following represents our goodwill balance by global reportable segment:
(in millions)
MedSurg*
 
Rhythm and Neuro*
 
Cardiovascular
 
Total
Balance as of December 31, 2017
$
2,877

 
$
417

 
$
3,704

 
$
6,998

Impact of reportable segment revisions
(1,379
)
 
1,379

 

 

Impact of foreign currency fluctuations and other changes in carrying amount
1

 
(22
)
 
3

 
(17
)
Goodwill acquired
3

 

 

 
3

Balance as of March 31, 2018
$
1,503

 
$
1,774

 
$
3,707

 
$
6,984

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows:
 
As of March 31, 2018
 
As of December 31, 2017
(in millions)
Gross Carrying
Amount
 
Accumulated
Amortization/
Write-offs
 
Gross Carrying
Amount
 
Accumulated
Amortization/
Write-offs
Amortizable intangible assets
 
 
 
 
 
 
 
Technology-related
$
9,396

 
$
(4,984
)
 
$
9,386

 
$
(4,880
)
Patents
517

 
(381
)
 
517

 
(379
)
Other intangible assets
1,636

 
(868
)
 
1,633

 
(838
)
 
$
11,549

 
$
(6,233
)
 
$
11,536

 
$
(6,097
)
Unamortizable intangible assets
 
 
 
 
 
 
 
Goodwill
$
16,884

 
$
(9,900
)
 
$
16,898

 
$
(9,900
)
In-process research and development (IPR&D)
278

 

 
278

 

Technology-related
120

 

 
120

 

 
$
17,281

 
$
(9,900
)
 
$
17,295

 
$
(9,900
)
XML 54 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2018
Derivative [Line Items]  
Schedule of Derivative Instruments [Table Text Block]
The following table presents the contractual amounts of our derivative instruments outstanding:
(in millions)
FASB ASC Topic 815 Designation
As of
March 31, 2018
 
December 31, 2017
Forward currency contracts
Cash flow hedge
$
3,595

 
$
3,252

Forward currency contracts
Non-designated
2,565

 
2,671

Total Notional Outstanding
 
$
6,161

 
$
5,923

Gains (losses) recognized in earnings for derivatives designed as hedging instruments
As of March 31, 2018, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as currency hedge contracts under FASB ASC Topic 815 that may be reclassified to earnings within the next twelve months are presented below:
(in millions)
Designated Derivative Instrument
 
FASB ASC Topic 815 Designation
 
Location in
Unaudited Condensed Consolidated Statements of Operations
Total Amounts
Presented in
Unaudited Condensed Consolidated
Statements of Operations
 
Amount of
Pre-Tax
Gain (Loss)
that may be Reclassified to Earnings
 
 
 
Interest rate derivative contracts
 
Fair value hedge
 
Interest expense
$
(61
)
 
$
12

Interest rate derivative contracts
 
Cash flow hedge
 
Interest expense
(61
)
 
1

Forward currency contracts
 
Cash flow hedge
 
Cost of products sold

672

 
(55
)

The following presents the effect of our derivative instruments designated as cash flow hedges under FASB ASC Topic 815 on our accompanying unaudited condensed consolidated statements of operations:
(in millions)
 
Location in Unaudited Condensed Consolidated Statements of Operations
Total Amounts Presented in Unaudited Condensed Consolidated Statements of Operations
 
Effective Amount
Recognized in OCI
 
Effective Amount Reclassified from AOCI into Earnings
 
 
Pre-Tax Gain (Loss)
Tax Benefit (Expense)
Gain (Loss) Net of Tax
 
Pre-Tax (Gain) Loss
Tax (Benefit) Expense
(Gain) Loss
Net of Tax
Three Months Ended March 31, 2018
 
 
 
 
 
 
 
 
 
 
 
Forward currency contracts
 
Cost of products sold
$
672

 
$
(118
)
$
27

$
(91
)
 
$
15

$
(3
)
$
12

 
 
 
 
 
$
(118
)
$
27

$
(91
)
 
$
15

$
(3
)
$
12

Three Months Ended March 31, 2017
 
 
 
 
 
 
 
 
 
 
 
Forward currency contracts
 
Cost of products sold
$
650

 
$
(58
)
$
21

$
(37
)
 
$
(28
)
$
10

$
(18
)
 
 
 
 
 
$
(58
)
$
21

$
(37
)
 
$
(28
)
$
10

$
(18
)
Net foreign currency gain (loss) [Table Text Block]
Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
 
 
Location in
Unaudited Condensed Consolidated Statements of Operations
 
 
 
 
 
 
 
Three Months Ended March 31,
(in millions)
 
 
2018
 
2017
Net gain (loss) on currency hedge contracts
 
Other, net
 
$
(23
)
 
$
(17
)
Net gain (loss) on currency transaction exposures
 
Other, net
 
16

 
17

Net currency exchange gain (loss)
 
 
 
$
(8
)
 
$

Classification of derivative assets and liabilities within level 2
The following are the balances of our derivative assets and liabilities:
 
Location in
Unaudited Condensed Consolidated
Balance Sheets (1)
As of
 
March 31,
 
December 31,
(in millions)
2018
 
2017
Derivative Assets:
 
 
 
 
Designated Derivative Instruments
 
 
 
 
Forward currency contracts
Other current assets
$
3

 
$
7

Forward currency contracts
Other long-term assets
15

 
57

 
 
17

 
64

Non-Designated Derivative Instruments
 
 
 
 
Forward currency contracts
Other current assets
15

 
18

Total Derivative Assets
 
$
32

 
$
82

 
 
 
 
 
Derivative Liabilities:
 
 
 
 
Designated Derivative Instruments
 
 
 
Forward currency contracts
Other current liabilities
$
54

 
$
37

Forward currency contracts
Other long-term liabilities
69

 
33

 
 
123

 
69

Non-Designated Derivative Instruments
 
 
 
 
Forward currency contracts
Other current liabilities
31

 
21

Total Derivative Liabilities
 
$
154

 
$
90


(1)
We classify derivative assets and liabilities as current when the remaining term of the derivative contract is one year or less.
Assets and liabilities measured at fair value on a recurring basis
Assets and liabilities measured at fair value on a recurring basis consist of the following:
 
As of
 
March 31, 2018
 
December 31, 2017
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets
 
 
 

 
 
 
 
 
 
 
 

 
 
 
 
Money market and government funds
$
42

 
$

 
$

 
$
42

 
$
21

 
$

 
$

 
$
21

Publicly-held securities
12

 

 

 
12

 
15

 

 

 
15

Forward currency contracts

 
32

 

 
32

 

 
82

 

 
82

 
$
54

 
$
32

 
$

 
$
86

 
$
36

 
$
82

 
$

 
$
118

Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Forward currency contracts
$

 
$
154

 
$

 
$
154

 
$

 
$
90

 
$

 
$
90

Accrued contingent consideration

 

 
152

 
152

 

 

 
169

 
169

 
$

 
$
154

 
$
152

 
$
306

 
$

 
$
90

 
$
169

 
$
259

XML 55 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Borrowings and Credit Arrangements (Tables)
3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]
 
Covenant Requirement
 
Actual
 
as of March 31, 2018
 
as of March 31, 2018
Maximum leverage ratio (1)
3.5 times
 
2.2 times

(1)
Ratio of total debt to consolidated EBITDA, as defined by the credit agreement, for the preceding four consecutive fiscal quarters.
Schedule of debt maturities
(in millions, except interest rates)
Issuance Date
Maturity Date
As of
 
Semi-annual Coupon Rate
March 31, 2018
 
December 31, 2017
 
October 2018 Notes
August 2013
October 2018

 

 
2.650
%
January 2020 Notes
December 2009
January 2020
850

 
850

 
6.000
%
May 2020 Notes
May 2015
May 2020
600

 
600

 
2.850
%
May 2022 Notes
May 2015
May 2022
500

 
500

 
3.375
%
October 2023 Notes
August 2013
October 2023
450

 
450

 
4.125
%
May 2025 Notes
May 2015
May 2025
750

 
750

 
3.850
%
March 2028 Notes
February 2018
March 2028
1,000

 

 
4.000
%
November 2035 Notes
November 2005
November 2035
350

 
350

 
7.000
%
January 2040 Notes
December 2009
January 2040
300

 
300

 
7.375
%
Unamortized Debt Issuance Discount
 
2020 - 2040
(14
)
 
(6
)
 
 
Unamortized Deferred Financing Costs
 
2020 - 2040
(19
)
 
(18
)
 
 
Unamortized Gain on Fair Value Hedges
 
2020 - 2023
35

 
38

 
 
Capital Lease Obligation
 
Various
1

 
1

 
 
Long-term debt
 
 
$
4,803

 
$
3,815

 
 
As of December 31, 2017, $600 million under the October 2018 Notes was outstanding and classified as short-term debt.
Note:
The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.
XML 56 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restructuring Related Activities (Tables)
3 Months Ended
Mar. 31, 2018
Restructuring and Related Cost [Line Items]  
Restructuring and related costs
The following presents these costs (credits) by major type and line item within our accompanying unaudited condensed consolidated statements of operations.
Three Months Ended March 31, 2018
 
 
 
 
 
 
 
(in millions)
Termination
Benefits
 
Transfer
Costs
 
Other
 
Total
Restructuring charges
$
12

 
$

 
$
1

 
$
13

Restructuring-related expenses:
 
 
 
 
 
 
 
Cost of products sold

 
7

 

 
7

Selling, general and administrative expenses

 

 
8

 
8

 

 
7

 
8

 
15

 
$
12

 
$
7

 
$
8

 
$
28

 
 
 
 
 
 
 
 

Three Months Ended March 31, 2017
 
 
 
 
 
 
 
 
 
(in millions)
Termination
Benefits
 
Accelerated
Depreciation
 
Transfer
Costs
 
Other
 
Total
Restructuring charges
$
3

 
$

 
$

 
$
1

 
$
4

Restructuring-related expenses:
 
 
 
 
 
 
 
 
 
Cost of products sold

 

 
12

 

 
12

Selling, general and administrative expenses

 
2

 

 
1

 
3

 

 
2

 
12

 
1

 
15

 
$
3

 
$
2

 
$
12

 
$
2

 
$
19

Cumulative restructuring charges
(in millions)
2016 Restructuring Plan
Termination benefits
$
61

Other (1)
16

Total restructuring charges
77

Accelerated depreciation
9

Transfer costs
68

Other (2)
15

Restructuring-related expenses
92

 
$
169

Cash payments associated with restructuring initiatives
were made using cash generated from operations and are comprised of the following:
(in millions)
2016 Restructuring Plan
Three Months Ended March 31, 2018
 
Termination benefits
$
8

Transfer costs
7

Other
9

 
$
25

 
 
Program to Date
 
Termination benefits
$
36

Transfer costs
67

Other
19

 
$
122

Summary of accrued expenses within accompanying unaudited condensed consolidated balance sheets
The following is a rollforward of the termination benefit liability associated with our 2016 Restructuring Plan, which is reported as a component of accrued expenses included in our accompanying unaudited condensed consolidated balance sheets:
(in millions)
2016 Restructuring Plan
Accrued as of December 31, 2017
$
22

Charges (credits)
12

Cash payments
(8
)
Accrued as of March 31, 2018
$
27

2016 Restructuring Plan [Member]  
Restructuring and Related Cost [Line Items]  
Restructuring and related costs
The following table provides a summary of our estimates of costs associated with the 2016 Restructuring Plan by major type of cost:
Type of cost
Total Estimated Amount Expected to be Incurred
Restructuring charges:
 
Termination benefits
$100 million to $110 million
Other (1)
$25 million to $50 million
Restructuring-related expenses:
 
Other (2)
$150 million to $165 million
 
$275 million to $325 million

(1) Consists primarily of consulting fees and costs associated with contract cancellations.
(2) Comprised of other costs directly related to the 2016 Restructuring Plan, including program management, accelerated depreciation and costs to transfer product lines among facilities.
XML 57 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Supplemental Balance Sheet Information (Tables)
3 Months Ended
Mar. 31, 2018
Supplemental Balance Sheet Information [Abstract]  
Schedule of Restricted Cash and Cash Equivalents [Table Text Block]
Cash, cash equivalents, restricted cash and restricted cash equivalents
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Cash and cash equivalents
 
$
287

 
$
188

Restricted cash included in Other current assets
 
850

 
803

Restricted cash included in Other long-term assets
 
31

 
26

Total cash, cash equivalents and restricted cash
 
$
1,168

 
$
1,017

Trade accounts receivable, net
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Accounts receivable
 
$
1,650

 
$
1,645

Allowance for doubtful accounts
 
(67
)
 
(68
)
Allowance for sales returns
 

 
(30
)
Other sales reserves
 
(3
)
 

 
 
$
1,580

 
$
1,548

Rollforward of allowances for doubtful accounts
 
 
Three Months Ended
March 31,
(in millions)
 
2018
 
2017
Beginning balance
 
$
68

 
$
73

Net charges to expenses
 
4

 
3

Utilization of allowances
 
(5
)
 
(1
)
Ending balance
 
$
67

 
$
75

Inventory Disclosure [Text Block]
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Finished goods
 
$
717

 
$
685

Work-in-process
 
105

 
110

Raw materials
 
291

 
284

 
 
$
1,113

 
$
1,078

Property, plant and equipment, net
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Land
 
$
103

 
$
102

Buildings and improvements
 
1,132

 
1,120

Equipment, furniture and fixtures
 
3,246

 
3,183

Capital in progress
 
215

 
219

 
 
4,696

 
4,625

Accumulated depreciation
 
(2,996
)
 
(2,928
)
 
 
$
1,700

 
$
1,697

Schedule of Accrued Liabilities
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Legal reserves
 
$
1,255

 
$
1,176

Payroll and related liabilities
 
488

 
591

Accrued contingent consideration
 
62

 
36

Other
 
643

 
653

 
 
$
2,447

 
$
2,456

Other long-term liabilities
 
 
As of
(in millions)
 
March 31, 2018
 
December 31, 2017
Accrued income taxes
 
$
1,119

 
$
1,275

Legal reserves
 
256

 
436

Accrued contingent consideration
 
92

 
133

Other
 
787

 
525

 
 
$
2,254

 
$
2,370

XML 58 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes (Tables)
3 Months Ended
Mar. 31, 2018
Schedule of Income Tax Rate Reconciliation [Line Items]  
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
 
 
Three Months Ended March 31,
 
2018
 
2017
Effective tax rate from continuing operations
 
8.0
%
 
4.9
%
XML 59 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Weighted Average Shares Outstanding (Tables)
3 Months Ended
Mar. 31, 2018
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares [Table Text Block]
 
 
Three Months Ended
March 31,
(in millions)
 
2018

2017
Weighted average shares outstanding - basic
 
1,376.5

 
1,365.4

Net effect of common stock equivalents
 
20.2

 
24.8

Weighted average shares outstanding - assuming dilution
 
1,396.8

 
1,390.2


XML 60 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
Segment Reporting Information By Segment
A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows:
 
 
Three Months Ended
March 31,
(in millions)
 
2018
 
2017
 
 
 
 
 
Net sales
 
 
 
 
MedSurg*
 
$
711

 
$
641

Rhythm and Neuro*
 
736

 
668

Cardiovascular
 
933

 
851

 
 
$
2,379

 
$
2,160

 
 
 
 
 
Income (loss) before income taxes
 
 
 
 
MedSurg*
 
$
259

 
$
215

Rhythm and Neuro*
 
153

 
109

Cardiovascular
 
290

 
233

Operating income allocated to reportable segments
 
703

 
557

Corporate expenses, including hedging activities
 
(100
)
 
(61
)
Intangible asset impairment charges, acquisition-related, restructuring- and restructuring-related and litigation-related net credits (charges)
 
(54
)
 
11

Amortization expense
 
(141
)
 
(143
)
Operating income (loss)
 
407

 
364

Other expense, net
 
(84
)
 
(59
)
Income (loss) before income taxes
 
$
323

 
$
305


 
 
Three Months Ended
March 31,
Operating income as a percentage of segment net sales
 
2018
 
2017
MedSurg*
 
36.4
%
 
33.5
%
Rhythm and Neuro*
 
20.8
%
 
16.3
%
Cardiovascular
 
31.1
%
 
27.3
%
XML 61 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2018
disaggregated revenue [Line Items]  
disaggregated revenue [Line Items]
The following tables disaggregate our revenue from contracts with customers by business and geographic region:
 
 
Three Months Ended March 31,
Businesses (in millions)
 
2018
 
2017
Endoscopy
 
 
 
 
U.S.
 
$
231

 
$
215

International
 
187

 
164

Worldwide
 
418

 
379

 
 
 
 
 
Urology and Pelvic Health
 
 
 
 
U.S.
 
197

 
183

International
 
96

 
79

Worldwide
 
293

 
262

 
 
 
 
 
Cardiac Rhythm Management
 
 
 
 
U.S.
 
290

 
283

International
 
203

 
180

Worldwide
 
493

 
463

 
 
 
 
 
Electrophysiology
 
 
 
 
U.S.
 
35

 
32

International
 
39

 
32

Worldwide
 
75

 
64

 
 
 
 
 
Neuromodulation
 
 
 
 
U.S.
 
131

 
116

International
 
38

 
25

Worldwide
 
169

 
141

 
 
 
 
 
Interventional Cardiology
 
 
 
 
U.S.
 
281

 
278

International
 
364

 
312

Worldwide
 
645

 
590

 
 
 
 
 
Peripheral Interventions
 
 
 
 
U.S.
 
145

 
142

International
 
142

 
119

Worldwide
 
288

 
261

 
 
 
 
 
Total Company
 
 
 
 
U.S.
 
1,310

 
1,249

International
 
1,069

 
911

Net Sales
 
$
2,379

 
$
2,160


 
 
Three Months Ended March 31,
Geographic Regions (in millions)
 
2018
 
2017
U.S.
 
$
1,310

 
$
1,249

EMEA (Europe, Middle East and Africa)
 
563

 
454

APAC (Asia-Pacific)
 
415

 
371

LACA (Latin America and Canada)
 
91

 
84

 
 
$
2,379

 
$
2,160

 
 
 
 
 
Emerging Markets (1)
 
$
255

 
$
208

XML 62 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Changes in Other Comprehensive Income (Tables)
3 Months Ended
Mar. 31, 2018
Changes in Other Comprehensive Income [Abstract]  
Changes in Other Comprehensive Income [Table Text Block]
The following table provides the reclassifications out of other comprehensive income, net of tax.
Three Months Ended March 31, 2018
 
 
 
 
 
 
 
 
 
 
(in millions)
 
Foreign Currency Translation Adjustments
 
Unrealized Gains/Losses on Derivative Financial Instruments
 
Unrealized Gains/Losses on Available-for-Sale Securities
 
Defined Benefit Pension Items/Other
 
Total
Balance as of December 31, 2017
 
$
(32
)
 
$
1

 
$
(1
)
 
$
(27
)
 
$
(59
)
Other comprehensive income (loss) before reclassifications
 
10

 
(91
)
 

 

 
(81
)
(Income) loss amounts reclassified from accumulated other comprehensive income
 

 
12

 
1

 

 
13

Net current-period other comprehensive income (loss)
 
10

 
(80
)
 

 

 
(69
)
Balance as of March 31, 2018
 
$
(22
)
 
$
(79
)
 
$

 
$
(27
)
 
$
(128
)


Three Months Ended March 31, 2017
 
 
 
 
 
 
 
 
 
 
(in millions)
 
Foreign Currency Translation Adjustments
 
Unrealized Gains/Losses on Derivative Financial Instruments
 
Unrealized Gains/Losses on Available-for-Sale Securities
 
Defined Benefit Pension Items/Other
 
Total
Balance as of December 31, 2016
 
$
(79
)
 
$
107

 
$
(6
)
 
$
(21
)
 
$
1

Other comprehensive income (loss) before reclassifications
 
8

 
(37
)
 

 
(3
)
 
(32
)
(Income) loss amounts reclassified from accumulated other comprehensive income
 

 
(18
)
 

 
3

 
(15
)
Net current-period other comprehensive income (loss)
 
8

 
(55
)
 

 

 
(47
)
Balance as of March 31, 2017
 
$
(71
)
 
$
52

 
$
(6
)
 
$
(21
)
 
$
(46
)

XML 63 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Basis of Presentation ASUs Implemented (Details) - Accounting Standards Update 2014-09 [Member] - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2018
Jan. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Cumulative Effect of New Accounting Principle in Period of Adoption $ 55 $ 177
Other Current Liabilities [Member]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items] 59  
Other Noncurrent Liabilities [Member]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items] 206  
Other Noncurrent Assets [Member]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items] 12  
Deferred Income Tax Charge [Member]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items] 41  
XML 64 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions and Strategic Investments (Details) - USD ($)
$ in Millions
3 Months Ended
Apr. 30, 2018
Apr. 16, 2018
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Business Acquisition [Line Items]          
Adjustments to accrued contingent consideration     $ (22)    
Contingent consideration expense (benefit)     5 $ (50)  
Other Nonoperating Income (Expense)     (23) (2)  
Goodwill     6,984   $ 6,998
Business Combination, Contingent Consideration, Asset     152   $ 169
Payments for acquisitions of businesses, net of cash acquired     9 0  
Payment of contingent consideration       $ (28)  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     1,320    
revenue-based payments [Member] | Discounted cash flow [Member]          
Business Acquisition [Line Items]          
Business Combination, Contingent Consideration, Liability     48    
R&D and Commercialization-based Milestone [Member] | Discounted cash flow [Member]          
Business Acquisition [Line Items]          
Business Combination, Contingent Consideration, Liability     $ 105    
Fair Value Inputs, Discount Rate     3.00%    
Minimum [Member] | revenue-based payments [Member] | Discounted cash flow [Member]          
Business Acquisition [Line Items]          
Fair Value Inputs, Discount Rate     11.00%    
contingent consideration liability, projected year of payment     2018    
Minimum [Member] | R&D and Commercialization-based Milestone [Member] | Discounted cash flow [Member]          
Business Acquisition [Line Items]          
contingent consideration liability, probability of payment     17.00%    
contingent consideration liability, projected year of payment     2018    
Maximum [Member] | revenue-based payments [Member] | Discounted cash flow [Member]          
Business Acquisition [Line Items]          
Fair Value Inputs, Discount Rate     15.00%    
contingent consideration liability, projected year of payment     2026    
Maximum [Member] | R&D and Commercialization-based Milestone [Member] | Discounted cash flow [Member]          
Business Acquisition [Line Items]          
contingent consideration liability, probability of payment     100.00%    
contingent consideration liability, projected year of payment     2022    
Subsequent Event [Member] | NxThera [Member]          
Business Acquisition [Line Items]          
Payments for acquisitions of businesses, net of cash acquired $ 240        
Potential payments based on acheiving certain milestones 85        
Payments to Acquire Businesses, Gross 306        
Potential payments based on certain milestones, gross $ 100        
Subsequent Event [Member] | nVision [Member]          
Business Acquisition [Line Items]          
Payments for acquisitions of businesses, net of cash acquired   $ 150      
Potential payments based on acheiving certain milestones   $ 125      
XML 65 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Strategic Investments (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Jan. 24, 2018
Dec. 31, 2017
Schedule of Investments [Line Items]        
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity $ 335      
Other Nonoperating Income (Expense) (23) $ (2)    
Equity Method Investments 304     $ 209
Measurement Alternative Investments 84     81
Publicly-held Securities 12     15
Notes Receivable 43     47
Strategic Investments $ 442     $ 353
Milipede [Member]        
Schedule of Investments [Line Items]        
Total consideration for share purchase     $ 90  
Closing payment     325  
Potential payments based on acheiving certain milestones     $ 125  
XML 66 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and Other Intangible Assets (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Goodwill [Line Items]    
Finite-Lived Intangible Assets, Gross $ 11,549 $ 11,536
Finite-Lived Intangible Assets, Accumulated Amortization (6,233) (6,097)
Indefinite-lived intangible assets, including goodwill 17,281 17,295
Indefinite-lived intangible assets, accumulated write-offs (9,900) (9,900)
Goodwill 6,984 6,998
Goodwill, Period Increase (Decrease) 0  
Goodwill, Purchase Accounting Adjustments (17)  
Goodwill, Acquired During Period 3  
Cardiovascular [Member]    
Goodwill [Line Items]    
Goodwill 3,707 3,704
Goodwill, Period Increase (Decrease) 0  
Goodwill, Purchase Accounting Adjustments 3  
Goodwill, Acquired During Period 0  
Rhythm and Neuro [Member]    
Goodwill [Line Items]    
Goodwill 1,774 417
Goodwill, Period Increase (Decrease) 1,379  
Goodwill, Purchase Accounting Adjustments (22)  
Goodwill, Acquired During Period 0  
MedSurg [Member]    
Goodwill [Line Items]    
Goodwill 1,503 2,877
Goodwill, Period Increase (Decrease) (1,379)  
Goodwill, Purchase Accounting Adjustments 1  
Goodwill, Acquired During Period 3  
Unclassified Indefinite-lived Intangible Assets [Member]    
Goodwill [Line Items]    
Goodwill, Gross 16,884 16,898
Goodwill, Impaired, Accumulated Impairment Loss (9,900) (9,900)
Technology-related [Member]    
Goodwill [Line Items]    
Indefinite-Lived Intangible Assets (Excluding Goodwill) 120 120
In-process research and development [Member]    
Goodwill [Line Items]    
Indefinite-Lived Intangible Assets (Excluding Goodwill) 278 278
Technology-related [Member]    
Goodwill [Line Items]    
Finite-Lived Intangible Assets, Gross 9,396 9,386
Finite-Lived Intangible Assets, Accumulated Amortization (4,984) (4,880)
Patents [Member]    
Goodwill [Line Items]    
Finite-Lived Intangible Assets, Gross 517 517
Finite-Lived Intangible Assets, Accumulated Amortization (381) (379)
Other Intangible Assets [Member]    
Goodwill [Line Items]    
Finite-Lived Intangible Assets, Gross 1,636 1,633
Finite-Lived Intangible Assets, Accumulated Amortization $ (868) $ (838)
XML 67 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements Fair Value Measurements (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Derivative Instruments, Gain (Loss) [Line Items]      
Cost of Goods and Services Sold $ 672 $ 650  
Interest Expense 61 57  
Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion (118)    
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 27    
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments at Fair Value, Net 2,565   $ 2,671
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (91)    
Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion 15    
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net 12    
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax (3)    
Derivative Assets 32   82
Derivative Liabilities 154   90
Publicly-held Securities 12   15
Foreign Currency Contracts, Liability, Fair Value Disclosure 3,595   3,252
Cash 245   167
Debt Instrument, Fair Value Disclosure 6,040   5,945
Derivative, Notional Amount 6,161   5,923
Fair Value, Measurements, Recurring [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Money Market Funds, at Carrying Value 42   21
Publicly-held Securities 12   15
Foreign Currency Contract, Asset, Fair Value Disclosure 32   82
Assets, Fair Value Disclosure 86   118
Foreign Currency Contracts, Liability, Fair Value Disclosure 154   90
Accrued Contingent Consideration 152   169
Liabilities, Fair Value Disclosure 306   259
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Money Market Funds, at Carrying Value 42   21
Publicly-held Securities 12   15
Foreign Currency Contract, Asset, Fair Value Disclosure 0   0
Assets, Fair Value Disclosure 54   36
Foreign Currency Contracts, Liability, Fair Value Disclosure 0   0
Accrued Contingent Consideration 0   0
Liabilities, Fair Value Disclosure 0   0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Money Market Funds, at Carrying Value 0   0
Publicly-held Securities 0   0
Foreign Currency Contract, Asset, Fair Value Disclosure 32   82
Assets, Fair Value Disclosure 32   82
Foreign Currency Contracts, Liability, Fair Value Disclosure 154   90
Accrued Contingent Consideration 0   0
Liabilities, Fair Value Disclosure 154   90
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Money Market Funds, at Carrying Value 0   0
Publicly-held Securities 0   0
Foreign Currency Contract, Asset, Fair Value Disclosure 0   0
Assets, Fair Value Disclosure 0   0
Foreign Currency Contracts, Liability, Fair Value Disclosure 0   0
Accrued Contingent Consideration 152   169
Liabilities, Fair Value Disclosure 152   169
Designated as Hedging Instrument [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Instruments in Hedges, Assets, at Fair Value 17   64
Derivative Instruments in Hedges, Liabilities, at Fair Value 123   69
Designated as Hedging Instrument [Member] | Prepaid And Other Current Assets [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Instruments in Hedges, Assets, at Fair Value 3   7
Designated as Hedging Instrument [Member] | Other Long Term Assets [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Instruments in Hedges, Assets, at Fair Value 15   57
Designated as Hedging Instrument [Member] | Other current liabilities [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Instruments in Hedges, Liabilities, at Fair Value 54   37
Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Instruments in Hedges, Liabilities, at Fair Value 69   33
Not Designated as Hedging Instrument [Member] | Prepaid And Other Current Assets [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value 15   18
Not Designated as Hedging Instrument [Member] | Other current liabilities [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value 31   $ 21
Not Designated as Hedging Instrument [Member] | Other, net [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net (23) (17)  
Net gain (loss) from foreign currency transaction exposures 16 17  
Foreign Currency Transaction Gain (Loss), Realized (8) 0  
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Cost of Sales [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion (118) (58)  
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 27 21  
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (91) (37)  
Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion 15 28  
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net 12 (18)  
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax (3) $ 10  
Fair Value Hedging [Member] | Interest Expense [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net 12    
Cash Flow Hedging [Member] | Interest Expense [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net 1    
Cash Flow Hedging [Member] | Cost of Goods, Product Line [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net $ (55)    
XML 68 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Borrowings and Credit Arrangements (Details)
¥ in Millions, $ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2018
USD ($)
Dec. 31, 2016
Mar. 31, 2018
JPY (¥)
Feb. 26, 2018
USD ($)
Dec. 31, 2017
USD ($)
Aug. 04, 2017
USD ($)
Debt Instrument [Line Items]            
Total debt $ 5,765       $ 5,616  
Debt, Current 962       1,801  
Line of Credit Facility, Maximum Borrowing Capacity         400  
Line of Credit Facility, Fair Value of Amount Outstanding 70          
Maximum amount of proceeds from sale of finance receivables $ 463          
Average interest rate of de-recognized receivables 2.10% 1.80%        
De-recognized receivables $ 178       171  
Long-term Debt $ (4,803)       (3,815)  
October 2018 Notes [Member]            
Debt Instrument [Line Items]            
Debt, Current         $ 600  
Debt Instrument, Interest Rate, Stated Percentage 2.65%   2.65%   2.65%  
Long-term Debt $ 0          
January 2020 Notes [Member]            
Debt Instrument [Line Items]            
Debt Instrument, Interest Rate, Stated Percentage 6.00%   6.00%   6.00%  
Long-term Debt $ (850)       $ (850)  
May 2020 Notes [Member]            
Debt Instrument [Line Items]            
Debt Instrument, Interest Rate, Stated Percentage 2.85%   2.85%   2.85%  
Long-term Debt $ (600)       $ (600)  
May 2022 Notes [Member]            
Debt Instrument [Line Items]            
Debt Instrument, Interest Rate, Stated Percentage 3.375%   3.375%   3.375%  
Long-term Debt $ (500)       $ (500)  
May 2025 Notes [Member]            
Debt Instrument [Line Items]            
Debt Instrument, Interest Rate, Stated Percentage 3.85%   3.85%   3.85%  
Long-term Debt $ (750)       $ (750)  
October 2023 Notes [Member]            
Debt Instrument [Line Items]            
Debt Instrument, Interest Rate, Stated Percentage 4.125%   4.125%   4.125%  
Long-term Debt $ (450)       $ (450)  
November 2035 Notes [Member]            
Debt Instrument [Line Items]            
Debt Instrument, Interest Rate, Stated Percentage 7.00%   7.00%   7.00%  
Long-term Debt $ (350)       $ (350)  
January 2040 Notes [Member]            
Debt Instrument [Line Items]            
Debt Instrument, Interest Rate, Stated Percentage 7.375%   7.375%   7.375%  
Long-term Debt $ (300)       $ (300)  
March 2028 Notes [Member]            
Debt Instrument [Line Items]            
Debt Instrument, Interest Rate, Stated Percentage 4.00%   4.00% 4.00% 4.00%  
Long-term Debt $ (1,000)     $ (1,000)    
Senior Notes [Member]            
Debt Instrument [Line Items]            
Long-term Debt (4,800)       $ (4,400)  
Premiums, accelerated amortization of debt issuance costs & investor discount costs [Member]            
Debt Instrument [Line Items]            
Long-term Debt (14)       (6)  
Securities Financing Transaction, Cost [Member]            
Debt Instrument [Line Items]            
Long-term Debt (19)       (18)  
Interest Rate Swap [Member]            
Debt Instrument [Line Items]            
Long-term Debt (35)       (38)  
Capital Lease Obligations [Member]            
Debt Instrument [Line Items]            
Long-term Debt (1)       $ (1)  
Line of Credit [Member]            
Debt Instrument [Line Items]            
Commercial Paper 2,250          
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]            
Debt Instrument [Line Items]            
Commercial Paper $ 886          
Commercial Paper [Member]            
Debt Instrument [Line Items]            
Short-term Debt, Weighted Average Interest Rate 2.46%   2.46%   1.85%  
the 2017 Facility [Member]            
Debt Instrument [Line Items]            
Exclusion from EBITDA for Restructuring Charges           $ 500
Line of Credit Facility, Maximum Borrowing Capacity $ 2,250          
Restructuring charges remaining to be excluded from calculation of consolidated EBITDA 415          
Litigation and Debt Exclusion from EBITDA           $ 2,624
Legal payments remaining to be excluded from calculation of consolidated EBITDA 1,690          
New Japanese Factoring March 2018 Program [Member]            
Debt Instrument [Line Items]            
Maximum amount of proceeds from sale of finance receivables 282   ¥ 30,000      
De-recognized receivables $ 95          
Average discounted rates of notes receivables 0.50%   0.50%      
Uncommitted Credit Facilities With A Commercial Japanese Banks [Member]            
Debt Instrument [Line Items]            
Maximum amount of proceeds from sale of finance receivables $ 207   ¥ 22,000      
De-recognized receivables $ 124       $ 157  
Average discounted rates of notes receivables 1.50%   1.50%   1.30%  
Current Requirement [Member]            
Debt Instrument [Line Items]            
Maximum Leverage Ratio 3.5   3.5      
Actual, Covenant [Member]            
Debt Instrument [Line Items]            
Maximum Leverage Ratio 2.2   2.2      
XML 69 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restructuring Related Activities (Details) - USD ($)
$ in Millions
3 Months Ended 22 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Dec. 31, 2017
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses $ 15 $ 15    
Restructuring and Related Cost, Incurred Cost 28 19    
Restructuring Charges 13 4    
2016 Restructuring Plan [Member]        
Restructuring and Related Cost [Line Items]        
Restructuring Charges Incurred to Date     $ 77  
Restructuring-related Costs Incurred to Date     92  
Estimated costs of restructuring program by major type of cost        
Restructuring and Related Cost, Cost Incurred to Date 169   169  
Payments for Restructuring (25)   (122)  
Termination Benefits [Member]        
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses 0 0    
Restructuring and Related Cost, Incurred Cost 12 3    
Restructuring Charges 12 3    
Termination Benefits [Member] | 2016 Restructuring Plan [Member]        
Restructuring and Related Cost [Line Items]        
Restructuring Reserve 27   27 $ 22
Restructuring Charges Incurred to Date     61  
Estimated costs of restructuring program by major type of cost        
Payments for Restructuring (8)   (36)  
Restructuring Charges 12      
Accelerated depreciation [Member]        
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses   2    
Restructuring and Related Cost, Incurred Cost   2    
Restructuring Charges   0    
Accelerated depreciation [Member] | 2016 Restructuring Plan [Member]        
Restructuring and Related Cost [Line Items]        
Restructuring-related Costs Incurred to Date     9  
Transfer costs [Member]        
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses 7 12    
Restructuring and Related Cost, Incurred Cost 7 12    
Restructuring Charges 0 0    
Transfer costs [Member] | 2016 Restructuring Plan [Member]        
Restructuring and Related Cost [Line Items]        
Restructuring-related Costs Incurred to Date     68  
Estimated costs of restructuring program by major type of cost        
Payments for Restructuring (7)   (67)  
Other [Member]        
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses 8 1    
Restructuring and Related Cost, Incurred Cost 8 2    
Restructuring Charges 1 1    
Other [Member] | 2016 Restructuring Plan [Member]        
Restructuring and Related Cost [Line Items]        
Restructuring Charges Incurred to Date     16  
Restructuring-related Costs Incurred to Date     15  
Estimated costs of restructuring program by major type of cost        
Payments for Restructuring (9)   (19)  
Minimum [Member] | 2016 Restructuring Plan [Member]        
Restructuring and Related Cost [Line Items]        
Restructuring and Related Cost, Expected Cost 275   275  
Estimated costs of restructuring program by major type of cost        
Restructuring plan estimated future cash outflow 250      
Minimum [Member] | Restructuring Plan [Member] | Termination Benefits [Member] | 2016 Restructuring Plan [Member]        
Restructuring and Related Cost [Line Items]        
Restructuring and Related Cost, Expected Cost 100   100  
Minimum [Member] | Restructuring Plan [Member] | Other [Member] | 2016 Restructuring Plan [Member]        
Restructuring and Related Cost [Line Items]        
Restructuring and Related Cost, Expected Cost 25   25  
Minimum [Member] | Restructuring Related To Plan [Member] | Other [Member] | 2016 Restructuring Plan [Member]        
Restructuring and Related Cost [Line Items]        
Restructuring and Related Cost, Expected Cost 150   150  
Maximum [Member] | 2016 Restructuring Plan [Member]        
Restructuring and Related Cost [Line Items]        
Restructuring and Related Cost, Expected Cost 325   325  
Estimated costs of restructuring program by major type of cost        
Restructuring plan estimated future cash outflow 300      
Maximum [Member] | Restructuring Plan [Member] | Termination Benefits [Member] | 2016 Restructuring Plan [Member]        
Restructuring and Related Cost [Line Items]        
Restructuring and Related Cost, Expected Cost 110   110  
Maximum [Member] | Restructuring Plan [Member] | Other [Member] | 2016 Restructuring Plan [Member]        
Restructuring and Related Cost [Line Items]        
Restructuring and Related Cost, Expected Cost 50   50  
Maximum [Member] | Restructuring Related To Plan [Member] | Other [Member] | 2016 Restructuring Plan [Member]        
Restructuring and Related Cost [Line Items]        
Restructuring and Related Cost, Expected Cost 165   $ 165  
Cost of Sales [Member]        
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses 7 12    
Cost of Sales [Member] | Termination Benefits [Member]        
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses 0 0    
Cost of Sales [Member] | Accelerated depreciation [Member]        
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses   0    
Cost of Sales [Member] | Transfer costs [Member]        
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses 7 12    
Cost of Sales [Member] | Other [Member]        
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses 0 0    
Selling, General and Administrative Expenses [Member]        
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses 8 3    
Selling, General and Administrative Expenses [Member] | Termination Benefits [Member]        
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses 0 0    
Selling, General and Administrative Expenses [Member] | Accelerated depreciation [Member]        
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses   2    
Selling, General and Administrative Expenses [Member] | Transfer costs [Member]        
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses 0 0    
Selling, General and Administrative Expenses [Member] | Other [Member]        
Estimated costs of restructuring program by major type of cost        
Restructuring Related Expenses $ 8 $ 1    
XML 70 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Cash and cash equivalents $ 287   $ 188  
Total cash, cash equivalents and restricted cash 1,168 $ 327    
Trade accounts receivable, net        
Accounts receivable 1,650   1,645  
Less: allowance for doubtful accounts (67)   (68)  
Less: allowance for sales returns 0   (30)  
Other sales reserves (3)   0  
Trade accounts receivable, net 1,580   1,548  
Allowance for doubtful accounts        
Beginning balance 68 73    
Charges to expenses 4 3    
Utilization of allowances (5) (1)    
Ending balance 67 75    
Inventories        
Finished goods 717   685  
Work-in-process 105   110  
Raw materials 291   284  
Inventories 1,113   1,078  
Property, plant and equipment, net        
Land 103   102  
Buildings and improvements 1,132   1,120  
Equipment, furniture and fixtures 3,246   3,183  
Capital in progress 215   219  
Property, plant and equipment 4,696   4,625  
Less: accumulated depreciation (2,996)   (2,928)  
Property, plant and equipment, net 1,700   1,697  
Accrued expenses        
Legal reserves 1,255   1,176  
Payroll and related liabilities 488   591  
Business Combination, Contingent Consideration, Liability, Current 62   36  
Other 643   653  
Accrued expenses 2,447   2,456  
Other long-term liabilities        
Accrued income taxes 1,119   1,275  
Legal reserves 256   436  
Business Combination, Contingent Consideration, Liability, Noncurrent 92   133  
Other Accrued Liabilities, Noncurrent 787   525  
Other long-term liabilities 2,254   2,370  
Supplemental Balance Sheet Information        
Depreciation expense 68 $ 63    
cash, cash equivalents, restricted cash and restricted cash equivalents, beginning of period     1,017 $ 487
Other Current Assets [Member]        
Restricted cash included in Other long-term assets 850   803  
Other Long Term Assets [Member]        
Restricted cash included in Other long-term assets $ 31   $ 26  
XML 71 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Apr. 30, 2018
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]            
Other Tax Expense (Benefit)   $ 9        
Total Impact of TCJA   852        
One-time transaction tax post-1986 E&P   1,035        
Effective Income Tax Rate Reconciliation, Percent [Abstract]            
Unrecognized Tax Benefits   1,240       $ 1,238
Unrecognized Tax Benefits that Would Impact Effective Tax Rate   1,157       1,150
Incremental tax liability asserted by IRS   $ 1,162        
Reported tax rate   8.00% 4.90%      
Net tax expense/benefits related to interest and penalties   $ 17 $ 13      
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total   675       $ 655
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent           35.00%
Deferred tax asset TCJA remeasurement benefit           $ 99
One-time transaction tax post-1986 E&P - net payment   $ 454        
Subsequent Event [Member]            
Effective Income Tax Rate Reconciliation, Percent [Abstract]            
Litigation Settlement, Amount $ 275          
Potential Reduction In Unrecognized Tax Benefits Over Next Twelve Months As Result Of Concluding Certain Matters         $ 897  
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent       21.00%    
XML 72 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Details)
$ in Millions
3 Months Ended
Apr. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Mar. 31, 2017
USD ($)
Apr. 24, 2018
claims
Dec. 31, 2017
USD ($)
Commitments and Contingencies (Textuals) [Abstract]          
Accrual for legal matters that are probable and estimable | $   $ 1,511     $ 1,612
Litigation Settlement, Expense | $   $ 0 $ 3    
Subsequent Event [Member]          
Loss Contingencies [Line Items]          
Litigation Settlement, Amount | $ $ 275        
Commitments and Contingencies (Textuals) [Abstract]          
Product liability cases or claims related to mesh product       49,500  
Putative class actions in the U.S., Mesh       8  
Product liability cases or claims related to mesh product - Canada       20  
Certified class actions in Canada, Mesh       1  
Putative class actions in Canada, Mesh       3  
Product liability cases or claims related to mesh product - United Kingdom       25  
Assigned to one judge in MA [Member] | Subsequent Event [Member]          
Commitments and Contingencies (Textuals) [Abstract]          
Product liability cases or claims related to mesh product       3,100  
Settled Litigation [Member] | Subsequent Event [Member]          
Commitments and Contingencies (Textuals) [Abstract]          
Product liability cases or claims related to mesh product       47,500  
Total Product liability cases and claims settled related to Mesh product       21,000  
XML 73 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Weighted Average Shares Outstanding (Details) - shares
shares in Millions
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Weighted average shares outstanding - basic 1,376.5 1,365.4
Weighted Average Number Diluted Shares Outstanding Adjustment 20.2 24.8
Weighted average shares outstanding - assuming dilution 1,396.8 1,390.2
Stock Issued During Period, Shares, New Issues 6.0 7.0
XML 74 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Reporting (Details)
$ in Millions
3 Months Ended
Mar. 31, 2018
USD ($)
reportablesegments
Mar. 31, 2017
USD ($)
Segment Reporting (Textuals) [Abstract]    
Number of reportable segments | reportablesegments 3  
Net sales    
Net sales $ 2,379 $ 2,160
Operating Income Allocated to Reportable Segments 703 557
Amortization expense (141) (143)
Operating income (loss) 407 364
Other expense, net (84) (59)
Income (loss) before income taxes 323 305
Rhythm and Neuro [Member]    
Net sales    
Net sales 736 668
Operating Income Allocated to Reportable Segments $ 153 $ 109
Segment operating income as percentage of net sales 20.80% 16.30%
Cardiovascular [Member]    
Net sales    
Net sales $ 933 $ 851
Operating Income Allocated to Reportable Segments $ 290 $ 233
Segment operating income as percentage of net sales 31.10% 27.30%
MedSurg [Member]    
Net sales    
Net sales $ 711 $ 641
Operating Income Allocated to Reportable Segments $ 259 $ 215
Segment operating income as percentage of net sales 36.40% 33.50%
Corporate expenses and currency exchange [Member]    
Net sales    
Operating (Loss) Income Unallocated to Segment $ (100) $ (61)
Special Charges [Member]    
Net sales    
Operating (Loss) Income Unallocated to Segment $ (54) $ 11
XML 75 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
Revenue Revenue Disclosure (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Jan. 01, 2018
disaggregated revenue [Line Items]      
Revenue, Net $ 2,379 $ 2,160  
Deferred Revenue 393   $ 411
Deferred Revenue, Revenue Recognized 26    
Emerging Markets [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 255 208  
UNITED STATES      
disaggregated revenue [Line Items]      
Revenue, Net 1,310 1,249  
Non-US [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 1,069 911  
EMEA [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 563 454  
Asia Pacific [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 415 371  
Latin America and Canada [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 91 84  
Endoscopy [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 418 379  
Endoscopy [Member] | UNITED STATES      
disaggregated revenue [Line Items]      
Revenue, Net 231 215  
Endoscopy [Member] | Non-US [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 187 164  
Urology and Pelvic Health [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 293 262  
Urology and Pelvic Health [Member] | UNITED STATES      
disaggregated revenue [Line Items]      
Revenue, Net 197 183  
Urology and Pelvic Health [Member] | Non-US [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 96 79  
Cardiac Rhythm Management [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 493 463  
Cardiac Rhythm Management [Member] | UNITED STATES      
disaggregated revenue [Line Items]      
Revenue, Net 290 283  
Cardiac Rhythm Management [Member] | Non-US [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 203 180  
Electrophysiology [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 75 64  
Electrophysiology [Member] | UNITED STATES      
disaggregated revenue [Line Items]      
Revenue, Net 35 32  
Electrophysiology [Member] | Non-US [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 39 32  
Neuromodulation [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 169 141  
Neuromodulation [Member] | UNITED STATES      
disaggregated revenue [Line Items]      
Revenue, Net 131 116  
Neuromodulation [Member] | Non-US [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 38 25  
Interventional Cardiology [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 645 590  
Interventional Cardiology [Member] | UNITED STATES      
disaggregated revenue [Line Items]      
Revenue, Net 281 278  
Interventional Cardiology [Member] | Non-US [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 364 312  
Peripheral Interventions [Member]      
disaggregated revenue [Line Items]      
Revenue, Net 288 261  
Peripheral Interventions [Member] | UNITED STATES      
disaggregated revenue [Line Items]      
Revenue, Net 145 142  
Peripheral Interventions [Member] | Non-US [Member]      
disaggregated revenue [Line Items]      
Revenue, Net $ 142 $ 119  
XML 76 R49.htm IDEA: XBRL DOCUMENT v3.8.0.1
Changes in Other Comprehensive Income (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Changes in Other Comprehensive Income [Abstract]        
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax $ (22) $ (71) $ (32) $ (79)
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax (79) 52 1 107
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax 0 (6) (1) (6)
Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax (27) (21) (27) (21)
Accumulated Other Comprehensive Income (Loss), Net of Tax (128) (46) $ (59) $ 1
Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease) 10 8    
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Before Reclassifications, Net of Tax (91) (37)    
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Reclassification Adjustments, Net of Tax 0 0    
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax 0 (3)    
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (81) (32)    
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Reclassified from OCI, Net of Tax 12 (18)    
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax 1 0    
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, Net of Tax 0 3    
Other Comprehensive Income (Loss), Reclassifications out of OCI, Net of Tax 13 (15)    
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax 10 8    
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax (80) (55)    
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Reclassification Adjustments and Tax 0 0    
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax 0 0    
Other Comprehensive Income (Loss), Net of Tax $ (69) $ (47)    
XML 77 R50.htm IDEA: XBRL DOCUMENT v3.8.0.1
New Accounting Pronouncements New ASU impacts (Details) - USD ($)
$ in Millions
Mar. 31, 2018
Jan. 01, 2018
Accounting Standards Update 2014-09 [Member]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Cumulative Effect of New Accounting Principle in Period of Adoption $ 55 $ 177
EXCEL 78 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
F2 6\0=/6:TRC L,ZXCS&B985AGT"%F6&=B'MD%P: H2AQ< M:#UB8L8Q'D!3M6 "=8< A:Z=0HL;P^HFXL0F0X%L>:- B4/>&*UO# L&PO M=V]R:W-H965T2M5Z;/+,@_]B6?#@M.K2MW4Z.ZRGB>ZZPN M#\?E>C7M^]RN5\U;7QV.[G.[Z-[JNFS_>W15\W&_9,OO.[X<7O?]N"-;KT[E MJ_O3]7^=/K?#5G:)LCO4[M@=FN.B=2_WRP=V]V3-V&!2_'UP']W5[\4XE.>F M^3IN_+:[7^9C1JYRVWX,40Y?[V[CJFJ,-.3Q[QQT>>ES;'C]^WOT7Z;!#X-Y M+CNW::I_#KM^?[^TR\7.O91O5?^E^?C5S0-2R\4\^M_=NZL&^9C)T,>VJ;KI M<[%]Z_JFGJ,,J=3EM_/WX3A]?YS_T6QNAAOPN0&_-!CZ_ED#,3<0/QK(GS:0 M

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

  •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end XML 79 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 80 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 238 298 1 false 86 0 false 7 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.bostonscientific.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss Condensed Consolidated Statements of Comprehensive Income (Loss) Statements 3 false false R4.htm 1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 4 false false R5.htm 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 2101100 - Disclosure - Basis of Presentation Sheet http://www.bostonscientific.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 2102100 - Disclosure - Acquisitions and Strategic Investments Sheet http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestments Acquisitions and Strategic Investments Notes 8 false false R9.htm 2104100 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 9 false false R10.htm 2105100 - Disclosure - Fair Value Measurements Sheet http://www.bostonscientific.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 2106100 - Disclosure - Borrowings and Credit Arrangements Sheet http://www.bostonscientific.com/role/BorrowingsAndCreditArrangements Borrowings and Credit Arrangements Notes 11 false false R12.htm 2107100 - Disclosure - Restructuring Related Activities Sheet http://www.bostonscientific.com/role/RestructuringRelatedActivities Restructuring Related Activities Notes 12 false false R13.htm 2108100 - Disclosure - Supplemental Balance Sheet Information Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation Supplemental Balance Sheet Information Notes 13 false false R14.htm 2109100 - Disclosure - Income Taxes Sheet http://www.bostonscientific.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 2110100 - Disclosure - Commitments and Contingencies Sheet http://www.bostonscientific.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 2111100 - Disclosure - Weighted Average Shares Outstanding Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding Weighted Average Shares Outstanding Notes 16 false false R17.htm 2112100 - Disclosure - Segment Reporting Sheet http://www.bostonscientific.com/role/SegmentReporting Segment Reporting Notes 17 false false R18.htm 2113100 - Disclosure - Revenue Revenue Sheet http://www.bostonscientific.com/role/RevenueRevenue Revenue Revenue Notes 18 false false R19.htm 2114100 - Disclosure - Changes in Other Comprehensive Income Sheet http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncome Changes in Other Comprehensive Income Notes 19 false false R20.htm 2115100 - Disclosure - New Accounting Pronouncements Sheet http://www.bostonscientific.com/role/NewAccountingPronouncements New Accounting Pronouncements Notes 20 false false R21.htm 2201201 - Disclosure - Basis of Presentation Standards Implemented Since Dec 31 (Policies) Sheet http://www.bostonscientific.com/role/BasisOfPresentationStandardsImplementedSinceDec31Policies Basis of Presentation Standards Implemented Since Dec 31 (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 21 false false R22.htm 2205201 - Disclosure - Fair Value Measurements Fair Value Measurements (Policies) Sheet http://www.bostonscientific.com/role/FairValueMeasurementsFairValueMeasurementsPolicies Fair Value Measurements Fair Value Measurements (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 22 false false R23.htm 2210201 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Policies) Sheet http://www.bostonscientific.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesPolicies Commitments and Contingencies Commitments and Contingencies (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 23 false false R24.htm 2215201 - Disclosure - New Accounting Pronouncements (Policies) Sheet http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies New Accounting Pronouncements (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 24 false false R25.htm 2302301 - Disclosure - Acquisitions and Strategic Investments (Tables) Sheet http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables Acquisitions and Strategic Investments (Tables) Tables http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestments 25 false false R26.htm 2304302 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Tables) Sheet http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillTables Goodwill and Other Intangible Assets Goodwill (Tables) Tables http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssets 26 false false R27.htm 2305302 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.bostonscientific.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.bostonscientific.com/role/FairValueMeasurements 27 false false R28.htm 2306301 - Disclosure - Borrowings and Credit Arrangements (Tables) Sheet http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables Borrowings and Credit Arrangements (Tables) Tables http://www.bostonscientific.com/role/BorrowingsAndCreditArrangements 28 false false R29.htm 2307302 - Disclosure - Restructuring Related Activities (Tables) Sheet http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables Restructuring Related Activities (Tables) Tables http://www.bostonscientific.com/role/RestructuringRelatedActivities 29 false false R30.htm 2308301 - Disclosure - Supplemental Balance Sheet Information (Tables) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables Supplemental Balance Sheet Information (Tables) Tables http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation 30 false false R31.htm 2309301 - Disclosure - Income Taxes (Tables) Sheet http://www.bostonscientific.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.bostonscientific.com/role/IncomeTaxes 31 false false R32.htm 2311301 - Disclosure - Weighted Average Shares Outstanding (Tables) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables Weighted Average Shares Outstanding (Tables) Tables http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding 32 false false R33.htm 2312301 - Disclosure - Segment Reporting (Tables) Sheet http://www.bostonscientific.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.bostonscientific.com/role/SegmentReporting 33 false false R34.htm 2313301 - Disclosure - Revenue (Tables) Sheet http://www.bostonscientific.com/role/RevenueTables Revenue (Tables) Tables http://www.bostonscientific.com/role/RevenueRevenue 34 false false R35.htm 2314301 - Disclosure - Changes in Other Comprehensive Income (Tables) Sheet http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeTables Changes in Other Comprehensive Income (Tables) Tables http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncome 35 false false R36.htm 2401402 - Disclosure - Basis of Presentation ASUs Implemented (Details) Sheet http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails Basis of Presentation ASUs Implemented (Details) Details 36 false false R37.htm 2402402 - Disclosure - Acquisitions and Strategic Investments (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails Acquisitions and Strategic Investments (Details) Details http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables 37 false false R38.htm 2402403 - Disclosure - Strategic Investments (Details) Sheet http://www.bostonscientific.com/role/StrategicInvestmentsDetails Strategic Investments (Details) Details 38 false false R39.htm 2404403 - Disclosure - Goodwill and Other Intangible Assets (Details) Sheet http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails Goodwill and Other Intangible Assets (Details) Details http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillTables 39 false false R40.htm 2405403 - Disclosure - Fair Value Measurements Fair Value Measurements (Details) Sheet http://www.bostonscientific.com/role/FairValueMeasurementsFairValueMeasurementsDetails Fair Value Measurements Fair Value Measurements (Details) Details http://www.bostonscientific.com/role/FairValueMeasurementsFairValueMeasurementsPolicies 40 false false R41.htm 2406402 - Disclosure - Borrowings and Credit Arrangements (Details) Sheet http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails Borrowings and Credit Arrangements (Details) Details http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables 41 false false R42.htm 2407403 - Disclosure - Restructuring Related Activities (Details) Sheet http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetails Restructuring Related Activities (Details) Details http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables 42 false false R43.htm 2408402 - Disclosure - Supplemental Balance Sheet Information (Details) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails Supplemental Balance Sheet Information (Details) Details http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables 43 false false R44.htm 2409402 - Disclosure - Income Taxes (Details) Sheet http://www.bostonscientific.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.bostonscientific.com/role/IncomeTaxesTables 44 false false R45.htm 2410402 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.bostonscientific.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesPolicies 45 false false R46.htm 2411402 - Disclosure - Weighted Average Shares Outstanding (Details) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails Weighted Average Shares Outstanding (Details) Details http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables 46 false false R47.htm 2412402 - Disclosure - Segment Reporting (Details) Sheet http://www.bostonscientific.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.bostonscientific.com/role/SegmentReportingTables 47 false false R48.htm 2413403 - Disclosure - Revenue Revenue Disclosure (Details) Sheet http://www.bostonscientific.com/role/RevenueRevenueDisclosureDetails Revenue Revenue Disclosure (Details) Details 48 false false R49.htm 2414402 - Disclosure - Changes in Other Comprehensive Income (Details) Sheet http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails Changes in Other Comprehensive Income (Details) Details http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeTables 49 false false R50.htm 2415402 - Disclosure - New Accounting Pronouncements New ASU impacts (Details) Sheet http://www.bostonscientific.com/role/NewAccountingPronouncementsNewAsuImpactsDetails New Accounting Pronouncements New ASU impacts (Details) Details 50 false false All Reports Book All Reports bsx-20180501.xml bsx-20180501.xsd bsx-20180501_cal.xml bsx-20180501_def.xml bsx-20180501_lab.xml bsx-20180501_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://xbrl.sec.gov/country/2016-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/us-gaap/2016-01-31 true true ZIP 84 0000885725-18-000021-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000885725-18-000021-xbrl.zip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

    ]IFG10Y?+K) M\^&;7BL;PC(M?-W[X4W>?]?KCI,,PS=%]J7H%,,B'S02MXG$;4'BLK5XH&;= M8KP,?_I<]HH9#/)ALTV.ODWFUZ'9(4?=(3Z_RF%-VJ^[K=YM_CG[[FZR_G5C M2XZP258OQ[[9X L>R3RGT9?!OF_1\!Z^ I_?+Z_RQ4GE4]@>B^XBW\]G MX@G;FXF?2$/WOXL$SF8*;/QLH\"F"FP>CPM58(^/2K'8FP3Z1@(;"=S%A#[( MX$8F].'Q/9E0TKA[C;NWD;9\\-[V?Z+J>F4L"%3!WP:PCOTR2K/W,YE*4OC1 M0ZCH>K>W>;]59)WB/^5#J7*T#4Y,GLIW\TM_.2T#78C86UP>T>Y32OP M(;LODR.-U#Z6VJ4@-5+Z]%K6O0GJQPR^9<'FO\V^%[>CVT:@GUN@9TOQX# L MK,5%[IM3RJ ^8:,U?DWCUYRSY#^;.]_8FY/='B_2_IRFW];LJV9?G?>^.BGK M=N2-6'2;C7BJ&W%^;9J->,EN9K,+FUW8N)E/3P\V^^ATTH,7OV].VGI%@'^8 MORF^IA)^V,37Q9=./K[J8N_?9O_J]5TG&PQF.Z%$M-?I7=]_S#NI=])Y;80M MV!V+RQ)^SU/+3MH#S!;_=;>=7[TL =B2Y>,+P4&:)3Q%"*:?^Z/;2J^EA6D_ M?$>G[CLN7$2F']P:D9G=W9Y=D=9. M.F4C!,Y70';U,::?^0!JMGMNFF,K[V+ZH05.S]>OF%_PQJ1\ZQL3<#XFX*1V_P6H_[/*4IZD M_6_R"Z>37WB.P\)/0Y#Z1.;TPMRG,=4/$N&R?KOH?R]D".MG<3A;=X>C/K7%R<'"WPU K!< #[>W ]O;K-N^UT^ZOL[3'6MJ#'Q$W*OC,%W,[%=S$6A>K@INE M/9-=6]-OUL,W?,V&Q=?\=3<-TBIY_RTKNF]Z@X&]_UO>OBZZUV4&$7 ;W!1W M"]GU:;WLY+E'U=.35WT^**Z[=2V[QZ_G;3.8//I Q*.O&O>2GJU6;=M:UQL, MWU]]RCKGUJIVMT5XR/77KL(J$=V"MOHUG&_VO781]T3)"A&8@^*Q#+R0 /=A M(%JSM9NMW6SM/6[M8P_PJ]G::W;?NUZW/5N[+79;9Q(_//4%7:Z/E3DOE&SS]' M\>S399XT,K\WF2>-S)^%GF]\F\:W.7D]OT3F7ZJ OG1Q6&+V&W$X>7$X!XO8 M>(&-%WA6*G"KXGJY\>I'/ MN0>);N^NB"Y*;#753/5[G4<9U:;+[!"/Z\@3W>$;UHJ5V M>]>OT;B-QCT-!W%>=E^.V#5+OHN1?5-D7XI.,2SR1F%M9FDKB#4JZ[@!3B/" M.]C3.K[6/)ZL?GOQM>]2'D]%?UZ(EY"DQ!M M$J(O3^LV7L&%>@4'UZIU+1T^%H,_ZVO;ZMMG;-+SXC70T,\'P_#]#K#/STM& M5X%44W9VB/86&S65J 7Y?/7HUG*ZNLM+(Z;E4X=LPM)(Z;-(Z;AYS&^]7GOP MH=]KCUI@%[N-L!Y"6%=!?1DR^Z;7O88->>OS+\.%R>-OLWN""'G7&YY;GZHZ MEB;=2BL\7?@B_CWKCK(^,,W012UD/5\7OICO6\,>L ,23"]J,>OY.M_%G$\ MK%&OE[4KJSQ=1I2\9A'Y!2XB?SD[\4,_ORU&MX.LU3^E>++;7G]8_*=T M"'M7;?A$,1B,4J*J!0[AH.A^A0"FUV\7@U9OU!V6+U[*^N\5CHO?__W6#>P6 M=6$:H,K5^>J +11Y8XW/>A%G0<&%+60]7^>[F&NM\D.J[*X89ITW>3;(WW_I M%-?CQM*7L*X/&:X5+)ZO]=QXB3^E>_GE@5XLNN!1%-WKS_VL"]Y'PB&EWRYI MM3?E]H(7ODDM7L@BONM]+?DAB%Y6 +R$L0M?SL9Y.H_%W,@3;O;FN?C":Y>S M<92.[B@=-PB:UDM\S(;YIV_9W24M\.W5@U-VF* M/4YQ@9+UD=)^>[^Y8NV.0^WL?\ MWZ-BW&'[G!=M&3?GO7"SS.$-F(W/R_RH=)_A_97KY^WB3-9PEB.LX^O!B:HR M=AG+F;A]N#/SD/+/O_T]N\NZ^2"/&=B-LM?]N) +JP_]WG4_NSVO]:TR.CD# MV)C3LUSPL==#@;5TT_F^=J-.WYRM_N>;/'UL^OIY+?0RSL;+7Z.WA9# M",H7U%:1#_Y1#&\^?^L]"/C45MFL^^>9K?DR"_Q$]L]WGR\DLAI[_,SV>.]+ MZN%+Q>_LGY_]LRW-%IP#=_VASX9YXEV\0AC^-\-R]M[>Y M7!?;Z_=[W\ O/S.%M\9K>4K]8X>E\4*?WPL]=M%]M^CU+\8)?2@:>\36 M62[E1-,N7L)KKB(^?T41>47$D0ZWFPUZ3@:T"1+/-4@\YA6H1EV?\D+ZL;J& MT'"VEA^S[O6BFGZ;?2]N1Y/#AH?G\K096L-1.ICXT,FZ#\?<*3*KO'U>BS]# MX4&M+\"P:KFW^9DZ$"='["M0/)RP+43C:KMH_)$%>GHTOIET%MU&.D$ZYV%H MI//YI/-WD,XD5[,6B^^OWM^E2K94.>ZRNR5]+3]EG7,QB&F]UW'WN)?D''LO M3QQJE5#"Q73;\%K>_[JHPL+M7:=WG^>?\J\ ;;=U9DU.U[#Y(!I+^&P$9)F ME&Q>< MN==V ;NA\2?W&G^^&._C@(%LX_M+\-Z/)M6-AWYP M#_VR)'5OGG4C1@<.]%Z&NWO2D5[C"F.Y_=&!>6BJX?.[?MXJRO4_#^G=RO*N MY/29A$1N)R3R@$+2*,]&>9Z,\CS7?='DR4X\Y&KD^_GT_F6)["G&7B]"C)ID MUB9*IPS"T ; M=?>\TGWVN>TSD>\FLWY,"3]#?^",Y+KQ1II[BR=Q;_%%P>;\79-I/-@/8 MF/U3VQDO*J0[R7W1A'MU';Z>*+N7IX(]\2[J?H[F6%%(UX/[W@ MY&+D^XRU=R/?C7R?NOY>*]^7+9:-.#S=G"\YK'V)XK2GT]:+D>8S--Z--#?2 M?**Z>>71PV6+XBG(P@%S];LJJI7'U"]13O9^GG_. GN2RBN)W0(2Y7)UTLJD MQ;/W:=;(^ZO%5;W)^M?EJ7<+'IM)[Q) GS8LH8GGZTH7GKYBXXVPPQ[89@<> M82Y$D]AXOM/L,]M,LO9G,>4^)?BJ0=U_-]DLEJ/-_S\WR/::@:S_:T*HQ5$U$=:'Z8\L<37-4=$**Y'ES-,V9T65IE.FFLUDG M!1.?;O)\^*;7RBI7UTOPW:C?!\+-8)"?2^.9Z>HN8_"1>-5P>+X+/'_%M5G@ MXR[PWF^&;KR#D^4L67_3ZUY_SONWE[6Z23\O9>_"]VZSM.>V:\>=8]@_/_MG M6YY=R^*V;B>R -6>*M3I._AO3-["&S=S?71&7P;YOT? 4?@*?R37>;'/SN+[ MY[4?EC WUP*GCKMGJI6$54;;75O0KRC:LU"P1A".+@A;WU\YA'; G[/OC2R< M@BRPN5V^@5)@^U0*$T_X;3ZX<;U1=]C8B:.(Q*)'S%X1MC>W:?D*ORF&Q77I M,J86-'B48?,?!N]6FCVE$IK1'-!-%TVF+N8-!@4 MU]V\/>SUNOF_1NWKO.B^-2]3,J? 3+*L*Y!I!',?PT9F;3;M:%!T\\'@TYCJ MP<.QT,W]\.8VZ[;?Y:-^[[SD:B5WDY.3&O:>+7(ZF9ZUFXO#V[P]&/7/;%S5 M!G*PP%OV[7KHK'"9]EDVW M/3Y1:=V'[ZV;=&)\>4*R,=.GFGLY!='Y=)>NEG?&-0UG=D2Q@9#4L?>"Q&%K MP]*(PR4;ENW]C,:PG(!A.4'1^=#OM4>MX?O^I[S_M6@]Y%'*".X6WNS4IO:F MZ/^6]Z[[V=U-TWAR CI]9 [+1E(KDOH:/M=/64Z %5R5,A3N]*[O M+T7X5O/7"$1%($*WW1NT>G<7(P&/&'I!2ZYV6_*7:J>V$)1SMU GF"W8HW1> MDG?_[$+Y(OWZ98G,"Q"M4UKJ4U [FQK%#_#5=S=ION2\"_FXW?4+,Y$K06D, MYG'2ZXV2NCA[M*EOM'(_GLOB'T#=7)@X;&JS_NB7N8VLV_Z0=^"=O^599WAS M*=*PBKL79 8V%8;5F:^+-".'2 .>J14[)TD-G;PU[/?N;NX'6XKH13K92^!H MW.O3D-8GZ]6+%-IC*]B7+;N'RZ5>I+"^H$S_.84O3TVY79+#>N1,6^.OKI#3 MTKIEK?$]HK=9-[LN4;P4[;B2O480JRN+&#MW,H?5$R>:P(^D4> M5NRH)R] S(Y2678*ZF@_N9+SEX"3J"X])X&HK04_?SG8NL3]PI9_4_>D.:!\ M ?[ IL+0A-$O0AP.?PK8A"[G&+J&$::M?$P9DJJG.2TJ:*^H2* M_%ZDI.ZE*J6)45]8C'H!SN!+E=D76/]_3GJVZ>UU_-BZT:O/$&%=I, >-]1J M-&R3'#I:CYPM;HXW+E1#-DKJB4JJ:<9Y>BT"7G8L^VSU Q'NY:GJU(+S)AD77 &+P:M9M.["D M[>RBQ&$%AR]#)^Z6U@EO@[D8.9@^\L!4HP^:I6]V?67IS:#(/F0M6)?6Q4E MA;<7I .V<@X;G^!E",76AJ'1#I=I)K:*&)K0\6($8=0MQE+03[<%YM?P-L\& MHW[^Z^2;X*_3+YF^\_"UZ5MJOK/5R8K;0=V7)J3'[V[]I:-!N^X;BT&/$2Q_ M^>.3W_HK^_E=KS_,OG3RR2(NI;GZY"[T?\C[GVZR?C[_*^WB*XCY_$JG3[P; M@3AFP]Y\0G!#GO_7 B&+7S3W"S[O]FZ+[M+?F(AB(K>&U\4?>?1=T[=FK*U! MYE]W]ZM6]N\?_KDUV&.ZEXOU,KX>?VU:>]-J]4=YV\$6 OT :P]_&P!CY<[I M_C#96A_S*U"IKTN5RF;Z-&9%_[^SSBBW][.__@WT6=9OW=R_R;_FBU9V]LSK M[MUH."@?P(^2YW-?^79,=Y+'V,__/ M*FZSSN"O/[X2/XY-0]8:OC+"8F$MB109+J.WUD1)!/:8Z:BX^?&'A%+)=[DW MT5]^7@_7B8!*C@4JHCS$8(31%/%(E3%&62Y%8,%KY.DY@TJ/!:K BABJ&0\T M(.Y]2Y02C$GWBK&I/7*".V$X4P< M!0F(0"]"(5*+6:22.14D#T@8Q!1GCC$7O32"/.O>W3.H1U.(0AFKP,XX2@Q' M,A@6(Z+2"D$,"4*?,ZA'4XB88FH5%X!"8((3YX)3GAE3$:]=D1C=IGO7>?O]\";ON][M73^_21'H M5Y"'5N\V?],;#-SX(7C-W63P;8/7W7?Y\+>LZ*9W8[]WZ[+!3>STOOTM;\/; MIMO^W"]YOG_3:_TY"%=7>6L('WE_]3G[7@58_,Z6XL"M3*9 2^,"#XIKC:*0 M%,Q%P-;JBM^!D7R$P_-S>&+PRM_Q\@W'(_C)QG@G+7?$&<(4)MA0JJGF.#Z& MMR)E#;HKA#> WF(,K"TC''QE:J4#@PO0PN:FU+JJ\#;@/E:]*\"EU'.P$#*" M[QB8E5@#V$YC$ABG_C&XK^1CE_&(\+;_-1H,2X,P[&5C7=V:Z>K6_%!=0BM0$IY'R&BP'_*$TV%,P'E@HK"J6@RQNZZS;BN/O?ZG MK).#C1N.^EV KM^'SVRW91P+B#NMN,>2I]6%_Z8R2A]!/0E7\0 H6J!^-2D[ M4[Q*#I7'+ 1IL2%8<07V2MJ -,"JA"1"+7,$-R3U*Z!]G?MB4-;%?01Y?7_U MKC=,S[?RXFM*[:V.X7S^9?BZ.QCV1VE5'RX;)A&_+88@_ZZ?MXLA,%-TBF&1 M#_Y1#&\^?^O!CKC-^ZTBZ_P]N\NZ^2"W6??/0=5QH?/K%ZV+1&M/80V1 RY=^F_":.>OUQK,=">1Q,=%]$@$J56PIJ G,'",ZJ(J\4 \1/"X$#"0:+G(JDC01DW M6EK$C-.$"<*<9&:)<.P 3-+)+?A_<,OAC4[29OTW([ M#\I($BWEW"L-9BABRV+ G@4?C&,JHHK"(@L.ZI,H/1"[J[2=E=IB[V#9*.AI M*;01D3@J$8Y(J9JX!(S.:?'[H3QC*KJM9*9S8+/\=]7,CD\8EZ][5 9Y89 - M&K:[M02LKD#@CG %YK?J?F"!]P9$/0_/"L\:+\1X+2"00#$JS27F.DK*6&"* M8P.!7*C&KV>!SI?\NNAVP2+TKL9GE=M%LQK\4A&$YYA1[JVQ'"):9#03(AB, M*@E?IO:G+"JD/Q<@J]P];ZC7'H'BC,P'16"3\(!42"P9$\GYY M?-]N=;+! .A,]Q^*[K3F9G"SP.1$9:;77;),#QF@3Z,O@S(S- SI%L7G^[M\ M(4/TZ/VJ\41S4 $^7C@$2@=C;C@S5#EDG0+/6&N-[1Q4TW-L/ %I'3LSOCL] M>/WZ+KN_?>P&3YC\-%=RT;K)VZ,.&.$ D [OW^;#FU[[=?=K/HX?JJ_F^;OL M]N'.S5OP*.Y@>Z[)A#'KG0#O20L&+H+#,G 209=8%&@R1E4#RQW$[NGWT7$HUEM_V.6_== L0J]FO3GTF\.8F MP6H5-I;L'@>>%50 ME$2E S(;+0(;&BP;KXIS2#)=YSUC^2RK\J\\J==_YEE_R;H\> QGOF$>+!?H M'\:\4#1$+AA27%(9L'(AB""5^_%7@@C9&/T:!"\(__UMC;D@&\R?%U1#Y,4I MPAI+9105,0CNO#8_EC6HYX]_#I[!"()K 'SRS8]OI3Z/O"O$I(@@VEXB3ID" M#:0]1L2 D1 TJE+>Q0O%^P#R[;%6%O,41#ENA-&H=-I(X*ZW>GWS[_"KO M]_/V,/L.[F$^_.S^;M)IY>S0\DO>S:^*&H3!LU\5 TJ&.==&8I>2\TQ@2WQD MA#*G/76ARH#U\+#YEN.Q;?T]\&O_5[@]K$SO+0 MA&BGB7'"20A?B1:6(,>(EI9*ZXFM1+ 4*SI/_WIZGD+YJAP-^,HZH."Q OR) MEQKV)U.(8R>]0:923$,)$SM2_KW5&:5RY700$KX4PW86>_V/*> :M>!Q$$IW MD_6O\T$EF)"_TTE2\7ZV8]X470@G%C*.][,]\_DF3Q^;OKXF:B *>W"58*G2 MX8;:.$@87/&IE"\3NF&!%K6^9Q]GVT] Z+;AYUG[U_W MMUQ&1F(PF$@:67IZ.)@[+/M'OTB)UZLM=Y.6!-L0/#*!<4ZIY4J >C-$(LVUK$1Q M4UWPP,S6!.Z5MU4+12P5V#D3+3-<2JJE\M@$)Y4.1H7*"=#S\08BT!FU05A_ MZ_7:WXI.9[M% \W'%%.@KC'F*#C+&1@DK7C$X +(:GVB))IOP5F%O/VQM6J] M.(?@B6F%2=2<6ZK!@??@NUO86,*RRGH!6PKO@ZTW^776F7H5'_/;K$C9I\\] MFY?ZIIVWQP?*G=9D& (H0S#HO4[13JL_UD.K ]X]JE!X$J)]KH*+DF.L%*,! M<\FMT#*RM'/V!WV ) &_ TY7_BTIO;Y#:""]?OM?*\718@I-/C]U>Q MZ*;3Y(>SL&T/=K@+2$@I#*.<&F; @ :$I/1.&^8JFX*)!6]G!_KVS=IA#G87 M33*(/J?:(F(=F#'FG$\GNZ G-:A\-Y^"*2^'3*L37AA,$IQ/!2+D5! !,X@5 M+,B2TPDEZG2U!$61,P-ICP?DBVX2 ?@R#TY" MP/6^YO!-#Y 8B"BRSO3E*I]X04UK![8F$ BI.2':",RC]I9A@RR8YFH2F/Q$ M%AA[95PX4 2@2+$$V\DIR'5,Q\4,0AV"":8U!PST M)[X!%P_) =,9YOUN6;CW<"2U;09 >(B8*:%16"ZT3V?8+H#5=T99Z2KW)A:= MQ+7$/('JE?5H4CK)->7&4Q (9:@.P1HFDTIQHA)I*;83U8^J("$ZSHOK[E@0 M6O>?^UEWLN=7@-,2DEPE#$A9)6$I+B.$$)#LC4!#SSV&T/ MR3[!5*<&)O+:&PRVS$+8H)#5GE 9.:-22T-83?RP-S"'V??\^UW>'>23).&@ MGY>I>UX8'LDXR/%L7_S@A,!@0DLY[N#00&$ME3#1@=RC#JLH: M?<3:E@3ND[4UA3O$,$'@N< 8 5MC%;8,26^Q5[ O=*6NJ;(%=F5ML9(OK?F' M7G]X!>%@\@C $:APLTY_*RZ#@^50@1A.$=%6@B"6%E1:'2OE]VR1E4T(>B+U MJ_0XUBY=AE*2<,IUT"9*AYRUB"%*P4Y6J*<[4_^^FP^+VWSXL*E@$6%7#<%A M%^'#UC*$(B*P09PE-G(K)#+(1! G:0RELJ;X"]&%M-$:>C8D&]ZMJV39A(% MA5D@;\XY<<,!(C[D%65R)YQM@7]#X3-.+DKCVRZUV/5FVK#6VG+?.Y] MG#5P^#1IX+"]LHH,W$0%NA@B>^*$TN! 1B8@C*4:')Q**IPO[(-M:-LG/]7> M+G8T*" <&$P_N=AENO1*F*)HYP3Z2QF3+K 3)#4P%L5'# _,QS&G;;!V)0C M9M?=0(_86$/ BA/-"8>_$ 36/%!P_(1&MJJS]''A6&?'%3$A\A ,-ISA:*CU M&('VPE$&6CV4D.C(8O[HN'[/NYX2$.Z84G;><..8)=P@;6'+:X9JSJ+)8B[[ M#.#8;-=[S6PJ%M/18NXDM8$04'NI-MTXV/D5'/A)B/FA=KW6B@;!$4?1\( 8 M1"96"I2.N)"QU=L;F.][E_P!?O#L4Y-G]V$2>WT@ )X*8U\\74RZN\ MR[C.0'"/J3<>&^6Y!I4AE75:^F"E#K@:#"_>;]B S>=%Y--=GG**DV/[-;R' M2*+T*&5^! ?OR<2 E%7^%G97Y9;\Q#BH,5%M0&A(*<28ZDMLX% MI142GK&(8K4< :W2H,>'9"MYB%0'A*/25*1R!6T<=N 86A")&$Q53SR*![;@ M?<5=9 CG4@%_ZO=8)F0&[T?#]U?O6T7]!>H-0@.A-86PV"N)(_<((@,.UC%E M:Y1C5%2LP:M'/N!3B#T0Q^ON)4F&@R-2.A4X ]\(I?H:S(WBJ=%$):>[F+DY M.,-_=/MYJK+-V]/DU_NNS_L0Q*!@&A>5.^U4;DI0GMG[D0072-R'B%-P?'$Q+-4]618 M2)FH(!F%OU0CBU<:7QBB#S\WKOEXBLJRI#S[0ACQR"FS.D@1E (M%CQ'N+*! M7V%U.#17,'8"2*Z1RQB#3>$M%Q[T/L,J.B24CI(+'D '5%0A.3Z0@]0IH9\/ MTEBB+;/!!F.L/1-@W"1$.M%*AE*?!G#[I6&BD@V>YW/A9[4Q MQ*"20ZM5M0$>KN-@$\KVPLR:;0LRHAV53 H*"I!$923VABHIO&,>R25RO#L7 MZ8K/<-QX-A\..WE^>]?IW>=Y7E[PS+YE_?;V26DFL(C1*,F9YBGWIJFU7DKN M-;A0"WR4BNI$&NV@M@6FR^.S.] M(7RB>"BO+.^KO.^:UDU>?$W%Z7E_"*IW=D6K6G]_G,N\D5A"110(7$Q.! :O M**3+O#[=:G&AVN!O\3+O]GSO%['N?Q>I/',&VS2X-"W 9U LG)*_&S_[>(3@ M4Z^$+\9O,9T'>FHQ4E)1Q315$1%E-?/1QVHE\TG!23;#\?OG-(SPL#C*0"V' MJ-!:IT0T@5,900LE#IU;ON)O<)W!\[.41_ M_S757'P??OZ6=[[F;P',FX&!H',PZHR-ZZ3F?/I;V7"8/[IQ,M9D-'T+)N-O M.!">X%V5%6E@-CLP?IJY926M8 >"I8*_I/SV$%YL14^-'[Z M=K9@UY5;6!.S *2DF7_9379.BV V,&X7B. M:&=ZO:@%'QKT^N,6%+/*C]M\<',W?G+<=N(8'30T)<)C\# @#D]FVFA/!0'7 M0SB'P7[7=- @4VQVXW)GD/Y(ETO:_P6"V^[='@,K@V"G@EL6?"3I<$1AB+13 MV@+YP+FB=5CQ';%:8/:)D)5YWUK;78/8PP4,!]_^4(\[2(5QZ>M!VO\U:E_G MH#C,OK?N@F0R"$0M%F6UCQ-(&1P< B=:2!4QES5H4XQVE.23>1CN092.3P>:<]2(VTBVJ)X]JB;HDD MM1I1KM-)%C'4R0"K#RZ(TTY6>_(NNGJU%.Q WT4,%B F4FFE9XP%SFQP7)* M/ 2],8 37:T5/7TLCS9/P#JI:>!8!.>T$"ZUV2BQQ"B(Q>VUD-8Y11"/-C_ MVYA.:BUC*)+ I1?$3D&$0'G9E)J#@GC@N3Q$*RRYI%121X,1TIDQQSA(RRIU M38?8@BNKF'T4$GE#M/<3YZ2DU'0>$H@6@@BH'V)N DTU3%X&/T3(:%"1:SP'3* MZVIN5G,]O,G_^.G33T=C.Z1I0T1'13VW@EDJD4"<.HAW8-%]#=MJ%=MS[$SY MKNLE]+J;I#!5A:7!J'7IQH\?L'AH1+;P%;W!T'3;'\>GP0NLA\E)TJ?RSFRW M56G8-_\]'SK90];2I'[&E;?7F2F(!PBV.!J0&4.YX*L"VUI.*$+1[M MK5?_*A4+#JJ] M5/?L>E L&(A@C&F,KA4Z>D\1]X()$R% J;@>Z@PP/)83(BUX'K"[A0V&:RNU M8%H338@@L,E%]<+'Y+L M&8/I?9WMKW8H"KXWDQ'"& C&%>B5B+3D)'A#3$UU[]K5FY+R%'+'-V^F=W/> M7TUNQH![X;*[2I.2A-7[JW(ZVKI[?&E& 4;,88;2F%3KA82_R30E(HCJM4:\ M=IU.@-O]F:SE[C;12#APKR-"W$BIG&/,:P;AOC;(5:3D@@"K,4LK#@TUL]*P M .+$ \1C3D?.RDRL3F')98O7FCS""H>&H&!)1)$QSCC6*=<:; B!"F+MLDKE M2X%KF;U>CA?R-FV]-/*86X-UX 193Z*WQ$E1B?I/"J]/>:<#W_U;WH6G.@") M:=]"( (_6^;#IC^V#@)A8>]@$U.K6229"@QCRYS4"N)>5=EH]/3VV59 /(.* M]UX')J3EQ&#N(S.P_9#E/$T12*=SU9:2+PC2;8R 8@;IU!((&<\-Q+X1+$&J M8-$H$>/@_R.A*H5< MSZ/7#J5\+('(.Y*(O<6<$&*,]NF A8%SI6A-,\738G=G1<%E( %XT2;5C7B# M(A+(@0H&9S+89551)\/OUKO9AVB4#QCV,N4Q)5.%)IY02E"ZMEC3.N^@RZP. M&K43IK0D!CAV$$4QJ1B#H#T2BC33AE22R,O/>DZ'V8-I ' U# RN.+\7!M?6 MZD?9U*V74 \Q*&>**^%5&HY"79!85>^DGQ1>^PE!F7LZY=MI!&*Z8 MT^E$P;#*,H),T!IL%\7:*BV(-]I&41ZN7HXL'5R-:0XN M@ B2(P%>KPJ&NZBD, X%0S"OR.0+@G+[>(D3&M/( 0B4.$52\0!"F?;WH3:ADX:GV8O1I>9# 1D27*3:$@OQH@_5>IJ3XG;7_4*0+GMC(/ K M>52I7#JR5+]H<%3&5+I+G!J_6PLUF*@0I?+"6<&#I-;&F*:W&<(U1,5'$.I5 M_3)L&N$NL/'$(RXHMP1'AKQ240AP;JM=(+8^FYQTU>M-&^\596^B; #_W8+7 ML^N\=Y7:;625,38':4!-YWT\=4YAJ#5HB M8>$,-<;5C#<"N<#X;+#8:'. LR>=,"P"XSRD;@ZGOK M1M---YG:&@6-O"91N\@($I@*+U EJP5QY;QYJQ"P0%GM/6J M_G%%#M$PWM8CD%CM+.'$X!FYD9-CC'W]] M]0J35Q2/?W[9+TTI\;U6.%1L#222!D> MB*#@_&K X?<)%4M_I9Z,1.>F1. T%2ZE]"+'W$ @1*E5. V($RQX[](9&59U M9,Q^Y3$18_HV7Q*'#0Y:PK* !I>6Z:BB1. "6U".08^+OYN^>OISH3N$W>K@U3ZH MZ&X[__Y?^?TF7"LEJ8<@)W5/QP%\&1JD3#?]GS1RZR06W.GH M @,??7[2U+@_86J++;7"J>'4 KTK2%HD/A:=O.]@):][_4T05$I1&T%V1!"@ M1T![&)QZM$&<:W00L')OTG66'^:.DG\H?V.>O(4?7:3G8WY=)J2ZPZ1]-R"( M CV,8:8$!Q5'X ^&D/#(":EQB.+'7^W[3Y_?O_OADWL=WGU^'5^[']S[CQ_> M?S2?7[]_-T_6XF\GNHK2$OSRT#+W72\IY:PS'DZZ7<.3-.]):44ECII'8S4W M!DAERJ0^T[Z2.^2:S*JJUA"R$ZTK)[-'9(CWB&)$&(AA\)&5W0Q@PWK.*C// M!'ZX/+@!K1.K_ M(2>GUE$/23+?]II=UYX:EOYTJ887BB <3 M6!#@1 ?EG!!U351D'>)+J=F=ZM7]S9U"%H'!<8J#D6^FV@;8BU5(!;I*BBV46&<)C^"Q#/*C:C.!F1<+"&Y2LJ.]*Z" M6%@ID8K@3B,0#!D-5XY'L)O&<0\>4I7>AQFGV]([NAUU'I?HP=\[>7G@UVV# MF>T/B_^4KT/@?9?WA_?IAE4ZXTAA[EUU;L^ZY9#$$.#.!0JN2^!,(P6R#\&+ MXQCBENIR:%)G4/="^?.@L6JQG1142VLL21;-03!#,0T&>>5B@JB*AJX3SD.B ML6HHA/F:%9UR%FVOGVI:/LT:H)CVOT;C=$C]+(L$C%@A)A8CP 1L$0\*:^+! MNR4^X90:(VE1*1)\M0J6?;'P[ C)57ZUYAPK:R#^)])RY;F4)4(0!G!;O59Q MJ0BM,+$DM:EF$?YAW 2CE M$@FV%\ ES6_'"7N%+1&B5^F&.,<4$F!4+9@8[ M*ZECA#(:05ALK*O9/RUH?'Y5=//VI'/XA_1VJ?#*SWSH00@.*G#<#RKINR4# MG]8I(X3 :K&(L2$NM?(U%$(E<)(1P&09JMBL5V172=J5GZ-"MTI+@>]ETV 9 MA!E$0BK=8+;$:B>EI %5 XL7!]T*QU6!LPJ[DS(%H9EV*GJADQ *XU,L4(6N MS@^\6.A6Z34(3 SH-,M J4$8J)7305GG6>#6QVK[E[. #C1H7EQWIR,^RXJQ M<3.?ISI;AB"=RC6T!T>"6Z<\\U1X[(ERS-'*M9M7LBZHVS<5WM0T'86UE MIHT)JR5QR14%670FM0C5:2XX266LE4S;*[PR%;4U;^UV,3[-^I 5[===E]T5 MPZPS=^"ZW4II8J5EA'B4+AHRE;HZ>12M,,)YC*JY63EWTK8Y44]E8>6Y24!4 M60V4L5-63D^U8Z'1ZWU+Y.6A,WQM]&5Z-.M7S M@)TRSS@0S$SJ*,/ _C$. 9!6008+NTA(59$O496N;8C;(U>KUB@*R;!CT:71 MH5%Z96&Q/&AUZ3W8M>IY;M6UWIFKN33F^ZO7W6'6O2[@49/JOK9OIV6)%DB MW4D]M+"F6EGCO;">$ @40O5LE]$**RLI>@KM:PH2):-14@/82O F?+I&*@AP M0'7P&EJ;TUY#XUIO,!B0%.)2W,_+[G*46" 3M*WUMN:@62-6=78V M)F5E!8(PSC#M! 0S'-2AP4IZ"2 Q1M)5TBHI!&U,RFY5!1"9.N^"UE9RKX*V MQH(N-A9;J92I["&J:AS!^9_?@JZ5QQ$<8?!/7?0A MFNJ U73-6K7[8M#J]%*W]LL=IH-Y@)!1I2.O5#(2K'56I_-I8C5QL>+PTJI; MN RTTT#V:+,>.,3C3'!P0)WCW@>M.!A:B@6"R%S82DI6+=D_)XOL\09 6(N0 MBQ)+L.^@*<'[PN! L(11-C4W4M]9D@/RS^5B&N#J92.<1]@YP:)/5=@ME+I M0]5PX:K;MF<<+F78C<#6>Y,"+20X\\Q&3#Q+$P*%(IY4U*':S86QHZ*32LI3 M/>GKV[M^[^N8S-\J0YK73X.,4H,74,ZSX5B =C%!.D6-8A)T3F7%\+2OUAS- M*\EY MTKDQ_@RL3 8Z V5=U:B[VQ =R9=!*/676*):[NXBWH'E_D<[W;+T5W M/"\7B(6/PN-N_MJ0Z??3.(+R:]Q-^NOK[KC\NIPA4?>1:=W9/=XZ)J? L Z: M!D(QA_C1.(^4A46,,412;1_UJEK-^4RLG02::[($ GD1.:+&D\@!/PTAN-26 M" O.C*TIF#Y;+,N1&>^OWH^&*>4ZF)B8ZYLMSV="T.G\*@2AN+?2H*"9!JWG MI= UK:5F._#)D"VC?T=DDLK=L@*<$FX@5C7$]3U! M]\R .P7;^X XH^B%X>5M6E8KD64Q@BL;F)2N$BN+)^BL/?.[ZY48@PQBI98&8RM35T>!DK)64JF M7.6H&=/*>!Z8?74_$RB-)"):D8@:,>4QM M)53@@J1N %*"*5>5&)54+Z_5$0$Q5/I7NB#Q->LD16Z&+NOW[P'8TD';TL,R M6$:;F@%[S1%3&J(]B.%8HI1I4KVIIBJZ>B.J]L#&2A]9"8EU2!D[RQ& 3901 M0J'(F?&>56(*HFI7?#LV9G[,A^PN[Z^VTY]N>OWAY[Q_Z_,OU7XEMM?O][ZE M$'E=^S4G5"3!\G0;W&ME02-;3Y@2JJ9S=J&KFXQ'9!^)H?ACEN@2LPD)H MK*+5X-6;-,?5<6!/I*X)S%;G1I!J>+V&J6(X;@R4G,^)"FK5SGHNM\K<12@9 M(\@3:'N=!G<;@ARWBF F4X.'Q_[B#]\'Q2_=HO/7'X?]4?[C#S_O3$8IZ@\F M"$(@^#\9%(1!&(&$@Y=A4S\'<%"C>7RLOI:,2<')AZS_OE\V46J7LOTA[Y?- M%-8J$#*OY7BZ2"P)!6O(&97+XU5#V9B4?J M8YZ)P(FWF"2CKCEV3GGJP*V3/&# /JI#,S'N86%&0]A2Q7_R]MH5F&^JX4PD MVE-$E:80(Z?KK\QQ<-!\\%8MU#1,FVI,\P./=] 20BJ7P\&HRUQ]@1)862Z7H.Y8D@& D"?*Z@>$S*3M2NP)<+++%3SJ?NTM8;Y1%C$(1%"UXKYK6M5@21 MI7G73Z-V67N8M0!C:@B3P0A)TE X;8C%4?B(;4H6^CJ2J:1,"X!X!L/L M1O<*J,%)ID !:#X*=BLBQ5,-OF0>6RS%0BOS^:XV(!N2KH)Z/=T[^'N>69!&X9!H&LZ$ZS8X]2&"B5%H$Q4EJ8L/.62(A#,/)@R0Q8N*H36(U##HE.=]P*&#[[.EU6OX8G=CD& MI* >-%(@YC@UHG404Z:UYV+&6U20E$Q:;G12'ND))@4 MJ6!;>%7)FH*9W)'F\>6 U!+_ZBIOP2?>Y=\FM^A3LG99OSWXXZX-KC-\.T-Z M76&4LQ@AXL!*1,R5<3'UEB/4@@$67%>K=ZK"N3,:!\#T%""U@G"K"0I&Q32/ M&T(Y Y"&U)4K6EP]\I?57,J>,5UY4VS\%:#B^WDVR'T^_O?6*H-)F5K;4!*% MXQ$XC<+R9)2"CU;(2@JI:G^>0NX!^5ZC=CS1AD M/DY!IB/+]ZUA#W1<0KIL"+AN%!,2:;0E!$')IBK+;*0!/++4^$R".:Z8WFHF M8A=65G<+\! D6 C53. L4(N"AS 3T;P.JYXBKIZUK:"I->E0U96YTU+X+9; M?89)1-X!2)9P[H1)I=D>*(0]9L%1K#;[K!YO+"%D)UI7>K",1!XC#^F:*"AX M15@0(ABP;,C"B]759;7+NQ6MTS#B(YC=<2;PPZP9_(Y"_?>L.\KZ]^D>T!*A M?OTN+J0UC0H,-J=CX+D;J8TP5B@#WB6G@LQK]EE+>R26\;R*H>/ P#:#(4:L M(@N2\Q!2%1%$,RI$ 3&7CF*QV\L##))*?O)(O$VURB .RW3<(@Y88+#RCH(& M81B;Z!UL@G1^'P2E5*):'-@9@+#YCA \S2D*P#_X>,(@S5UT!)0!2L.U;>T$ M%(#W'"0A@4 V D%ZS6T G4BEY&!D;!KQ:R$P9FE.EZJ==('H>>R'A +?3#D2 MSRBUDF$EN,/@^P::YCD'H1'X@KX>A3,0A7>IO+KT?>AF2"@9@P(0(L?@:8!Q M"!XB'^HEUMQ :%VO'Y<;QY-!8KT3^$@[."NM48R*=+2CF,$4(RT^2*UEL*3(Z*Q'S:9&\N M5 1%&6T:IR.()@)Y!6XD,E2DVTPF@RXKH M0PE#L"Z=>YVD"[41$MNY4,IY;(E!6$?P("CS#.+QA(,)T@1<[TH>U87:$(0M M@@HII6 XNG2-#Z<^_9J6$%"(^IBN#RJ.[$)M <)F+I0+P0="/(]81FZ$16RL M%E@ OU+43H\[N@NU!0J;.0[):[2&XM2C3P>)(;3 )0J::$P6FH*?C NU$0A; MNU#!QW);).>)I["*"UAVT=*$:,386C/EH?O0A.>)0F 2O# M+?6LWI,\L@.U'1 ;.E 2B]1TT(I4U20HEUB.[:44H#*5/C4':CJF;\$8[MUX MNDH2ENE*S\>CW-R5M[?4Q"%)343Z2T1F%9>J6"I1%%KEE3%1. M;1BN2;YO2MGL7ZW>=3?5UFU_Z3/-W4WCBI3T/B@L4F^A&'7*NT@3J[T 2,UA MS!J:ZACXG'T?W_3>==024D;Q=#%51?AWL 8\WR@CX<$C&ZN%Y6(IW36D[$SQ MZF%*VC(B"4/&<2ZEU8)&4,O4$@N;K7KP59/KWI;BN9D>N]ZS(2R /!B0#A0Y M]^!6NJLEPKT,H*>1OS*NQ[4(* XFL@5]SC-G#1!!:X@;N+: MU,S-J9P>;T?\PT2-K<^YO6$X0 CCJ)4\(J:CL%)[DR[\(%[MG2EJ5-K#SV]. MUAH%H3'VL.8, FO/A8E6,4,,IUPH""1K.OC5(+B,K/Y,28SE>=KO'UYXWR]? M^I*U_LS;L>AFW5;1O9Z[!#W^1!I7TKTOFVE.'LHZXW?>9EVP..W/O>N\[*X] M+FV8#H/;IA9V$0Z&60Q&%L-T#;:\U@+K--FE_RB&-Y^_]1XNH?P]N\NZ^2"W6??/M6?/ MUJ:;_0JE^?0\1@NF'):8EF,Q474_8EXIMSD16,]BI503+&B5T$GR?RU*LVW3O\F_3O916J%?V!AI''5B5A:39[;HN M5(;!E@I!&IXZ?T8I4CE0:DQE!#:BX@_IFCJ%DP#P4M;T4(I4@\Y$0ML0(9#F MA"A&B%,0OEF.) [5[@ZDTLGM1&!]M-*3,;.[-+SE+@#_KIQ@S"D.J?+<60F^ M*DGYB(I77>U(^?CWMZ-M90=<;9QC+(A@"%/ MN[P\^-MS4K_BA^W]W_+V-2SQQWQ<)CFX*>X6:G>G+38FSSWJTC%YU>>#XGI\ MIW[AP]/7D_1.'GT@XM%7C3DL4R?IW3>]5O7[QO7D:436NLVG7.H@#LK5$Q4Y M4RQ0D#"O'#BPBE1ONU?[4QYJP8XC%*H1BN$K;%/-&7A1,GYA:-1I>?3.G)=2 M.["OW 2JA+5:8!JT!>M;;9Q8ER&]$&%8F4E$L%D4)X;!GL'6&8HCQ^#V@I>) ME:JV+CH=F'95T(WVK)<$[3V6B,,^(52DV6_:C>TI8ZFG9+4KT,:2L.M*/;,8 M-'HSW?](77S2::.@A'.51NI@K[F4@49#0C6M5YUXO56*6/S]PF M:9M]B_ER Q]H<#S"8C##!4JY&D)3TTRM;>HU\W@=-G/VEB)U7(P?CC:?&V8I MC':(::L-YRB5=[M4ZBR,C-2 B:A>L#Q-G \($4:"(801PX'PH+F5E+)TE0R# M[QEL!2)1ETH]$D3S*>B3WNZ,0&Q'+;CN@+ ,6*7FJE1;0XR0N!KNUQS$GP_& MQ]ON!F$LR_RW1]P;JQVE41NI$+5.H^I$O.8&)XNAP:0M06 M!2T954[A&$GU#/JY-.)<*"N!^T$,'_0 4>!/5U!CVE.<*J23!/EM4)@S(Q&2%(A*OF3:B?G4X/] M@&#%:'A$R$EBTWS,:"37(6!D8L!IKFK% Z@TJCH%L';V!8XBH"[(U$J#.(\, M!^_ >A!49#WFRGMP$-:/(CM/S(^L%ZS$D0/2$I0!1RJF27 :@^WC3$I4'<5Q M^J)^R!@5@\\DE(:8 &0T@JM@P(*!=V69 ?^AZDV19]&BNV9FF\QI?=F[1J"$ M)"-."JX$U:""'%C,8"-VEE7;NVR6.=UUE9YQ^9N,:=G5.RK!A(*UQMQ%KSTQ M2.'@O0BI9^D&XT;/>/U7=DNCW$3&E4K]8UBD-FK.J2J!D5%73/31D7G7&ZZ4 MHW%P=CKY4_ %VC-ZU\Y;]DXR9DGJ+.UV!JRYUB$ M9\UJ;;,(. 1%* G2:\4MI@JP-XZGNR44!U2)JC9,KQQA$:9J?9-RE.T!W$A5 MEY=-2Y("4$9-UH0SU+C.E;V_9=HW+N,VYIBH M<(@+N-:.NX TH=)A"=*.O:/5*:ZO-G1^GQ?SV;RE$TNI;:-U/$(^8J&D3BD= MG@:T"AE8D+!$ <5*D0?9K,AC)^R>:T6>/YFQS8I0%1%'4C"6VB"XU"><6125 ME*"@0O6F+'WV%9F#8H"X%7IHR5DAJS?36.JI@-M;#8H6IM< M09T?M^,4DL@XC[5%G'J0$N:H\. ]1\6B? 3G_+@=,C=NIY:4'6BM.OSSM')* M(/"E.JI(N25:14*IPIKH-(/K<6YH@5;R!%I]T1D-'X]\68^LB)I 0)+@U!PS MKR+6(+O")E7IC=\-V0DQ.]&[&EWJM",:L6 8X8'3,YX.W^6GT99#_>P1R$;["'Y79@H_>K_HE\Q!98\"VL$ L#21- MN*):1T80(HQ3M-#>?@;1@G)Y.K.'Q&XB]6R%D(#4QS1>!BPLISQRL HDEAW< M3&!X8<3G# '*#X? [5VG=Y_G9:REZ(OFKG#8'ZV'![Q$82[ =1*<6,Z"2K,&2F.I4*%:=O[H= M^:!SA_=O\^%-&L7P-1^/:/ %K#$\VLIM/OR6Y]WIT-/QU530UW] (-#OI)?& MW[ =EP+8U)0P6!!+7/1(.6"228R$1Z0RP?)72BM)HGT1OAZ,+8,#(P+%2D4/ M_B"W&M2+!\,??:3>,F,K DA0Y?AP"1T[D;KRQFVZ+!(]Q @,?%<[>C8:#Z?3X>M4UMF]S1Q0;C;/W61JA.KTD7ORG M?.A+FF[_MN@ 3;UNOM_Q]O/ZE(3@&94D*LLX)^"TZC37742E*(97ZML>/D"X M I]GAG'<0LLFW#YD]^5"/H+M8W+<%HSOV^Q[<3NZ/1R\RE/.M)?>",-CB%J& MB+D'HGM8>#7G+*9) (XH0%6G$6Z8!1^%"B3&VAZ-&&\/ M+_ QS-^ UP!J8@AL%E\ZDUOZ#1!8Y*VD+7":>NJ\V,4K?AHYP_9WG'.P5[D%K:FY8*F<3;>V3H"I9 M@(-!M<.8X&")],0A3HWA7DC+'<%:(QXPTKQZX(0QIY7&L^M(>C+YSZ9"$/%, M*$:I)Y*G[E5E2@^ $$%@PRH&6%-U)F@\13UX@2BG+! ,YA8)\%$B2#6$I=Y' M+UW-N/2M3-$)H++9WK;50IC#PK R,T:5 M#80PA5WDC <3.$@X(N Y<5K3C1=V.MO&9=H/^<\8I&!*-(2A.@@NG##>@), M_W/!"EZ] :VI?N:=?@Q' 5G4@$N2M/,D4.:,G #+$N]+>"U:M&I>&YK\#Q6 MWC"I,6:IM$%RV.":(@O*3VFF9,2R$ET\=:?W^GEQW1UGT5OW\[7<^;0@ZW// MYO,]#OPHM2A]!^!@\A90NED#5EW-R\=B\.<65>2;EWZ7@^$_]'OM46OXIICF M2)?'O2Y-LPD -;%<2_"LM(NIF,18*5GU7LRKZG#U_4!XH8LR'6$1OM_EW<&Z MU0!UB$10%AM'.3)4$Y2\($N(,K@F"U%U<"]W+69)R>=:#(>]])28X!3AV!F- M->4B#17UEAI5-=N51GV'7PUXH ^TELIM!E#*UW9Z@U%_3<7G[ /V_@'<(N^G MWLOW;_*O>:=^ <99X?(!_&@5YK[R;9XE$M)BQ'YYE-^ZK_^^N2?3_0C@;;:\ MR^-F3E*VB9 T28*B-.U8,NL#=PA91"IZ:\6JK,'PE.$GQX(_M5$AQA"+P&53 M$)13$1"$X]H8+26I)'RJ/8=?G MM0D.BY7%@E-0$"%(!TK"&X>,9]AX!]$6PY5TRVE)[(+O?<9J&[2#"Y%&C2#R MA2#8!F\T U]'H]0MHY+#NTSXCZ:VJ=:I-3S6@0B.0%_0U(:,"(2%PD95@LQJ M._8+6H6CJ6VJM%40OC-K&<>8VC1S-SDQUF'*3"7G?]KP'Q8KIZ+@D2F2)#9X MJQC1F@7KB+&:51-_SR&Q#]=1-C5WRP\!B(=@P@4E!.)8XW1TCS6+( W8,5DS M'X%ORN!**@_"Y458J)@*_ 6$?#:F&0?(AS-:A%!F#!I;HN1Z5#?:$M\JBZ* M%A-%_A][[]J[T?]IR.6,\^-;?MJG&5IV,^W:!@ MJ\1I!#J JJSSZR=S@R14"\1#&PFDW=UN2P@VF;GRG;DRB\3LJ1S$@;G8,VVI M4!9X5W('EC\K8&7)[?.AHL7X01T\G[[(CUD5H))X/7I86W43(9<'3^TSXHE::@F(1#PZ(RJMVK@[12I.&ZF M+7J*3^4@#DNU!!;,49<(MNES30W!S0T>L@3 (VFB3!XNE*VW>Q$16S2^#H;#';>%$ZI"\"0ZABO5M86 M\-Y\\];0W-W'OB&VOYH.1M5T^J'Z/)>T&Z*'[J0_&'_I3GM7P^YDDT&)&@N' MN!8[RA"HSSYX&B"B%,SJ\D8OU^4UQ4,B\VO5!P.TR2Q*ZI@VG(=@B.2>.&^2 MX90F<"XHE44U@QE=-"L=$HO?SZ]GYQ?=4?^WZFHRWKR&SN&H%F[ 7PT,(H@4 MZF(-Q!$ZYD*7B++Q:C=<'C(D(HH80J2,X_@8RHQ,TF7-L$\^6E/NIEAQH6!G M: [%[(R*R&7F5JD$R!@O#B$\*-M\PDH1,AE#GER\$G6N_$ M7Z[WGU>#R4TWSWOP8<9;#X6V?Z$,"UE"&1U V@9&0Y"J7."GS'J3OY84;R\N MN\@]2[>]YB_-XXCCYQANB77.0:S"M:26&TV!7AG,@8V6Y:(*8V\*"BNHM)$8 M#5'PN!C-28W>HB.,8A)+>,^(IQ)\F,R5IX>GX%QG00P[J;K3*E;S?^_L'1 ) MVB,I"@)#L1$PA42RL]H300-31?2Z OS5D#P>YD/Y!E$+GC@G+.(H'N-<8\;C8-A*D0K%[C*X,OC?4-7W+,_(JQW\A.$5%99 MX&C)&&X=(<#=-P>M5HP8: ;W.GTS7_+@1OWW5Y/>.;P39!N'G^"\J?Y_7*V< MR;2%M 8B0B00]?% I=392**9@X [6@['6U3D5DSRW@/, V%Y*/FF7B8/YYT9 M85(EX[20WBM!@!N2DX4/L-8G/BD2;9EK\B9I9D0@"F@#S@_QVF#.,L1,O"KO M![X(VNP6U NCP'-DQCH-Y-(^Y^@C-1QKWM$6[/.&%;UTCR42^IWO)^.SP=KM M NL;U%WB44A-,I/2^>R25EE'0JP%C;SN=J>8PF1,$<9]('W/'HI&-,!,%4C&6W$2E*C =$Y]FHMDF, MO6(AZA BO%3(H\""D4)9%6&X\9%^&)-C(I7W:@'QV_/99\ MN_);R"IH38WA6$+&,59XXQ*9S0MP"\OM)$WSV_TW_U;-MA/*]4&7)B$F[X)/ M.)1*.>WA_P6.=_80410V1)IRC?BX>*Z39!7*TB5UYDF8"1DV44C)+W MP,S6%'ZCU'2%\=\9B^51"SM;;S"#*:B T]X@W'714>NXMLRZ["TO;RK*571? MAF GX#98:W":0/Q9A@@(VZN-@R]. 6PU22D:5>A557KB#P&'"P_&DVL<8S,] MK_KU1)<=>X6D%RPE)XQE4ACJX*"5#,GRY+DKAPDIL\+Y607&/H ^Q)K&8 [7 ML$BHQRJH3=88%K1C,2=?]D?K,BVV Z []WS2D"W(._'4)VF3=!0GPH(6H,11 M5K:A4++*!-Q]^_90/42TK(@13@4/4BIC,D[0G*U*(6H@97D3A])5\KP!JM^[ M7W\%E3\9P/?O1C10D])+],K@AX37[)VGW JAB!>6E6:SK..MA&(/,!_L5[H!L-:-@K0,BVT&HQ] 'WP&E#@P7'BC")2@HJT$)AS7(1@ MG(JR+*S158'Y-H#NM<(A)YWK5 %A6D:\/9P=1,144URKP\NK[W*ES*Q(^NV] MJ@&[VI(%H^&"!:\ ]/?NJ+^CIZ/ 39,>11:" M*NIQPK,2G+%L('AV9:A "ECP2S<#\1!!4G:)85 '7I?441D5J!#2.RZQU6P% M!Q5G5 "QM&I^U/\P&_?^>3X>]JO)=-V.DP>I1#U8 "J5Y& QD_$1Y!+86P8+ MCBXM91$T24FG#2 ]#OR'Z,LS PI[ED(2$MQ!+Y1+B6?"G=;"E_ZY92N.>3_P M]UK\ ]X+'#ON>@;!C=R;K#5)1.9(<8!DT0P&!U/8DH=WY3QVMX_PVC.'ZVY( MDHD*[U3&7#GQN"R<%Q *6R[WV1K"UW417T7P#IW+>.4X8P;?6A*)I"X03O5# M=Q@?)MD1$??9[B5Z[QSQN.;2"-R[8BT$5A%T@N"..E:P;7DM^61H_&Q7#4.* M#,(%3I,Q4CH'WA!X;!*72'*EOUU\B1UM10_#DQ/YT->274S>H"O+)?B(3G-4 MUY)Y)R#6+R,#^804>2EWOXGC"K<>2L>S=$8;3[S1B5&(_F4LQ^2?(G&?36\* MY[4BN \>^)5+;T(R OUD#K+-4ND /NB/'#>1GTUQ:I.,=.#X6Q8E>*P>N%DP MP325\&-Y+X^6,Y&>G,@'OG^-:ZAQT4[*J#:)T\38*'.@2")9[E8D17UP%XJ, MJG=G85+U!S/X]ON7L]^=S;L$#AU$'R$G$D2] MU5JSHGRO5W@>N\&W";?%MCL_GDS&7^']H7L)?]DU-$Q8DHTX74]A?**\I2;E M9.$?C;O7BD" ;(78.N":0VJ9H5<]Z:X:=%XA#6Z_8>/]ECJ';TAPTEME\,(8 MKOQ,$,9)6^1;&),-$F0V^%RW)&#=;_*EVBOX%#$(0R!25N"M4"NMQ5A42LWA M2&UY1Y6"42@Q6 W)?M ^)%=16A^MAO_R*+%_EA #-BI$'PS6R\O:6SG)?2]H ML:-C'_)R7Z_O]4Y3)Q,$^I(+HQ0N]C'.RX)!1+GOX %8]@;Y01IKEF,$$Q1P MF*P %>P\=J2'&)3PJ3!,3#X>Y _5;#:LK<5]<.LV8FY^RLRA)[0!FN M6)+8,Q=4+%5QF41<#\S>,&\H*5+P'Q--G*")=YE9SC(-GFN('JEGA?CN >UX M]/EC-;F(U:<=)343(4(F0#T-1EH;!U%L(@"O9RER7R0+N"E[J9:_?2>H[FP3 MO'.V>.>]':S_LSNZZDZN,57YVWA6;;K_(W5F(COBH\0IHHYRRN?8\!16[*HS M*^S2$R CMD)&",-94,YGJ@1EX'3H?',T"CSG-:S^1,C\VMWZ5+B-P8!SFT+V M=;Z7X="R^:F IBE2_^H9$&';(.*#$\!7.;@4<(8KB$JX.1%7DM_&7&GQ&^%;8*$[@3""B=$J(Y'&( M@;GA+^95.8/A2;%YUYN-:V08WP89PM$$1Z.E2A34&+%)W4H]&)#"=7I29-Y# M<#NXNIAV>[UJB*W!5;^[M%%Q?-:'3PRFTZONJ%?UQM/9=%!7,;%/>+YHNGYQ MDQJWP3&2G(/#E()X*S"B="+'@*7;PLB7GMAA*'#S1XA+!K/N\.]XV>S=I^'" M0F]D4QURIIJSZ(34H-T==M!1@1O2!+RVL<7_P%C=]"WA*O /7[N7F^ZW:X(] M41G<&BF%!L4HP<_A=1L:6*S2$RMK8X?%YP,F8.9)D<$(^!$"RJ4A3KA1:Y.# M++,-)O@8(;[53EE0_,I8" 9T=K)L*Z!/C^%H,)YL9X)IYMCQ2"R5B7,7!5/4 M*17P1K$K,QBK4AA[(?-@DP0+@=$4P$Y\ M,A&M8AZUE)'""LNQVX)*JJTD6A3Q5&/.YV[(;.=\2J9X &(+%Z@$(^J-9=$D MIG/4,JRZB?.4R/R*J6XX%[,-*A#ASCMZ(Q.4"H@:+4W$49L]=8ZO6[SV=+AL MS6'&*7 \C;40H$L*+ARXT8Y%< &H59RNLXM/BLA6CK0#QI(*)T5C:3 3\*?Q MVAO3D@;*R][+QASI'1#9RO7TTEEMG3"XV1@;G*015,N8HS):^S+C_:0ROZLC MC1U9V1.&N3L,H#T+FA/C#&$ZZ ,ZTEMA<^M(TZW$WFE@K!"-(,%+L#(N*.S" MBT&2"-'.0_.(G@*)[:(![F7&.KK&%?)P&M[R$#@'CUBX+%TA*(U% ULA\S31 M _46IYD)IY+!_Z8"$QDRJC@@; 53;)E6?8P)'A<.."TSTHE\'@R^#H,RP]4 M2>6UM%;0\F@;"@>VQFK'<" 2$[7B/(68P?N)WD8J* ]" [NR6.3/>4-IQ*WQ M>70XX+B.QB=J) 3G45!PBH@C1IM87^TO>W[*!I=#8[AM. #ZT JO()X)1/($ M?K7U&A"S5J7,R@*>, T8X 4N]WVWAGT]X@R30ECM-/P'3L6#TTJP-QP0"[8\ MHSU]/3?JKY'ZW=+OQF4-AE9#M !R'Q,H!3"UU$,,$1,+Y=7M#>GW]7 U@Y*H[=+/0 MG4RNX<6Z;V"W(PG@SQ&.!R"8Y"(YO&\5-/,6XJ!4;G"CJEP.O!58#>#QT('@ M>%_C NZ=XU):#/DYB]EP.!(([/PZ'E77(+'_K&;Y:M2?;G,2 M+Z(S3T?NG5.>03P@P4]S/J3 P7V&WY/*9?FXH/4&TAT3E9^M12\G4.7<2M N MTD1'%"6@WJ-VE"2?RDK2:9+WV9KS(@N$"^\CF")K6<@$QR8C>6EBNBP+/2]Y M#TL+9$![Q6*(/3#D>H\V22 M@O]Q6U"YO'%U0E1^-K7)2!3 S Y7U=5.C "OP!-IZTFIY67$TR3OLZE-E2TX M6T$Z\-PE%HV K-8F"(>]B. #'!=Y#VQ"I/?@/',MK)3"1T>U]#0HZ5, $UU& MEH\1Z-\J^-OT_/UD_&70K_K^^H\ICA6YC>\=A/9?ZI!_YSXSQV56,B6:F9*. M.N.MRC$&!N<+(E.DVM^4<=GVT#6%TX8^-"]PKK1QSN)8>BIL9!2;"I@/025; M9IQNBCH'PFE^P?EQYY0]J+80$DV"2Z.H(3I[EDEDV-CHBVCMS4UV<#-2*\!K M"JF-,T@T :F).1$G"]1)4>6!VSB/ M-D"$%,!_IQ[\^>2"L^#+%ZF9-\4TD.V!:PJE38/W$@NX[D#@,*D@P%6TC :2 MH[)4^UP.;;3;'M-&G+[>S2N%SX[@QUZMJ-]-PGD7HO6WH^4W#$ X+X=5K*:] MR> 2LRCOSN#5\>1R,4#Y;#RY6'0NSR;CZ66%7UL-K^>S4+?8^+4T-#6/)^OA MNS_Y_>Y-'_!"1W?2G_YQV>_.JGH9D/W&H/ON$ L)'\ZKZOY>L)LWQ.JLFDR0 M?HMY>4"+R>>[I.&=UHC49&,$\UCK AUO+,\9G".=C=4FX@:DY3-Z8FJW1[WQ MJ.LU<(LK#$O7GXJ3QO*9YDY&J[D%L63413AI#:ZP(BR1[_XJ;7O21W_2=SE#?LUP*S)\2;_%@01"E45HX3:9.S(5JPM"0PAJLX2XC+:6';07R% M#/+N[/?J.1V&"B83(;9A+$#9Q90;D,7I<7 MJJDHVJ4+*'8$<0,;6!43>,A@[DEQE;AW26N+O0^16N-5#;Z7E'JN"OVFRC%A M*Z'8 \P'AV)&KXV@EMBL(-#-WA%!C0Y [*QH:2GT.L;8!&887UQ.JG-0T_5F M]QLMX[YT!T,TA.!C?NBB/;QIR+KS/^=;!GZO;A;"+?S$.__4C?H0U^^^,$3X M0'@FC"9&@N.&> ENHV=2!IQK_4"*_HE0.@HJ;K ^6:K$LF4J4",AOK)@ADS2 M$KQ]G Q:I/!>.!5_JV;OSO;A1F^\H]9S*ZRS!E0TV/.:&[ET49=3=)^2CC=( M'0DE-T48RFJ(^1W#&=@F07 !; FZC";PW'-9/SYU2N[-R4#-.(!!RV& M0%C-/!;U:8. K2&XBAUS6(/A\U M5K/9_KH'PD(/ ;G-U.%88N^MP(8JCY=3<59Q$9/SHD+["' /AO6FA:HZ;_GO5 M_UQ-'SCLI0+(S0/>CJ:SR56MA_[6'8QJ(*_Q0?#$>N$'PG<^N/SF(L/T/ _' M7Q?O^R:#MW@U5M/!Y]&JXLO\]:H_A[B.,&^ ^.91SJ#*T"WAP4<&?CA$.P0G).5"MY6M6H\YE,,=KFD/%Q2VP\F6!#U- M*T46-EHN!9-@W),*9=,"6QT.'N/A/ICHJ1>0:-!8QCH'?G>,*9%H@N1"V7([ MS?.@#7:N KZ8)S5ZUTOW:= =7]JS^7@'QDH)R,/)(SD\IC9!OIG7&7T94R[& M6!UB-X['8S1 )6HE)992Y@S623]!]4]J6:#>6/@8A7A^R$<_%.$SB)[A9-%A3-* M6J>20F)CAR/BL5-J47C29&"L, MQ74YCGH;N:=6!<&%3T$_--W\F:FTGBUQG:Y[%]Z^&RWY7&THM[9BJ$SF+B1F ME13.4\O^+"@'MLREI$ M+R,$U=%X)W%]II',BH)V#9-N9P2/BK:;?$0@I@ F9!E8T?%@C +[HCR2NDD M]W5NGHFJ?XPF5754]^:Q>&H:;;JSY( :3EB3K9#2X@7&P"*SW">%MTC* MQ/W6'D&#-'ITHY1).7)P?9354NO@A09) BNHM='*%>4)HU9G+K9H-'IL:Q33 M63 <("&#EE(S:P++Q*)ZS4KQ MY[P3CI4%8L;+I23K8=D7X@<7$:@4K!(4/%\A 1JO/"/" __C*RLNGK-R#]$. M$#?7GTQ Z7O98D*;ID!)Z%@ZC=LM8.P/>R@119_6ABJWH?O?F]7:<-6>BM_?4W7K[]][-SK_ M8*,7.S'N5LY@KO@,-?/M"+C5GT<3?OLID&:JBC]ONI3L,H/SU<32+"/+.-,4 MS*T(\!_N>2%2I79=1XDGH=;-^]+%Y7!\754?JB_ 8Z->=5BJ\4"BLYH9D&II M!+,)AR&Q8!)H3EI.="IWN!P%U6HVO_?FPY+-$4%\CA*4-8'(S'AP@Q6..]6@ MR#DKMRT7@OET9&M M)02.6EG+).@_T'[&, ZJ&Q=(HJ4PQE9H?4;0W=):QZK M)K)9AZ ]=]Q:*7@TCJ#-%,D:[E?LW#F<(MJ'6,^DB$ -28OFCCHEG6? :Y9K M[H%@E)IRJ%]1^CT*HCVU'K+>0@A.:2;:20(BZKA!%]UDC;<#"JH=3@UMI-KC MD=71,,.B!T7D<3>=!44K!([N,-[H6"C=LK5]%VP_CEWO/Z\&D\I?08A83:?5 M]&^3;Z_SK-C?=?/V^M/3P6V:M)[5_.='X(_N-SS1[,8O<,*]DA!-9**P#RXS M\(P(4SY2B*;I-JLF-Y%@2W+5D32FJ!=_Z1\[Z31 !%&C,D$[ >8\>P@H"3A# M6B8>23%GA)5C1G8A1Y-D'/WO :;)MB/E_+T'):5)A"82*3>.,4,#4-$#*<$ M4L=]F=*AY4SK)R?E-O$OYTQH[7&]!BY$ 1VDH_ 8%2=!G"Y:$YX=GTVMTH(' M$=&1XU0F3%+6MYH"QS*$+\/]?H))C-DUVEWT9A*\>GE1)+*V(;X%%U<)3A.(A#'&.L.-#(;K9+S5*Y*% M:Z.#S= UA=.FC+37V>%]N4"Q)S$9[A*+D6!;O=;E7@&U67MMA])D,=WFPVS< M^^?[[N3=I"ZZ]NNQ:.^KR8?S[JJEUM]D1]FR8RV\Y&# B-)2.I=-X)ED2S.E MWA'_3?!V\Q6@N7XD2^-QM@.L"52^29LNHQ(L8B%(2"+)&)07AH$;J' S7^#? M;IP]%"KUGZ?N:G8^GF!A8>-I+,\>2!I8*RIB)?POR&QPZ338#Y:RM8XMB_RT M_IZ[O2CK,/@6GL= _@WQER$7S$6!BRHY7CFFW@;!DO4JCN?5' &3!E5$(LS&XWDE$5-5:(TN!50;P!W#L2^H#Y 8.^Y"R[BO3:*?3'@ M3=0]H=PP[MF]$FNCH#ZX"?X!TN; ,A"3:,$AUF31AABY2> 1X74;:W>'=\W. M]YV!?H#(,B3/130NI2RYL-8;1I4FN'L@RT@/!/1#(^KO;FT90RFU1@>5454; M907)G@"1P<;J;^/;SI_3P<^CP?#?OH- MOJN\]/.7U_3Z@7%WDQ0BISU&;UJ">0OC ZY=8R$2O.V9J64B*5L@MA&C+8 \$*8;CA!. M+CHC%+-$N0RN$]YTA>#))4/PSE"A"^P*/Z1AC&\^^G>,?8$;0/.N*O=N.$,( M^X+-#F^X4&F4-T$$G(NBDZ "8MI21= R>;<)JD>BL.EBDG,DR*1!=R6IG8/ M5BJP8A8,&EV14"@[,?9&X'?0C?.@:RZ.U:0WZ [?=R'LVKV7,!$.SEABH!:D M2@:<,2-T%D]1YD;7+Y>!D M_C _;8_.V6"VUX0NB.>T8@)'WF49LC;@"W,*GHC3WJS8M%:>/\ M"264#0 (P!1!+"-1,3/B& 4WC1PJF[$:IM4I@;+0L-%! D<-##(F79F3 M&0(UJ363QN>D5=)E8PZHS[(\\B \CX'\(;](9)MB C_.8Y>S"$8EZ2,NJ1\L(2;:*X9U8'QR$2MD02KK%!QT"\!A$0#4R5>2]ERTKO ]#L M#_6# Z*DL-):8'L70<"BX>"%"O 66-!1Y$+ Z(V"W@/JWZM>-?B"LS+^,9B= MO[VXO)KAW.;YRL%T=C8?J?E_!M6PO[R(L!10];_$-P+Z]K=\+S>1G.7"2V6X MQ$%N(E$O70+IS-RKY>@ ^[;&\Y20N<-H3T@/@FRIC?B]J=: EL8]H2#Q!._^ M@E725DN208[6H,IHPZC>F8'U:PVWB2:2QUM? +C%V]Z@Y$6 $ _$RE(7U=J* M+EE&9S4L^\&[Z7:&1W>,*:8]F%1E;"1:A6C!VQ'$LJ(11I$B"MT7WD(WW!7K M2.*VWC%0D'Y_R*<5[J,!M19QX]>N)_?.*UMM1[1[A KWI M[JX7 7+#;R<_[#J5/8&]V!8;SA)*36Z)[@]ADA- MA /D%5C_Q*.W213A&U/%*)?FL)Y-!CW0?W65@5TW9R]8+;[X\S7,3CSP-)>9F.LU E'7YA$3!*&PW]R43%GA1.T"9TG0/U> M'U18-=%2PR)T7!_FZ'<9^$- MD1%T9'9&9^N3T\FIG*(N7?-R),ANV&U)%]2KO<7/:RB".#_P!'^-[40X)WVY MC;+>VW+S\%O2K:':'=%QEO\]EONU^^?@XNKBH4[+X^ES==D'[-"C*@6<^&0, MR#Q54Y;'%5[O,_0D0M>J<P>ATI%<+D3VI$VH,O'=C'4^."4:SUDSK]:OGV^,]">F-G)DH0&1E MYM)("%-2=DI".,:%MJ3(Z94YU)=SO(MG?!R_0"TM0"4GEN'X+)=.9,/![7(T M))ZL\K'<5J+:@SY)@>;>>>&$I,+@]61<.J&958%JQ9(K+\BLZ$-_^H-^E)0] MGF:>@%0D$-0YQ."$+WMM^#%HP49:.=9)%)1JQ5U@4;]T2 ML@:1V>DZJ.OUJB%>XJ_ZL;J< !7J5,8FR< -7#QQ8AWNX=(^,2K1-> ^64/+ MU.6)467%)=GUA422/8W&^T %.$C:!9HLWH9FF?*\8N'7*1%C0WBQOGV!>AF= M3323(#U(?U Z*I=T=@%8I.PN.T&:K#/AZZ5&9QV9T@Y7DW-.#$[["Q -QT22 M*>^"/2NCF,-*C=;!$C"PNZ,@I.@:.F!9["XV@*

    JI.@Y>F*B/-B')IQ)01&(K;E,BCJ!@PVEI4)936,YW[]Q9!9+PG=VA%0P M>)LM,:F\Y)&[:/%^1B(BFLQ]X0@54YI60;$OE$_@X0"J1(,)MT*")Q$9)L2#S OZ(QF69:N"_E MQJC-I)IU!Z.JG[J3$;QC"F[DU<75<.Y&G@UZW[9N;NR2ET%8YT&'&R7!9.$U M+9*RDT18F7.YY\;P\DK'9J >B\*#PUH=SUK0C#> I*#X!L MH M&ZR(4RZR%'G"^?\,7#-OZ!WT$21U?5/E9]YCW=_;"I7]C):SOWX!H8]P+O5'>\GXSY(ZKO)!Q#20>_. M9PS=27_0[?U^?CT[O_BU.^I^KNYV-JSWJL!.2XA^P%,.64B!XP9P2JH0T>9< M=AX)51CP9T?N;AK5S2J*OU7CSY/NY?F@UQW6S^B-KT:SR?7__\>'!RYT>4,] M,;2>$\U-%B#02 D2*5X_*M,1)TF)FW?\-A[]L7$G"^@&#<2@*8-T:O@YR)HD M+'-P7PJ2T'($^U.0) VKWFPROCR_G@[&P_'GZTWI5D\IU4D'8R75U'FFYSR? M$K;AE7-\BOS-,V+5#+,GL%LXN]59O*L&X; 1J2:!;F#LFK[D(+">1-(486>'E M\4 YPRM)J>P;UT65]AG0:8:KF6-X]PI<22VM38Y D(6XLV0AB"ZYFM&BWGZ< MN._"SBE(M&$04F83&:@V(VMVYI0R[-DHNYB>1;W5UPAQ9N1@/.H.:ZNVC>Y6 M'BQ/B/7Z":JX=XG54]T5%4H3410-9!DW/#]VS7"[M=X*HDQ2>-<0?F)SUTU& M>#V4:P"8+KSFDR#%+LSOB6<2XH@$0;#5X*SG.7O(#,&F,RMNS3R+,O^MNIJ, M+^"/PVW*+RR1'!6+@8-+3KS!U2 U4D:!U9+EV%11Y *?#:EF6-V!+=,N1[#3 MCE@?4K"\I@!XHEZNT&GEQ(ICIL N',ZC=X:9Z!4CB6M!$ZUMG%2! (U*J7\6 M$X=;DRYQ-/-P6?PWEC+@; EQBG+'<6",9KS&3660YUR.85IQ"?39D6O(DY$A M)^P>5 EOP$=B-*TI@5/-F2TCKW*RV2E08B>_!LOL%G.;4>*5>Y!Q79,D=.NPLL M,%/F'M2S'/=#N#7#]P84&@V1J&2)#DR .I@[KQJBFDQ69!R>)0GS2$+LPO:, M!,88<2ZGZ$#YB\!KX\^M,N#R%F7/@X9SMRC=S//^4'VN9RC<3T^-OW2G/3"" MDTT%>JMHX#QP[(J6AE,O,\3<)";)LRIG*!EY2'V_&;E?J_[T:K*I<)LS/!TB M%(BXF8XV<A&KX^R+:E)O0.Y._KGYRGD4-@L1(IP5G)O0WB23 M85A *XITPF86IKJ15PHW/E]1TFGD0IKM7S;CKH MON_V<*'MIO@U,\DAWDL^YQ"FM4A@I,L1=L(VZH,U@EPSBB9B]M0% M08V53-,HC!$+2H#N<:5;WFRR\:DHL5."33I+/:][F(P)U!K/YB3Q3J2RIY*5 M(WF>@B2[E@0S8=P("+^B4RR!DN+!W*!%N"^"R_*BWC-BU0RS$XB]B#,2EX*X MS)G)?L'L$&LG6MY2.C$2[,+EX/P)ZG$'1P:/D$?I)5_0 M@AE>711OV+K6FQ M94D0@JO(%<1.'CQ<;26%<'*.35:!J"(@$65[S3.@TPQ7BR!L9$(1'4,B0D=F MY.(D$^.B7 )5SM$Z3MQW86>BO:7&.2D2$^A5VIP6#,"B*N\A4U.T?CT%$?8L M"4)(+7D"F^0R$50Z32&BF1\Q5O:+P$V)9]%<3U$2!(NLE04G11$]\9,XP\-*9X,'?,+^CY9YBWFP]?%N:[%82!.>+ M9P&:W A/@^>*D052/E%!R[;[%0?I+TN"SV+FGK(D M:#U5.2:/:U"B%<+:L&!\G)GJR\THS59)MR7)7B5!82G.?I5"Z$2I].#3D$7N M@3E7"C5[GBS,X4N"B7J?E8C6,,H3;D&5MX00N6SIH>5"A1,@Q$[Z/F6F S5& M.6]"ID*0172:DH8 IL@^-MH,8PY7@K%)1P7NBPT^"(+#_Z.H2S#4"^'*J;_U M=:=GPFR?$@S'6&^W;J*:>-G06^;WD.2-5@A"C&E M2\;C?I.PEGYU1VBI%%VE03GG' M3(PAZXQ=^XO8&=+3<^/BERVS5NT$!BS#09 M1Y4**46?1-VX80$[&XM80S=>U=L-JYT:-XP5'%Q)#WZRIN N$T-HW;BA;8BN MW%*C^4Y>0S4<@IG_6S5"S]^-^JY_,1@-IC-<-_2EVO?*JC,V)LN58L++))/) M+)* I;B4GS%61-X+)IW)$Q@8#>38X8:;FT(#%& ^E!>&S@Y>BF M%==(=\<%MQ'[[A0'(5W@7^LLQ.XKF0!8)P,S@4,,'H(7)#CFI (3VM_Y5O4X']D 0<&X/U\$_EOUM?[3[D/&(.+GTH,&S.!A"NX=)O.- M EQ"9(XLSW^Y64I>!KY;@=8$,AND$IPTEXA26EHMJ:JEDD"X2G$A)>&KUL*7 M;;0%> \R@"M7+TP/61JE!+.,$=";3I&RDX"LN(+4"-Q/08F')F1PJ2EA M43LX;LW*]'%EA-AJGQ,=)U05?\+I^\IQW-AXP6=8Q!F31 M$VL8V#^\?H=CL#.54D2MLEHEEDQHL)1,+^&U HJ=@?R&]N1>HH&!OLA& +%Q M[;(3D8/H,0Y>("-.-@_D_^X.KU;;N_57.87*,F9%F> R:PE\0H5P '5V*:JR MC5.7$TE*&':%\"$.)M13$$]%K=&XV=$')6+T67.OM2G=GMTA_&,TJ7KCSZ/! M?U7]C]T_/7AV9X,UB];6JQSP;CB$79HY)IGGX/R$9(D@*2A/RQX'RLH*T!I M]H+U0:4 HA*4 3): N(3+#@I2H"G%G,]BF!%[VZA%/:'%93'^**"%]Y7H^X0 MM[>#$WVC)5RO-P';LAOMF<7N2)H"ZGVB,H3\&9@&>)EA?W*Y_+-,63X"UH.A M_- 1&B831(T)+V1))Y@'YG->@7TSX'>7C>2J;)8[+,H?S[NS?XROAOVW%Y< M\.WZ6GC+6J]\/;:"1:\BI]0FZ:RPF9$LE<:&9L[*;;1TQ;*(_> \!*8/+H%6 MQ!-<;0/A*+@MVL,I:Y<5<+(AU*W"M-!VC\<45>1\@>!P./Z*P].F=U/6IHM- M@R5BZH$C)-BT6F<(@Y("!)8SW)XG;2(X3;+,(A3)JJV :@ +_9#F9-ESO.<0 M!&!! ,;.=AXJ9PSN>SM*:7NZ;!8?Q8ZL:@RV%.2O4S66*\WT"=N#(>0.GDNNK3<47!FF(C8JT'+E@RH$I6$LYI,@^Q_'BZF$ M^R;<(%C!3<.9JBPD2=%JRPR1A 8FI2M3H#M*RAHP#X#GIIW=*6MM!<_@A.(L M0N.LQK#4$&<-*1?>%VG% ^,9*ZPR8^/$SD>8N1$"/%]NYI-9]U1O5"Z_Q]7TQEFYKN'!@4P:S,6]&1TW>%)NM\-T M/9B-8KCA)"%NBSE9B(>EEM)$Z["M-A AJ>.*J-48JJUX]U$8%I_QW>F@M_,) M*@I>/YR=SD3BWG7/.4[2=39"H)J=7XF?6MQL!4[\?#0>_Z(V#JA^/>/]>CO=0D M("GX,R192Q+U48/3'[VCGH0H?!+?_?5?AK-?^H,OG>GL>EC]VW=G\,@W9]V+ MP?#ZYX^#BVK:^:WZVOE]?-$=_5+_;0J1S<^47,Y^^>Y?/L]^^>;CP\&H>G-> MD^5GRLA??D'XWG2'@\^CGU$1#<^33J]8=6=_-MWH_&H M^NZG6Q"/$-ZWH\ZOW>N:JC]T9N=5)[L/OC.H:Q*=U:3_H<"EF8/N+,2F@W+3 MN16<#DI.YU9T.H_]]OJ[OJ\EL ,B^*\_=+Z>#WKGG:_=:6=Z]6E:_><5&-?A M=>>JQKS_8^=_=D=7W3G$ MS]0'@2=P"VIG-JXUQ)PLL_/N#-X_J3JC,3HN%Y?#"@YJ)5 =@+ASE\>H@5O, MY4: JCI[@9\;@)8<=(> /8)Q?8/(,LK=$5#CUF$"D/ -8X@&\,V?%K$G/&JR MF 3>J1:CP'^$ YY>#0'TL_$$_GR)Y0[XS&5=])IV/E6?!Z/Z*=VS&1"FP %0 MO00]#%\+3QT &+W>>-*OOZ_FD9)B/W;>P[,GBZ_H="^P#W!:/PF)-L<#'H;D MP1?G0*U^^K#ZW.U==_[FW'MXWW]>#29U+\L4WUM\L_SAT7RZ1DINA.3W^6FB MI]^(1/Q8 GPD*NK45&J$TUF(1:TVL.<#Y*'DSEK<42HG?>3!SJB:P:^+\ T? M<2-5A2CA\QHY]?].M>[ NX9-L5$'("\TXN4$?+8)?!0PJ5<2WO%F 'JMBW!<7:)LUI^L)D@/T& +FW"KPBOP#T$J M07XO+N![)J#*4#QK=3=WK? ;ZY.93'"#+DHP*.++\6B[\SJO1O@MTVHXA /K M5]@P/U'H+[G3>FU]_U>#1 M)[7. "^ZL7[H?)[W8\WUXKV.K$XU3_PT9(?OV:7. %3RK,;W!8#=1(!8F&EBKZDX7;T8J OSC+[6!K6[Y[H:.36=4WHZMZ5@8+X,QE=3X-4%IK71&RR6[W7Z<^&>7@&[W3SL[BC!AJU@Y%:U M-@4O'!=*67?NK,RE%>B]PE5"&;Z:-,.D5Z/N57\PFU<5^W.>@)^F$+S5'N*M MUS,]KZK9M!D]VFU.R?_:G?3._Z5[KF19_\ HH5.W<)G&J&D M3&HYA%\/I*?JQ6.=6B#A<<-!]]-@.,#::D,6K"G;*FVSIK76QD](X>%X]/D- M6-&+(Z8Q UEODL@_U"'.@JEK)8.F!)4,!BVH4C98\WFX.)R.[SR[?G56U<9C MUOT3[1CHB-4NT:I'WP@8@O#$$G9W_@N@&Z%P M@GQQ=((E:*/4K5TM(.X%..XU*V]EQ3$G@X'ZK3./01'(X-E@! 9W,/>M!W./ M?;(0E-IN0N14]T./IC\>JR^SE^]U\_/_^*G9S/.:7+8B--^0^NT(-^K5*8_= MT];*$Q(R\Y89Z5P2SF4:O1,\<2%U"*\A;:W>$/JBF/%YT]8W60:D[#:I:R3_ MP;)RMU+261*3SIO..RPD#8<-):T_7'V:U;K1,/F&DG\]$#(_+R<7:[/X:]WQ M6V=+ZM3(+;9N[AC@>^Y>_/N=M[@B]-TW[KN\FH"RKU/+Y<%B+@!L UB5"<3\ M2_;A+LV,_MO=ZX.E8_IT/;?Z-]GN45WVJ]/AL^IB>N?(H?69QQYC^*+J'$)! M3(G,K?B].L$J".P[FS^'T-[P&.1QBI@,"I/H,ZOS2U721]E_WY$MX;K=W_N-=G(B=C\ 46"_X#%9[ M?LK#\123/TMIDF7J'(@AUQ.]&:>ISOP 'D/P<^?$F8T/E6,K;[]79^H-^[?B>=Y&F=_[OC=L\ MVMT-OI7K^HOGF>G%XX"Z"[ZYJ<5]0YH5[(1/!Q"J^@K3O>. DP057%3#L/.L.C[[[=J#I!>;27I;;?E2>Z?X!QG;AP-I8 M@OT=TQ;S$,0(MGL40:AGU&OL^L2!8<&X2+V5*5B6B*'IE401[ AY[=1DXR:* MR-6GR:YA!#M8&#$7D$9;7$#0#A4GE#IZ+]=EDW//;IS[F[PG'E)MB"^[DVK4 MNZZ='_0.NY-YX'&-G1Y@N\:3S]W1X+_F%G#NYL]+C6C8YM7"[ET ,W]A*=6] ML$_WRSL_(!SS^[KP1X1YR1=>\B"Q?C.WOC??->U03V:7PUJY]1-\?<5:ZG/ZZA5G5S':GV4;JC45V& M7M-G$ZM>/8.@0^5-P?X.Q0'>51M8'[_P3]V4A=]I%NG!@"!/UT, M9K%OUE0XL?.^_E#)IB7/F <]]L8P,B=-YV_SV4/"#.O-+R_FH!?"2^] MNZVC-!07#>;DO<#X X)Y<[-N?;W:EZY&6'D<]&AY,W_5[/3V?5Q0_U'^ONQ!O(%A,"IC<)@E[5O\+X"?'!C/MLD76OA?#N>3IO_\VI4[>!I4O[D">N MP?JL\_=YFJ])1Y0S=;B$]3<)ZOM8H(I?A6Z#A+N369VHK?-@\W[$>X^H/2 P M[YC!FR[\%GS[G$Z+I.[6&L4= M(5QQ;S.7BCC",]Z3?@567;^A;0ZI.:ONKC[#@VO";F/7D?H'L^M+$E9+^T)B MF@FF;E)*5![.DM]H@ZX"G,.9[=PIQ/ZW;_L^NY%L8B M5^_65IX#K3,\'EXL;<)/!])\0S-WL M0NR,/_W'W/05QK$&$ENGGBD-!+:LNC.0135\3L,'JN$;:F/G7:R-/:84MK>M M>P(3=F<\_[AO9=7M+*E%]*L%>8LM7@F+I-'*DO'D>G=C&8/B2FNB+-/14Y(#T=BVE5P4D1/S&HPEN)KJ6(W/"1K+=[W9 M&+7,#E&P.MB-X[E(=3XVUW^[,)$@F__Z\Z%L?"WU;^9BW[F5>U1RBW:L>5(5 M9;]S*_Q/%.RJA77LXFP:[%:OYF#>RY'731.WK<]UJ%G?NN[-^PKJ'G=$\>:S M"Q07?ZL#X$4CUNR\?O,"Q_G]O-OR4/V1'@38\Q3Z^!*AKOM>OG8'M<5%K3R\ MN5Z&O3#3SG0\K-_2Q8O98&TNP31=_X#&9!Z=XVVS%5@_VMSJQYC;=6UG -C] MMIN'S.ZWE\2?YT*JE,UV]<]3^JMY#3MLONED6^ ^_]0*'IPSZ%S,5K!@W?+H M[OJP'N#R/1]_KX_K]CK_9'SU^7SYVQ:7%W?S=0[M<=SZ-O4]_'=GH3L]?]\= M]-^.YH.O/X[SU7!X_6[R'ABS'D/P 7SF8?4!&+@N&^(P]7=GOU>8PNO-ZI'9 M.(]L%Y>&$\)(A+B?:"HE]I P:F3RF@N1@CIEEV:IF?&BVZ\6/:4](/+B0F^= MGJI;W6Z=X=O1!W5WY0#UX\+?/ANC"HY?SWY>_9809Q.'M]\S&E_C@/^\>/$]&]JKA>JHT_CZ%Z.'F M]]U/^NN@/SN''P')3W5OX)L>D*M[.:U^OOEA^: 1F26@)K<_8<8601G58_\G MXZ_SG^E=H]:L?_?C9.43%M#/03( T;T'W7W!RH=^^WGZR(^;)_WZ#23Y4DWJ MOLS%*7P:SV;CBYL#F__V,[W\LU-7WCO_;3YH[S[7,N"F9?9:_GWQA.67)C5; MXBL;T5CB^6\YY; ASO?@!"Q,[+3,X]RS#_<.ZA8'_MW1$?AAHF+9OYHLD=7^-OYM)-&V,I>WW#OK+W8W@1//R&Q5Q 8!UF< M@3G^^7S0!TO8;!+AMC/\H.QZCU#TE-ERSH5U5>YFZL=\*/@.C+<]J;:DU+'0 MY;\W383F<:Z9J5&D=U$Y#R)]+*>X5V+Q:0S:"U =-\FI>N[0/M:*/:6UVL'1 M:EZR=%.2M98DQ\(5SR)R+TRRZ@S4003J "'-L\K5PP-T=Y&K#90Y%M8X8HMV M\F*W>P2Q&U=QX*K^^ I3>8\1N&,V :M#W<:)ZMT/+1JK>T.6N[]9/QYTKW GWL MSLJ9*&WZ\PB8\X5%6FWZLTU_WGZ./]P@V>8_V_QGF__;_KJ MPWPVY]M1[0:$Y7FY-ZW\ /0NW?)!&N*U5#%;(S4+CEBN-4_>1&HM=:?>+?]Q MN=&],UL,?\6%9#AT]GQY*G!OT3"/L]CP/NG:F<0_U/=FL(N^^V>C8TPWML9O M0>!7VU[/:"/]]5P^;W_](S_^S+<#6N1;Y%OD7S3R)U(F?JH@IOZ>/H[PW2>#$B'I3RH"CXF#WI3L88HGPS=EX\N9# M=UAU/MRN%&W9MV7?(V#?6)W5DRS]_!)#YSW6\H%WW^+JYY]V[:<\-NJVG/IR M./7C&$*OP\:SAVW67)Q9W49RC%VRJ\GN%\OXNO5LUMNQO8L"W>';\UNMT'RV M:BVQ3Y-%FVN2?40/["%(]P0-LM_SYAID-U'O3AR?B9Z'9\7FTH G8HM:97EB M'-HJRT?<)C@X[8Z=IQJY1]#JOE;WM;KOQ'3?]X=7?JV?V.K*5E<>"8>VNO(1 MNI(]75ZL59:MLFR59:LL3U=9RN9&D;3*[?V$GOG^^%X.OW7 MSJ?J;#Q9<0W^.77G"ZMN;3V#:1]:/>^,)=(4FQR+P!PZ\]>*PPL6A^]M8RFD MO>SYL0A18^%,*RTO6%KFY#",LL:TZ[$(0&M%6KEHY:*5BU8NFO2N3.M='3[_ M<41MJH8G_VL$L2*=;#VZ<+F5!JG[G;#*^Z'1[O:N+JV%W!B^LGPCX M9.F]5K$]?I+URYD=?P!/86_B'8M@']K%>%+N:D7XI8LP/=#TYE9R6\EM)?>@ MDOOL?-D*;BNXK>"V7G,KPJT(ORX1IOS9&?.E2&[;)/7+;]6LTZNGB7-8+ M6QY(]2WZIIK.1+?Z[36NJ&NL?>JUK*AK)_"TXK9_S<<\F;R]C@)C*XVM-)Y2 M&'XL M9:P5;N6KEKY:Z5NU\AEX=907=$M#TZO;># M/+>KX-M5\'L.Y3B"5?"G:GM6D_1 J9!]"-HJSV-0GJR59ZM\GP]RI.RYNH=K?;'+1'=[C2HKO MN7UP?7R=7C4<+M[S;]^1[^K?@2M[-[^O(,O'P44U[?Q6?>W\/K[H%E;GZZ _ M.X%> &C#[N7T^KGFQ]^^9:Y[X!:+@/?=1K0E77_[2O)_'R4E#WR+?(M\B?]S(O^Z;9(5K5']/O^J-)_5 [9_!"ZPF:&/G7_'Q M?%)5G5_A4^?33H*_]>]WY306X[>!Y?9+IP] JU.@3\L_+?^T_-/R3\L_QTF? MEG]:_FGYYT#TV>\:P='=]#ED6%.__>?!#![?6Z31!Z,.?&R(FX+:Z\)'*,G/ M0,N'F;)7C6;59(D2=C\"VK5EB#R>P$NC3JA'N?2N.Q\GW=%T6$??'=?'//X% M -'89JN675MV?02[_C&:5/!=_U7U.W_K#D;3G_X^GDZK:0>8-<)#O@#??JDZ M>3#JCGJ#[K#S=C2=3:Y:#FXY^ 0XV'WI#H98(GQS-IZ\^= =5IT/5>\*GCRH M6O9MV?<8V#=69X,1\*ZO1O#3K/,>Y[P![[Z=51?3G^K-F2VGMIQZ!)SZ<0RA MUV'CV1/9&_Z,=^9CU:LN/E63FP*=:DPYM"VA3Y?9:R]V[LF$[;W-QU"OO99Y M-/JP,>JVRO+$.+15EOO3CI+F+AV=*E?MW[K=:K]6^[7:[W2UW_=/%^RUGF*K M*UM=V>K*T]65K+G->*VR;)5EJRR/G$-;9?F(L+H-JIL(JE_WU;/Z<^\V;2SK M?*K.QI.J,ZEZP^YT.C@#BF!K7&/M&&VY:OOI]OO0ZEFGUS;Q6 M&EZP-'S/&[^>>VJC8)H-3EII><'27B$5:D-2*M$6F%94MA M:6RYR>N0EF/L SX6(G[_MLZ,_&L',R.=[@4@/)LN94:J?N=L,K[H='N]JXNK M87=6/;02_LGRGZUB>_S>P$:)_-+X?/&Q M1'O9WE KV*U@M[:YM_ M_%;-.KUZX-CLS26\:_Q0HG#1B=76.XY/_9VR&MM+UB:?M> M/IE/\3IS:L0A8:P5;N6OEKI6[5NY>D=Q]+PZT\?NU>I]M;]S> M8S /LZ3NB&A[='IO!WENUZ(__T[OTUR+KIN[B=YN13]D*F0?@K;*LU6>K?(\ M&/UD8S=3]B?@$3#7,\3)K3)LE6&K#(]*&38X*K-U)%M'LM6=K>Y\/;JSP=&9 MK?)LE6>K/%OE^7J4IV@]S^=2GDOUM)]FN/9SY?N7?E[":#@856_.YU]-&?G+ M+P^MUGNN!,7BY__QTZ?IGS^'\^[H-KMVX$!1DB"WZNS?_LN1T:H M^5_T_WR,WW4&?7BAVYN]B42X5GMP=MWX&:T]BX?@NF$VJ*[[E]<,W]G5XU'"[>\V_?D>_JWT&H>S>_[WXL7P?] MV3G\"$@NM!/HB6'W0=N[9D<[[87>TA\%NN@&&GC('UY_[6$TN!J-Z.';GTWPY]+,.R3[M MV>[M>H"M2:7:=0"-%!$??R_U])78?!_ ]W0O@_OJ.FP;W.;]2AK:VQ;:'1(I M'\?@#G>@U\MJD_7G_82ZCFK:4A58S'W MYAZU(^>RII7>=HUGWW1R;=>2==/!%:MI;S*XQ 32N[,_1N-/TVKR!;_U[>CR M:C;]8UKUWX[^7GVIACQW!Y/_W1U>5;]6W>G5I+JH1K/I_;ZP+1J]DK$Q<^N2 M=$HZ*:V1401.B60Q9R-.O='KXWF]C_IJ4F?$:\IU>.<,:-?Y@L3K7"Q1#Z=/ MC*\F-=G@[? 2_C@=]#&_A[7ZX:#[:3 /,,SJE]WX 8]9L<_%J@Q_N M=%6XIZO^?J>KFO((VG-8?PYHCCNU/5XUQJBQ;&U[!.N/ *D_Y_V/5>]\-/C/ MJ^86)SY)_^=6QS)_^\LYM64OMU.[N4' MU3&HK>.B?IU(PG]BISOJ@^F^N*@FO0% \%^U"GOSJ0NQ7N?7P1#"1@A:=['A M[:ELV3<,4>[-M8$3)^^>VNDYJ1\'TQYN108N#]WI>2=#!/UHS;^@_'%6E@Y( MQ,[OW=GCG9VGH=X+]W+JS_&_'*:HTJAF.1YRO9^,/\VCU6L,G=YWKS$?UQ0_ M'P';'@^IJ?Y+YTT',VD'Y=!7HX&!=?^CZJ$5^S]5=W( [CUF;7P\QX Y%N!K M1MC6]?Z-0I,"1.7CK^EZ^5*.K:A':+,1DK\"FJ9/97/\]*;+/ MHQIA'A/4G!#3MT'/X=R<8W>P#Q+X'#_O'@OY*:V]2'E@)_)TUC:?NI/YO)1^ M<4[HUI=]']E>U&R_T&T7TF#:_?QY4GW&QN3)W&O;N;,HVBR\3RRDF#6C@D6B MB2&>2),BBR^BL^BN[Z<^NVFGOT2YNI5H0;W.V61\41-M K29=KX.9N>='D U MOJ@FT\ZGZ\ZGJRD@,)W6Y8#/U?CSI'MY/NC! S[#X;9]0T?3-V0;Z1M2ZGF' M6CWRXX_M&CKICS\M\B?2=7]:$V%;^MR!JX_[>M]39*8^GD^JJO,K_.U\VDE@ MYOIW[5N'B7!>Y>"^-S5XX',[- MSWEBO+%QV,=RCOBY0V[';75 JP->E@YH;MC;L9SC8W7 (2/ODW>HWF*69+ZZ MHSML8Y\GC'W:(7>WW7>FN1GEKWVH72N:K6@V*9I*M*+9SIMLBH3_&$^&_:^# M?F.#3%JM==AU"TU5XYK73**Y(O"K&/S82E(K26LN]^NF9ZR^;$DZ]4K^MW)W MTUYO+M>O?SZ.;&1+Q!T5V8G55X^*B$=#N)837S,GONZHL?ZUG+$X 1;Y?%W? M+7M?#;\,>IU_K[K#V7GK##^]Y+[&5IR6?UK^>7*E_EI*DDWV>!VQGW8\$OIZ MUDQ2VVY#;D6K%:V#%/%Y*UI/%].=O)4_2.-1JWI>\9I;N_64HG;-;2M.K3AM M(%?C5<$7+TZG7A@\J,C[/'ZO"?6_O?LA#L:8K4<]QHXKBU(MJ.E3NDRU3-G M$TE3?'(LO'_HO& K#R]9'IKK_'DI\M#V][8CATY0];R>N2:,-%<1?.US35K1 M;$6S03I2TYA[_>I%\T1*@R?5>-1JK=VA^G%5RE:R6HE M:Q?).OR]P9LWM+J)57UCHI6 M+5^U?'52E>,3CC+K7XO^H-^JJ\GX8MR_&M:9YM;1/2)!/K)&OVFGO?V,Z=-\:"-;?5Y*?+0=O2VPX5. M4/6\G@DFW#3&>*]]@$DKF:UD-DA'UEQ]_K5+YHF4 T^JU:A56J]U( I53?<4 MO^QFA%:26DE:(TFBL03:JY"D4Z_R'F_]O"7BZZZZ'141CX9P+2>^9DY\W5%C M_6O1.E2GK+]4HWG.NE,O+&M'#+VJIK]GIT_+/RW_'&6CZ,D7)-L10T>6[GA! MU0S37*KCI967\E8E%:> M6GE:+T^T'3/TRDJ#)]7[TNHEU?:.BE8M7[5\=5+UXQ..,^M?BVZA]_#62WA_=]A9;AR:MB[O M$4GTD?7_/3OACH98+<>]!HYK*Y+MQ*%3NDWUS!>F&DLF'@OO'SHMV,K#BY:' MQ@J%+T4>V@;?=N+0":J>US/7I$&=]>H'F[2BV8IFDZ))GVQ;X(L7S1.I#)Y4 MWU&KM5[KI!1FFIY3^++[$EI):B5IC22I=N;0L>037GW;04O$5UQW.RHB'@WA M6DY\S9SXNJ/&^M>BB^CC>(:CAL87 $\[9^C5]/P].WU:_FGYYRC[1$^^#-G. M&3JR%,<+*F'\P.GA[S8=BR =.DW8"E$BXGF*H0O7;C:SMYVUM#S*Y^7 M-AN%_D :WS_RXJ>CM!+52M1:R/KSX-JT?IKI,= +*:6__[DQ%[(QLWTE^R/6T;M2RKB;;7H,VA18.?G)_"Q7[EWY>PFLX M&%5O%KTEE)&__+*$:*_"S-CSH]H,N$M/N:?\,']9/V7P?]G[TN?&;:3OS\_^ M%:AYDWH\5;*CP^=,LE7R-?$^[":-XR(,I46WA,T7#1'+FB2#(GOGM3?,- M?09^\O+/3);/&E<+JI(UO+ )UVLV7L/*3C1,>)K^+$@VK57+5AREH$,5R^ M;$WM_GK'SLP%<=?3KKLJVS-(Y&HL$^ 3H&@IUQE3 >^JS;BX$ +I2R@N35VB6G[NUW3/&) M+<)1M8'DY&&-Y6%WS]A5R^LB#S:&E6RA;?=K]X1M=97DVU^Y)WO2,Z9V+:)@ M??%G?,A]YW:O!(O6[\RH,43:D".C3IR<.#U(KD-C3OVFB%/=G7[KA,\1 MKA+"N;."[JS@RW=Q2.20R"'1RI&H:>YN9(MYPW1PX7GEW/*_?_WE1OUX=RH5 M[_=CT>>)\&-Q*\)47&,SUS#GXR#ROO_S'__S*S[Y623G40Q+%9ZD<2Q";_R! MR_!CI-3T\T#+$ EV*7J_O3D_Q<(._V[]Y_KT#9,^?,&]9+N[>WIZ?-@Y/SD] M.]YK[QX<'1YTC]K'9V>'^WOG[=W6FW_>6X R,9^H@S9O_1ZK _=7JA+9&QM= M4ZP/W0?B*,I2"H!$,.(H9%Y&.#80?E\0H6*@AV)AE#!?*!@/+@/CBIY *QD: M2>)T*$)X*NKU%+1\,V;AO YZ<32<= $MAPH:E]"O^#&*5!K#,SP6; 1_8!T% MG]T(U N/144QFNUC%3&VUUM;;GV7JUKT[5K/?I:3;ZF M,>[U,X;7C#[%T!^,.0[I+.[2BL<]VU*2I+]'2.(E0Y2O]%RT,&3I7"?R3&S?LRTC$-"%C]VHX ;(]:+]R M^CC^QU2./HX^9D"I;N6:C9M8KECS,Z*TKZ4Z/>TJ*#O@6SE]-J6N MKW&D:\2D-I2>;M4^R2S?@&-;N#?V]K&]-U.@X#(^ZD^X:F\S M^Y+ ;PWOMULS-][,KXN&0?'-=%<=!&UP,K+5O3 EN2#$P)TY.G!X6 M)W,VY8:(DSN0_8+35VAE%F:E^.$->-@79;O3!0Y-5C"B@\;7T4\SYF&[U5X>9]K,9:;] MOD6*(SRWY$%>(N$RJY_P@E((1^W3\[/N\?[Y;OOL[.1\_ZQ]>-(\;!X>M8[W MS_8ZNY670JC6E?QR?<8^LH*W6^_9Y=D?9Y^_GQ3CU7->G$F76%U MBC_!F148;ZX ME9[0Q2>R:A)%2UB: M^"MQ5+^ _XKPQ9E,:SB[7(X-/B2*E7'"GURD=*U=21 MTNCA(Z6+]+[#KH$RO2@ ZP3(P@A3%/-+151HJCDQ=$F.*"_S<2>3 ?-@2:.A MB!46\KA)@;Q":5+V1=2/^6@@/6B@#X->O#3'\[>':E>L _BT+T,]2)XF4?Z% MMC7IFPKJ>1P9*>>QOU_KDA*K+4:R49-W)TO78IO>.OK4]N1D!=:I.SNYFE#! M<6;TS,E/6J1]>CP_G?F8AFWXE'QXD;RXDV'&M< M/T4*-DNDO&@T-A8QMH>0-0: )1*Q#H2SAEB.XS:!XPQ$3IHUUA3TWK>=JQUG M^]D;5+*%3XQMVM=DZUV;HYV6J6G;LH[XGCMNX## 8==>X/J J,D(642\,#Y/DOT?5Y[NLLHD5=[[.MP:>>^UCXQT(FF$TV3HKF_ MZT1SE7;(V@3Z=89F% ?^G?2%\]^6CUH+'=9X66RG MV2.A3VYWK,]VQE'U5/ M/G+%V-V>H!,G4^0ROBNX]N)4]XW!6F7^6$2W&H.622+:F^'0/JK>-]F(U E_*R><-<1R'+<)'. ML,*\ XIEK%P&'1$W>-_-*B):0SC'B9O,B9OM-=+'V1OI N$E<30:C)6DXD/. M"%Z^Q&YB:H;C'\<_MB:+UGXKTI4:LBS,L3[;&!UC]S"M_2Z%DRPG62^1K.K/ M#:Z+9+F\7E=H:/7(LVZ543JN,HK;"73B9*$^WQ!QJOMV8*WR?2RB6XU!:S-J MFAQ4[_1O1+Z#DTDGDZ:(:/ &TXV6R9KL"MN[K>YHM4Z[>E;1RO&5XZM:[1S7 MV,NDCS/Y09]%&D?#R$\#BC0[0]+_J8*"3AW66AY:Q6WW611Y<1J\K+E1#Z-F<"B:=0V.,M^D% M3)QD.LDT2,>VN?WY39?,FFP'UBK5R('6IA9$:>V;SBE>[V0$)TE.DAZ0I%UC M ;2-D*2Z[_+:NW_NB+C9NVY6$=$:PCE.W&1.W&ROD3[.I Y1R/I6A#IFS>C" M,E=B:*.2_E9.'\<_CG^L3!2M_8:D*S%D6;ACC78S#LV%.M9]N\*)EA.MEXC6 M@;D]_'47+9??ZXH,K1YZUJXJBL%SRQM2%L7)DY.GA^6IY9;*&O\.@(GND*1] M5W/(EGC"QJ<=.")N\+Z;542TAG".$S>9$S?;:Z2/,UE$UU&"I8:B(8S'U1G: MF)R_E=/'\8_C'ROS1&N_#>GJ#%D6XEBC+8Q&IU7]V29;!*GJ,*$3+B=<4\+5 MWC6W0[CNPN4R>UVMH=6#S[K51FDUFL;O'UG[ZBA.HIQ$/4BNHY;I'<&UEZ>Z M;PHN-7[[623LB@?"'?M<==!R6CP[()Y^E-X$XE785=L"(/.Y]:>E$?M)-C:2 M7_)\VAK5+/.)VVYT#BHRWEY"8-LYT\5V'(K6A5<=BJX 18&=5T]@VSG3M*7_ M2\*!+G.?+_U=FE<@0[&=Y9:TVLV?WY*AHGDS!-!D#WSVYOF&_H,_.3EG^<0ZEH.A6*?Q1V[ MC(9\1J4,>=R7H1XD3Y,H_T+K+_KF3OK) )X&0F2<#EP<\)$2[_(_WM_GW,FX MRUYAP?U'<_W\Y_N5>DC[^S\_+5YS$2";TFI?WZWUZ&LU^9IDD]7+_'/TF0SW MP.Y8J5DE.]\8NQ[$0K!/\-M L3-0I"-Z_)U,8!Z>[FE+A@Q>"["/MPY%S*/(D]GB2^%T4T>V ME@$Z[6;+V'E(QXF.$U_%B0?5JKEJPY2U"&*X?-F:VOWUCIV9"^*N":UT9<'8 Y ', MGP 6T9J=RVXYK4 5I.H:Y4D//MTUF5;9VD_4HDOG$=2>N M[3'Q'(HZ%'4H6D\4=2>NK;;L5X^@^<'IP]&J[Q!PM%JG,N96T.K6I7* MK_M>SME08%V*/IXI_BX2Q;9:+H&CCD!G\\9KU0[%*_P%BUV"/9?OXI#((9%# MHI4C4=/ ML!NNH)THA+>$C)GPHC :2@^:"WV)%T*H!AL('B0#C\?0C/"2*%:4J12E,>L' MT0VTXO$1OY$!O"#4#CM)XQB:#\8-'(8,O2#UQ:OKOF129*29$K6 =#@1HBA- MF$6]&9H_?JY_A0Q2-X;^$UDH"(CDHSCR4P\8>A3+(8_A56!"@+7^@''FRQA8 MC2FL2,YZ4>R)'781%MPNRS>6L*%>)6*WV>;S1K&ZX4A0B4-H'@1"WJ3(S#L, M1@7\KJ0O8A:#R(2I8$D$ L2 K"AG=P,1,HX-]U!08$ !6!_((![,%&;+&4K' M4"3O< PD<1S;3&(.L[B3"<[) X)&P%E:0KU8\ 0F)T*:'I50)#V42=<-+ )- M4+W'N0PE"FHQJ2B&F<:WTH,6L&N)TY(]*?SW-$+H.%30-S(TT-<3#7P%?^%# MY'TRS5=_PFB-1,PRP- M@3T4CA!I$(N_4XFC@\=@1-@X0Q,AXY*<7K3>"5*?J8$@-8T4 M]-.C)(!@BJV%K>B8 KK&/3RJ1 M]4$/(\=BM[@<(?Q$S :HB2CJTV#QS7X(DE1P9P\(KGFV'U(O/ 82]P7^K2:@ MGK$+2Y&NQ %R. IXF("H#*1',@'V19)K#9P%BAPNCA?!H\ +]T; ,V;1[*%? M&44@CXBDB1R*B0"$L#Z%'H$%(.ZFQ>%C'.@.^ZK_8,AQFH^3\0@-'L""3I/Y M?$P C7U@=94& XD%:1^C: :@SV M'@*#G5F%8PD&U@BSJ64?^9:H^PY,3A%C M_[K%4Y'!P:5F2PMG4#>*YUHR XN2$@FD-K'&),=^3OH,$1H:-DJR-U$@4WA8 M8,)$@\S *J)5)J.(!)EV\*G?%"TZ@-5;#L"-R$>Z5F,E?@5PD0V$-#%HJ9C"X>[A^WW@'U@+4/+I4ZNQ@KT9X[- ML1C%H"H0T!^AVP[[($(1(V1J$D8LC!+-!=$-/D](G:O:7%>I!&C& 4-%H7_( M3"C(!#R!(W^P7T5V1BQ@.0CR!8C!$-[4K4\UF2JM8C.#@\P'T(FC(,69Z9K. MC(^ N-P;D+J!V41>WMB,*9,U6"RJO'UD/F"3#7"9KY&3E%Z?(-,7MY-AXTJF M 7*12@/296B#XC*3=M4V$[R;LY66/QXXS\#0>$_NXYS,+%LO +.0+%LTER)D M.N9I#W/Z632:Z5>T#+;1I)CZ/4,3<%<)/=1 "+! OJ2S6%H\@_WUS#BN5&UV M$EKLM!IL;GG(A;S9._[ZLJHZAM*EK($5G:O5D>*N$HLMV+-,!.;E!EVE?K-7^BRP#< M8_24IG59;M.7'(!,$6F%KGLCN_D6[(@==IK&.9 :(6E/QBHQLSA_PZ(DVF$T M%#@R)&RD9$MK8H:YV_MF>;NDJ70XD*L\$.?G'A6_ 7ZZS_]S[,T<#DDSDUTA M JW&T= _O:E\L ]?TA;Y\J<9"&%'Q.I",[G&W-*6[+85@0>HT2?KF0X9*/S M4^V2(+>CTA^#FD/[%.,!%"G*'?]&81/C:"=A$H9:/\80Z-/V)46@"JNLD$QL MT,MCG04".(N@H=, 0 MW(*0>-Y+*'+H\R%H)!]530,1IMB7 %6D&BC!%)HK I@H41Y\(Q/"%=18U$WA M1^ #.ORK.U,Z2 B^71+A:>D 8WBAK^[%UG);G4)KT'[JY2YP+KEW9?\4WZ# M/[27C6T6/C#BI DQCPC@I=W**%5 K5$*5AY7]^<9PH)EMM]!YWU&W0PA[SF4 M.^Q8E$^^5W'/6\Z=4/P;&"Z0\,:<#K6%0!1%QRPG>O;BQ-_) MG]?A<#WC/"".3TY/;7NV)VTT4:!U8@U-(L/?PIQ18 1HC$"?V.:,L# M(,8M(8!63W+R1,#3$#!: >42T9?(>/E/0#580LTM]+;6'J48:0+-_3>+)V#D MHH>\/<63JFS53?,F-JL]2(^CFYD9C_G/I"5QC77D5J]OT:Q3&>:@"]@CTN)4 MK- -+1VN$%HJR-FT( 5"Y3)=WAAXY-5[R%(206("[:Z.-9]'8!&H$<; @;4G M%A7NVVK#@?HLQ"_O$$&CD)\[#+/H8 M:'2KM]:1'IGP)"V5(=HOFWELN ]*/ M%/@#C/5TG/XV"M(A"7EA4&7QG:QC@+Y>OIN2AGD34Z&=XLU\K$ O%>&SX\(T MIL#E9+:];.=IR'_(83K,WD1;"VO?ZQT?#+3X)0L30_IH[V5KQ/NQR#8W**B& MZ0^C'&X)-N(^#S/QI=6=LP^(&P^83R'1%8)W!I$:X14B"OBI(C.('K8K<0N2E5",%DA3L J-QF/.&TUN2S%;&F M$]R%LW N=:-]#KY>060,C@PE("%P?4],:\[6)3%58%0&CD:6$L^5L% M]$SMS5-0A.&K;5YO'TW0J!] +]QB,$8L2*;HFDR=XCMB\"<"+B M<6Y_%K2]%,,HH8N[)&HZP-Y+HD0G,96HEB'$ MI$TY+"(&V=X([K_CX3Z:24^&//3P5Y7 %Z06GK@.)/O[UU]NU(]W6<3O&F3T M.(B\[__\Q__\2M^#9@%FN..Q_Z7712V#P0D%7L)IE-XD,/^NIPV3XE4:/7RX M%+W?WIR?8ECGWZW_7)^^8=*'+V!:VYV]T_VSW?9QIWW2W6NWC[K'AZ<'9V>= MT]VSP\.3UMZ;?]X#DS((/'%KY[QLPQDL>L8[4VFSUMY1:N\%I.U:W\%9[^M3 M:S7YFI[E-6IK69'TOV;T<1>0/G8!Z4/FO;N7U/QA%7K<71=JTWEJ=TFC_=>% M&JMDXMATK=C4W25:4+ J*A^+O@Q##'ADV1>FD,&=XK7A%*_M-:+F,Z451WQK M6IQLO_KCO[8SE:M2L#'X9@&W60QA]J+4@;%[_&QF#=-%"A:,FK;J'%>A]SZ+ MA'D#'O>%*NUM/KZC[N(I"SFJZW='HBDNL448JK9LG#2LL32X^W.7%SJJO][] M5LI5I@.M>5J(\Z(L J&G8L?K<_?AEKDJBZ^EV83)JG/$C,NSJQ;KY'8E"^2OZO#N<\E6RS#O_K-W\%]- M)PM8Q45G' XY'+(1APXJ\AO7&(>>51O[D6-&+S].-/2,TE[)Z>[!^V3UG%SK[W7;>\>[K5.S]O-X_;N<;?=/=^O M_$Q2U17.!EBAM2AHV@,*LELD85Y]T"L(690CUB&^<@FJ.SP&SO,3QXI-)3*_ M>Y2+GCGW)Y((:W="2Q<8U(/D:1+E7VBM2]]4<(AKU\@AKL/=U1Y$6F[W-J:+ M6J WYNO.XZDBA:?"$\,;$;.LLJ Q ]^E!;FTH/>M?7.W4UO,&Y;D!=49J^B] M[E!7RM&U8*B(0W'HKU*AT,>C[_T+H5*XM1+J,![U_/B5/AG67;^2V*R MN]V#=JNSWSHZ/-C;.VT==X^;G:/CPV;SX.STJ'5T4O>8[/7496Z2*GM.%B(O M1Y9=B$:QV!L1BIY,IHIY%O72BN)P0,M]-K4(["NHB,:D1'\L1E&;NC9C MUF5;I,_%@]4S<>>UB57;&XANKC80?5B#0+0KJ;-021W+:G&\IMS&T6)4/7JL MV,8\/;(I09)*+>#,++JW@3)S1Y/;27$[*>;(8R[,:S-K6!)HJO]!KY/L/B&+ M^9Q[%*7OYG&Q@;H _8PF-QR@ MWSMX782\O=HK+U[:?4WLHWJ=T5OI#L4R:E?G4,\NQ=^IC,4+\^(L(YYC+JN8 MJTM7OJZ9@U>IS5GQ(6/+MF"7P8-5NLH.X!SS5<9\==^IKA(G/V7W)@9U_<)-FUXY-\YK/CB^O3;@/WEGS1DWB1^,V8 MDKUUI@7C><"X07=QTQW9L? $TAV^R:Y_%EZ:R%O!>E(!*=C?*8\!/YZZ^/D% MLGXO/%Y%H!NCZ3*\%2IY=T'_X-LOCH4?=,\/3HX/CDZ.S@_WNON'QZ>GQV>' M!V>=UEFK=;*WU.HMQBTP/"; ^T#9/C /\W@<4^H]IW/.>?D6E8!=)OK28[(@ M8U:O!=/U8XE)]=F)@LF9 P_?B6(IU&P^O(N.F[H,>V^Y^>/USGZW[/4:I/[7 M-O%B<E+ZROBZ*W IK$;*.O-,U6[W!7#U_I:/ [;'+8MN.?;RUXYK78 M5I-H<*791X*K5*=*,QZ KX*%L&Y%%8:NLV?7^-#^H;OPVXF#$X="'(Q=O;DN MXN!B3 _3]FMZ$T@O&&\/1 4$5X:TW5 -?'1-@.#UJ?,A[D".VM?IR# .N%SA*N$<)56E_VB;/M>/P]5=M] MSD?OCE,E0Z'4232\R2Y\.Y7*"R+,@'G):?B3O4ZK>W1PTMEM'N\=[)]T#_9. M3]O'9ZWV<:=]?KJQD&,#*($'4]>X,U_?3X7E#5Z[J-1U3\8JR4MJ&&D1 MJR\8:6CNN;#%1A0;&]%LG&F1AAXO7>(DY]GC_1*R[BB6 >LT]4'"!KM#\0E! MA7O"U[5F0*109K(*(B5QPJ\^_[B&YGF#783>#MO*/KYM,,Z@X5L0PCPA)+L. ME-UPI6\)_<1'8#I\B,&>;[!/,@2E%B5\)V^2^>)6!-$H&\:E^*\&[O9>Z_W0 M"!OA>RH=/6#S8+&@1VH<'8R2LL=PL*O7%=J;N^ +"=[56"5BB+01", M,:65*\QM39!((_P"?@>CJURI94PU7&+!R99@T4BC'Q8)&H'%H(N^X#VP-R*$ MN<)212J!'SPV&(]$/ J@"\ZVCK_^_G:'86&9).:A J,!5QUK"DF54"%%'K)T MU(MQ_@EO@JD("%/<&L30,299"0$U=/VG,0"1VIEXM: J!_P6 M19R)'["(R#/ 6U&,IP,GV=+8:RZ&Q6W >-6OAW6I@'2Q4&F0:-X+15(P06G] M^0BXZH<<$@08HFY[US!UTQ$RM$8XS1KSZ-K+&,;,) [WC,YA IAWT"I(-*P* M@$!,)<3@SXA@^UL,_EA_3%/\*H);$/7?!0\0 C)_PBE5TTJUM;^@4@W_@ _P MYR?AHT)B)U$\BO2=ZFPK^_$Q%=N+O)0*>87L+@(>+CR>@_>*#6C9=XI.IM6L M-FB12Z(0Q!9^E)[0M)^4G_NV<[7#SJ/(IP=/X[3/NCZJ*"HO1J,\/^V^U07M M@@!00]?M8@ 20]T-Z+)H) &&DO1&J ;,NB?(-.LJUI[9M&I.EEGWA9;#S+@U]$6/_NL43>!JD%<7G!$4,?J3G+)Q)W2B?AS1B M)+Z/5\N1A27T!5/P=< S(XP4R8"'>/DJB%Z/RYC=\B 5N5KQ)JODE5>)!9+? M8"5.*90Y^#,,)BY4L\"($!0UOX!G)WHRL9E?#-ORF\4PAB)I#)!FR'U#)/NI M?6AV38%@):8L/#*WU"YHNK+QGDP@5+LR"\$HU5SF*JNRK-A4#<+9,LL+S/V) MJEVU*]P\Y'%?AGJ0/$VB_ N=8D+?6'OSX>'N:NL3+[?[NB?'+C7YY9@'&+S( M;I#.R^"QEU:_6VHM'FN):47]'7MS@5K[U=?]UZ>X(-0E% ME)S)42RCJ<#U2\[YKV_)C*VVL7SG6;ZH#GN,L\ZSRV@[6^%A(IY/7 ONHROS MPKN -_#LNCNZ[O2;*5M\&37631T(L#R_NFIK_;DT7;_T_M;>$@]866E\S.Y FU61C-?:Z;2;[,9D*INMK%4W M4< TJ!@+\-$VV4?,\&*=\D[%<%(P5[UHVT*&7I#ZXMX%D0HF(GN@4>#=-(QN ME(BI%A \/DJ3.;=&NNV,%6UG[!G9SFB_]K[#U[[?>=W[[=?NAQS4YL+&C'&H MD5FCK0J+;AFW!3V4?\8^3K#*=!S.KDO9X\NB'U^?5?M6MI(NT$JR4E;6C>R7F+KSV@AI,;L';_D; M2M\/A VP91?UR6O%_Y]2INI)<2I _I<@;%L?#OU4'!%X@5"X57FNW]Y\.%.[ M7N1=$)U62?W3(H3#3O 0TCEXT*]&_HSR=NZ*5DA$=LF3UQL[RZ'>FELY]%[G MY]>JUB4@BSWD^AI'-]I;I?/Z7W5VNRE^MH!M[2%UZ^!GMLTPDE8IAVX, @/K M_J6+ ?Q'\+@"[K49C>U9!HRQ %^WF\_/.GO2J7DP5RA?&7N" I89> \X/>)6 MA*G(7)M,3!9R;$RMS--)$+4BN_9J=A\^>;9$TMIK(]I@KU?A]%A6G+:&CH_] MO&L+^5LMLB+W*C8BG\ :9V0:,S)72^FU,T+W%Y"+^N38V9&IN,*LHHD\SI[) MSQ+95/F(D(J&Q9GH4NB_4:H&-!WWQSV!>,I<+A4+XC&6>2T,"93-HJA%&LEC&*E0[6"$S%M R MG1P?S>D9WA\5(:&LU$9.WB$?EXKN#6#-L732_(2N>UWE9& X'MT-$BV1L#HZ M17!.#T"JYW40QTU7!S),2Y;,^["(T" )D">25U;"^7+D((56,9;P?"Q(Q72WV$SK8(^&+O-QO\<5C MU0@I07G U;U*@Q>7%U?L&FOU>1P^PUA8-PQ3>"#@,'5VB2"N*^!2_3_"K$E) MVQY3T!R ]5 ";P8 (OTT[LN$V'>'?4/^U>^(>*@T)(G)A!31AFJACM+8&VC] MPT91G!=AQ,L-!2H;3VPZ#DJ4A[S M(7(/:*5O6,UUME5=<+/<4*.TALB9TQ/#MT4 9L0+9[G#SK@WR#]-%=W,&L\, M%/%C)/'UK)RFP&J;/938HQW,B9@:NE13@GE'6?XEC5E!7QF@>V%K6\@;4XA"'"_.@?"VJ&@Q++0&!BG+'564*)C"79]+U[)Q>R@NE@;<\> M4JC=D8(*S@L<&3DOL/?:?/_5OE[OT==J\C4YE6X3%*]\+.Y2]Y?0IQCN@=VW M3"]C;YR.[%:SF6+MM>=55EB@Q]^!$QQ(+ZM'5"XK:4J*[2.JO5+^8+KT*L[8 M/&.#=?6@L(RR*ZNGLV/HC6'HO*;G3$&)9Q?W=$72'N;FL[]33* >BF00^67? MWQARV$-'ZU#!N+%?[QN$K2@_:WTA*WU6I+E;.;%JP3-5N]S+26):0XO'89O# MMD4SXJHOLUT+GGDMMM4D&EPE"3]-\IP8#RC]+,'K?RLP=)T]N\:%R0^-F5NV M2$;5AI,3AW46AY83!Q=C>BYMOZ8W@?3RQ$:%E36-EIBSB(SUQ:#UN<2@9:ZD M][K?8N DRTG62R3+W0_B?.]GD_!SA >F\.R7I$*-SK-8 ?:L-@O*/ 3M=HQ! MT!.DL46,*M?Q+AW)B=N#XF;L!M5-$;>Z!P*L$SY'N$H(5\D]:G7=;J./*[Q@ M;:TW=><3=W=WB3>OU94O5V +L*=+@?&(;!#X+HA<&>O(E_:(?##/D%]"G95 M4.NLRN%6=!&@FLH5HOI67L"5DCV))4\4BZCV E6NPEHI\)7" AM8FT'J$EC< MRVI: &R8*=*0ACSU959*##2=TG^1\'!=WDO?Q*P&6.W#2)\-JI8F&X%O]'O":%*E6&8KK-%@A6*))>] MFW$E-[9V.F8KHS38W4#"(L1B% /.$+P,L8+2?[/+/Q,>]B7^FR)#J,&%YW2#"=,MK$(/C(/*^__,?__-K M_@9>5R3UPG=#O[B"$!%BSIM4)!$^7(K>;V_.3Y%)_]WZS_7I&R9]^()[R7;W M[+C5W&_MM8[A/\?=[N%AZW2_N7]\>+S7Z1R?[[WYYSUQ+2_,$[5 YED82Y3V M^0;;YR_79^R"%0+0>L].OGSZ='']Z>SS]17K?CZ%SY^O+SY_./M\DM1UC%1RH6 M\+B/X);@O85@4_?'S(_EK0AW&.@)GE6Y:E#5S2 07I)"/X =([#@QXS\"]7( M&DVA,>HAT3"$12YC[@M,UHH%/1?P\72!2;#-":6P33_UDC($:4B2/0 >^"2S MJG)?;K.BGDX$HE,(OP)K#-)Y::HVAG]G-4WC6*L(3>$,>0CCG" \"R6WNSA M'Z(@0707HEX"RP[6A0PL76YLB-4[YQ&T/'IL;T!3!Z+J:FH_B"1I"% /*TY. M +94E!]KY+.@0EDQX7,/[R+7C?0DT'H(ZRFA+:9 H5)YM0"+^/%BV%2 KP=F M5X1ES^((E$0^561N)'G.+ 7^BZ@?\]$@_PR-YL9C+-5W7>KPQXC &98IN<.5 MPC7,!DF3H%*U'M8P;>BZ@E2BKU@4LIKS24G]NN)4RRY" X#6,A"=2]3H"8YWORM=1PPKHP69D8[?:,F"<6IC'CC FR8M"0WTFR2! M/B<01L 98: K#DK0H;?2QZ7.)GB3)KJHGRY(.!GP2&A]2Y5HHX08/PC&Q40T M ^2?J#40U0"LHK0_8$/ JP3+3VHM_U<:>G12 9Z7HH<\E8Q'B!70HL(W0+3Q M8(.?KQQ0 ,B=ZLJ30'#0K;@0\#A.R,0R""KO(=RI$J%_I)8TMJE M<3)%>.P A!XX (O_:N<'^QF-! ]@%N07(.7'C;ST(S" ILM]$F:UB'L]Q)V$ M2AF",@:(T:*!B_QW"@ #>$O]:K,0Z F30!KC&J5YK<)R1]H5\_):NOICB<$W MLIQ<%>,]31$L\[+.&9K?(2YY:)GV4N(ZT8\R$,^,NZ+L*' ".V-TA%4P$>,Z4B%;Z M6AKR(MO4SB\$G>")@;H9.T$P--X+#4*Z9"'!IB*>N,F\HT9)_V:KW2@EP&M8 MG12^)-M%XR.Z?/&T ;3#KL"R 4LM?PZK?]_,?337LKT4-6.YJCR62P?^0)7P M/00C![\#_P=L"&VW)5JY:X>4@)FJV&+E5N)-*H0,PDP6 D5XQCA'P'>28QB@ M#DME=DD^I-*<\TG"U $R<*XJO4&1S-0EB$)OF_J ABC*A+XLB@V66[]/SG)S M&G<>?7^^Q.?6'Y% -TCV D@HD,'3P%6R?).!C/UMM&C&)6H4DY:3\NX@N84I M,+&C8"!IB!/6UKR?3P(-B@PI?.%)5,R*RNS/G?-CG%2R1@E$=)"24+:LUJ?8 M!-&CSV,_$"JOS2OC'/D:+T(V!TTK'^^4;Q'([R(WCR@67;+$[[F@8*W!:.)Q MHR2=?V72 R,&7TA;I?U47T* ?E&87>8 ')F@::[OI@YLH,881ME*#H,3Y1J) M\KV-%R,!Z//NU3'K7IVPZP@\2[:[UVR\NF']$1^?*J0X%>XU%3T72)8X1;PI MJ=)(:/0-YO,AP ](!S@BJ)?1=7_,E&CHG87"(L=M-N)]###E'6!JGG^%)P3C,L%);P"P#--AJ8YX\::3?$/C_:)W5&.T5I%G MI_UDBG ^S#SL#EC#S-97:V>OU6(W)J\%X(;W,F?* YK9U"22FB+B?JMM+1%? M4&9Q83KJL+V87#^2X]3CL)UM-%/([NI9Q*6N<%- / >&&[58\QGQ"5E'^7;?"0Y*5Z?,PF'3'>>Q4-A_F!* MY)XA!6+)!LEC2:3?]4I3'_##; M-L4U)>]8BS'>0S4;1]*^,7!MF%U=."7Z]^^!Q(O*H(%+@;"#=O,Y""5K-;?_ M+[M>$5O(C63B+XF;/GK7"40ANLL8L5':6X*G]!YB4K[N9M&P56'P-^9XN!,N MQIO2*%QV'Q6G$13Y/+?C:SM+34\FM<1!A,M !0R)/;YSH&Y["<7D/K9C# M_67 #3I\[B:DJ&>>KWG'_6("LA2.O&Z6USQ.RSP#X:/&P([)S]AKL MS+_CL:^ W#VA//*K09U\_'A"F1'Y_8PP*+]PY(N]!]JORVZY2F\4/,(QSMA@ M5]R/.?NDXY_YI8STY=M&CB2_P[S9">V'0QO_POEZ@"HG [0JXC$[!;&D#?2O M6>*(?C:/<8:T'?)_()U^- 11#T!HB^04SLY2W(+@89Z_H;-.;L;9T&C?AAZ/ M2-/G$3CR[@:PG@GF2-X*G7%"T]]AI9LLD7) OWW"=4THK53)E,[V#/"*WUA3 M3&C1*=P\("(521$@;.0932@*TS5IWH81R[H MY'&,H\E6<,S2,'?M+),=D&CPZ23,\E M6[GB:N')/8G96PCJ19L[[!AT29%.0XJMD($\'Z.80/LPO\L46R[XN$O/@:KI M]60\S*X4S;><\E%.6-]I$7/8UAW%,F"MHUP>^ 24Z.KGXPBO/F17"'()10GU MZF+.5P%I\^ 0EBH>91<03^VQG$KMH67+G]\&6WP-G9Z".-VAX4>!T9PM)R*8 MW61*HDF0D V@G(M]U?UZ==@?&IVREM!=>:'\(IBE(&L%N?*9 M9RP_C1_3\(K"^3%*4E4>DQY1=C'N9&#)(!;WD__N8=D7+XE0)[7:#XV%\MV0 M^CIQ#._D13&E(CBW4MQ-(X8V[HI5RNP)!(%K3+W$S2?V!9.D!-OZ=O7U^@LH MI>RA:VW#PJ-:D(%I8"!EL3\J Q>]S?I@92:9J,\;'&7$J81:R9CT,&_E_DQS M %MTPCB@\G [9932P]4XJS,-RS"I-^9/LIMQZ7)XXB)-"%KX',@<;)F&K?;^ M?=Z?0J"O?UQG9E0A$K-8DFV0EK-5^+1&G;;29@$1+;;_(KL!3LCO[,/PYO?" M7KL'=HAM6OS;>^WW2H$)$,6]!OL@XB'=K)PCQJPMMG5%>RTQ^]^]O>;;&4S0 M-E?)[BG@YMZUW+^3G5;&' M=S:9::&9,1PY@0VCQJS]HR^>D!F40KG/G+595O=#V\G0AV( M$#E5I<,AA44R29Z5U(]9/A@V/?OKASA*1TQ7ARV842K%2*IH/WC5$^C C U]?B!ZQ69OEM M?;M^JVTMJ50J/N"I&>W_%U^\Q?RZ^)8X'JSC*?M[DF'Y)QY*C,,I:YIZTJA* M\6S,G9Q2=V1(J[G*$7VONTB;A#/FZ+?KQE1,(&?*=O/]:9SV8>:PC'0U_+&, M? $6GT^A@G.)Y+K H<""YB^ULCVJ%S6"J@"\!22LIBHL%1^)-)&>:MQOFE-T M5>ET ?"R>Z#Z:1LAS:(/B@>%UK\:AR+NC\O&^A71IR296A]F%OAA62'Z4@UA MY3(5F)L8^AQ3J+(#D#+),S&RP,P5IJNIEWA(3I K"ZAF^3@?BWP<%UNU^ !Y MYA#L&CU 7L&Q[=VCQEZS:69+?T[*F$[S+E+R2W$- IY;WJ>L397&??/"XY#BG$_"0_8H(DE0[V[3(EDM"DK@ENPEJ(8W09H)^ C)704 MD Y1SCTW@)HH/YTV.8(%&NP6C/T(-%)/^'24AC"94G@)5=6].'8&EZ4T #-K M1 )@:(G21*>ZZ@. 63(ND2#&G&$\6H&']RK@M+8A+BL.L)WP$'1O=MJ5TJY- M"2\ E:&Q8CD@70K%5+H+A>*J9 9]5D3>(,7#I/?VDE-5V%O/P*<,.4J]$+IDL$5TG)AU MDPV+!NMQ&60'7 M41,M@&&POU*?ML#*4(P?/\�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

    B7OR)M:A)Z._$GFC4/) M4UV!GR^3QJVOIQ*C;B9W6:G M_Z8M['!#Y7A;VO->RT%:W.I>S*!4GT@[!VK/X9/4H1RO!A]+;@GPU]E]>?.T M,&',WZOJYJ_Y8G&PB)1D$F0ZU4*9_T- "M+J"L.%TW6?Y^Q(A*$JS*-(LX)X4H7O?@X)T&[V9\L;91*SS?/[Y6VU>MCF9-_6F]5TMID !+#(4\*Y MQ!(##331!>(JRP M"FSSXI>5'4(X0CR7!2L@@B"C!08I) I(S5F&0<0 =@>O M>6EJ"S Y0IC\V6)TB4:#4.L08_9-L6?D>$RUJ!X>I\L77/]+M^C/@H13,5U( M_D80J05UIXK4S^R4ZJ:<3[:VOI1W\]K$!X8484[3P@Q3!;E"&2XH8AF7-%.Q+Y[;R= !5%*CLM,??\+. M2WDO7+E)MR--9^*@=3G[E[OJ^_\R3M8A$*R_J!4&'D4^IPAX0U,Z4 S-Y%X_>DY MT ID#(,"9X@22H6BBB%8:,(SJF*_J;#K_CM420,K,;A<=<*9-%NAB,F7EU+8 M4Q5,*UYQ<%8L?/D:BUIXX_])+KHQ8:,7;2AS;?[%!!"B&

    ESJ]../WVH("+CBF&HJ3+Q$"8F%"*<*JB0QH+&5H=]L%V#L9<$-UXN*T$T M2CRSO+-L!!CUQ_Z>&.Q>E P_QOU@5QV[@ON(_ERNYI7)3V[D=%-.5*H S"#@ M2M%Z,VL.\+X+:VVW+GOZTSG/"%=%II!D2&A&F222ISFG*&60Q:ZS[GOU%E5B M8"4U+O?A[DB:_;B/QY>G -A2%5 +7G!P013\^!J/.GCB?T,FNC!AHQ?,&+FI M#>G%]&XB4Y5CJ5&JA "9AGE.0-OES0^LWOO^^5/K8"5%4$-($:)*<:1U"G)N MOE Z!S*R/NS!)#4:>U5PI.:R&L1CQ4T%+ D),/9?>'QBS/NQ,OQ8]\1==>T/ M[K& GJ]GTT5]OD6;[ZPGIN.:F".'14[-QP-5Y 5ONW(*A=5C%N<^GPM",XAX M)H1& /-ZZ@2$HUSA-$4L]MU;^TENBRNI@24-,O>(P)DZ^Y@@)FN>48$]80'C M@E<\7(@,?%D;7B\Z>_!&=-"-#7<-V48C6UL@A28ZQAA0G $S,?*<%OL"6::M M=G&^_OOUL-C%S)V4Q(E 5RV)Q5TW M-;&B+;B>''%AI2@^W(U-4[Q\.*DJ_HS8Z(IX6JU>"%B;X@@BD1*IADRE1<89 MRM+]A@""H-4S=V<-*$"!9 1*!@A"P-A+"ZF5)*D@$!6Q[UG;X7HQU[I7+/SI MNRPJO3#GIBE>I 70E%-4G)"4SLP-KRC=7:@"]B37E4\]7Y0K82S<5:OG"2]R M!,V'\U0:I2(X*Y!HQX*0*7!;]WSYV3+C*!/UWB5!4&;B+I(#K)&&&9$\%[%C MD]U27H,I:4&Y+GDZLF6[X!F/**_E3DN.@JUUOG#_[$JG'U'#:T0G]#^M3TVON7K:K#?3Y3=1),4FID$4,RX9,B,AS?=9 M/;8[7FUI*LNDPH@)F*(<49[15&$JD:@?V5,Y[6E/U19BTF!\EVQ1)D<;#YZ/CC: C-#8[S:,Y'NL[,AFB'23&U\.(Q\A>\W0&?D)0.LX5"B$(R?/CW7D MQN;XV/N'Q^E\59L0)BBX*]?LQWP]R2A23&4FZ.6I$!Q3!=3.CN @LW[WR._3 M(RO0 52R0V7F;(/+X628)VOG):IO/EI "PWA(CT[I2K(E2**.M)<6EU:)0E\\? M0%*WR+H(A2UW'K(:@;;NPMH?8QW$-0)S?O+:TM4\_MJ3UFY-VJJM(U4CU%M7 M#\XIKA<;[FFU^H^G^>;Y8[FYKVX.\?//WRW+^@AC,PU A$A>)Z?,PH8B-AQ:%PH9ZHHG<\^7_\X7\P?RYOR8_GP MK5Q-&&(BA317FM 4PMR(8MX:R#'-;=-TQX^-K#\MFN3/+1Z'#-.5G\NI>$1J MW/2D1U;LT^V([/AEV?8LV234+]T[D4=[* U5H" "&LD"MT2+75D_K!C(UU%ITC3!I((98D':@ML.B=!Q6 RU, MVQ#:W^KTGBK7%6IWCL<1KH5RQF:EVIIXO[]A#]=1<=?C'TI"\J+^U_80)QQB+O""<9R#%3!2UIMDZTYS'^C!H63[65USW%B-ZYL-CZ!=W32YQR;M M*>'V:P*GU#QR*X]C5NC?[8OI?B^\VQ0&KJO-=/'B<<3;:K6N]TT_FG%V/UV7 M$Y":V8S)@K."P#0EJ#X.O3.*$+%:-@ID*O*LT"!\]2!QO>K:@$Q:E/;YN;5397'2*E]F:)G:OU*%QTIMJEG7.;A1(TC(('#USU".E-%Z60A,HSU M1"%58$ %)%AK6>]@R-/6FM1N^P1\;0P4_UO>%]*9P2Y1>5CRP@397A>&A(Z5 MSY4YNE(YYDC6P0NKP-25%:L%J,.[5FQA!FS]QN;W\MBFH!G7/*.9E!P#H0$J MD)F&():%DH BZS6ISI9B+U,= "9'"-U5*!"O%FM9O5+JN+PU,C8=UL!Z9=5S M6:P#NU8+996\Q;5[S6LY.L>E[WJ^-)V6;A[ M8,Q-K1]?D+7ND2Q[7>Z!-#\Q=B;/1H'?]O:$[':D9GBM[>I %:R;V*OJIVI3 MKK^4LW+>/!ZKC4.?J]7FMEK,J^VS=+5=GA*F=095"B7,4C$)F7I;=_'MV4^#6%28TPV4-,]AA[Y]9>J?OGV$^XNW-M MH^16;)P0]K!,#J_S@?VI8O4Y[WN&)AF!&6$<09+#/(4I$H+LS_3FJ=5+,3Z? M&WNKVF95WS WG_D799U8LBO$QB+(3;('*[?:E5A]2!I'6=4+^>FKE1R]MXD! MQ:):SY=WC]/GVL*$F!2]$!QJ0%3.<%:_C=H:@""%ML&>X\=&'OL[-,D.CGW@ MX@M(C%N8[XW3NRCKHC<^(57MAS9!%$OG3L1+7DR,'Q8Y N\ZMSZ]E(G MY^OIW=VJO#-QP,VJ_%XNG\KMK5"84L@XSB46&"*36T.!4I)IIE7!4VZ=XOI; MB"R -\? DATRMQOC.C)X61G[(<]-)(?GS5X]^^'/3TC]>+21U9->GU#8[BP- M+[8!?*A"]ANW7//SJKIYFFVN5E_+U??Y;'N 7M>/BK!"D*+@.0 0F-S6F.*% MR&!>,"L%[F0@]EK.%M.ZV0^^P^5V$UPW^NRRT>C,N:FO%VE1\M2WB#F3L';B M<1R9:S<7JH#]RDM=UFQYT_:8]NR[XH!SH3.I%:$Y$5@5K3W*E=71].Y6AM$9 MK^LR.E#I)#>160RB.8/E/%S_>%J'.S/BFFA_VQSHY9D)S MG.J484 U*%#6QE4DS:#5N>_E$7W->99^L],/9\[.AZ-OG%FJAQ\7,E5?9CH5#*_+'QMN_/SG!#)!80I2 MQ(D4D&%<0&,TY2FA4F-J?<][ %._N)Z[$MNAH!B'TW"5Q:0&F#0(>R8U0+4Q M#KF>2O\3G0/H_4M67,N2[G2.4_E]G;$I5/IR9%M38#/3^9X6M=FKS7VYJG?C MK,K[ZVI5SN^6VR=/9\_7J^ERO6@Z++OYQ]-V"?]3N;FZ MO9[^F*@\3U5!59:FA6 %*A3-#=*,I4I 0IS>*AH"7^39YLBEI/$I>>%4LO4J M^5OMUV_ODIUK2>M;I MX41HG3/5GR'[PCCJ1H,R4(UG9-IG.98HQ?:7S/?$O1FPY?K]TH#Z^W2^;'PP M#2&FZWN]J/[ZU_*F?A]F>7.]:HZ*/7\P4_-:W=Z6LX,?-!,0,H*H8%#G0*H4 MZ=8/#G V^5ZNOE4VJ=,X\;LHY+&KL83RX'ZR\S^9+QM5K"G8_5I2CZ>DYB&I MB4BV3+Q+MKX[3Y[C;1V+['&?2XW0@?GK^ MRW0YF]1_D$8\44T8=X<:OD Q+\G#P_8UP MF$J(?ZQ]723,K-O_EK=' MWP;K/E=&[RJ_U+P9GPV_.;2G5@H\GQZ61QC6FG%1*)%GA JBD=@OCZ1YC'S0 MVO:XYKN1ZU0XW7%NGU]*1]R]\],%3Q9MQ_FA@'5V^?-SN9K7%PK/ZN)5*C_-. Z-[\G7:HB!8K\!Y=RT\\?2 M6%W,_[.\:1X%^SU;R^,T0^K5NMRB_E;#%=K^>W\UGC MWF'^$D3BE&GS!X(8U6>]$&SQ2X*M#U^-"W7D><4BGCSX_&(YUBC9D>?)SO5D MZ_M.S-XE6_>3G_QW+[.,KVDL]IJ,"W"\J>Y_NE&';F2_GV11GWX^0%_EM9O7#(E10%4AA0E M9%^GE)IE+K6"\: >/OZSWT'P[6TY/?J=#LMKXVD2R[+%> /&O?UWWVB5$5Z M:\TS%93Q]:AQ5%M&R$LU=BT(-XN?74ILEQOK%44?=UA!J2P(+RC0)@@1/*_O M?MBZDW$5;%(?U(D!YOB_;5W_+:F==]\+,8I9?]B.UST(^&7Z7/>88(3=K?P8-H^B!XX\AQD&30T@Q#L#!(HR+E8M"*0)(@15 &'),:)&UB J5ZU!! M0E<36;[[&G!:1ID5%-"J!YG@LA]N= <%98S0KC0CS\_-%IM>W8 M]>UI[BOQ?@PKN)UZ4=^; /KJ0./: /!?L^\,M?+?5Q\:YZJ_?U_J?\G_3$OU MLMP?HJ?\5UOJ#\))M&7^<"W6UQ+_ 5ZJOR%@CAN!UZQ]N0]Q)QSNHA= MSX?,!'O6]?'#LCJ65*N,OUQKA2F ]]MJT8K:/X4LCHW7M3I]D4:/BG.XIAEW%3F@ MGY:5X=#,ALB\WWKP8CK;;$.%\\]?<,9SC8I<*,BXI !#W):F95H &2K!C@AQ M^-GZ[4=SMN[M;DH?UR,Z<5K*,WOIH6N,/TGI@P2'7*2W-NDJ?^X+=8>+MW!! M!$DAS"4O8,JR7.5[H #S$-(7$=[PLM=I-\#8I,^_I3QDKX=N,6[)ZX, 2[GK MK2U&MM\#BZ(_NV M':B?705#])T!-QV$Z#:CW)5@V8Y#'M1W[$GCGH,'8Z7O0_I>K3;0$?U];%%D M6E B30[%"_,'4@JTUT)* D1J]Y[GT"A=--7KU<[(IYY'OE=TGW+'TAV" M;TV(W ]^A8/M_9];=^X:XY\S>V$A[JESSU8),2?N3>>\0"0G"C&EI>9:,I[M MIV.M@JT\6!L/[Z\_JD_77Q/V22;BZM/U M^T]_5Y_$>_75\4&'P+S;A7D#$NX6O1T!;<*S%U"3 ];DSQIMTL#]_WM^GL&) MRS-J&:E1QJ&;L9Q[_>)"3 YMM?1K>5/?=/IIHD[=,D>WCATT(*T,^(7DO)Q*%Y0CZIX'=1^ MAW>]R/EH(M3IXOW2Y#G?#8)ZG]O'\N%;N9H(19"2%!G91"*G#.L4I"1C&A6" MLP+8[N#N9B5RKG8 E[Q E_RYQ7=ZS(5F\[R2]4NDFWZ-AT/[W<[]<>FWF]F? M4YM-RF>]/[$).0QCPV\R#N1'%;HOVQ?R^EB<[\S MIZ&B%&5($ I2A"GD*6W-J1Q9[?7H;"2R:.^P-0GD%EVRA>>A.-W(O"S:O?'H MIMGCH=!>LWNCTD^R.U!JH]GGO#\AV4$(&UZQP[A1!>Y(]GJMEC?5>E8]/N\L M4 I%+CAFC&K"%,5<[RUD2!6V$NWZN9%5>0_'0T*<*;HLO#'9<=/:7HFQE].8 M!/DIJ -1-HKYRL$3(NE+P_"ZZ(V\ZMX)[-5/3%R#.,^YU)] J_GW;X5-Q<$=ZAE?99B1D7&$1> HYT=); MM@Y&E;VNQJ?,3U6=J;/1U#>=/:&HW8@97D\[XJ]"=1%[+3U>?YLNFGCY6+Q) M+D&1*@@TYUS)7.6ZV!G4F #K'0T=S416UY?HD@,\#_'H2NAEP>V12S?E'1.- M]F+<(YU^JMR!5AM]/N__":$.1-KPBAW*D2IXAW+<<&LZ55/;^'M9W:VFC_?S MV73!?LS7$YDRAHP=K1G-TYSFDHBM/0)D+JVN%>UN);*"'^-)_JP166I- /[. M*W:_U+D)M@MK<3;,GB+E#=D)1^1(-L=V]^/UEMA S#AN\C^V)JN'Z7PY 2@' M5 F400$D%AI*1EI[@FBGIPG\K?2J.5M,KJKCSZ"EZO1"7A?5N<1;S(WZ/]-R M3GGNQ]M;\3LS/WQCN'G0,.ZY] %?>3>\6(:B/BK6E*UV_YZC[]/)W5%XWM["@*I,YE*E@*,$9%KNIK0'=V$,I M_36@9(?(4P4\&+,3@[ADN6F"&T]1M.$G.LY(A#]UXU"*#OBK4)W(33<^5.F#+:L M1-&$(PK.J($/4>/0 2_D5?=N8K_Z_&&ZF2_90[F:SZ;3Y8V8+J(\3UMKD.3:=NFYBXW(FM! 2W;8MI?[-.@\UDL[,7E>,?HDT4T] MQL*?_6)S7SSZK33[\VFST'S&]Q.KS"'8&GZ).8@75=@^Y+"EW1BZFR_O/DY7 M_RPW^R/Z(,V9Q) 57&7<))$I8ZT= H3UOB"_3X]=U-F!2G:H?#9G^[%V68CC M$^98[AF,*X=M[-$Y\]S$[LR=U1[VM[P](;#=F!E>6COBKT+U$<=U\]E]>?.T M**]NV7(SOYDOGNK7= [7]ZL?L\7337E3/VU<7X7ZM.U75[=JNEH:C.O/Y>KK M_7157M>W_T^0R A54$HA=$X)U[P@A= B1RJ%$EL="(T$C>!"8,5Y5A0IHEHP M#K6!Q5)("DA0[.I\ZTU];5]@/_*I_D>M5_7+7$GC5_)GXYGK M.G_/+6Y7 AAQ8[M-0D.TP7 3[17J%XW*:7R/&65>+Q_"Y%;H1 MM.LXYK)1,/%ZU7 ,F +,%BGWWS@EY>9?4$#TW.GA_H ML._E:GI7?GJJ5T^N;AO;ZZNGS7HS7=X80'RZGL\F/(44 (:1I 4D!($BDZWF M4%*D+E.*FV4B,X&+/.,%(X@B2E*QYXT6;#+=HDW6#'4R>,480Q4)H# M!DT.IS#=YW!,\N[CV@:#EI+G(LT@ B+@E L$5-2D@SGE+"^1O@.=[(%GNR0 M;T.$=7*$_>@I9;<0,%HKV45\8V@@MP O3MOTI\>7R755YH#--6*-#NFEC5H' M9[5C%'8*S\38YH!G,M.:,:,$'!&^S_VH9)--M9DN.L5A)VU3@#4%5'!>9$@6 ME$HA5(9ESK$P0:E;C7,/,W D-EVOGQ[J+[>A=[4<@0J]2&\ MLXO- K%H?]-3-?OG>],SRQMI\L#E7?V85K4S_ZG\J_G1>F)F=BH"9^[[:?G3>KXLUVLV^X^G^7K>/"K(GX_^MMTJE7$B-$AA"D@AF $ M:&!B($,KD!0HYOCR=&CS+N/6[QGJH_V2+>;D&/1VK]#A&T/OAK0CUFJ_8^ V M&LGHCN;>R3V+47BT'?'OE[/JH=S?=_>AIM^8W-YU9](9@C"6 +&F&1$D-:B MTIG3W7-=[$2.=K;0DCVVI 7GM9>O$Z%V04U?7+I%,MXT1E&\,QR=$;<0S(Y# MQX)X4H7O=T'4:;??0YL\4+."Y%F12R@%S$7:VJP7Q0+HDZ6EX13*:P]91UH[ MJ50$1H/IU" [Q\[RY*Y5COR.6JUJ30%=1\N'.XA;/K0!#Z)2 M%"8T(YGFI$B-!B+9XBDR8/T2>%P4D37K"'Q=PJGA)PW^^F\'#Y(7+GC+6P^- M=EX Q]5>;A+Y7ZZI[*_=&$^3^5W/$;WI;&[SZ$3B&[-@?PTS_.T@/?E9]=WE M/5\&,C"FZWN]J/Y:LV_KS6HZVTPPXE10R:A,ZV.V J0:9@0CE*5:9H7M]O]. M-F(N4[;9?/R&T>_.MV3 \P$S@M6+WSF M+1Y"?EAI^RNW)SZKO,="3.GPK[^;+^N1.=;OM MR),L-;BXY QKG4HE!("B!<@5P3NY,!*XVD06#'=P[@IR\&,(#=E[. 8E^8GN M&-+BWZ:_N-9T<#R4^'3EWOIR_7)3X_R\JKZ;S..&/_^Q+F_>+Z\>FRQD><=F MF_GW[0T;;="48XXUE##%"FI1$(WKOKT+FB1P.O0=P7SD\EJ3*3SN\-8[H?[V MM*[/_U:KWY*JA9U,][@=[_*/T!QV6=K +>&6NQFPVY3M\W%#U(B3^?*W9 \Z M.: >+*]S)_9,MA>QE<:1 \9T\/7K!;&Y#*_!DXQAF&6$Z]2$IKB02"G: J , M.%TU%-#L?Q/-O4Q_:*T-RGQTC1VKL 815.NF^-6$U-XQ;P%UY*ZC<&[7J]]6 M< !SP3),,6$(%)AJR=462*8SG&5NN_LC (B^OW\/[D@P_W<0Q>S$>R?E[(OP MH IZ:(CQ1JEGB'47U1"M-&IQ#>*@G#!33KM ;A?BG8N36(^1LEM5@5M@5MK&6S(.4RZZ88ASC&<,R[/.;(74?AU//E=#E[NSXG *-89P6%P(!(4Q.7 M\A8(T$@&6,3M8C[R8NX>6O#UATZ<=U+-ON@.JIZ'AACO^L,98MT%-40KC5I8 M@SAH)[#AN+05VB_EXRXLOKK]4"WOKLO5@RR_;28PA;GB@DDJ )*JH&F1[@-B MI/=Y]K6]JGK;\DBTK]TE=)\#5LMD8>#];F3X(?E6K5;57_7+#FYJZD^LG6;& M)=/OX.T>4EV/^+"GL(;5K^Z=(N>,NG7FYF>0YE3D7@A5Y#G-6'^>4+1Z40JN+4^*C MB!P&ML"W+R>]I6+[4O^-\2*9[YS;KJ+^J&/[I_GZOCG .:O69RI??;>>97EQ M% WG6'M\T68MZI\EM&FC'?:7KQF6?2_ ^K)\KGH9O>7&(= ]^/FZ[MD3LSX2 M?SR[B.KAH5S-YM/%Y^ECN9H@A)G,C"V24X%1@1'!K?4<4>TKZ%UL1I;O.K>< M+V>K,6:?)80_47YDZE:WL_VM);/C6TOFR]NV,C#! M ,H\%10JI;E*07W!0FL]S47ND)B'-MUKGMZL>1^N!'H!.ID^5$_U8'Y2YADS20/FD!;[C?(T%= W;O>SUFO!Y5!FJ8O(LP9A MNQ<",.T>K<;*$[I[9AFL*ZDM ?_9TJ":,GW+F6T#OQ MW6H) 1K H9I@0\[Y:D)0>D=330CKU<_5A BL==ON41?WFC"8";%]+OVU6 DTX<1VEVT8 ML8@.M=UBBR_Y>I;8'C=4'/'EO''"A^MQA-H!_;':".'/5/C##!,J)%!(::P! MH2H'&9)[ !!B&> 4F(]9)]D+>PKL]HV##;'.-5RFWT[^!F+>30<]SC&,]?#" M&76,T!3CD,D8CGD?4G#DSE8XU>UM.=M>6.=$@[JEV4E4QC*%.P/HF5(9"Z!8E##D6/&+=8Z?C%Z6<[OEDFY0YVL M#.SM2I2!["::8:FWD\W!6'<3S@/A+="D1EKS+-I;[YLOCN#VJYPN1)[1SBCM M,0[UC.-:U4-_[NE9C,_-]?CM7M1V)^J$FK@8HU0 R% F,L)INK_PI8#0:FU_ M*&P#[MT-\UZ&?9%SD*:_7'T>>ZN[S0.!7D%YEVP]>ZOSC+S%[C:I9?.(YR15 M&&,.F)* 95H2P//#Y9%*0?N7N,+:=5&67_R1K3 )B17M9S*1L,TVCA0DL$]5 MS(X>8W!S6C"-",Y37BA.C$6A]^?'12IL7^4,:]5]:/]R+W#^2D/:MKE^I2%M M[9/7D'9CS/I%ZZ?'QT7SX.]T40.H'_Q]O[RM5@]-Q+R_I(8@C1C,\XPCD4&E MF"KV>]6DXL+M(9!05ET&M=?K'\= DR.$;C778"3;E5N'8- M$SSV1)^:/^NG04.T\J+;4M M/H>.4E8#VI%W#*EGU7J3EG,BU8W'D6A21R=>2U (3JP59W9?WCPMRJO;?R_G M=_"93!W&4MW \!5H72DA4:9AH514$!);!@2IF(E&/H=![:8S&F!5UG M1RWL9(<[V0*O?[2%GOS9@$]J]$D#_W0PT6TY0 MH[;62/0VKH^OY;@'1FW5NGTKQ4P,W^;+9EZ0\_5L4:V?5D?&4R4(UCIC*!=2 M%R2'.:Y'OIE >(H1=(L7+8T27.1(%YDT\Q)"&-,L*W0*$VO;EK(]O4Y1GFI&H,H1K3= $1-/4Y8#VP$:U&:\87J MF>QP;I]3K)$F1U 'JVZY\'AFS$9ICG&,W#BN53UT9]>S*W\=4'Q>54OSY:S< MGE=?;5&]7Q[_QGPYFS^:2*L.MR9 $(@*FN64*)/BF+B*\!832G7A]B9'3"31 M-P?^E1R-^I?PDWK4;S<2SY=G22/I]G<-#IVBT4Z,M.! M[#-"WD\CCD/9>_+UI[,V_3%L'<'=_.-I]SZ>KE9G$+(?\_4$2I-0F\B1@,)$ MC9B8*2=M,4")D(O6A[4<6=N/P#8/=9Y7CC]KR(Y"'K@A+&/IP=K ,9@.27^< M:-J%R7/A=)06&8?J1O+M=4 =D4%;5;TVOWUURVZJQSI^_UC61 M(8" 1 I+KG>FF%+ ZK$KX-Z]46MCX#YLAI/P\ZP=4G& M0A ](B4+XLY;8A:.)T\]8^MUN6DMYE!#35.I@("0Z"(%F.^SW_J!)G\I<[+3 MMXIMP841,#="O;0K&I<=9['R8G:4.N7GR7F)ZL".K3K)\K8T MMF[>+V?50WD]_2'NIZN[O21JH!%(M8!,I[+>B:]X6_9G!""G6GQ'4Y$UJD67 M;.$E!E^R!>@I4UV9M5.J'DEU$ZLN?$;1J_-,G9&L0!2/0[5".5-%Z8;][,?[ M,%^6[S?EPWH").5I#BD2$E)6% )QW.(J3&;;QYX\>S1CWY=7>Y(TKO2T.<^A M(>W4=%QMZ":XO33?J';J[5F/L%O/O47'H>\]^AMHUYXOT]8W,#T]/"VFF_GW MLKV#]A72'8[WR^VM;X4Y%N^E%H8R[3 \1842>%P[( MD\-USS^I32LC1EYV-S@>;=APFPYBMIC=/#"2QG*; &*V4YQKL[Q9/B/X/33= M.)2^#T=?W[K5%[?=,X"S4XXLU[/5O %V=6N^6ZVVM\8=79[SI=RLJO5C?;#H M>[EXWFZ6+&\F*16"%)"FL,@9H 4CYNN='[( 3B\KC _]?\,,8[".TC4C^17Z M2+@,YG+O>)<<.5U/:HW;OV_]?G%/VBO/D];UL60]D5K6*TL:NI>-8ZX=,3_6 M6=C@2+TOV>331?T\W=?[LMP!+C.<]GA MILV+IC&$&$C!BCR%*"68(TBH)+I^'13)W.E09O?K-G=PDP;OT647CJ_$A27? M;J(;C'6W.$3Y@0.4N9ID 5/$,%42PO"L X MT7DJB@+%OF"@1I6\@.5W9X O@7:"UP-W;M+F05L4!7N;F#-:U9')<:A25R>J MH+W+46GFF_E=$R1^W4PW3]L3HQ1)1A FD$EDQDH&8,;:89(R))UTYBT#.522 M4$P1(?7]QJ"^XH4*7LA4I2(#;@_U>JC,'E.R!>5UG-V/.DN%B-<61RG"KCZL0%G?'BQ+K85&XVB_+F8+/=S%Z]+-D%8<8]NQ'1=-F&4PJE44JA" M**9(H9F4N!TJFDBG[49O?#R'*)-YCEDF%"(YY:@ @'!N,D"3!3+57U130^J8 M+=F3YAK-1.'+.Y*QH2IR%-,28A7!.+,W#BWIXL#)R,63"S\%J6_7V05)(M<\ ME:EF&&&@!,@H(^V0@"EQ"EM.&D%:%"S-BS25&DGC% +F"S,(:8YQD3I=[!Y" M33IF2*X4^JA*)/8Z:LO .=)+8JPUQH/+,2J-CQMG]<:;ETNJ4[^IS=;K^=VR MO-E4U;+\Q]/-73E??F1MH,]1FF+$,:J]%XT(*/.,"\ P M,*;RC%(*&=62FB M)1F)K#HMMF13)09=TL"K-R1]9(YI4WN%OK-DE1NE7M2_Z_H=K!*!M6M<.Y407N M2AWW GS8G[H1H* %AP4OI 80,YKJ?0*EI"*=]@,FQAWIGJAE%6&H*92$H+PC(B>;[>;N@P#.#_=E,:I25 M\4)KQI"4DDJN.=:%1D0BI?O<0;"']B[9@O->ZG/FTGFY+R:-_DM^]@S&7O5[ MQ8_=RI\OJ2/1HP".G%X![,:-368KJH>'^?8R?+:\>;EQJORQ>9HN#H]+ 9DS MS3)L@C-A1!!F1.WW_Q6<*[O=YJY6(>:<4JDS3#0"M-Y<;5282T8*)# 6+H/, M:Z/Y$=CFA;:7@<#?6L"_V3S4%I?_RYGQ4,2[J=LQXVS4C-NGT4,Q[Y=5G^_S M+>!_Z918.S!R(L^.P>GP:7<4KZJX/;%+4O[,9K.5L/R<[A$/F]2=8LD[QN[(\DN@ZK$]G$_\PC'6I :@?C^5R M74XX807!+"\@Y!@ F6JZCSH0 LQ1^,Y8 E04&$F(@?H_[7U;CQLYEN;[_(IX M6O0 [AHR> MB@ %XBUGOVF6ORSWS4%@(R M>T$\,UE?>">RV%)HXI#+AJ'CDLR^7[6W#S>;^_T%UX\W\[6=>JN;^_GBZWK5 MW,\WW=[#UV;]Y=ON3_YMN;"_U#7:-NN98$J7B%"--48480!J?6A]0(2[[N/& M2<&YJ+# 2."*$Z$LWT!1@BT9 /OKN9O5]L(7!^F+K?C=+10[!8J]!MU^6Z=# ML5?"/0'+;*7K2?!T#.07IP3;IOAKL5.AV.DP&5NYI\_3L5E80GW==O/UNEEU M-CICQ/-6CO5AL[W]S JP7L]ONIF_7BPW M7YJ__?+;+V^M&#/KKRO-.,=:L!(H0 $WA[/A0CD]_.PX$D.,:@@!+BDADMJP MP5!8,5TK+2C*[B#W A9;"8N]B%W#B16RZ*1\571R>G!L/+@./F]07#W]VA0A M]7!-@T(;Z'YB(7;R,=> ..='D@$X 5^13I7&$,D)J:&L#4( "E#;?Y#,?88Y)DC?:9 Q M.G)F.8C E3!@/E2I6"#94E4]J-F2I'\C3#!#Q>;@UC\J(@ M-)WZ9FRNOKA;-+=/7?)NO*U'MDNWY)H:S9F"5-18EX?-,P.9TR/K;B-Q3CB1 ME0184\)-654,=!/PYN-P)Z1N])\#6H1-F4%@]^U\FB*A' MI\N@R ;VMT0B[-3?<@V'/Y:RAX5;T"P!N?Y=.ITVR;U,[&RY;3T$.FPW>5# Y ML!\Z;7^!KW$FX#\'4C2^PR ,6Q??^['=S.]?E&J^O-V)M=[=4W>0[NU1NAD# M4E24E$1JQE0E-9#'N^DKXWP)2Z08G )0:DTJ#3BI9&G_$01S@2$B1(+<[XQM MI2_.<4)W7F!/"GL=3LGA;5 S7VZS7?>\$[*8G^?]KVY_CW\K9KQN^. :[;^\5M-^CILSWOYZNF:S39 M+&[F]X=C@<@&VE*6O%(5XDB!$D/-I 0(EG8\8N61045V7R$!,&%:2 M4FMW 27A"-8P8Z'N('!Q*O&SI[#^\D3JT /*>6SB"[6"SV>_<7W?XNKO:O[WYPP[[;K5MV;[=GC1\WZQ^^V)% MF6DB:V9 61G**&,&UN:PDC'&7@]]N(QG SBL..(,5XP ) 2KN%:58I7H#GWG M3EIV(A9;&5\55LJN>+&3L]@*VKW77FQ%]3ODG 3KRYYL+)A]75<\PEF.7#K M]@)!Y@!]&D/IS6=9H8SA,7<4P4I2:2I2(BH,H=ON.V@'@2SW2P(OK:97 MQ4ZV2$)R!3&0C#+@%T]$5Z$;AH5V0O@PD">:$V4?7RVN,4\0*L&L\^YAL][, ME[>+Y>>9_2XI#:XD,<(.Q BN2;]J:B2][J6^.)#].!;*\!HA3F@-!5%UQ04N M34V5J8?-^_I%=")@) EY81K(1+G@3$%'+D@.PTDGDO@04PBX$V6G(%6N450X M/JX\]=[.BF:UZFX6N)@VEIC8M05K"FL"E8W(JH.?AR46/HSE.*0T@H *@+JK MSBG[(ZL1$, H4VJIA-=K\4%-;GLI,Y2M4H'N1FDCX.U';HF@SL)T;N!=X+S$ MZ$^#_5(KU6:=L3&,^%.2RH7$95EU#[W6LM8<(HWZ16D#2*_2_96A)*J8U:PV M3)6$<"%**#$SG"JL[&]E/P;R?%E&%K5B@0UANZR81K+[.2)ZG29R5<1!U8* MPB:&D4YS6J1*4"M#>%I7+"FH:K1JF)7H/(DK1"0I\M<0=HXT%306<(:@D-(H*3"M:($L /E1D;T&$?WGKI^PQ074)A%(:," TE M*:FQ^9$FO+L]._LAD[U(3Q>6'ST%P>9&2;D1\Z,A3["R,,\+B%Q@FQC\IL$P M41JTZ6:3>QO^K\W?Q6]_6WS]-K_9'!_?$1 R38P!JD14,8Y,24$I)*@4D<:X M7'4>]N%\R\'*4UB!BKU$0?WQ@6"YM[_G!RVLNST /)?&]1?5?8$@XJ$9O^T\ M4OXVU21QIX;?;KXTMP_W37OW>GG3?FT^SG]\F&^:#TVG[>)^L9U"'[L7H&8* M&QO8:,9M "\H$5#2BE7 E P8&]\[Q1V>0R)2DDH"2(CB'?M)C0&2E180D+(N MF7T/['?+7H/M^-*GXLUC.M)*( ,4F- M4;+F @#=KS:$F/+)9G_Z.)588B YU9H274F;^ &%8(D$QIKRW)N8O3R[-?1[ M)Y(C987#Y9;%9D7*C_6]0,J2P#X'XT+V&HS;-%+7"$5I@;5#-E& <*&"-S/__R M;#'LA(K@#%?0_%DC UY1O'$-JNS,L1/ D3L\T9L>>_@J<($_@K!(EMN^62R; MUYOFZWI&%!)E*6O3W?=8E4)77.T62?=R9.5\H[KGL%A45)%:33]3?"5ULI4Z=>7E8(5&RF\< ^1+>26"?.//-8X.P[/<4X.WS MZ%-,AP^ Q:3$_JC_2=+B ,5\4^-0[%P#WEZ(=W?F[JZYZ2XHOI:H?VQ^;*3% MZ8\9XJ2[MA22JC;(AN"*U[)?OL"F\CZA<90@!%6JHITSAS511%1*:4 @ &75 M'2/)W>URNG(/TKNMX:)3HMAJX1EUY[6<6WP^&:.%N\$<]LH2^L=@?2%)&,2$ MTT@GAE&U'6&)>'+^XO-R<;>XF2\WZHM=%U:@ORU75@[[R_]H;JU@LEDV=XO- M^O7Z0S-?MTLKU>/[=KU>=-)MB[4:515"6M=$*\6 U-VQ8J8%YAPP"IT>EQ]2 MGMP>X*A"L=.A>Y+A5(LMK_1Z%(MU<=2DZ%7QVV4:U)R._F!BEO1T"\,8,8]W MB$?^DI,8T*X3\15#:OS<90R.]C">XYC+U$98 8W1BE-2EY0B.ZWWTB%AO&KJ M0\GT)_$@WF6;P6T[A"O)8]9QW(F+12?H4RZ5CL8R\G\%WQ*@=5+_$HJZJX]Y MM_G2K*P,YL>W[I;;O2@S(HG-@D1%):- *@R DOU@Q&BO,YV!0V3V %NIMI2P MEZOXRUZR?_9C\E $W8AY /#\>#8$MRQ\^3(R%^@O$LIIL%FL$FW2Z>7Y0,_K M;;]S>_=1_0\QPXS!BO'NZ(.B'%"HV8'/9%4Z=8:%?3DSL^P>]]A)U-4\.YD\ M7UGQ ^KZEFE>C/P(Y"=9LF+C^:A,-HPBWHEQPLKYP9?3KYW99@Q'8OR=Q C9 MG[^T$H& "R.^6S:;Q==FLYHO]P^4;N8_OK7K#>05->]G2M>$&E,S&_-)C CL M;+D?45'E_")T[#BYX[!E\]=.ON)$P,)*6'0B_K63L3#_;?[UV[^^=^>):&BO M,^J0J'H&:%,$U)V&AP0VC)03 .S"UE> .,/=J> ;G\F3:=*FGUQ^.?;+6Y'* M#KY8/BR6G]]]:U;;*;A^<9?R<#R0_9.@8F,()N%#P$>'Z4ZH];%KX\ \P% M_HN%&;CU_FF_]L'^YO=YGT@3/WE#C3H$:E@1P:8J.M&B(; M>/7"8%21!'04*\)8;%5LK.#%5O*^DG@,>OIH)PFE11LIBO&&M$\B0HPSS9"L M>05]OT\?5J M/1.4T9H25M>5%HH8 1#NAX68.#TCDVRPS"Q\(N.VCG-\CWV^%[/X]%B\_O"; M>\$L#<;7RY"#P^M'HI-%UKT>.3C"845)9Z1_B2I*NJ!QIC*9%,CQRY-IU6DS M3;AK&+O9FUQ_U:1^TKYK[ M[LF@3;M86A9IMK=$VS\PO]\LFO4,ZN[]:TB-H8#9Z)UCV1;^!'JG]4,/I?L MCFJ.T!MXDYO%[89>7ZS.1/ 901\_GL^I7#O(Q$U2LS^XV/?]^&)Y^WHOEKBY M674/NE18E$@(J!'G6!MF9YS:2P0UQU[!?TXYQJK>OSH-9 \*;)=TKT*QU^%5 ML>TU3%+*3V.[J'K^X&9+5-3WL-@D2OLN./O7]Y-:;QKIR2":NE7Z,Z#KDL"\ M;SS!]#>?6]6OS8_-A__WMQ_;][:!.O+6JP_-.N'^\V[ M.YMPW=P_=*_AJ&:UF2^6;^>;CC5GO!*55H8+J@V6-0,50[W,E%+MFN^,+VEF MAW%0L#AH:.GEPB'53LVBT[/8*5KL-"U$=WBUT[5X=U<4@OVVZJ++NI M LOBZVZ:S.T_]N]O)TI[5]P<)\K-?J)\W2D@S>EASZ/4T MZ1#R9 Z+W/=_YIMBKTEQ4.7Y7[J^2S2>76,V[<8S::[=O#36''#/S\L$WIN! M>0P\C31\4(V=M@]SHNV2ENO]>[,V4NLZ=#;=*>.N[Z-[+W+;_K$/WV9,&U13 MC@"I$8%,U8ST#8!05L#Y''"R 3-[@U[.;0R[E71[@T+Q1-8^N'5/8]+A?3U1 M'05J/Y:>/,KN.=\H:(>E;FE0=TF\7$$YDS\EQW3\-"B]2FW&.9CL'@G[N]_F MCYT(,\4U*GF%F9$::4?,[$K<3^H7?RVLV,5>[F07(_B M?]VMC(.[GU_Y4T&>[%:*3-#GOI_"T00);JLX G3&X:0'>'R/DT$G][LL@A%S M+81U3UC?W+0/71?FY_>K=FE_O-GZNO7[]GYQ\[C[]_%Z?3L^)@@))H545".$ M$:B%,+5&5 H*9M^;U:?6M>Z5?'B?A7DJJ4?[U]^+H\C%4YFWK0:[^T'7737_ MR1]P_#%^X+U8]LEIM&J2.?>NU *\"/!U3[]=NJ^=(LUX<2 MRZ_MYN19#1OA4L@-,@1RQ0#@K,26DKC]K]%6#)]J]]7!E#(##9(!/@__2J=-FFIA^_*:;U>+[?%<_7F]6VX!\_>_SQ;*;=_+QOS>WGRW_ M?NA:>+LC*%\6W^2^>-S5DK=\_*8SB?U-^?C2QSXLUG_LGI'@3 A0\QHR* D" MB-8EV05JVNH"O!Y+GY#8V0O&O7#%B:JOBD[9GAT^/19[C8M3E5]M#\7N>.2@ M=M'KO?W=%[]>=,J'O1\T(;LX.H0)29RS'GY]$HWRU-!PZ%]P41.< M-P=E,$ MIIW\\O5SP/5\L?J/^?U#LQ?U;?/U4[/J;F2FUJM7-4%US1$0L+^164M:4:\G M*@*'R.S8.JF*K5@'Y_7[3C)/GQ.*H)M_& \/RX/P2T+=[^,S 6>C81R&IP8 MJT2;='IY%C/FZR_U??OWIV,QHXW272I!I.*B%%#+?BQ!*Z<#W7$CY"Y;6*&* M3JI(H@F$S[$PD1TYSVJ$/VAY2@\OX7*IWA"%XS0X)E*'YY6%!(CD*R>('XOU MK*9(("D)H$90J2M**.V%,12Y^NI,H^=;9"]E[<7OG5"3S\,Z(9/F5%ZFF,8Z MS:UD=*X3@*GK2G]A--U^M<+,-"2Z0DPRP7G-!4&:JGZ\JL2N[S^'#S#T>MV) M-?"*/0O/A449#^DTUET"/=K4DRUH]>AFO?B\W/5H=TM5U! H3$MN.Q3>+ZV3 MOK>C(!U&BLI2H/G/9C1:+BNE/ZBJ/U+ MW?NQ;$3)((4:8\P)001#W%82-DWIDXW+[6OS8?MC$1B)X;T^0' MSH]K_#'+PBLOPG*!6>)@G :W1.K0IIQ8'D<(-U^Z&U9Z5U]3A'''7,*&W(** MDNJ^C4.AJKS62!SPQ7QK82O(J^TQ)S_F",'%XSQ9/GP"#XUU CV!*>[BIZ<* MOK#J(U"8P,FN0,';Z!G@>S9CO7EW]^]M>[M^OVJ[>Y;>+)8]CQ B)>= E(#; M4)YKQ"CNARQ+MP?FDPR4N[G!RM;=<;:5[E6QEZ_H! QM M8L#,=/+B/%"7NB!2X#N-H".-*C^=MDB&CRM;;2E1/:Q6UGMUSQUMUOOA()%: M55*42I=E#:2$X!#QB I[,57P()E9ZOVJ^39?W!9B>5OLG/%>R&(GY4BKZQQ< M%U96-,+36%7Q:K2)9U[ :OK5ZOK"B"6K;( A;=!F,";*& B/(S*"_8YBQXSD MLZJ"3EWOUM*;=OFY^-BLODY@-;V,U+4%%8GOA-94K"8O+:LDZ(3XJ?Y]OD73 MCREK;"@5HI82"]AEYZSLQS0*X%!GY3]29H^U6UE[V \/3G;/)HSOJGX"R]%? MA8,\H046K\L%SQ6+D/>I'_GX]GB-5KUJ_N]#L[QYW#94&,,(Z3QGYR\!P)S6 M_1D .R[V6FHIQLN\X$[D*@Z"7>L2R@>N6QX[-*Y^Z6P0I'G/"IW'Z0*'I41Y M&DR65*-S1XJ2H>7-:B^-N^]W$50:@Y&&$)9E*:D$E/4C5[7T>ETKQ7B96>UX M6N]5<68Y7FOMR@>U)\<-A+(?QR4 ."_CG4?-A?$28#XQQDNAT3G&2X96#..M M/S1=VG \:J5+HHA4$"-.=:EJP^O]L[U:(X6]+CY),N XG+=^51P$C3WJ'05W M..UE13H)[_F!/!CS/0?.D_J"<9\N]X6KY$!^D7@%9+''<^R+9F7__I?'-\UW M"V\7;"I<$T2!%D0R2*1$]2&%UAIP$)C(Q@PY( ,>I(O-9:,@]DYGAT(WG/6< M@C^+L8\W2P$9JVM--<2EX;+B2/0R M"$U)=- 7//)HT=_IS37'M9LL_8VP141$.(@90DG2!^?A8L%SD/D&A='03XPS MT^KF$B8F0M";05\OOSULUEO"AOV-1XA790DJR8 =5Y *'#8SM;*!:Q!?!HPS M(#ONI'M5;.4K8&Q.' *J)_%EQC,\%O2&,B_;_8R3"[=%H#LQ)HO1Y!QO1:,3 MPU+E?D1:JJH[)(CJ2I:2" (X.HP(RK!4-F"-7W0P"Z3#"9 ML?'CDR%A<3^7FA&>L'.I'C"Y'$M]JM\+-!D!POC'4D,%;Z,G0 CG':YW@C61 ML.2UJ3BI='?I;C^$_7_#OUDLF]>;YNMZ)NU_6&FPQ)P* MSFA9*GQD9>+U]$FB(3.3J=/S3)VTQ5;<#NEM^.@+@?.2<#>_B+V _P M72P-*+4 M5 />#P@T,WX'F2,&\EF-0>>8GUR\L7TMNI>OZ 0<[;GX1W/[>KD[]OSSJ\/F[JZYZ?[N M^W:US2>%@+*6"!I50B.!T50=]J]J@?5LV7SN+@C]&!F69Q/0:07RW0K\29?H MN+)3JSCJ5=@HZ2Y0QD ;_+9WX>OA/S*/_Z?SW,[Q=WCXOEY]V5[LWZX_S' MC!+"N!V;U=K^1+0H#P_T:J3+@(O4,@F2.21T()T3%8JC#OW%[8TE,ZN'G\O) M:SHW#S,9J_DYE.P&RW@C41C8%QS%(#:S].,9O8\/8+I M;7.IMW#$F3 -?S4J L][&4>W1J!W.WV.N^DWF3ZVLK%IV/U\O5[<+9I;_=!= MWO!K\V,#R[?M0$0XMETA#E;X_6/L63Q^L M;Y[LYV[:XE-3G&I3[-0I.GT*6!8[C>)=5S;K!GFK*1@VTD&E,.NH7BG0!NZ. M*+>1)^E[LBM]V=T,@WF2QJJ0ZE[G#!G3DM>H.^TM<%4C*-E!5%Q55:IMG]QR MCKO[.J7:PNWN+EY^/IPW[']._7:9A+MF7TN#$H*4(F0(K!4E$K)^G-Q MQDKJ=>)_>.G&;%Q^$I=W4[PX4:NP>ED&M!'\3K,\'0]Y+1_IY"9A](0>+IN] MA_5IH68)<6C9I\#$O5E^_5U=V4"62)71!%EGQP3]XN# MP>"9Z0UDEQ3=@D=I;[;GD<7M_WE8;W8O0UC9K<3OEB?M+EUS"Q<:<,D0(J#2 MI6058_TEZ::$U.F&DI%$&[^C\+E2Q5&K/0]VY&=__42SQ%V&.4P>WWQZ32(9T!]76+DC$B[ M7#MEO]H/T)':LV:%CZOY_KV>L(I4RL*)UA26M<$59W\EM M !1.^QJ9ALXT1=B%7#KNX7-;E#]8+_C SZN-?^)53N7:0F1O5/7TR M\K$N-;_O^@]FD@O1O69G0*5H+4J$:M,+0+F$LTV[F=\'=4C'#.OES@X2AG?, MGLCZ-.#M)8YJ<(XR0% 3\U#81S8JA\,^1!?R!1#=.XU36&(:Z4,.Q2YW#*?# M+JK>\'JY.\PIUNOFR?F762E*1G5%L61550*N&.XOPS6XZM@SX%+JFL&8E*C&M#Z$SU)Q%6FBJ4C"?ZH;WQS/7,$[H82=0*%F[8N5+NQE@"B;0K2QCT=\. M""]^3E&'_T=/]$[GPY?ZAQ$B3^ ]@E=?8?8)+A2P OXQI:!XBTTM3X-(.& M/A6!)&CF+0OT(CZ>"EA17D*$A< 8"<'LCW5_0;XA ,2?/\TCUJ3+ P>-1B@1 MA!DY9YD@NWV'+!5XFW9"Y8*7#)&\9!!E[0G[E,R*)RD=),#>WP.=.+X98];' M484A%[@41'"IV:%4(4P55D/P&6&X0L*)5*&\[@6=+T7G0BV8;0^SDPDI+>:@35-#M'>]<8V?FN9^O9-T+?-B8/:99Q5'LN&MTH^WA MQH1CFL*/&5-;89"K;Z_ Z=YYFLPPT^#2;-I=N;4V+8JN7+O; 'MIO))Q9#A4 MLJ8"0 *$4<>M\Q+7/OEH^"B9<]*^<3$!2T8@Z<:'PX#HQWQA^&7AM[/P7&"R M>$BGP5D)]&A33[8D,=^Q+/FV69Q%@K.CO M:;$]7P@8:9ZH.' XRR0*!F.,,F1$>!%8_[ PC9VFP;-Y570+$%/BZ7)_@;BY M63TTM]WP-N]OEAO[TWIA@=X=L498*J-419%B)5.0"ZX/82F63LEW@F$R,^U> MNN(H7O%$/O=#[[%P7N;,@9'T#!8G Z+[+0$#@AEV(X!9;Q9?M]ONMY8%VH=E M]^.W=F,_M)C?%]_FC[L]^H>E%;JX.4)_;[9_])>JJ@,N(O> _ M$L(\_A4 J11IDT]!OWC\9+?J13=C1$VAKABE=4THQO@X*,0E\"D.1 Z5N4+P MI+DQ020="ZQ;S#P@II[1\6(Y7]YTS#1?WA:_MLN[PR]$()TE/+Z,X85 .!'X MTPAY4RG39IF@?J36O0PV4X94M"2T1MP @J5& !\^37CE4S1P^F#FT+23P8^" MW&!P(YKD"/C1R47EL[!"-^*%M>^%QS16N)_(;83]?=OD/FV.#7HGI\6UK"%& MH :L*I&0$HMR/UI=8NYU%73H&)G7="?62>]LDL C&$XW(A@"23]NB 0Q4T/= MBRA=;*F+PW4:'!.MQ4]M=2E0N<9$B^7W9KTYZ>'[M>U2KOF]^-HEVC,J>46X M!@H";ACGN.:'T;ABPH6)8L?(SD2]7*^*7K)B)YH;_41C>)E^AH3/EW[\D;O M.>OFYI?/[?=_V2G<,0[:_]QQ#3KAFBN0O, UJ4 D[H[""[$*?;R^(;RGD"YAO#Y,/+UG8[P9 K2G^!P,3@/0VP:[! L_4_! M> P*@>QP^)_^B6-H6:EF&D$,34D%51 +3?IQF< J@B\"1AN805[U/YP\8Q[% M*B$ !_%,9FSCF,<+UB'8Z&>TW/DI NE),E:,/IKK=H]7/NY_\V/S8R,M('_,D""6774I2EFIFM9E MI2$CTD $- :XG'UO5I]:Y\0@4 H.*#;%+]_ MG'^R?Z=3H-AJ\+\'S@+#<+Z4+6:VW#18.+N6S[//05 ],O;I+'QC?_JW?^I_ MQ?[KTWS=_-L__3]02P,$% @ )C2A3%6B&^.$B 0V$& !0 !B6@R);&+8KIYL:W^]0N08DJ6>4F"F6"*[C[599<$(($O/@0B@$#@W__7 MU[O)3Y_+V7Q<3?_R,_P5_/Q3.1U6H_'TYB\___'^%_7>O'KU\__ZG__MW__[ M+[_\/_WN]4^V&B[ORNGB)S,K!XMR]-.7\>+VI[^-ROF?/UW/JKN?_E;-_AQ_ M'OSRR[K23ZN_3,;3/S\.YN5/7^?C?YL/;\N[P>MJ.%BL/GN[6'SZM]]^^_+E MRZ]?/\XFOU:SF]\0 /BWNM;.$O&_?MD4^R7^Z!>(?L'PUZ_ST<\_A<%-YPW: M?RCY;U_C#[XI_P6O2D,IY6^KW]9%Y^-M!4.S\+?_]_OK]ZLA_C*>SA>#Z;#\ M^7_^MY]^^O=9-2G?E=<_Q3__>/?JF_H?J_FBFLZ'XP#M^'H\_'58W?T6"_ZF MAO]8CN?C"-5<34?O%[, ^\UX^&KZN9POHBCFH5.Q;_]V.RNO__+SQ_G7@ 04 M@((5#O_CB!86]Y_*O_P\']]]F@14?NNVV[9<#,:3%GK_K*&L@_@P^#@I6QC# MM^VT-P0]F(_G5]=O9^4\_&XUXPYT=D^-3KNEYLOYJ]ARQ*,<-6/'T>UT.H3W M8;:/!K/1T^^_'P<%8,LAAF^KR3BTDS"DX]IM<8C5;%9]"8M!9&U0^*/Q0LUF M@^E-V43O-*R=K;L-&754(]DZWTC/'-5&>UTWM_$3\U?3J\5M.3/5W:=9>5M. MY^//Y:M@3=R5![K=N'[&+C:>7S54].TTGF6P#6=#XP;:[/1T% A;QL_- S2CZ)3HP22:W>]O MRW(Q?SN8A5JWY6(\'$P.CB"IM9S#^6,Z6 :]7HY.'LIW+74\C&#%+-8+T=6U M&P/;;%L$ MO>3"[Q;WKZ;7U>RNB3_4I&I['?6#\>P_!Y-E^7LYF"]GC0SMO74Z[MK6'S9; M+I+;.\>0&J[IZ0UV/*A&YF"#FNUU\Z]5-?HRGDS"O%I9GZ^"LSN]&8>/J?F\ M/$CZIM7S=;@9ZX]L)5_W-[]OR/34YO(/J!'UTQIK;S ;=^OKP9YN*=E)-YK1 M>7>%3CK52)8[R[?7I3?E%S4<5LN5B_-V5DW#7X>-%NL&-;-T,_YJOGQU]VDP M;*JZ$EO+,IR&6NN(%MKK]KMROI@MAXOE+'ST73F)%K :+L:?QXO#/6Y6.5=G MFQ'EJ#9R=7W_;QORI\U/Y!IX(YUY3!-M=OQS.5TVW&S=7KCUSCS\T:PSSPIW MU1D[G@\G533)CX+J4.W6N]N0:EO*MM>5]^5-U.?ORD_5+&KY [W95;R[#C43 MX8%:W76OD0SW5VJQ<\EQ UD#!=XO/STO"Q?':.M:W>9#;[IEJ,CI,Q.@ZR5?>W MM=9>)]^4BW;[^;S!]KKZMIR-JY&;M@SL]F;;[O;[Q6#6,M*[&FZOZQ_*V;QL MM]/?-]EB=ZNP(K3^:;*6["4Q8?-_#PV+_]"0V[74H]% T-ME^5.NZ ^77 M13D=E:-5*&WHPJ0:;AOF:HC7@_G'U3B7\U]N!H-/ 2/(?BLGB_GF)U&3LU\ M? @5_A\//R[TEO,8?_%Q/%V?2JJ/P3,>#!>;_DPB.G_Y.72@:%*MD!QZ M@8AVT!HJ(1822 6Q0YHXS8WZ=IR3&!9=S1Z0SCG01R_Q0P!;A^_^>=R0MS10 M",8Q]1Q:;B&EC$D(N0>$"JA-A.+ X)\23QA M =L3Y+VB6UBB Q>_51"#V? [PGY;]:'$;Y]6,1^_#&_'D_IH.L:Z=T&"*@/, M85R;F?S;\ZF<;WYOM>Y>[C1GF"BE$ 340*,XYN&_(+>**("AE>8LTSS>0Q@M M)^75]:;O3P6C[Y_\U\I\N.\_,Z9U)W0G[.K%:3/0R);W0W&T^-HM*Y3$,XTMD(ZK<(( MM78RK,7KX1'G"+@<(ITJW\-\28(T/V-^+^\^EK/F;%F7+PQW&G+C.2=4*T(< MH7XS+$0LN62F'"O9_5Q) C0#3[9HV /+TXX:A0+&! ,\6-V4N6"! T-I/32A M<1I74 ^YDFMY:@?I,Y$H_G56'EZF#M8M,-(4.:IHP([",&>"LMX,ERMJ+T8) MG2SO!OPY!=J]3/KN8"#\H'CS]<-M.1OL7'V^*U, 0@1FC#"#C'$06<_TID<, MF4,>9H(CBL)P226P8W$./".3\8A:) MCL1[ I@9U@$_GHX7Y>OQYW+T/'!8W_\^^'LU,Y-!P&2_@7%$*P764,E@E2&& M@".>"EHOK01S[M+XA/O'IVQ&1W?HGY> CUU_,[@[;)83JM)=7/_$&*\UX+:4;JP'#AE;=#EVDB' MG::2/?220H\254X/;:FN*=$>R!E4R[N8JN* !567*92GU@'FE MP,,P(,G7W M 92):H.\>"LG%:%< CZX5CPI54BGA#4L^ ) 4T6PP8C4'+4X?8.D&R$G8+]- M>DF#SR"_WX.VNEO>'93@-^4*2Y '" 1W3@!IE5*\WF:FRF-]01$B2=*KV@,O M!P<&7YMQX&FY@E#MF:<.Z.#_<\J\%!NS@R*1NO=U](+^8CAP G@9.% G_EG$ ME!_CT4-Z#WW?( 3@8-T"6B>P5A0;J;4G6$%:@^8-3]3YM'_&7S:3H&W,ST>Q M1N$!!^L6@ED:#6$*DB*WJ -D$%MA!S$1W M=U?.AN/!9/S/U7ABTN?1[^-)&<-7=[LK0( MM92)D8ZL?Q3*9MRT O19&'30D-E5I1 & 8]>D7<6+H ZY-(1ZPHB3&B&&:[VH&607+/AC M)56U#N=YPLU>AQ^\6I1W1P8NUM4*XS#E 21M?%BB$0&.UY-%^A><8;@I@315CG SJB.GEQ\VN$:/'V%8)US_M54W46E&Y,; M;ZWR>CSX.)Z,%_>P@6;KN >% Y)81S%ES&NE*?(4/T ?S R0&&W50]>N58+W M6TJYHF'>5--JG>)Z>K/.3.F^?HH9L0\%Q.RL6#"HK(608>0P4= 31396#@L# M3U2[/0S^ZX2.K8*;@46;U+-[^+(I4CB%E/$.\V &&\\UTV:SG\9,L(F3PQY^ M"&8DPMBOI3:&![6S9,:6"F.!8U80RK!7CF%EC:^A,"31I^SA>=NYE[X$M'M% MO'HA;H5\=6N%H@ARYBQ2 " D;/"]ZKEH$4D\?.GAGNB9"9B*>([H]LV[!*^F MGY:+^6;#YEUP^O9%LN^N55A.E"#.0(" =$1X)U ]SU1JY%@/=STZ(55[R!Z_ MP7&(O6]GU<>'OUY=/YPV[MCI2&FJL%IX#["!),P/I)WE?..%,VQX8JR2N'#F M9(([@R[:'&!_J!ZNM6UP*N=ORL7Z':J'WXSV**=CFBFPY@PB3)UE<6(1ZWGM MDE"($D^6Y85S+@/4QZNOM]4B]&4\F&QZM8J*N)JJX6TY_ARFAREGB\%X6A]Y M;]O83VNH$$Q+YY3UVF&-%*9&R7HNA3\3=VO!A?,H"]KGU5Q_G3UY3NXX;;6J M6G@!O%204B"H%IPAJ6J_)5B0J9EU>GCTF%M%I>![@EKZ]-"35=Q--1VN:7U7 MT_IF!U..;Z20!F'KO+6,$D889HK6JI9;E+A7!2]]5[USI#NQR?]>#A?EZ+_* MP:P%JWQ+8X6WE$#E@4:04F\.G08T,U SYEE&6IA/ ($ M(,&-,D@@OP$D0.-RI<X+UQL0X-<_R<8"?)R@T,9$E,(P K9#%8716:&@0 MV0R-2GLY&;N[$WK#1);'(7TF$K67R%(@P V@X7\X3$UMC+9^,UPKX.40ZV1Y M'YW(\CAH,S!I'4SU/DAK94R]CL(\K)+VU"HL]%Y0%H^>D5+**F'$9HC.P\L) MOLRFEMI#^WR$.JB6]M8KO)0VF 71?L>66$.P 9MA(L4NYXY4*[)NQI\D:#,P MJ.[H*E_6U?7[137\\]!;%+OJ%)9J9+A3#&I,H=.6RWIXG*O+";[-IH[:PCI' MXHDG/3R<:>*[P@51V$A*8%BVC89,"J-Q/3<,@A>C=EJ0Z?.4$J>B^4(OZ$'F M#4#>0FRU(9(J">5FD ;H1,KT,*3[G%Y9*MR-.34OA[_>5)]_&Z]VYB*C\,/? M(Y?P$RZM?UH\;N&M!KOO3;X#-0K""5-*.J\E]AH(:IC;# GX@T^3O1RETXY@ MJRY034A=4DTFU]7LRV VNKJN(RYWGKD<9,G);1;14^7!+A30:\%!,.ZHK34W M1)>7P[Z5G<;D'RCGP]GX4_SRU?4?T^KCO)Q]CEU8A_?^,8_I9U^7G\L) MKOO^>SF(3U ^'C$LZP#-0JAO-502Z\,1 A3((6P6@&B-:(" M'@HB[\9X?5-^4<-5(']026]GU33\=;B6^=MJ,A[>K__=Y'7@8YLJ%&-,$,FT M%IY936*FC0@(94'3&??RMV-:8T25%>DP'Y7&.L]"#!]QLUDU,U6@W;!IL,8QS02J M.(TQEA0#'^^(X6#8!M]=<.JDP@??;#! ]%[JA3<*:\5YU18BV,N#/4(G7$D<=7KX9[W>5:]EG _$ZD.AT;N MK%1 HZ0,FEQ!X+VDPAFAZCF)4_.N]E CG2[B!IQ) C57!D"SG$6@-O?IQF7# M%S%WU2LDCSMXA@%E&%9&",/J86J7;;EO^O)6QS4>A--1TFLFA/ MU0)"B9'61 A@M1-*@,?!4N-S[5^>1PFU0:/VP,W/I&,>Y]U>J\#$$R^!=<@0 M(CP'B.E'[ R^G%/8SOES JX9J&,?Q+&._/TP^!HLPME- Q6TOV+AD:<(>$.4 M!]902)S>^+9*()KH\O^!B5-EY'+W< LH1"[Z\6TZ"P#^7[OJZ'"ZNKI\-\F$(KZ9OR]FX M&CUNR^R+&4]NM%#. .ZL=]X1[0C#6)J-:!R%N5[2[2^#$[CT/ 8]EW3.JH[W M@OA-^%CX:37[M!KJJ^EU-;M;L>==N9A5\T_Q].YS.;E?[W;OS8:8O2\%D,8( M3B0@'"LDN0I>WT8Q.BAYW.^R=)WH9XG!*3>27\2!_(^##V,>XCA*EIK M?)Y\'4]D\="+HP) GEV<0@<%NNJ"+7FT0X/E]P"X@ M/CXL7KTWZ].N-]6OZP.OAX=L(P@QR;QF;1440HF8-1AIAS1ECG&S&:$2SY^!?\$NR::'#9Z-9M57P*",?34!-&.%T^3 M 9[#$K?EQ\5CB'L#*WQ[A4(QSH4B4E"DJ(%>!-<-*4X$#LI%RT,9EG,,KHG) MO:-&P3P2P"$6;#U.K0K\5L)2*3&'#DAY2;GO3A7P=T<';2!Z_LEYQ@L4;5A(@@[EWE@*%UEZI8M\S,T[ \WA(T55BKH[.]/4;R>9$"2P%1S"-O%1;!V?8< MF;H_4ER6;).%4;6"7KHT=P8G?E^HT(01*R3&E%!+.1,,P4V?C$A^BJ$_$DV7 MPA8Q)H&6(,AU8,B[PO?%RZX$9)*QHU4@BC,&>-R,R!&76(80(_8T.;JW!J.V8GQ9G!W M.#7SKBH%LU92Q:2")GAVRN+PYV9PE./+.9XZ1;![.9(,YO'KPYORR_\>?!I, M ^8^^!;5+/C#OX=F;F/)M[/J9C:XV[MJ-&^@0(APRK@(^M5YX+$-HZDGD.>7 M<_'\=&E6&0 ^GBQ_Q W;N_%B43[LEX0./<2E_VV\N/WPI3+A]^4LGCYL^JP' MTS]WA_*VT&H!'*46A$764T6"-\R85IM1:T<3 \5[E2BE$V+EQ3W#(A;#BJZN MOQG+_0$;9U>50@K#5R;@*FFUBZ>O=C,XS,3EY(!KT])I"5UW-F=';1[ M#E4MN"2(2(\]!B9,@S!''M'S2%].K.SIXF[ GQ.@/7Z!^W ;KY_SS;?W+EM; MRQ;>!?]=6R$(1UYP"T*930\1A9=CX[0GJZI=3#-HC_?+C_/R'\N DHLGT3$O MPJ&4_]MK%%(1XHWV1 O(D>8&/#S>$M=MHB[GCE*;RTP[8)Z')P>7EYUU"H", M%MX2*)USE@J( *VWI2B_G!0V)\OW,%^2(,W/F(-7(+>6+ZA&1$BJE:( 00\( MEO4!H13N)#.;N+>K7)^K.M?,&(E!"I^"\#**$, MNGJWRGJ5>'K3PP=@6UU]6H#R' PYO/)LKU$$6TUB:) EFD$4IA/0?C,T(=7+ M/\!M2;*'>)($9V9?^.""\WWA@H7_68Z4$,',)X03[5R]+,,+"MDX6:)[W-TD M+'.HD7(ZKF9OJD6#? S?E2V(YPH;2YFAS@+MB. U,D;H7%NS+X\:IT*9@1F/ MX9,'B?&\: &=]5(#9QWS(F;VL[:VY!E(W27IX>YJV[PX$[HNT39 VX,QA%H2:);[=R_K'D5:/:$Y'\@ST.'PHL[5"H1R7DBDH M+* X3*=X&ZB>1>R"7IT_3:P'.)($YO&'+U?#11645?SY?GMS=^'"2&<(--): M&.8$0(834?<1F+^W\/ILO![!X!! Z+>WOAX)M;#('1\4&P M^/B0"@Y3W4?!+B?32HOB;@7*X\7]^Z"AJ+\O6"B(D:'"(>610"!T3SP> &J8 M&(3<0W>A13&?#&.JB%%3$3\M6/# .H\),UQ;@" ,ZJ;6-IC:RSD(;5W$)\"8 M*F+:5,1/"Q;22T%<3#R@O">**VEKDU5PDNCT]_"TH741GP#C"688PD>88=\4 M+J@1W@77U3%("8%!X:AZJ(#:1/>]AZY9%V;8*5 F!(!7GU8+A38XQO+\I7""B(8C!O\IJZI'D M\/$*,B0@4=[BHN7="I0I2_;JK@!JX%1O*UIH+P!7%DD*D(6::@YXW3_F$X,$ MY$6+N@4@OQ'TKGT)<+$H9CD(VSI?WL[*N_'R;CX8#LM).1LLRM'@KIHM'MZ3 MK:Y'863C^7P9!]*/Q?)4Q:?7#O1.MU6\4E)+X@!N*V?PM M5 $04%_$\ HE;H3#R][U.J<(LIS;#Y>SU5V>AWQPTYM50JW!#R>MR,"^O M/D[&-RM9'0X9V5NO ,8R9XP06MC@'1'@7'W!R""7JG$N=[NP"U@SL.?;D^_7 M#1YKV5&C,!8[32 EE /&>>4U;MFG)%$&ZF'&Q3=9:Y(!?-X$]Q]'4Z6\P"U M#\-S'\>+TU;>8 M]84EDSM)F%4&?%.V-[Z.[Y9WK\O/P8B_*=]%2>S?V->_ (K*[8B&!!A Y;;0R7FHD]&/, MI3?TK?7W@TGHTGJ_L7Q7 M#LOQY^@C[O*D$EHJ0E<\B)GO6'0O,0),UG%F097G\K7S)^1JQ:CN$.H,^NNQ M@,- MI/5F%N4^\='=HT,47A(+\T*>Q8"?EKQZ?J9]6>GA0?3 -SN_H0W53QM\^O#(9?GO$(MV3 M'A9(!8$IIBQGCAF,PG_7OA>Q.'%'_>@HCY-07.ZR()E4+BHA&(*@.H(+KS[ $]/$J:] CB3NQ1\?(O"0.=@1N]J.= M;XXS%S$8XVTY&T9QWC1_'69?(P60P482R#NOE246"FOK304 ?>(KEGT,DNEB M:Z83D//?1M]WX/QMR<(RCR "2@II*7>(0UC?A^(N.8OY!1\,M(-DCMBHIW?N M_U:.;VX#BQ^T:$.GI&D3!=52!S.88FJ@1@1)8.L\9,K0U$B%'^"PH".(,]U> MWW1\W_[-M)][LR1N;$$+Y*EZL#\E&P^.-3SX/)<#E9B>;JVE33>349QW=01^N# M\QTF+3T$89A V"\6FC&L#@:B92Z()/!SJ"-H$:0:<'6^Q^ M]:QIRVJJE;8+CC 62AF+/(::4FUTO81305*?D>M]>-Z)Y#H#]H_L.]>[O!^^ M.:Y:]^IE/W9KT/>]I]WY M-PLA$0/.(\6%H$ (2<-4@=80 4GXKU0+N9\JXA365/V42 ['?GA;CI;QJ/3W MP>+A9LW5]5//X""/4YLJE'-*^:!&@<&4$*R(@=RJL*9CABE.O,G2VU>H6B!H M)J@SK%C!-PBKT_S5='6 $R?0K+PMI_/QY_)5?&2K/&ZUVOYB[Z%O[%F/CJI? M$.ZU01HSHBPEPBK+H9 60TJD$N+0SF=G&[G/.QR/.)I,Y4-5"V.'*DL7GFZ2N9]UQZZJ2W M&FBG*8A1^5 !IZ5SAW)N=S-]U7"XO(M>2#G:-8#7U7SNJUDYOIFN X&']ZO+ ML&O718W^OIPO5J\>EHM@SPR^[IGQ'7RM^6I$*U=\?NLGU9?_*$?AU\$6 M_S K!\&&NG\=U.-\'5BUA]YGZTLAH2%$"2J-(AXCZP#U&X0URI9GLTOCMEOZ MOQ3197#2&L*@/H>5-]K]017$\-?'7 E=+ 7'?*V0EC#L'1+><04]CZ?E2)?3\)?%V_CKU9'!JL[;8,#.RL5XMMJ? M>3L):V%[S$_] MPQ_M1!5OGFO#G<'!HS7"4U/;B0 GZNT>'8+WBK&)L.<("JPMK+U^Q=MR-JY& M84#1NBIMN?YSWT;3*>T6%EEB/:?8. &0=!@IL($)N=0ST!Z=K^=A9TXA'.]* M[ILP?TQ#'R;QTL#&V+^:VM#-SZO1S-5L/!]/;^PJ&F7=?5U>!S_Y73F<#.;S MN+6UODA_P(7,VH?"",N \N$/2A@5ACE*-HA:P1*/[7ITLM^]X]AG@650UZ1F-X88^!FJ7.)MZE+SZ_+.I1_([\^0Z MWAQKH=4B^%5.(,&90Y01S83D< ,1=SC;MHJ35%V95XT-LQ-)WT%/"LBL]#'7 M/0\6H'9!*%0^B,)J:E.?M/CASEC[+;=V#:'OS+.K9>C5:<;-P38+2!$7W"&# M,:48,.[E1FG8^&Q#(E-_F'/0W!(XL]K>%MBV?NYC%<>3%N_8S0<+K33VE&/C MB-)6(D;8QKJS@*/$/,=]NC5\?B6<33QGY/WQ/L<)G$__6.$8%T8 0K#5G % ML<,UH"CU$8%.)H'MT#C]#_OD=2Z!X5F5@=7GFF/C!-:$>YM MO;Q:D.JF_C GN/V6U\L[C\I_W%1K(0Z]D<*&Y5;S\ =U#FVB0ZQ )C%!-NQ5 M3MGS3X9\$CHS^4]DO!]8SWKM4._U?IYRG@]V'2XPI M"3/.?(<1& .9,@1+:RGC3C/#F)>(*"4Y8X>V_]H93:.<%T>V4GC#K8*<>F8Y M)=)+H*55'&)LD,$@-8W22YVJC05=Y8(\QXRM[N[&M][E79;\0(39X5DD@KA MJ2)(6H"DT=P"!PQ,/J/M'W5.%>IW3_:=#.89&&*KF.3U"(ZL*Q24>*F0Y]1X M0ZDQFEI*)7#4DO!OF9K_NX< M3>%"QP2O&#,%C:,"2TTY0D+KH'2#XE6)<9D]"EGN?+E)A#([-SZ$SQZQW'Q; MI:#>< 4P!\!Z:L/H* I_,4X%#XOQ"]CF;D.P>SF2#&9"?KOY?'PS+4>+JIJ6 M?U^.;LKQ]'>U2*.FM#.H0"/CR4R6V)[&J$TAS MV!S+C_/R'\L DOL<_A7'?F UV5&C0#$SC/5(0FDH)E)IH"RVAF&'/+*)^UL] MBO3O:$EI!\_S4.7@PK*S3L$"0-(YA#QE%!"EF$$ *X4#7$"YU)LA_:/+R?(] MS)W1U=YNO)N MVH(T[Y;:RFE?O<&]>DN[V;;:LTI%F$?2*QV?%U346BNM]IIY[JFPU/D+WH!- M$/+N#;;38#W>Y]ES$A%/!)>#R?Q0-%OS%@K"M);2>LB$IT@B[7& 2%LE.#6, M)5X2[%7^[ YHTBW*V=>G>S4A:P=P,^TIKFOG\KIWG2E>VH52!K. MJ"4,.42Y%Q(2;IP72-"@D%-?/^^5PLK&J=9@/GZ5>SNK1LOA8C(>?%P]\C8< MS,MY-1M.!N.[^:QW64BI!%'QS2XA MJ3)A\D"%XO/,A 3_A"2Z[SW:[>F:5KE%D$"ZY6)UH7-U46U]EWD^GBYNRS]^ M??_K[Z%3NXAUJ%ZA..;,!IN!Q+=)-0O3Q3$HN/7&!D_TY9.G(R.J;60S*"(S MF YV/CJI0;(NO:DPQL-AOX_X3Q MCZJ[=HW@AT8+:HP!4@ L=6"^!I);)J2FX=\:F-2D43U*J="7A>@4V(^GVH=J M,9AL[>-@.EIW#B8 M?-N_M.OBA[[XS07$:,8"M1345&+HX:%5N[L;-#'P MM!K^&7I]-5OYY:/5WN+;SM5R<5O-8@ZN9A1[7JO G+KX#KCQ MCE'+D<86*PH=A892:A+O*O4H OB\U#H1[W-0ZM5\OCR.3NL:!=?,>X0(1D10 M;XD*(R0$$X"4IQ@E;L?T:#NO#U1*POH<-+I:+N:+8%L%^^T8+CVI5B 78WC3H@.>#$(,;,. M\1B%D,BI'FT\]H1327"?B4_-#*\#-0LJU@^%>B,D)8H)RQW"1"@H,=(L\7RD M1_N,/6%6.N89Z/4AOJ*\G-T_Z>\>2FTI7=AXC04(R+ "E+@PJ(@=]@!PA'WJ M^U]]2V6:ET:GX]R+_>D_IH/E*![G'+3M]5\ MO"+:X61'3:J'Z>RP1A!20Z#U"C.,Q"JU+&:<E(AUSP_E-OJV8,$,-E3% M3 ="&0VEYQ!O!F,PN*#;5ZV*]OE%K%- S7%3;]._]\-R.IB-JT.7@+>5+SPQ ME"M! *,2465Q/#U[&);WR6\H]2G:^%2![N+%"3CFH,=#[_Z8SC^5PU5@T.&K MO[OJ!.\L+'H<$N0<9\Q(1!!]&)[ A"0&9?59I:1)]SE76@(TISHQ,5KHZGIE ML315*<_K%%QCB;RR5F 7GT<* X2;X5FG$FW)'AU5=:543D0RQ^G!DQX>U"C? M%RXL<$Y[H94*8U%<$TXWZ[$0T!_*&_L"54FZ3)\?")R*9DX]\KK!A?#O"QI=WO! E'-C0%0 M.FN(,I11R.IYPGSJJW"]-DX3Q%BU"&(V-JR?75PT)L6S\O'\DRAAC+%.:(^Q M)-YMAL6TRN7DYN!&JD"W\N(T''/8%X/Y;;RZ%_YP_UB./P\FJ\M\C6]N-ZI? M<&00$',HG>$P)K>8OZD69;P9^KH: M3.,#QV4805A^WY2+!X#V*:*F;13>2TBUE0I#9+ CQ+#:NU/>7L(=[F[8U17$ M&1CV:AKS-56S^]#)/21Z6JR0EB B:9@>S&I,N,>.;P;AQ,'4^FT9NR^/)R>@ MF($*]@'\#X.OZV$W4B][:A4,2,8HM6%HVB$(/="/'J--#7HZ.KSNY1&E/5#S MA A\&HQ'#RDJ-J]P?@/(_C"!0[6+F'- &4EYMXC$N:)W&QD"BEDKN"YE\>C M]L'-[6DU]; *R!02D ))3;#@+"+!!:VGA>>)'#D^^"W> GM!##D%Q"RZI?I4 MSA;W\?G>1>!O--X_/3S@NU>I[*Y6",.E<91X): AVFF-Z\U'1G!B^JL>F[DG M^^ MPIF!,W^MJM&7\62RAQ^;(H73 CNDB/1604P)H=X_(H(2N=!C4_9D+B1" ME\6560RF-^/@<-4VD_LZG"QCY%L#3C2I7F#!F!=<424MU-P1(TV]6'*7Z\+( M"^)+![!FX-(3.^E--1T>M$6VEB]03+9/K2,2:XN"QP]M;5H9A!.O/O;HTD?+ M7&D#Q6P&ZD'+M( 8(QW I%#YL#)JC&C=<<)YHK+HK4G:TE;_D;!ED/?KAVP. MX]7FWNH<^[::!&',HR&TN&]P&M2TB0)C8B7#7&&K/8>6,[JQXR5G)%<(R@L[ M/.P(WKS<:GZVN+M2822 'B ,G(\9LK!2;+.K*)40EQ09V;[0=[/J-)BS;-Y^ M;+196Y4B'T6:'34*XR#F4*A@ M^AD.G/ZO=<*T@^E9#-VC#-Q"46"(56%%Y=J@,!,0K!=9 MZ&%BZ-/Q>RF=.],=D.1D.'/PHYK>?"AG=]&P6D5J?1I'I,O!O+SZ.'EX$&'_ M,UU-&BB(ELX&=\ H+@ QE+%:@R=OR0'NWL'J0O(\T:Z/,&HT4;OH:H%L=HH MH!$1GF"!=1ARK7@-2XU5Z+O]TPV_6@;[#$91\\.#[0.DD!K(N?42>Z.)-\+5 MR,GD9W5Z>=[4.9M:@SE'./GN!V'V!9'OKE5@C3#2PA*H@0L "EQOK4JH3#;[ M*:>1W0V/VD,YR\6VA-.*/: YJ9 !V@FDL330VE(/5*S?W+3S#=IECW9G5*P3/3BO60]O/@ M7:=G10LN.*3*QKQ4&$#GE7CT:P'#B6M3+WVR#NAQ(IP9N/%-/JE#[/B^<*$\ M=H SYB3G2E@*B)3U@(+UW[5/)=?\F)8W,H0TY&-<=!Q&BT2H(TF+P= MC$>OI@_["4_XO>]$XF#E G/.0!B:AU@[#?3J2=8-=HPGIH/II3/5 8-:!S@# MH]Z5B\%X6H[<8#8-1OI<#8?+N^7J]15;7H^'XWU6\.'*A54.,^ZT]00X)"2% M8+,**\A3\X?W\F)*!XQJ'> \AZ6;/J[V$P+]@ZQNR^E\_+E\-1U6=V5\5^A- MN;BZ_C#XNO\(]9B68D8X"2ADFD'-/!;0:[N!@H4_,GE>+Y1KW:)]%D<^]'H= M1OVVFJVDNEC,QA^7BQAL\*&*NUO5=!%0#UVY>34-GD\Y/\[I3_E X6A\*4+B M8$LP25@P*ARN@<,R<9$]/F%TY^=T'9#T+"+H00#M"8&S!5($.V(1HL0YKISE M>I.S03FB$K/M])!O.<,=VX#ZD5=Y4P#78<7SJ^N8[\-/JB^]205<=^BX%,#? M52L8U=)(JZ0-9K80!@%/H& T&$C>0G[HXEK' STR]2\GZR=^,03:&@B9YW(S M&(5-KHQ965/_GB#2_2E_CP,SB^721LI?X)G0!HK515/O( ="/:)#$LW?7H8K MIPJT49U62)MW&*7^/ S2G M.GF=F*J3 84!AX #B*D@W@*S&1##+M=A0_94G2>KD50(]W)B^T/ 86TV"=,8C44M!.Y,I,2O MIE>AOX,8FJ2&B_'GM5M_V.D\OK$",\T\L00P1[SAPK,XV1XL!)LMATK&!36= MC]E@[A7O6N%; 14C$ KM05@9&+?4N=J D0HEWD;LH6G?)3F2>7@D_.?C7TRR M.6]+[^UIK$ $&Q7\(28419Q);[5; P(]9/"28K.[UWSM 9TC'')PO]I@_E"I M83 59N7.!&G[HB0;-Q)3K!$)F?*.6T6Q@TZJ#0".L,0+DLTUW[?Q3^?0?:W0 MXWE895<". <#]7(>IN9\7JZ/L%?YSM>_V?OP[Q'-%%K$T%(<;%XI,=88($AJ MG"U,/-EM[GW\("QL3P3GX.$:HKL=&S%-JA4*6L0Y 98.>:]LNU9LN@);9)2@4A+E--.&!PPV A'129;KOLH@HR,ZPS^ M\_'OX;W6=GR+/8T5!BG)/.22H & $'IZPT@R-/$]\1Z>%NO>\^B/9BS!"Q_ M>M#35]=/;]?O#5/>7J4@@&"GC;+2(&H=EQ'0C5*G/G$=3?4:NK\UT:7\OXM< M;@7S+#?WJF%9CN8^P/5J/E_&U]&_[?-CXH;WY7 Y6U^-/I1=/:W- F-IL39& M<8P)5EIP8#?P4$ 2DT/U\.PU(Q=S22,S69].L7C'I)RMWDD?! ^](37WM%!0 MRI2%8: "2\,H9U2PS= QE;F>,+I8(K:'_?$GNP^>3G4]W%S-7X2_S^P9ET5QNHG\E5:$JR M@W4+*I5P$!)G&/.2*1RF5&T;&)RX0#:_;7;^3;A@R^#V6A7(-T1+134,06-A $<8Z%&"D"Y&8V'+-'> M;WXYY[(7QPY$<#:/M-DE_X-U"TPL$5PYR#"'1@L@Z".[7RA=S?M %[3J#/P/_W/5U.5Q<7;NO MP]M!\%[>A?7G:KK]%?(]##RFF:#IO10:,6:158X1&SRA^IR&FL1XI!ZF9FOQ MS*!#@#.'I+]=12>/I\.8Z*<L_NXA+W_ZE0@;5SR@PB"@* _A:@CHV@1.2 MZ)8>?Q'[)="O'S+(D15NZTQ20;'/9O=!AQ],%=>D?@$<8RR8MLXB!;V-:1<> MP[.<2Z3>T4;?"[H7T26^%T,K+;GR5# ,-'=:A,$:7Q_F&9#HO1YMU+V82U]= MHIOC8NGRTZ?)"H+!9',[_]7TNIK=K478(&-#LQ8*03U5!&.H@]5 G%..UYL\ MUNG41]K A8>.=P-O#F;%/1H]6"4JN?M43N>K_NXCTM8*!?' <4X==";,&!$\ M*5L/S*C44\M^YD!H6];/N=0&PKU(<;,]D=FW'YV;=D55Z].^Z=USJFR8M M%5[3X)Q9X3%"5%I!'=IDO'*0^D/AFQW#<60V'&$X5LH 3X*S*3GQ#&V>YG%! M05Y@"HNVI;P_0;Y*O..G;!"7(:"[11@ISC M<'QQ"7(01Q":\"\KJ2'1G3.;Y.".R]1(]SYKES3I-DZ0*^,KK,X.P%3WQSJ89!FVVHD%<(\AZ[7X\53PW#[Z>I#H2+8TU(2PJW5 M3D'B"8:;#*:>6I-XGM5G+9$@O.^/2=/@RR#_)CF/UWO*KQ[VE.W#GG(#:_WT MQ@M/O;1A]G&CA 44450_H>T1T;E>97Q1?,L.^YEYZJM9.;Z9KE\P'=Y_F V" MUSY_4P]F037 ]L6-. MM%0*;*BD1$M$*5?8>>Y9;;R%X2?J[N/O!G4>R]5#KIX@B!S'SM]W>-/9EA_C M:/E+\?:"93KF%G<4A#^%MZ"&TKAL.?HRO,K1FGU]7AGTX6SI(0U<^.U9WT]8 M8U]WK(%'NJ-&H86C2!%K#:%*:NB)C8&ISCB#'4:'TOCVZYQ(.B$X,@!PI97C MA"AE-H.Q7N7:\._>9SY9FOO/@X[#\>6 MNJ"I FUV'G04CB_N/(C%K#M40*>L9,(J[KE]&!ZA)EM,R=G.@YI*M_%YT'& MOH#S(*J1]09XCP724E+)J:D'%"R9R]N;;4F-I$*8@Q.#23E_5WXNI\MR?[*7 M9R4+NKIL[[4EW!"AH))2;(9B+;NDGAF,6UG0?7YJ]5-5H]_E;. M/H^'Y?Q]]8C/5B]U5Z5"0D:1MY)HK)&T/#A?9#- 0_@%*HW32=(:G!GX\M=9 M-9^O3SSW$.1)J0(%YY= K3@6CEA@I;,UY;G7B6%M+V,+(I41Z?CEV(O=)(EW M7V, ;:-4B#OK%(( [*C67EH4+#+.XI7US?"$2Z3'2\FFGDJ0MO#,87*4J^VP MOY;3T.5)4'!J=#>>CF-WXSG$PP#V62*-&BB\0,$^,\9H+Y3P5 "'-@/'PE[. M8Y(MR/ZYE=(%PEE2XKN';R>T6ECB-%\]NVL\ ,X%R&J( EZ)N3=[:/ZT3\)\L.=@9G4_F"SN#RNW M;PL6+JST0%J'&0GP"2)0[7L2PD#BYET/\Q-VP)]3D,Q "747SXS^N9)-O/BP M&$QOQA\GI9K/R[W)(/97+ Q&%#&"'/=0TGB%R3]RG])$E7-\"O,72)E6D;FS+>]K35D]"._C">3/8PZJIV".:((M89CYG%,AR<%W< @$$Q\ MA::'>0?;)UB70.>QKQ:SY7"Q"A$RMX/9S=Z\2=N*%YS'?51H)/: F2$D7 S M*,!1HGHZ.CM-EABP+FRB4Q'-0)/-RS6FNOLXGJY$9>KLK>9I]E8UF\5L.ZLP M [-*O/-J&I3P,LZ/'55>CPOE^E:WQB5>SA]%[:A5*Z6#7*J@]8%13 M3HURFR%BG;K3T<-LP&:X&\(E+C, V"[00X) QS261\Z&8#(I6,)OJ%O;3L MVZ10%^#FV'MX"&<^;+H\*UDX@26UF'*DB'?20R]KBRQHY,SO475_LZ)%X3[? M3C@)V;.KGF254R AG!'4$TN17EVIMIN=. H52TQ>T=^+9-U1J%6@LZB=^F)G M@&KM_BU#MQ^O*.CRNIH]W-/X,/A:SMW7 %$062C?!C$PZ34Y;3<'VZUHT;!L%9, M*TP-"Q:JL\IZ69NF//7^;0\W"EJGVJE8]C"UB_"AVY3B&$-&F$4D& ^; 7B4 MNA'?P_V %LF0#%\&^;O!;!KT6$P)ODEJ.1[NH<+6\H4(N@XB"1F#T#+G'2*\ M7O U3501QZ>D?5$ZH@THS\ 0.YXLGUSE;,"1AQJ%IP0C*A"1A$L+L4-0;88& MM$]-3=G#X+H.69(&9@:>_*TGYU7(Q7PRF MJ]BKPUM'QS95((04L,QJ$QQUCYQ K%:K >G4:R6]=.U:Y%;'./>(=(>6M:/: M*3 13 "'%:(<,@$18K V]@W(E04S!]NZHT@B%U,D<#XB/FCK[T9Q/!5WM50( MRJA$7%"CD$0HGB+4)P>>',Q>_9)VM2<&Q]:VI?\WO6]Z95"R$TI1I;KCBA!$')&0)$N+#,:049.L#I?5-\ M7@Y_O:D^_S8JQW%VD_B7.$#R9%*''Q7KSKTK;U87&*:+-X.[;5O/NXH61 ,D M*=,2<$21(]I1R+BD"FHK86K.G![9NNT+LVH5TL9*_SA&F##02B&E<=(I2K@7&@9MD4E5OVA.G(9IZZ38C/9#:'X' M%YX6*8PP4#O%B)BU]NC.118NG()IZZ10H4>CV"L_ M&6PS\K\K4T2E!2CQ),:$2>+-HA=-0 M[9@::Y75G!Q/RA=8(@>L?3HL+Y3>K0$:T>NIQ]/ MRID)W;FI9OL=SV]*%A9J"@UB!AM!8="$ B/FJ2T MJYV(ZNZNFKY?5,,_F^PO-ZM80&@=H\H00#&5P84&CDE+#6#&."POX"@_QR9% M>PAGV"SV@_%L]:KR[^5@OIRM[\P=MTOD&M9IQ@?_!MH'P#_1 PUN%S?QXYTKI>8:B%T#@/F8+44"U( M&"*EQ&' %66)>KZ7QY+MB+SJ#MUS3=NM/[3E8C">7,R41CA( AKK.&<.2H4) MM)!;1:35ANM#2U0W WU\$^75-%ZW7P&_>3)%W_]'.;H)RO]=N7XW:'X[_J3O MGZ4F?QU[&GZI[[.Z5I,8(O1EDS(U[,6SL(W$: M<#M14%G9&"^$Q$D=#Y<.IL3?5ZU@#!#MH% 82TF0=]ZPS2"!$;FR7)^'C<>+ M>B=_3H8V W_JY>%AZOU>QEBA)J;--Q4*$E<0AX2GV'N)@0HF[&9@3+#+>4FA M'?'N,MU/ 34#6\Q@?NLGU9>F9-E:ON#..A-& C51BJDH*UGEF+B4'A4_^-( M.N5*&YB>R4S:O](G&%"'&RP\PPIK30%SBFDK&&4US(ZE9JM"_S*0NA5$!H9N MZ>A!NVEGG<)":@7FFBLIO5046V8VPXO77)(7P+[P[#@A5MW@]F+6..V)QI1S M APEQ()H1-:>M1/I=RRZH4,+\FFT3!T'2SXE8,OY^&:=D._ ,K2]0J$\!(8P M%!=R$H]"+*YW4CB"BDB:L\3PA^L5 %B'B9!,'#%JRND> *8%DXZ,;;V1B2M(>;L6W)-W]^263 M0,VQ3;%Z+W/UM.KA+8KG90MN""688""D@T!1AX&MAP, 3;8S?@R.G KH7GYL MO;*^3EE9[G8NOB\4-^L(B1:3"F:88@HQ2^O1"93^CM9+$-7)>&2;PZLW;]_. MJM%RN$J*TW Z;Z]64*JUE$ A(.,-8HLY(YM!(F02M7^/;F7FF-FM8)N!0'HP M&4R'Y?O;LFSJANRJ4E@KP_K&&1 (!6<-2*_JV6$13=S![-%-SA?DO;0DI#,Q M\*#?LKM289"'5@H O5(Q82"RL!X@A>QR'K ]7<0-.),$:@;6K!;FA]MJZX?@ M#BYZNZH4D&IKA%8HH(,\T!J"VC)7@ER.N].&@+-^EEXK&NF-,*LIG5S>:5M'$#OWEOO7B6[1A3 MRFM-%(P[ AQMAND,2"10CW+A9%(\IR*;7_L@'PY)GNK\M_%K=: /A.WYN_*J+^/NGRRIWH1G&1#=5#N6#*+3'P3;!-C M:''0^I?'KC88T(!=)R*==W5]O%(S+F?AT[?WK\O/Y:3Y KNG@<(03S$#5E'- M@ZNLL:\-5&N!3$Q3U*,L5B]SC6U/9.=2A=^/(&G!W=E.@13DW'O++"3(22TD M5AL8E&6)![]]5HXMT:*)?FP)]9SD>S7]M%S,5WC YLOO][6*L 8(A(#0'(2! M*AJV_+C88Q/#&ZND=)15^ M7ZR M6$ZARDX;>ENQ@@'HJ89(>BK-_T*_S7RT]_?Q ML)R_KQ[%L3\2]%FE0EN@/(0&2HB<0F&1!W(S0&!YKK"8'.$-;8M\=TCH:2#G MOT&RASK/2A:< ^R0 H[8@ V7TGM>[^7JU&#Q'GI<';/E-%S/M2C&L;\KA]7- M=/S//L;7=.U,_4ZA%-1>8^@, M@DX#9YFIO52O2.([,\U=.+FFY[2\B3=3/[QTEIY3.-D"OK[O>1SAX]#G_WHMF3?EWKS4[7^M@%B#^'2$=] : M+QTWI)[\W-G$!Y]>VKV1TWE]?MGDI_O3)%'E!LH/E2[#,C09S.?CZW$YLLL8 MX#?R@<*Z+SCED*B T\HQIQ1_KBB@<1K*"\MB*YU4N<1 MQ[EWEE)LJ/UZNXO/!<_$:NEQW.E71'@,-:]!)2(U15WS()8?P:3.*Z-S$O_I M#/8!>S4<+N^6DRC:*_,J>,55.Q[D*=\J"$ ,8(2QH1 9QH*D-Z=3+@#Z\I^7 M.S?7,TFF!QH^:9BG:?G43Q8&:<: -U99C!P#,%XQ?0"7$YL8]-7\?.('T_29 MY'3F?93'@3Y<7A[]?3E?K&.0P[##8*^F3_SQ])V5XS]42&6!U!QC"H1%F@M> MIYEUZ.G3=R_V%< >;+9T+I=S:?F#7O8&WP1U?DS;!?3!R+/0,.B8"?! [7$- M%X&I]V3.DU2\([W;(:#'AYR$;VP^%^? ,^_WPVPPG0^&41SNZZ?U4UP[@E*. M;ZC@@@KCH&!>$,T$$8QOMC8=@"K1MH4_S@E>%MSS[[$]Z?2CC3*81%^T^3[: MGD8*+96*UWT<$(9Y%6QX[S8 ,*E34Q4?'UY9+0:3ETB\SC$_UT+Z:KH^>5EG MAWBR-WWLJKFSH0(IQ)D5C 1C0B @#2>;P#5'1#+Y?KQCM4YQ[ZTEMQK8"<0\ M^@,%X!X1I*QGT'.$4L.KLTR^["A3%. M(XN5A-!YK3C5\M$%1SKU9=L>753,L.';"K9G")Q\>$]ZY9W4"Z@=SX>3U;;T M$1&2!UHJK" ,RJ!@F014$&.UKJ$0,/4Z+/IQSA7R )^!@VM7^#BV[:Q3("ZQ MD]!HSQ2 %"AG'C=>$$E57S_>L4%;$)]/BSUZ ZVHLKW-%5;'=$\6.V&"2\&1 M$6;SEIA#EB5N6Z ?[\0@ _K'&U9J.)PMRU'L3##FPH##W^;C(*+!CF#3PY4* M3+1QQ@B]/,D@E;:V(B4Y= 7^<+?O6,K'VZ)O%><<"1X&\]L]M(F_+HRC@B'*/)8.4*(M!J3N-)6) M.T7HQ]M23T SRW;BQ\7C<)MM>&^M42"K/208>, %PBJ^D[!)6^D1D8D!KNA' MW+UN ^#&W)F7PU]OJL^_C:>?R_DB,@<__#UR!C_AS/JG3X;_IHK2&DS47;6< M;HL[/5"CB"]G4VE!?%/*<2F)E_60I.&)%W712TM3E,Z9=@%^Y,R___84V]"_ M/U<_??[#A]K?(?6QFB^"+34.OPZ3^;C/I0&X5!@!"+H68"4^&\<,!#9P5!'C.# M4^] ]&^VMT.$!OF=V\ YZZ'EO#FO=E:[U8I>.[F(6!B" Y%<@1(*:0>!TDP- J*X8D"!_*(]7UC%V! MW6B:KK,D6HT-)9YQ'-,CJ&"D L6"S^MU?+_1I4:QO+"YV5BH.^=F"IIG"JJ* M*3(/O&*RKUI!%4=< ^&TX51H*K'"(J@R3BRR!J5&S/>/,LG2;1#@E(AF5LIL M-N0_A$\??$5D7[7"*4VPT]IXA:@)DPT;KBDFPDD)&$P-8.HS94X1]4[^G QM MYI"W8Q(D/[K5SD@#&->8(4H1@@J$L04;61@.")>I![M]9DM;"B85Q R\>#^\ M+4?+27EUO75WI8F/T;2)0GG)H!(6>@LI$T82 Z 0VB &',J6NS@G@Q(D7V5! M]_S4VFSY_%O)09["+ZG\?^XZI7AAF@ X6 M!:6GRD[NGKV'^=5JFY(D E^GU'ASV]-#W5$;Y9E]5Z# _WN*>C M;UY*7^WUC:ZF]?.N>C ?'U9JG7RGD! #H9$7T"L:MUN#JV4)"Q/628%](DV/ MCK5Z:30]IQ R[$S'US>^C">3,)I52JI7H;7IS3AT^MM+TCFWIY_TZ7EW'C6H.$';WV<$8HFNN2XA@IIH4%$O M$!.F 0$"0(41Q18?VKKMVC+9#.;0N=>.&@5VQCI+)&9,QG=UO%-V,[QX9>MB M=HHZDOI.*^(4F(]WK9\/:<_;GMN*%MIJ1A#EB(N81Q(XX=RF?X:"Q,>K>DB# MDP54M8KDZ9+>^S3G]L(%P5BY> JC(*1<*4YIW4>L4Z.D>R3MTZ6S1\Q)(&9P M5]^%7I8'#K;K,@4EV%/,?:"WTRSZ*F'\#]VW'E].4%);,_Y4"',QX.!#WT]* M%1Y#B812<5)H0XA&Q#P,@7F9G%FC?RQ(D-HVN2?!EB-CQG@ZOEO>'93]-^4* M13!0TDF/F)6( J[$1H4QB>GE!#\ER>YYQHL3H,O!@,'79@QX6JX(WBT"FG@" M)4#..V2!_/_E?6N3VSB2[??[8W;Q?D3H2BFQJGAL:K03@"#O10E!U*E# M7;0-X3WJVHKH#^;+,NUEZ)\FC_51/Z:;>N]'-W,3GP=H(O;L0,2<5]$YG@? MEV2EW0U+3>$Z1J74FP#SKF$>0"E]B8-;Q(G7&4!OO@O>$*V5YW',DFO&=7'M MO)^&@2HUF'=LJ? C6+1X.3& N6C!4"]*Z\H&,0^T74S MPBQ,79O>_0)]>@O"0>"DE=@PHDGA1\>5]R,>J!,S(8S0#.^-*^TX MV8$0!N#E'XN7RHTO$YH?G%#=CMNZKV 1<5B3(GY"8("=$K@R2"5-+F1S=9P\ MCROYL&)XP\IKBN0?0@@#';^.Y%=>3K]/5MG=URB3V/R[6MS9[$(K[[S%?*@HZ.NSCKN$=0CV[$97 M:^6^^2X@!3RQ$ EF.9%((B,KMX2'J=G?1F@K="3-]QPY \SV6Y&9+.]F^8_) M:KJ93Y8G=YY#GP:M)!9 :ZPUP,8R@DVE2S74B<7;QRCL-+'DG>+77KY?OS^O MOS].%G>?LLTR/RG?0Y\&RY 6#AC".%9($>),>>;BE"K,N'.AO&P4P=^6^2HQ M2&7;-'"F'9;*,R:X1U:0(F/U?K(,F-O9\\^0<_-H@!1,+TL@-9UN'C=;AXEZ MS)?KV;^.E2]([RS@B 9PR%("N,*,B+A&*T $37PTT=SPD#N2+;*'8FC?;H-K MW8 ]X,96IZO>?!>XYM1PJ""24FAEN8*5J64I2HPW&*%ATQU9S@'P\K=Q[N=T MOKF;+1[*::1?Q?W259".Q6,[4P9!SZQ3 *C2F[:-_ M7\://M_?'W\1VKJG$ ^I6$-J+;>2&6DT,A6$\=B::& W/YA=G^TS#-(#&CX- M;)Y@O/,N2@M3*!AB'C#CR\%KPQ)I,L)R/-V;.RVQ&U#P7[+E+(_DG2ZSR2JS MV>Z?#>APN&&(!CV &/M%5)>05? MI^HX#@QFFB$I7BZ)TDGB Y(G6_+R6(U MWXEJ<5?>6$>]5]1_B;NGNOO'9K7>WE UX%.+WH+'*!IK%G%L"=#$%DNHA 0K MDTBR$=;NZ9YD_<$\(//4])^;6922W10YNW;KI@'%#C4+P$.I%2&XJ%$"-&!6 MO?@BL$A]-SO"*O+=DZD#0 =DS8?'ITDQVE>6V>Z/"K9_;.;XJ>TC<&(5\,Q M Z@UWFA18+D_8GJ2^JJMN;OZ^JSIOD%N?QZKM&7V<[V9S$\56CGU>5!$ 6Z! M4A1C9 V(1\C*[',\-1TR'.&3I&[.5!T!.<1]19E8\L/B:;-+.U7LH%\C64]= M3!QO%0@!TAAC 3<2$DZ)4KJI.%XTV&)NMILO94R&\S_=_ M+/(_5]GR1X'SCLA_K J'TL &8\LYB%Z$*@W>LQ]N$HC% $AF(9;<,A&V%$\J6RN7LE% 1!%M!&#,R:B,I4>>[R>HJ/-#O2RY M#063B.K%:).@:%X]X.4R6ME*(DNB-TI:2".!0'6B7>9L(*2IUEB$/& M>#PJ,UI.P<$;RE:2(+43B;?;P3;DWO&*YA\;/'4[V2Z0B BU<4J&(^(M0%KJ M2G,*R&XFKKM'PZ,#8(?D3[LR7Z>:!8Z!%0@#S&W<>RT5C,-JBS0P,=1IE ^B M>_6DG(_ML([."];FZM[?"0B.EAY''$,.# 74(P'C,95(X3G&=2JPISN*V<.B M@'^R6)OOQ;;T8?''8IE-\_C'_\KNXDQTMLCN9^O5A]77;++*%U&7/7_)5ZO" M(U];H^O\WH/%0F -@DX@S=X[CB'.^]O. 87P!#W:IL_5]D_ M-Q%2]R/^S[?XNW69E0ZW"(I&?2<,)%X)H! C3NER:I3I&RH2-B0/WG.P$_ O MPZOZ+$S'VD3#WG@++4*>$HB@8@Z3L9PW%*>^BP+Z-H-QZ*IZRQ2K;S^($;0\W"%13 M**$23',&M"$ F)>MP]D;THA#,^%098)S\6__LN!;\42^>,TP7>?WW\S_5P0?$$ X^T"(AJA Q$"A(B MK(>:<5AM[)XF:L01&E:#<^&7,A-=".!RW/KV?;+^>[Z9W^W,@ K./5KMJ5?3 M8;# 8^2BU>EHW"8\Q*Y(#KH#AF"1F%=EA(;=2)G9K7Q2DC]-=\]Z)O/XDQ]G MDS_CC-?/Q9N/Y3J[T\\?EL>S/=4W#8IQYAGEW@NK#'4*O'B8(*&)#TM': M> MBE\]26( %?AQMIX];"?_>[9>S[<34(_%$]H3:NYXHV",9DAAA@T"QB@CI%+5 M4M$^,1)JA+$NEU9EG.3@X6P4)'0(0/0LN$])A0Y%]\DRHQX&J$Y6(N M3<+>9-)^#_T45\'D9[;SY?VYW]B7NRI;ZWRVB,+(5NO)XBY^,)FO7[VN?[>C MMN\H0"MX'$L\Z3/ HZD@":W@B^>YQ (T(\QK?\G]M7>Y7.[ 4:'YI1SZ[NWO M=D9J.EUNLE/9K<[H-0BB$([;@\52$NMX7%9F#Q&TDB2JRA&F=+RTJAQ.2.UU MYY>\J/(]F\R_9G>;K1OSJ/?J\X]L^2G[N?[V5S;_D?T6X?N^4JNOV6HS7W^^ MCW#N$^>::/1.9HO?)NM"M$=4;>^_&Z10PAHG%;,NFCXD( MDU%>4C./38P7LVC?8;KV6:3+9%Z4;=M$7CV_^;BUJ=NJ]U#D#,7<<"T1ME!C M354I2.@E3/2?C] &'J?GO4]AM5?P=B^R:$!-BD0BQ;UFX:RH\LG\>31:H4WS MP*W#GDD,J,<4TK1.AY@-@/("I_-^3Y:P863'@FJ_?AP8\X)J)#'7@$I?Y,9ARDI& M.+,*WU#VJ'11GN!$$HCM#<9&3/]X(N*_?2=QR<3S%"5:0T@IYTA)Q.*8B.," M2*T3??,CBJWH687T#OD03U"J7)=-#NNUF76[Z#;HXJT/4U$8#%$FM%(41H-: M V-\:FVT(AXV8BF_\F69+^*_3K,W97.&/,>\&LL^#WF# M8\SQ1D40-."6,$$()\1:!B7V2CEO,0.RUHCK9Y(G,-].X'GWOTW40-NN0B0; MH1@KKI4VS&),,"@!T8JE%IP98T:/+FB1#PKW9==[\5>KS2X,,2T#R)'@B+_4 M[W_,=MW6E#(Y^&U01:0N=0X8A)GA$CO$ "KJ*9AH=+K1+>+/R])_]OJ+6=P4 MGNI3=YS5;\ (1%IC)7SDMN/1B@:\A,H .=3R[M?B/),ES==TYX /8&^^*J'F M\^6)R=7X0UKU$R"@RL?3&A)"**"HP!:4,& O^=7S;F"VY,,)8P!.%@D'/M^K MNWQ;J/I[MXR(K?$R!KF=2H?6#84L"4P)!C@I!!S-IRV@BD5HT=(;7.$_I[ MG=0#M@-0*E6!GW(-=M9WD%$:BB)G&$1( :HU*(7!J$6)(9$C],Q<9A\=6D # M\-GLBE3.?F0[=]3G^W>3W$_APV)7(?5E_9\@ :5D" M!%!J6NH1*M,!N91?2#J7]4?45"*\*C\D(0QACCU$),(,B-9Z%T0J//#67*;F MTKLD7JV=CXW:ATCD.&F-+?3,"^FLT[:0 L8R5TZ<,)/H>1IFDN@>*]87S #2S<7?[L=T' M5\UY=;Q1B)@QBQ6-)V30M&:+E!(U/K1K7^JGZE1*I,V"'>'F>/4SF)AHE M+8ASM$T07'F/*" 8JFWL@>6ZG!ZF.C'R?(3OSGM@35>HM@\(4K^;G;_B4_X? M!4T ^A@U8+;ZEC_-IH*@>F8D]!*LB$=71H4H\O)RK21%IMJK!;F=IS$=S8G.$2O M]L3)XNZ_LKN'.-L=92']-ED^9.NL2/RSS'_LSKSK_ 65^WRY;Z&***-9\4 W MB60##"00Y8V(PF+$*\"H!HK%]>:X!G^)=P_;T:D%G>_#*J!-ZAQ'T%QQ 6*TJ"<4NKC7F4(M)1( M(!A4J.X >R$(VI692NDN:!97#I?$2JNI-4@"KREV$D*BE,*W%*S6 UO>%[_K M7P(7UQ47K%LUK,K@' ,4K5H"1%%C(6XX905F(S0VEU$9+Y'11R:R/>?5UJYJ MWDMP&%+H+20.BZ+:A$86ES!$QMY.K9<>F'$TK+UKV!/>ZD21;&V;S_^2N/SJR5V'FO2'=+4../N%KUC 8 M:Y0%F,7-#@IO((VKIAQ[DK6K#R7[Y M-@ #A,#$":(@H<9[K5TY'1S_\N:YTE:L[T,9SD1TB =\V3SV^?"W;%$DT8DJ M5-T]SA:S8KO=AF#LD@+6DZ=5/P%9: T%%CJ >+3J#7W9QCF5UY^6NV=B]8GV M *2K:IV?.BU4]=")8Y8K&O=Q!"DRP I,R^$3B1)3%:!KM$[.!6U MZI63@F"**"$:&LJ$T=4B,%JF!RCW=%AIC_TAZ25-?@#Y_1;UR./FL5:";[X+ M$#H+E(#>1'UBE>&0J4K%>)B8![]?&;:50-X= $/(]0>M.UG?>"XSG/P[DC0-:CM:?"M2&(>T=WN@">%?^#+()S0G#H+K/)0"X,@ M,>7HJ/6W4R^S6Y&?#^4 ^\/G]?=L^6;&M1O$L2;!<>.\$@HQ@B%&T,3=M)R< M$"3Q7-'ZT=%U[A =H3KT@:,X&;4Y9I3?1PO<"RI1Y+R&A1O&,V3+:*(RT"XY9I#)6.A/:4&TM@Z8N3QN/K#VOJ2+)U/$F" M,\&8+ C1SMUXJDE@"#'EJ(#%\Q3-N1*TV@PU$M$+VL<^IC@^Q5 M39H'5ZP@ (S"(BI:8KG@I)PTQLRDT6B$KQ,O[.!*17QHFKW%H[S\*?X=-J7: MB2Y"-, HA9(!:S6)QAZ6N++'K$\M$3MVK74V%9H]_3D7[J&YML>C*:_VGX>H M\[UT0!(0#7N" =50EI/RD"3N?"-TH@S'H31HS[R4VUTW%56+-P7HWW)[N))I MLX8!0.[FUG:[,;=GR?'600K) M("78>VF C):C!2]N!F$3@S9&F.!E&*ITAG3"NZ'-X^-D^?SYOMSWON7KR?RW MR3_RY:]S/UVK(*6KP DS6*BX&(0ACE#/O7]9#VZH]"^#OVCNDDL# ']9*[KX M_[?K(M&6/M!1P-()#B2VP'@23RP$HO+4JD1]19SQ6]3]4Z2Y=7V^ #H(47.K M]>RQ&)'?Q#_,S&3U_?-F?3_/_VH:MG:\AR PMHPH+I7ESBG"+2B/O@K!&[BA M'(Q._2(_@$;[LJO07%0M>#./$[KK6)/@(FR("$>$E) +2XN+VOWDXK:0>&9K M;IS+':T6V4,!_G43JV.PNS'2RP=X+2SSLDG0D?(.<\0Q]01!@5_>,4144NNM MCM '.:@YG@CO94VE?!40L$I<07EP&[:Z82-*4Q3XS?$?_.%$J#]H4O M%TI&=?IO:ZH;[$?>]QBW]U?_!OFR@(VZQ49[61!%1?P/K+4F7B)O(R-IG=^E M'PB&SY<5K4;@E=9>8!VUKY0 .^2<4(YRS=6_8[ZLQLPX(U]6.]BO)JI,@GCX M),AS@!$E%LC"J2$8(\PJ1EUZ1-'E;_0;2ZQ15%D[H*XJJLQ8:P0A&B-%J40T M3M-XY:4%/*XAEGY!/V1L6&/Y-(P-:P?*"&+#'',44X1M'*S@7&$??T\*(1V# MDJ>_-!KUMI BL,:Q8:T0O9'8, 8@DA!R1CFD G)-)-3>*F>!0: VC_'X?<$7 MVTFZ07P FC5$IDEQL78]!240(1XY21RGE /%%8VH4^FEM"CUG?4H7\QU2XTT MNS81]_9[W4NQPT,^@;I*" U;!VTX,,!0;PRDW&#ML, *.<4-Q5!?_S56K]SI M#^D$V^BQ*(7P^;ZX*OLRF=V513"_Y7XSGS]_7GZ9+->S2?S7W[/U>I[]_I1- M9_>S[.Y0@H.(3VVMC;Y^+R@/1;&D& *6 A[_PQ51YD S3;1+S4,[RG)DO;%R M+-(Y(U+IK1J>3I>;E[N:.G*VZR2PJ+ZQ)2R:PYH"5)24!%S%!6N=5HPG7G^, M\DUA;XSK%?)!?-H_LL4FNV@EA>T(OF;3_&$QVY*IB2OX6*-09+H3FG@CF(CK M56(I=M=,<>%23>O*.C9:K7:VFCP\+'?A LO=6(XY;D]^'Q R1ACLI,4:&"<+ MER00R/EX'N4^]0IRE&?Q\R66=X_H$($RR_PN*H;/R]^CNIE-ZS(''?H\1)4A M'=/>0&VT80P 0DJ(4/R#JZ=)1S)]'P-S/I;#$605]Z3].%>U#MJC;8(Q6#)- M);&>60XYA;A:38"^K_E^A53I1KB'F7(VGNTMO\)"??I>I"W_L%@7!LEBFQ?] MI'OW9)L0[52F$0;.F7A4AX( +LL1*Z9NQ[_;@=#R?D!M3X,_XKSSA^?)XNY+ M-H]3^:]L,E]_/\F"4TT")IY+09$L,EMX3IV1%0(8UEZ!7X^+HUL2=(AI>PZX MQ5V^FN9/SR?%_NZKP!G1%E%O) (",J'M_M%5'%4\OZ1G*;YM29\'8X)G<[*\ MFTVF7[\_K[\__C993!ZVM3!.BOIDFP T< 9X;Q"5VCFEBK(9^Q$S X?*"71M M@N\2U(0U/L^FZV7^]/UY-=NJFM-K_?#7P7-F"OLWSM\5Z=TA(VH_2D8P2HR) M'F%=\8[7?"=PMA?ZIVP39Q9G,J]/$7CPVT"+S+C%2WUHB.-6*R5*[<2DA8E6 M_0B#X+L5>!=@MA?W:_MQ,M_JF_JE?KI1$''>3B OB"02<,&XT>68.6:W4W&[ M6P)TBNH0-^IEC:R_9?G#_H:)M@->%%*G>/F+) >DPT+J>G$4]4,B/T''0@ MX5\JT'4#:F/.K++I?SSD/_YS6EQY+I]WE-G_QWNV[/\X_/'[ 5J\_&6@V$%B M;!$L=>E)5P)/$><80^IVZ%W@68[<5]Z!3\\<13C]HV@2FDE=(2.JJC M 4.*8K[Q'T1J[#5UB=<+(]KXNW4>= WH<,%_^W_<0O ?CZA"#!&@'GB%B[H. M46CQ),8HB6*K2R34:*7M?[XN&/?]9T%BKI2/"L1+J)"4VKLB[XZ01,5?8.FO ML?M1BEV@G'<&Q^"K(2[EZ3Q?;9:W%!N+/90T[C]">2NB #0#'+IB4'::U$7 M1CAP;*R(&Z8RTFH/L.3<8J=Q-5KETXOGCF4#ZE)BC6)CVR%Z);&QQA"$G-0, M>T(E*"Z%7#DIH%.3QXV()AW)M$EL;#LLKRXV5DC('> J&N+&4>[BJ;M:3.(:$4J0AJ$;EZ/4'RWU@O'S$ MJR2:&J:A-5A(@(2AVI;C%30UK<4(;R^Z%7N'F(XA*-)":8SD'D#'K,"&8L#+ M$4/G$R/C1N2UZ(<%78)ZL:#((C)?4DJL!=!P:QFEY2@9&JQ&YK6)OALX+Q(4 M":BSU'G /1<".XY<-4(J26)R^Q'>2G0K\"[ '$=0I%-.(&H0%M1BHK@70)=C M=H8FQK>-\(:B6P)TBNH87KP)@23"V#L.#<9 D2(4I]R?>*W;]Q:"8U-XT"6H M5Q<;*[&.RLX5%.?1N*%&P&IZPKGKKQ/7C]NH*T"O+C:6G0S7H4.)-PX-K8=J)<(@N!1!PH+#*/>"08E!,*7([3Q.'0[8C]?2+5! M$.W O&@H-(%&(PLUQ(0I7-Q42E$.E3"?& H_HNVA>[DGHS?*.$=%C")"K[$3J2NB/ ^3".,"C>2\@!L0AQ0*!5KK*>H;*)N\,(/4_=D^)<,"\="HVI]\A' M<\5ZSY#!WJ+JH$UH:GWQ$?JT0 QD#ECFOI;?65I154"9N M"B,R#KIU'G0-Z!#.@\F\J.FT'>:G[%2\W;LO@U;208"Q0E@ZZC6T4)5300#7 M): <_XFQ0VF^=Q24 K+![";P+F3[ BG=?!HV8AQ11&+$ D/M)*HV.9": MP&.$Y\D.@QF[P7)X6KR%X%_9W:F"WK5MXRKP4<5" AUBBAE(E*UNYG@\7UW] M9C,<=08<6!8%)Q+8U!P(D2 M(L7I]:?*Z$BF3:+.VV%Y=5'G!$1SV ,#A%>,:DG(RVJ2.K5&\(BHTHUP&T>= MM\-S#.X"S93QF@$/BG22'G$*R]42QTVNO]Y0M\JB:T"[H(* M.8>U$D5EJ[B!RKVO VN(3=W6T],$JQ*4[\?]87&?+Q^W8M3/^[\\=J@_H[= M.966N6B?1JM",.>5LB4LA.+$'7F$!OKYQ#A:/K0OM(>,*]:;5;0P5ZO]<%=- M8XL/M0O1" &>,V^HY!Q(;D49 H6UEO9V3GV]Z+1[0M&PKF+Q3!!/?*.<_)JOI9CY9UC]- M?O=ID,QIZB 5%GD5-U,,4;6W&F6OW_G3G7P[P*^]?'_+[N)IY.&D8-]\$Q3P MFG $!8*$ NRPD^QE:NQV*BZ=+]%S@$M8JODRFAYQ4RDK[ZK%G=E$0!?39_=S M^GVR>,A.+^#&'00!,)'(%VF>#<&,"(QP9<(HF.@3&&7UY X6=E^XMN?(MN;W M9+ZO5'^2#8<^C68)UU0SY#7WR +ON='E^)!1Z:&_8Y5=!R@,9VH?.GNSLQ7(,>Z;I'/D$IO!M$X9K<3.:K$\ZV)LV" ME<)(33'0CF(?#S).5J!0K8?R+%W"<7R>'//>0![BL=FFT)&?[W=#+E9'>; ] MH8&.-PI0&*T8=]HI0ABT"A/RLB7>0)'X;L7\_C5:5\ .'W7>Q-=_N$606EG$ MI++2#LKV=\ODI6TYV')_FCYF:;Z61W7W+&^TU;;L(RCNGB_O> M>!!C@" J1.6#=11=_SNGWJV7'N$^FSY_+"8OP]D/HAEK#K4,TA+M=#P#0.<, M,%AII*I%I%+SKC;WB,@=61:["*%O-\.9#L >XD'U8X'"O[;3_WS_(0IR\3"+ MY%:K57;2\#W=,'!JC7':$R814E(;#"J?H=&I.9N;/[5^RZKK(U0O, _ IW>+ MX&.^.D6B U\'I9B7BD.LN #$.>$5**MSIK0PMM)*-@K<;K"=P#ZO%#;1XQ,OHAC MWL1A[[F?+U8ZB\ADN^^^37YF*_+R?)Y"U2<[S2VC/#/MS..XLM6 MITYB/?YJ8)IJ01FG% NFE:905?%\/9E?+X7'(Z%DIW:U!&?; M,4Y6\;^GA6@?LOQ^$??^R:MWIH<=W(VZ"(0KH[%4 @%J@7$>L.JBWBF9F(!? M_ILHS9[AOD#0].5>,'<9,XVAQXQ9K!$W5"B@A<,<, &<%\2:"SUY:'=!U^09 M1%J/00(FG<>"XJ+ZFTC:+!RC_P=5 8&(Z\)QP*[XSF1$3[U"HBO1;Q_RZ\ MZ%\-N?E[B/>-@C;QS"\%Q,8 PS0 Q,-RDI; VXE0/TO"1]?LF7@.<26T^7.5 M_7,31^B*W.[?XN_6/6DXW"+00L$Q[1T4A#MHB:-L/S7C ;^A+,@=B/<]8SK! M]#)TJ7^Y<*Q-B$L*66^==T)BH(F@I(3+ )Z:7W^,E#E7OO5\28)T>,;4)E(] M^'VP148 XAT'\>3"N":>RG):W*@;>N]ROF1/M08'D:W@0A"A8B:U!/%I$; 6%Z"!!6_H;B5'NS5X8 ?@)W'1EMKV9YN M&(01 %&&G#%>"JTH@KJ2$ (CM/&Y9@PD]>?$+!KV>0=03GH%O=*RWYL\JSH9,,@%?.:.8T< M]P0A1BRGE:&.?>+C[S'6%NESF^H VHML1-MW>;/[**AL,QILYQ^GQP,GVK6," 0L5*6 M:\4% 4!04#RNV8V=4I%H@U_+&3^=1+W .T3 YOI[MDP)PSO=,'#)@'9:&Z^X M0TS B&(Y4<9HXDNF:SG+G:^,.H7W8AOE*2OK2(O@J.,,24,$\]X6'A,,RJE9 MG^H%N!;SJJ]MK"VN*1E9)D5^R.+'U#RBMX@B^)&=YD*C=L%(J+V&$EJK&3(> MT8B$ (19[BR2B5<-8ZS;UOV>U#6Z[7GQ9?/G?#:=/W_/YG>K;+I9SM:SHZ&+ MAS\.@NG(6&R1T5'92>:\J=RGRKG$H([)_R=?'(GR>(X"QJU#44E4N\A<8!8@K&$WE9@6$ 3:WZ,,=R_ M>U+T@? @ ?]-+(O7V@T* H72E A,,"" &B.J2QP,ZLK8=!90?VTD.1_+]BK# MS/-5M'2?)L\GWK2^_2B(N$MQHXE'PF'%('2J\E43!!+/&6,,7^]>"9P%98(A M$'7.8CV;S+_L?G"EXXGX[O-"Q9G-?L2!F&RYGLP6O\WF61&S>MQ(:-U18-Y$ M&T<@Y A$1>81]7*E8:E,I$GQY.G?@">]XSU$L//FZ6F^-8,GYP&L? M-+SY,""N+"C>#%-H(W<,L)25DXD4O?YRC;U)]UAJ_11CZ0Q'/%6K>"Y 78DEMJ-?Q1L$5(2M, M20!WJZG*7CWJ]RX=3^Y3A6),@#51% M44)-G0+1I#$25W@IA&_I06P7(CYT67D^K FIT8H?_I@7>4>7CS4<./E],-Q) MR;UE'A,;K5@,"2E'RN(_;B;NH4/Q=XGH$/& Y;;ZL4D,X"\?!^"**6#&M)/& MQU,/X*:<$. L\6W<""G2D?UQ-H0#<,),5M^+J@;Q'\6]^8_)O/!OJ749Y/7? MD_GFU+FF4?M@F$?Q*(Z5=DSA>%I6JK+N/4C-L3A">^0?](YMP)1%_?AK_ M/WL90I$%:#F;KK.[XB\FB[NW?_#JRV,W&.?T&;0' $!B](-"C#HG9?5:K1F MJ(UJD-0=Y[-I:+P'4%E?JZ$>7B(GM%5=TV U)5,,"G;%W:\O5Y6%KW%0360D(I MI4>:8>X\>U'9$?&AXONN1($-A?. M'L9]=^6^6JU'W<#CAUN&! VG'.$!8MF MJ0:>,S+QNQWBP7 M)Y16@U;!4D&Q5UA@PX!DS%')7TXM.C&@N;F9=5/$Z1[P1#_D-L%G(9KECZ.A M2[]^&+!6S"MD=>R28< (L-5\-2*)9!AO 89A&'$VT&.RP[NPOX, 5CL!'6(X M&IZ26:9 M6FSU'ID[5]1])Y:>G@SJ6OP!^#>;_F/[.(%)9C;[9O;B#8%]&7-I8:&MSX7/F7+67X7*;!<]TJR M7IF1]R^ B_-NE['K[EMN\E7QKK_^#712?\%!0(FCSEC L948 X]>EGYJA9L1 MWB..AY'=B.+B#+79W6:ZK5^13,J7+@(2D"E?A!U"")'VBJ#J4&0TOJ53Z'B8 MF(S_Q<06>.ME H[Y(FJ+!\%8:+Z:^W_WVW+;O'O0KPT^ =ZT[F( M(GYN5CKYT.>!,R$\U8(SB A"W!%67=("*A/CR<=9-*Z[LT0'4 [)#S];S%;? ML[N_Y?E=W?/?7QL$K8D13F+HO=)>*!8W_')B0J6^!![A-=%Y8CW&D7/ ')(E M?\^7__-A\6691_77B"5O&@2@I#$1)FX(%U$=*F"J8#>*7&($Q B-\WY8<@Z8 M0[+DZ^2OWZ(>7?U]L$X"XRPK0#+6,0MPI6\AQ;>3VZH?CIR!Y<#F M2$,S)"C)/!48($!TG !!U6#PBK)^_ M1+-YZS+XYV;V5-A=S;*S-8>H!V M3Q\GBU,W*,5?!Z"E)APP*+GA"G'-7Z(9>%24-V.B=BO"_&PHAWCCN(F(S!8/ MQ9G\P^/3 &J^+VQ3I N 9 65[=;-/D@@HFBZAJ;GQ6B? O3(?4]>X#N%@BL-\V,II?^5?'SQ^K$E0<1X\GEVD M!50)@X6%JIQ<7(NWD["@0SF_]T)U@^T Q'&/3_/\.SE74P:N5R1__G"VVTHN' MWZ*.31RN>5TBJ9S-FY?AQV%Z@0%3S<,!'%!-4(24.^U!< M$F24$O&,BY34FMAJI1"46EMTA,ZQ_@C4%;A#J:%7 _V4+Z:-CW[UC8/'T% L MXH09\H(C&0_0Y80M4XGJJ'5QC"L[^W4.['!::%)H:&3?"TU^/'.H.WW$>_!J1[*Q^@^3*2"*)5PAY(YUP5E?0Z]0[QQ$> M_WJDX9 2N-P1L!$9:]L&)I#A6N BE;(!#%,G2#E=845BK8(1'@1[)%S7*%_4 MH$\RY(.**P-*2!3P'$/,+535B05@F$BC$1X'^Z91%_"VC^QK4 &F**:TFM]3D,: >'(F % :P0*"D@HPPT7BZ:]]S;LK.?X- _, 2NAUF,4)M?/Z ML^#B[BP(P@1"&?\!L<&5)N6MZU(<7W%^R2!U#.J(>/1TN#02VV]5P @PB2G=4$X_>P3+Y5BZU*8-RK8 MV;ZW@ !#EB+)@7"2>\@H=MX;#0CC1.KK?^_4&T_>EUKI'?P![):72;S)J[A- MJKA]<[&(V$4%]I)@L1TO6_<:M/*4NL( P$1I3R(XJA1'W/S%0-[+$5A%'3*T M;S&T-YZ*Y#OWN^0[<7A5\IP#":A/$2ZQI^"ET40BH0$6%#)CX@S+V3&#$]/7 MM_9-7C/)AH%^R.0#+^66F^BX4\V"I2S"B:Q3V!MOJ5&85JM'^J'J;5S_)MLA MRI=\G=".6FVZ"<#&TX3U7#HJK6..2>$J9!%/M.=&E=)W*++UB/O0IMP[__VW M),OM9">!&ZZ$4<8160)@B4O4<:/*_W810ZU+U"]P_=).U35H'1S" MQGE4)'"GB'A$'!?EE./:2WQ//ZJ,+4,1K7NX!W!1_3V;/7R/AVL5)3!YB*!$ M*%>?-^O5>K(H,DBT\TQU]'YCLBS\>JLOV7([G@:Q@\>:!.VH]5![C+RD+IZT MJ.%><<0=ER3^T44<5>]'VV0Q'VT3.) *.:ULD9><>2X@!UA[@8VVD6N)2WA$ M3J?NA/S^'4I'F(Y@G=IL/9G-6SJ2Q[=28&5(RKB#K1W7'D/8=2-$ONZ M9RV]&W]1+'>S^68]^Y']GDTWRZVB=S^G\TV$V4?&FOSQ:;,3].?[7_A5F!O- M#,0.?B@(Q@US6D/. 97>*$T\+@K7$\&)H(G>OFM2#(WI=-QF'%X00T17GS M$, I@Q@D\O?V5',"MH"T.SNESFHNW]L5NN:U&^)/0;EK=78 $@0 MHLQP(9FEREDK8-P.1:(O:(0J=YR4[5Q"E].MQZ;27KL>ZRE(Q+Q$TFC-(;5< M2FN,@\QBS4R4PU"!(@/D!A@E63N3S!#WK^M\^C\?5JM-=FY=9'P"/P+&> M$J ]/K^ZMM=1[PG"E7,"0LT(OADK_WQR'/62]X?W:0WP?_^S^/3/R2K[?__G?P%0 M2P$"% ,4 " F-*%,$AJL>2;) 0"H&"$ $ @ $ M8G-X+3(P,3@P-3 Q+GAM;%!+ 0(4 Q0 ( "8TH4R:ZW-C\A4 &?P 0 M " 53) 0!B'-D4$L! A0#% @ M)C2A3/;"-S7+' C20! !0 ( !=-\! &)S>"TR,#$X,#4P M,5]C86PN>&UL4$L! A0#% @ )C2A3-P&C[?A<@ 0CL% !0 M ( !"TR,#$X,#4P,5]D968N>&UL4$L! A0#% @ )C2A M3,^8]#\\X@ SIH+ !0 ( !A&\" &)S>"TR,#$X,#4P,5]L M86(N>&UL4$L! A0#% @ )C2A3%6B&^.$B 0V$& !0 M ( !\E$# &)S>"TR,#$X,#4P,5]P&UL4$L%!@ & 8 A $ *C: $ P $! end

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